Orange Book Cumulative Supplement 06 June 2019

CUMULATIVE SUPPLEMENT 6 JUNE 2019

APPROVED DRUG PRODUCTS

WITH THERAPEUTIC EQUIVALENCE EVALUATIONS

39th EDITION

Department of Health and Human Services Food and Drug Administration Office of Medical Products and Tobacco Center for Drug Evaluation and Research Office of Generic Drugs Office of Generic Drug Policy

2019

Prepared By Food and Drug Administration Office of Medical Products and Tobacco Center for Drug Evaluation and Research Office of Generic Drugs Office of Generic Drug Policy

APPROVED DRUG PRODUCTS with THERAPEUTIC EQUIVALENCE EVALUATIONS

39th EDITION

Cumulative Supplement 6 June 2019

CONTENTS

PAGE

1.0 INTRODUCTION ...... v 1.1 How to use the Cumulative Supplement ...... v 1.2 Cumulative Supplement Content ...... vi 1.3 Applicant Name Changes ...... vii 1.4 Levothyroxine Sodium...... viii 1.5 Availability of the Edition ...... x 1.6 Report of Counts for the Prescription Drug Product List ...... x 1.7 Cumulative Supplement Legend ...... xii

DRUG PRODUCT LISTS Prescription Drug Product List ...... 1-1 OTC Drug Product List ...... 2-1 Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List ...... 3-1 Orphan Product Designations and Approvals List ...... 4-1 Drug Products Which Must Demonstrate in vivo Bioavailability Only if Product Fails to Achieve Adequate Dissolution ...... 5-1

PATENT AND EXCLUSIVITY INFORMATION ADDENDUM A. Patent and Exclusivity Lists ...... A-1 B. Patent and Exclusivity Terms ...... B-1

APPROVED DRUG PRODUCTS with THERAPEUTIC EQUIVALENCE EVALUATIONS

39th EDITION

CUMULATIVE SUPPLEMENT 6 JUNE 2019

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 39th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; approved over-the-counter (OTC) drug products for those drugs that may not be marketed without NDAs or ANDAs because they are not covered under existing OTC monographs; drug products with approval under Section 505 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) administered by the Center for Biologics Evaluation and Research; and approved products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons, or that have had their approvals withdrawn for other than safety or efficacy reasons. The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, Discontinued Drug Product, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists. Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision. The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.) Products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the

"@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug Product List" appearing in the next Edition. The current Annual Edition Section 2.1, How To Use The Drug Product Lists, describes the layout and usage of the List. New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item. New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item. The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month’s second work week (e.g., November’s supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

• Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.

• All product changes received and processed as of the date of publication. o Refer to CS Section 1.8 Cumulative Supplement Legend for types of changes o Discontinued products will be processed as of the date of publication. There will be circumstances where a product is discontinued in one month, however, it will be reported in

a different month's CS. For example, the Orange Book Staff received a letter November 7 that the product has been discontinued from manufacturing and marketing. The Orange Book subsequently publishes the October CS on November 14. The product will show in the October CS that it is discontinued even though the date of discontinuance is the day that the Orange Book Staff receives notification (November 7).

• New Drug Application (NDA) approvals appear in the CS month they were approved.

• Patent information, also updated daily in the EOB, is current to the date of publication.

• Exclusivity information is updated monthly and current to the date of publication.

Every effort is made to ensure the Cumulative Supplement is current and accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at [email protected].

mail to: FDA/CDER Orange Book Staff Office of Generic Drugs 7620 Standish Place Rockville, MD 20855-2773

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

FORMER APPLICANT NAME NEW APPLICANT NAME (FORMER ABBREVIATED NAME) (NEW ABBREVIATED NAME)

G AND W LABORATORIES INC ACP NIMBLE BUYER INC (G AND W LABS) (ACP NIMBLE)

vii

G AND W LABORATORIES INC ACP NIMBLE BUYER INC (G AND W LABS INC) (ACP NIMBLE)

IVAX PHARMACEUTICALS INC ANI PHARMACEUTICALS INC (IVAX PHARMS) (ANI PHARMS INC)

IVAX PHARMACEUTICALS INC SUB ANI PHARMACEUTICALS INC TEVA PHARMACEUTICALS USA (ANI PHARMS INC) (IVAX PHARMS)

RISING PHARMACEUTICALS INC RISING PHARMA HOLDINGS INC (RISING PHARMS) (RISING)

SUN PHARMA GLOBAL FZE SUN PHARMACEUTCIAL (SUN PHARMA GLOBAL) INDUSTRIES LTD (SUN PHARM)

SUN PHARMA GLOBAL INC SUN PHARMACEUTCIAL (SUN PHARMA GLOBAL) INDUSTRIES LTD (SUN PHARM)

TEVA PHARMACEUTICALS USA ANI PHARMACEUTICALS INC (TEVA PHARMS) (ANI PHARMS INC)

TEVA PHARMACEUTICALS USA ANI PHARMACEUTICALS INC (TEVA PHARMS USA) (ANI PHARMS INC)

TEVA PHARMACEUTICALS USA INC ANI PHARMACEUTICALS INC (TEVA) (ANI PHARMS INC)

WATSON LABORATORIES INC ANI PHARMACEUTICALS INC (WATSON LABS) (ANI PHARMS INC)

WATSON LABORATORIES INC DR REDDYS LABORATORIES LTD (WATSON LABS) (DR REDDYS)

WATSON LABORATORIES INC HERITAGE PHARMA LABS INC (WATSON LABS) (HERITAGE PHARMA)

WATSON LABORATORIES INC ANI PHARMACEUTICALS INC (WATSON LABS INC) (ANI PHARMS INC)

WATSON LABORATORIES INC DR REDDYS LABORATORIES LTD (WATSON LABS INC) (DR REDDYS)

WATSON LABORATORIES INC HERITAGE PHARMA LABS INC (WATSON LABS INC) (HERITAGE PHARMA)

1.4 LEVOTHYROXINE SODIUM

Because there are multiple reference listed drugs of levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate for these drug products. Accordingly, FDA provides the following

viii

explanation and chart of therapeutic equivalence evaluations for levothyroxine sodium drug products.

Levothyroxine Sodium (Mylan ANDA 076187), Levoxyl (King Pharmas NDA 021301), Synthroid (Abbvie NDA 021402), and Levo-T (Cediprof Inc NDA 021342) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Jerome Stevens NDA 021210) tablets.

Levo-T (Cediprof Inc NDA 021342), Euthyrox (Provell Pharma LLC NDA 021292), Levothyroxine Sodium (Mylan ANDA 076187), and Unithroid (Jerome Stevens NDA 021210) tablets have been determined to be therapeutically equivalent to corresponding strengths of Synthroid (Abbvie NDA 021402) tablets.

Levo-T (Cediprof Inc NDA 021342), Unithroid (Jerome Stevens NDA 021210), and Levothyroxine Sodium (Mylan ANDA 076187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King Pharms NDA 021301) tablets.

Levothyroxine Sodium (Mylan ANDA 076187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levothroid (Lloyd NDA 021116) tablets.

The chart outlines TE codes for all 0.025mg products in the active section of the Orange Book. Other product strengths may be similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some products. One common TE code indicates therapeutic equivalence between products.

Trade Name Applicant Strength TE Code Appl No Product No UNITHROID STEVENS J 0.025MG AB1 021210 001 LEVOTHYROXINE MYLAN 0.025MG AB1 076187 001 SODIUM LEVOXYL KING PHARMS 0.025MG AB1 021301 001 SYNTHROID ABBVIE 0.025MG AB1 021402 001 LEVO-T CEDIPROF 0.025MG AB1 021342 001 INC

SYNTHROID ABBVIE 0.025MG AB2 021402 001 LEVOTHYROXINE MYLAN 0.025MG AB2 076187 001 SODIUM LEVOTHYROXINE LUPIN 0.025MG AB2 209713 001 SODIUM ATLANTIS EUTHYROX PROVELL 0.025MG AB2 021292 001 PHARMS LEVO-T CEDIPROF 0.025MG AB2 021342 001 INC UNITHROID STEVENS J 0.025MG AB2 021210 001

LEVOXYL KING PHARMS 0.025MG AB3 021301 001 LEVO-T CEDIPROF 0.025MG AB3 021342 001 INC UNITHROID STEVENS J 0.025MG AB3 021210 001 LEVOTHYROXINE MYLAN 0.025MG AB3 076187 001 SODIUM

LEVOTHYROXINE MYLAN 0.025MG AB4 076187 001 SODIUM

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: http://bookstore.gpo.gov; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, http://www.fda.gov/opacom/morechoices/fdaforms/default.html.

The current listing of the Orphan Product Designations and Approvals is available at http://www.fda.gov/orphan/designat/list.htm.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and

those now regarded as medical devices, biologics or foods.

The baseline column (December of the previous Annual Edition) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST COUNTS CUMULATIVE BY QUARTER

CATEGORIES COUNTED DEC 2018 MAR 2019 JUN 2019 SEP 2019 DEC 2019

DRUG PRODUCTS 20295 20580 20693

LISTED SINGLE 2724 2713 2729

SOURCE (13.4%) (13.2%) (13.2%)

MULTISOURCE 17571 17867 17964

(86.6%) (86.8%) (86.8%)

THERAPEUTICALLY 17483 17777 17964

EQUIVALENT (86.1%) (86.4%) (86.8)

NOT THERAPEUTICALLY 88 90 85

EQUIVALENT (0.4%) (0.4%) (0.4%)

EXCEPTIONS1 58 58 58

(0.3%) (0.3%) (0.3%)

NEW MOLECULAR 25 3 16 ENTITIES APPROVED

NUMBER OF 1133 1129 1132 APPLICANTS

1Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route of Administration and then by trade name (or established name of the active ingredient, if no trade name exists).

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, Reference Standard symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by “N” is a New Drug Application (NDA or innovator). The application number preceded by an “A” is an Abbreviated New Drug

Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form, new route(s) of administration, new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be proceeded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA New drug product approval usually in the supplement month. NFTG New first time generic approval. CAHN** Applicant holder firm name has changed. CAIN Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name. CDFR Change. Dosage Form; Route of Administration. CFTG Change. A first time generic for the innovator product. A TE Code is added. CMFD Change. The product is moved from the Discontinued Section due to a change in marketing status. CMS1 Change. Miscellaneous addition to list. CMS2 Change. Miscellaneous deletion from list. CPOT Change. Potency amount/unit. CRLD Change. Reference Listed Drug. CHRS Change. Reference Standard. CTEC Change. Therapeutic Equivalence Code. CTNA Change. Trade Name. DISC Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.

**Note:

xii

The Cumulative Supplement (CS) currently displays a condensed 20 character collapsed applicant holder firm name and the Electronic Orange Book (EOB) query may display up to a 240 character full applicant holder firm name. An applicant holder firm name change usually changes both the collapsed name and long name. On occasion, only the long name is changed resulting in the CS displaying only the collapsed name for the >D> and >A> action. The new firm long name will display in the EOB query.

xiii

PRESCRIPTION DRUG PRODUCT LIST - 39TH EDITION RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019 1 -1

ABACAVIR SULFATE; LAMIVUDINE TABLET;ORAL ABACAVIR SULFATE AND LAMIVUDINE @ ZYDUS PHARMS EQ 600MG BASE;300MG A 208990 001 Nov 15, 2018 Mar DISC

ABIRATERONE ACETATE TABLET;ORAL ABIRATERONE ACETATE >A> AB MSN LABS PVT LTD 250MG A 210686 001 Jul 10, 2019 Jun NEWA AB WOCKHARDT BIO AG 250MG A 208380 001 Feb 27, 2019 Feb NEWA

ACARBOSE TABLET;ORAL ACARBOSE >D> AB MYLAN 25MG A 091053 001 Jan 06, 2011 Jun DISC >A> @ 25MG A 091053 001 Jan 06, 2011 Jun DISC >D> AB 50MG A 091053 002 Jan 06, 2011 Jun DISC >A> @ 50MG A 091053 002 Jan 06, 2011 Jun DISC >D> AB 100MG A 091053 003 Jan 06, 2011 Jun DISC >A> @ 100MG A 091053 003 Jan 06, 2011 Jun DISC

ACETAMINOPHEN; BENZHYDROCODONE HYDROCHLORIDE TABLET;ORAL APADAZ + KEMPHARM 325MG;EQ 4.08MG BASE N 208653 002 Jan 04, 2019 Jan NEWA + 325MG;EQ 8.16MG BASE N 208653 003 Jan 04, 2019 Jan NEWA + KVK TECH INC 325MG;EQ 4.08MG BASE N 208653 002 Jan 04, 2019 Feb CAHN + 325MG;EQ 6.12MG BASE N 208653 001 Feb 23, 2018 Feb CAHN + 325MG;EQ 8.16MG BASE N 208653 003 Jan 04, 2019 Feb CAHN

ACETAMINOPHEN; CODEINE PHOSPHATE SOLUTION;ORAL ACETAMINOPHEN AND CODEINE PHOSPHATE @ LANNETT CO INC 120MG/5ML;12MG/5ML A 091238 001 Nov 10, 2011 Jan DISC TABLET;ORAL ACETAMINOPHEN AND CODEINE PHOSPHATE >A> AA WES PHARMA INC 300MG;15MG A 211610 001 Jun 27, 2019 Jun NEWA >A> AA 300MG;30MG A 211610 002 Jun 27, 2019 Jun NEWA >A> AA 300MG;60MG A 211610 003 Jun 27, 2019 Jun NEWA

ACETAMINOPHEN; HYDROCODONE BITARTRATE SOLUTION;ORAL HYDROCODONE BITARTRATE AND ACETAMINOPHEN AA WES PHARMA INC 325MG/15ML;7.5MG/15ML A 211023 001 Mar 08, 2019 Feb NEWA TABLET;ORAL HYDROCODONE BITARTRATE AND ACETAMINOPHEN @ ALVOGEN PINE BROOK 300MG;5MG A 208540 001 Nov 08, 2018 Apr DISC @ 300MG;7.5MG A 208540 002 Nov 08, 2018 Apr DISC @ 300MG;10MG A 208540 003 Nov 08, 2018 Apr DISC @ 325MG;2.5MG A 209958 001 Oct 24, 2018 Apr DISC @ 325MG;5MG A 209958 002 Oct 24, 2018 Apr DISC @ 325MG;7.5MG A 209958 003 Oct 24, 2018 Apr DISC @ 325MG;10MG A 209958 004 Oct 24, 2018 Apr DISC @ ELITE LABS INC 325MG;2.5MG A 209924 001 Nov 16, 2018 May DISC @ 325MG;5MG A 209924 002 Nov 16, 2018 May DISC @ 325MG;7.5MG A 209924 003 Nov 16, 2018 May DISC @ 325MG;10MG A 209924 004 Nov 16, 2018 May DISC @ UPSHER SMITH LABS 325MG;5MG A 206484 001 Mar 24, 2017 Jan DISC @ 325MG;7.5MG A 206484 002 Mar 24, 2017 Jan DISC @ 325MG;10MG A 206484 003 Mar 24, 2017 Jan DISC

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE SOLUTION;ORAL OXYCODONE AND ACETAMINOPHEN @ MIKART INC 300MG/5ML;10MG/5ML A 202142 001 Nov 27, 2018 May DISC RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019 1 -2

ACETAZOLAMIDE CAPSULE, EXTENDED RELEASE;ORAL ACETAZOLAMIDE @ ACCORD HLTHCARE 500MG A 207659 001 Oct 18, 2018 Apr DISC AB ALEMBIC PHARMS LTD 500MG A 210423 001 Feb 19, 2019 Feb NEWA AB CADILA 500MG A 205301 001 Jan 16, 2019 Mar CAHN >A> AB MYLAN 500MG A 203917 001 Jun 18, 2019 Jun NEWA >D> INJECTABLE;INJECTION >D> ACETAZOLAMIDE SODIUM >D> AP ZYDUS PHARMS EQ 500MG BASE/VIAL A 206533 001 Apr 15, 2019 Jun CAIN AP EQ 500MG BASE/VIAL A 206533 001 Apr 15, 2019 Apr NEWA

ACETAZOLAMIDE SODIUM INJECTABLE;INJECTION ACETAZOLAMIDE SODIUM @ PAR STERILE PRODUCTS EQ 500MG BASE/VIAL A 205358 001 Jun 20, 2017 Apr DISC >A> AP ZYDUS PHARMS EQ 500MG BASE/VIAL A 206533 001 Apr 15, 2019 Jun CAIN

ACETIC ACID, GLACIAL SOLUTION/DROPS;OTIC ACETIC ACID AT SAPTALIS PHARMS 2% A 040607 001 Feb 24, 2005 May CAHN

ACETIC ACID, GLACIAL; HYDROCORTISONE SOLUTION/DROPS;OTIC ACETASOL HC >D> AT ACTAVIS MID ATLANTIC 2%;1% A 087143 001 Jan 13, 1982 Jun DISC >A> @ 2%;1% A 087143 001 Jan 13, 1982 Jun DISC

ACETYLCHOLINE CHLORIDE FOR SOLUTION;OPHTHALMIC MIOCHOL + @ NOVARTIS 20MG/VIAL N 016211 001 Apr CRLD

ACETYLCYSTEINE INJECTABLE;INTRAVENOUS ACETYLCYSTEINE @ MYLAN INSTITUTIONAL 6GM/30ML (200MG/ML) A 203624 001 Jun 19, 2015 Mar DISC TABLET, EFFERVESCENT;ORAL CETYLEV + @ ARBOR PHARMS LLC 500MG N 207916 001 Jan 29, 2016 Mar DISC + @ 2.5GM N 207916 002 Jan 29, 2016 Mar DISC

ACITRETIN CAPSULE;ORAL SORIATANE + @ STIEFEL LABS INC 17.5MG N 019821 003 Aug 06, 2009 Jan DISC + @ 22.5MG N 019821 004 Aug 06, 2009 Jan DISC

ACLIDINIUM BROMIDE POWDER, METERED;INHALATION TUDORZA PRESSAIR >D> +! ASTRAZENECA PHARMS 0.4MG/INH N 202450 001 Jul 23, 2012 Jun CAHN >A> +! CIRCASSIA 0.4MG/INH N 202450 001 Jul 23, 2012 Jun CAHN

ACLIDINIUM BROMIDE; FORMOTEROL FUMARATE POWDER, METERED;INHALATION DUAKLIR PRESSAIR ASTRAZENECA PHARMS 0.4MG/INH;0.012MG/INH N 210595 001 Mar 29, 2019 Mar NEWA CIRCASSIA 0.4MG/INH;0.012MG/INH N 210595 001 Mar 29, 2019 Apr CAHN

ACYCLOVIR CAPSULE;ORAL ACYCLOVIR AB KENTON 200MG A 075090 001 Jan 26, 1999 Mar CAHN CREAM;TOPICAL ACYCLOVIR AB PERRIGO UK FINCO 5% A 208702 001 Feb 04, 2019 Jan NFTG ZOVIRAX AB +! BAUSCH 5% N 021478 001 Dec 30, 2002 Feb CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019 1 -3

CREAM;TOPICAL ZOVIRAX AB +! VIB 5% N 021478 001 Dec 30, 2002 Jan CFTG OINTMENT;OPHTHALMIC AVACLYR +! FERA PHARMS LLC 3% N 202408 001 Mar 29, 2019 Mar NEWA OINTMENT;TOPICAL ACYCLOVIR AB CIPLA 5% A 211794 001 Jan 18, 2019 Jan NEWA >D> AB GLENMARK PHARMS LTD 5% A 205510 001 Jul 31, 2017 Jun CAHN >A> AB GLENMARK PHARMS SA 5% A 205510 001 Jul 31, 2017 Jun CAHN AB PERRIGO UK FINCO 5% A 205659 001 Feb 20, 2019 Feb NEWA AB ZYDUS PHARMS 5% A 205974 001 Mar 15, 2019 Mar NEWA ZOVIRAX AB +! BAUSCH 5% N 018604 001 Mar 29, 1982 Feb CAHN

ACYCLOVIR SODIUM INJECTABLE;INJECTION ACYCLOVIR SODIUM ! ZYDUS PHARMS EQ 500MG BASE/VIAL A 206535 001 Aug 31, 2018 Jan CHRS ! EQ 1GM BASE/VIAL A 206535 002 Aug 31, 2018 Jan CHRS

ACYCLOVIR; HYDROCORTISONE CREAM;TOPICAL XERESE +! BAUSCH 5%;1% N 022436 001 Jul 31, 2009 Feb CAHN

ADAPALENE; BENZOYL PEROXIDE GEL;TOPICAL ADAPALENE AND BENZOYL PEROXIDE AB PERRIGO UK FINCO 0.1%;2.5% A 205033 001 Jan 23, 2018 May CAHN @ TARO 0.3%;2.5% A 209148 001 Oct 17, 2018 May DISC

ADENOSINE INJECTABLE;INJECTION ADENOSINE @ LUITPOLD 3MG/ML A 090010 001 Apr 28, 2009 Mar DISC

ALBENDAZOLE TABLET;ORAL ALBENDAZOLE AB ACTAVIS ELIZABETH 200MG A 208094 001 May 20, 2019 May NEWA AB EDENBRIDGE PHARMS 200MG A 211117 001 May 14, 2019 Apr NEWA

ALBUTEROL SULFATE POWDER, METERED;INHALATION PROAIR DIGIHALER + TEVA BRANDED PHARM EQ 0.09MG BASE/INH N 205636 002 Dec 21, 2018 Jan NEWA PROAIR RESPICLICK +! TEVA BRANDED PHARM EQ 0.09MG BASE/INH N 205636 001 Mar 31, 2015 Jan CPOT TABLET;ORAL ALBUTEROL SULFATE AB AIZANT EQ 2MG BASE A 210948 001 Mar 15, 2019 Mar NEWA AB EQ 4MG BASE A 210948 002 Mar 15, 2019 Mar NEWA AB APPCO PHARMA LLC EQ 2MG BASE A 207046 001 Jun 29, 2018 Feb CAHN AB EQ 4MG BASE A 207046 002 Jun 29, 2018 Feb CAHN

ALFUZOSIN HYDROCHLORIDE TABLET, EXTENDED RELEASE;ORAL ALFUZOSIN HYDROCHLORIDE AB HERITAGE PHARMA 10MG A 079056 001 Jul 18, 2011 May CAHN

ALISKIREN HEMIFUMARATE TABLET;ORAL ALISKIREN HEMIFUMARATE AB ANCHEN PHARMS EQ 150MG BASE A 206665 001 Mar 22, 2019 Mar NFTG AB EQ 300MG BASE A 206665 002 Mar 22, 2019 Mar NFTG TEKTURNA AB + NODEN PHARMA EQ 150MG BASE N 021985 001 Mar 05, 2007 Mar CFTG AB +! EQ 300MG BASE N 021985 002 Mar 05, 2007 Mar CFTG RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019 1 -4

ALLOPURINOL TABLET;ORAL ALLOPURINOL AB UNICHEM LABS LTD 100MG A 211820 001 Mar 12, 2019 Feb NEWA AB 300MG A 211820 002 Mar 12, 2019 Feb NEWA

ALLOPURINOL; LESINURAD TABLET;ORAL DUZALLO + @ IRONWOOD PHARMS INC 200MG;200MG N 209203 001 Aug 18, 2017 Apr DISC + @ 300MG;200MG N 209203 002 Aug 18, 2017 Apr DISC

ALPELISIB TABLET;ORAL PIQRAY + NOVARTIS PHARMS CORP 50MG N 212526 001 May 24, 2019 May NEWA + 150MG N 212526 002 May 24, 2019 May NEWA +! 200MG N 212526 003 May 24, 2019 May NEWA

ALTRETAMINE CAPSULE;ORAL HEXALEN + @ EISAI INC 50MG N 019926 001 Dec 26, 1990 Feb DISC

AMBRISENTAN TABLET;ORAL AMBRISENTAN AB CIPLA 5MG A 210715 001 Apr 26, 2019 Apr NEWA AB 10MG A 210715 002 Apr 26, 2019 Apr NEWA AB MYLAN 5MG A 208441 001 Mar 28, 2019 Mar NFTG AB 10MG A 208441 002 Mar 28, 2019 Mar NFTG AB PAR PHARM INC 5MG A 209509 001 Apr 10, 2019 Mar NEWA AB 10MG A 209509 002 Apr 10, 2019 Mar NEWA AB SIGMAPHARM LABS LLC 5MG A 208354 001 Apr 10, 2019 Mar NEWA AB 10MG A 208354 002 Apr 10, 2019 Mar NEWA AB SUN PHARM 5MG A 210784 001 Mar 28, 2019 Mar NFTG AB 10MG A 210784 002 Mar 28, 2019 Mar NFTG AB WATSON LABS INC 5MG A 208252 001 Mar 28, 2019 Mar NFTG AB 10MG A 208252 002 Mar 28, 2019 Mar NFTG AB ZYDUS PHARMS 5MG A 210058 001 Mar 28, 2019 Mar NFTG AB 10MG A 210058 002 Mar 28, 2019 Mar NFTG LETAIRIS AB + GILEAD 5MG N 022081 001 Jun 15, 2007 Mar CFTG AB +! 10MG N 022081 002 Jun 15, 2007 Mar CFTG

AMIFAMPRIDINE TABLET;ORAL RUZURGI +! JACOBUS PHARM CO INC 10MG N 209321 001 May 06, 2019 May NEWA

AMILORIDE HYDROCHLORIDE TABLET;ORAL AMILORIDE HYDROCHLORIDE AB WINDLAS HLTHCARE 5MG A 204180 001 Aug 07, 2015 Feb CAHN

AMINOCAPROIC ACID TABLET;ORAL AMICAR AB + CLOVER PHARMS 1GM N 015197 002 Jun 24, 2004 Feb CHRS AMINOCAPROIC ACID AB ! SUNNY PHARMTECH INC 1GM A 209060 002 Nov 27, 2018 Feb CHRS

AMINOPHYLLINE INJECTABLE;INJECTION AMINOPHYLLINE ! HOSPIRA 25MG/ML A 087242 001 Oct 26, 1983 Feb CTEC @ LUITPOLD 25MG/ML A 087600 001 Feb DISC RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019 1 -5

AMIODARONE HYDROCHLORIDE INJECTABLE;INJECTION AMIODARONE HYDROCHLORIDE @ DR REDDYS 50MG/ML A 076163 001 Sep 05, 2003 May CAHN

AMLODIPINE BESYLATE TABLET;ORAL AMLODIPINE BESYLATE AB STRIDES PHARMA EQ 2.5MG BASE A 077516 001 Jul 11, 2007 Apr CAHN AB EQ 5MG BASE A 077516 002 Jul 11, 2007 Apr CAHN AB EQ 10MG BASE A 077516 003 Jul 11, 2007 Apr CAHN

AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM TABLET;ORAL AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM >D> AB ZYDUS PHARMS EQ 2.5MG BASE;EQ 10MG BASE A 207762 001 Jan 11, 2019 Jun DISC >A> @ EQ 2.5MG BASE;EQ 10MG BASE A 207762 001 Jan 11, 2019 Jun DISC >D> AB EQ 2.5MG BASE;EQ 20MG BASE A 207762 002 Jan 11, 2019 Jun DISC >A> @ EQ 2.5MG BASE;EQ 20MG BASE A 207762 002 Jan 11, 2019 Jun DISC >D> AB EQ 2.5MG BASE;EQ 40MG BASE A 207762 003 Jan 11, 2019 Jun DISC >A> @ EQ 2.5MG BASE;EQ 40MG BASE A 207762 003 Jan 11, 2019 Jun DISC >D> AB EQ 5MG BASE;EQ 10MG BASE A 207762 004 Jan 11, 2019 Jun DISC >A> @ EQ 5MG BASE;EQ 10MG BASE A 207762 004 Jan 11, 2019 Jun DISC >D> AB EQ 5MG BASE;EQ 20MG BASE A 207762 005 Jan 11, 2019 Jun DISC >A> @ EQ 5MG BASE;EQ 20MG BASE A 207762 005 Jan 11, 2019 Jun DISC >D> AB EQ 5MG BASE;EQ 40MG BASE A 207762 006 Jan 11, 2019 Jun DISC >A> @ EQ 5MG BASE;EQ 40MG BASE A 207762 006 Jan 11, 2019 Jun DISC >D> AB EQ 5MG BASE;EQ 80MG BASE A 207762 007 Jan 11, 2019 Jun DISC >A> @ EQ 5MG BASE;EQ 80MG BASE A 207762 007 Jan 11, 2019 Jun DISC >D> AB EQ 10MG BASE;EQ 10MG BASE A 207762 008 Jan 11, 2019 Jun DISC >A> @ EQ 10MG BASE;EQ 10MG BASE A 207762 008 Jan 11, 2019 Jun DISC >D> AB EQ 10MG BASE;EQ 20MG BASE A 207762 009 Jan 11, 2019 Jun DISC >A> @ EQ 10MG BASE;EQ 20MG BASE A 207762 009 Jan 11, 2019 Jun DISC >D> AB EQ 10MG BASE;EQ 40MG BASE A 207762 010 Jan 11, 2019 Jun DISC >A> @ EQ 10MG BASE;EQ 40MG BASE A 207762 010 Jan 11, 2019 Jun DISC >D> AB EQ 10MG BASE;EQ 80MG BASE A 207762 011 Jan 11, 2019 Jun DISC >A> @ EQ 10MG BASE;EQ 80MG BASE A 207762 011 Jan 11, 2019 Jun DISC

AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE CAPSULE;ORAL AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE @ CIPLA EQ 2.5MG BASE;10MG A 077215 001 Dec 07, 2018 May DISC @ EQ 5MG BASE;10MG A 077215 002 Dec 07, 2018 May DISC @ EQ 5MG BASE;20MG A 077215 003 Dec 07, 2018 May DISC @ EQ 10MG BASE;20MG A 077215 004 Dec 07, 2018 May DISC @ MYLAN EQ 2.5MG BASE;10MG A 077375 001 May 21, 2010 Feb DISC @ EQ 5MG BASE;10MG A 077375 002 May 21, 2010 Feb DISC @ EQ 5MG BASE;20MG A 077375 003 May 21, 2010 Feb DISC @ EQ 5MG BASE;40MG A 079047 001 Jul 05, 2011 Feb DISC @ EQ 10MG BASE;20MG A 077375 004 May 21, 2010 Feb DISC @ EQ 10MG BASE;40MG A 079047 002 Jul 05, 2011 Feb DISC >D> AB TEVA PHARMS EQ 2.5MG BASE;10MG A 077179 001 May 18, 2007 Jun DISC >A> @ EQ 2.5MG BASE;10MG A 077179 001 May 18, 2007 Jun DISC >D> AB EQ 5MG BASE;10MG A 077179 002 May 18, 2007 Jun DISC >A> @ EQ 5MG BASE;10MG A 077179 002 May 18, 2007 Jun DISC >D> AB EQ 5MG BASE;20MG A 077179 003 May 18, 2007 Jun DISC >A> @ EQ 5MG BASE;20MG A 077179 003 May 18, 2007 Jun DISC >D> AB EQ 5MG BASE;40MG A 077179 005 Jul 05, 2011 Jun DISC >A> @ EQ 5MG BASE;40MG A 077179 005 Jul 05, 2011 Jun DISC >D> AB EQ 10MG BASE;20MG A 077179 004 May 18, 2007 Jun DISC >A> @ EQ 10MG BASE;20MG A 077179 004 May 18, 2007 Jun DISC >D> AB EQ 10MG BASE;40MG A 077179 006 Jul 05, 2011 Jun DISC >A> @ EQ 10MG BASE;40MG A 077179 006 Jul 05, 2011 Jun DISC

AMLODIPINE BESYLATE; CELECOXIB TABLET;ORAL CONSENSI + COEPTIS EQ 2.5MG BASE;200MG N 210045 001 May 31, 2018 Mar CAHN + EQ 5MG BASE;200MG N 210045 002 May 31, 2018 Mar CAHN +! EQ 10MG BASE;200MG N 210045 003 May 31, 2018 Mar CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019 1 -6

AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMIL TABLET;ORAL AMLODIPINE AND OLMESARTAN MEDOXOMIL @ ACCORD HLTHCARE INC EQ 5MG BASE;20MG A 209600 001 Aug 30, 2018 Mar DISC @ EQ 5MG BASE;40MG A 209600 003 Aug 30, 2018 Mar DISC @ EQ 10MG BASE;20MG A 209600 002 Aug 30, 2018 Mar DISC @ EQ 10MG BASE;40MG A 209600 004 Aug 30, 2018 Mar DISC >D> AB TEVA PHARMS USA EQ 5MG BASE;20MG A 091154 001 Oct 26, 2016 Jun DISC >A> @ EQ 5MG BASE;20MG A 091154 001 Oct 26, 2016 Jun DISC >D> AB EQ 5MG BASE;40MG A 091154 002 Oct 26, 2016 Jun DISC >A> @ EQ 5MG BASE;40MG A 091154 002 Oct 26, 2016 Jun DISC >D> AB EQ 10MG BASE;20MG A 091154 003 Oct 26, 2016 Jun DISC >A> @ EQ 10MG BASE;20MG A 091154 003 Oct 26, 2016 Jun DISC >D> AB EQ 10MG BASE;40MG A 091154 004 Oct 26, 2016 Jun DISC >A> @ EQ 10MG BASE;40MG A 091154 004 Oct 26, 2016 Jun DISC

AMLODIPINE BESYLATE; PERINDOPRIL ARGININE TABLET;ORAL PRESTALIA + ADHERA EQ 2.5MG BASE;3.5MG N 205003 001 Jan 21, 2015 Apr CAHN + EQ 5MG BASE;7MG N 205003 002 Jan 21, 2015 Apr CAHN +! EQ 10MG BASE;14MG N 205003 003 Jan 21, 2015 Apr CAHN

AMMONIA N-13 INJECTABLE;INTRAVENOUS AMMONIA N 13 AP DECATUR 30mCi-300mCi/8ML (3.75-37.5mCi/ML) A 204465 001 Oct 23, 2014 Apr CAHN

AMMONIUM LACTATE CREAM;TOPICAL AMMONIUM LACTATE AB ! PERRIGO ISRAEL EQ 12% BASE A 075774 001 May 01, 2002 May CAHN LOTION;TOPICAL AMMONIUM LACTATE AB ! PERRIGO ISRAEL EQ 12% BASE A 075570 001 Jun 23, 2004 May CAHN

AMOXICILLIN FOR SUSPENSION;ORAL AMOXICILLIN >D> AB TEVA 125MG/5ML A 061931 001 Jun DISC >A> @ 125MG/5ML A 061931 001 Jun DISC

AMOXICILLIN; CLAVULANATE POTASSIUM FOR SUSPENSION;ORAL AMOXICILLIN AND CLAVULANATE POTASSIUM AB AUROBINDO PHARMA LTD 125MG/5ML;EQ 31.25MG BASE/5ML A 209371 001 Apr 19, 2019 Apr NFTG AB 250MG/5ML;EQ 62.5MG BASE/5ML A 209371 002 Apr 19, 2019 Apr NEWA AUGMENTIN '125' AB + NEOPHARMA 125MG/5ML;EQ 31.25MG BASE/5ML N 050575 001 Aug 06, 1984 Apr CFTG TABLET;ORAL AUGMENTIN '875' AB + NEOPHARMA 875MG;EQ 125MG BASE N 050720 001 Feb 13, 1996 Feb CAHN

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE CAPSULE, EXTENDED RELEASE;ORAL DEXTROAMP SACCHARATE, AMP ASPARTATE, DETROAMP SULFATE AND AMP SULFATE AB PAR PHARM INC 1.25MG;1.25MG;1.25MG;1.25MG A 206159 001 May 31, 2019 May NEWA AB 2.5MG;2.5MG;2.5MG;2.5MG A 206159 002 May 31, 2019 May NEWA AB 3.75MG;3.75MG;3.75MG;3.75MG A 206159 003 May 31, 2019 May NEWA AB 5MG;5MG;5MG;5MG A 206159 004 May 31, 2019 May NEWA AB 6.25MG;6.25MG;6.25MG;6.25MG A 206159 005 May 31, 2019 May NEWA AB 7.5MG;7.5MG;7.5MG;7.5MG A 206159 006 May 31, 2019 May NEWA DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE AB AMERIGEN PHARMS LTD 1.25MG;1.25MG;1.25MG;1.25MG A 205401 001 Jan 22, 2019 Jan NEWA AB 2.5MG;2.5MG;2.5MG;2.5MG A 205401 002 Jan 22, 2019 Jan NEWA AB 3.75MG;3.75MG;3.75MG;3.75MG A 205401 003 Jan 22, 2019 Jan NEWA AB 5MG;5MG;5MG;5MG A 205401 004 Jan 22, 2019 Jan NEWA AB 6.25MG;6.25MG;6.25MG;6.25MG A 205401 005 Jan 22, 2019 Jan NEWA AB 7.5MG;7.5MG;7.5MG;7.5MG A 205401 006 Jan 22, 2019 Jan NEWA AB RHODES PHARMS 1.25MG;1.25MG;1.25MG;1.25MG A 210651 001 May 17, 2019 May NEWA AB 2.5MG;2.5MG;2.5MG;2.5MG A 210651 002 May 17, 2019 May NEWA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019 1 -7

CAPSULE, EXTENDED RELEASE;ORAL DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE AB 3.75MG;3.75MG;3.75MG;3.75MG A 210651 003 May 17, 2019 May NEWA AB 5MG;5MG;5MG;5MG A 210651 004 May 17, 2019 May NEWA AB 6.25MG;6.25MG;6.25MG;6.25MG A 210651 005 May 17, 2019 May NEWA AB 7.5MG;7.5MG;7.5MG;7.5MG A 210651 006 May 17, 2019 May NEWA AB SPECGX LLC 1.25MG;1.25MG;1.25MG;1.25MG A 211547 001 Apr 22, 2019 Apr NEWA AB 2.5MG;2.5MG;2.5MG;2.5MG A 211547 002 Apr 22, 2019 Apr NEWA AB 3.75MG;3.75MG;3.75MG;3.75MG A 211547 003 Apr 22, 2019 Apr NEWA AB 5MG;5MG;5MG;5MG A 211547 004 Apr 22, 2019 Apr NEWA AB 6.25MG;6.25MG;6.25MG;6.25MG A 211547 005 Apr 22, 2019 Apr NEWA AB 7.5MG;7.5MG;7.5MG;7.5MG A 211547 006 Apr 22, 2019 Apr NEWA AB SUN PHARM INDUSTRIES 1.25MG;1.25MG;1.25MG;1.25MG A 211715 001 May 17, 2019 May NEWA AB 2.5MG;2.5MG;2.5MG;2.5MG A 211715 002 May 17, 2019 May NEWA AB 3.75MG;3.75MG;3.75MG;3.75MG A 211715 003 May 17, 2019 May NEWA AB 5MG;5MG;5MG;5MG A 211715 004 May 17, 2019 May NEWA AB 6.25MG;6.25MG;6.25MG;6.25MG A 211715 005 May 17, 2019 May NEWA AB 7.5MG;7.5MG;7.5MG;7.5MG A 211715 006 May 17, 2019 May NEWA

AMPHETAMINE SULFATE TABLET;ORAL AMPHETAMINE SULFATE AA AUROLIFE PHARMA LLC 5MG A 211639 001 Apr 17, 2019 Apr NEWA AA 10MG A 211639 002 Apr 17, 2019 Apr NEWA TABLET, ORALLY DISINTEGRATING;ORAL EVEKEO ODT + ARBOR PHARMS LLC 5MG N 209905 001 Jan 30, 2019 Jan NEWA + 10MG N 209905 002 Jan 30, 2019 Jan NEWA + 15MG N 209905 003 Jan 30, 2019 Jan NEWA + 20MG N 209905 004 Jan 30, 2019 Jan NEWA

AMPICILLIN/AMPICILLIN TRIHYDRATE CAPSULE;ORAL AMPICILLIN TRIHYDRATE @ HERITAGE PHARMA EQ 250MG BASE A 061502 001 May CAHN @ EQ 500MG BASE A 061502 002 May CAHN

ANASTROZOLE TABLET;ORAL ANASTROZOLE AB FRESENIUS KABI USA 1MG A 090088 001 Jun 28, 2010 Feb CAHN AB KENTON 1MG A 078944 001 Jun 28, 2010 Mar CAHN

ARIPIPRAZOLE SOLUTION;ORAL ARIPIPRAZOLE AA AUROBINDO PHARMA LTD 1MG/ML A 210479 001 Jan 29, 2019 Jan NEWA TABLET;ORAL ARIPIPRAZOLE AB ALKEM LABS LTD 2MG A 207105 001 Feb 21, 2019 Feb NEWA AB 5MG A 207105 002 Feb 21, 2019 Feb NEWA AB 10MG A 207105 003 Feb 21, 2019 Feb NEWA AB 15MG A 207105 004 Feb 21, 2019 Feb NEWA AB 20MG A 207105 005 Feb 21, 2019 Feb NEWA AB 30MG A 207105 006 Feb 21, 2019 Feb NEWA >D> AB TEVA PHARMS USA 2MG A 078607 001 Apr 28, 2015 Jun DISC >A> @ 2MG A 078607 001 Apr 28, 2015 Jun DISC >D> AB 5MG A 078607 002 Apr 28, 2015 Jun DISC >A> @ 5MG A 078607 002 Apr 28, 2015 Jun DISC @ 10MG A 078608 001 Apr 28, 2015 May DISC @ 15MG A 078708 001 Apr 28, 2015 May DISC @ 20MG A 078708 002 Apr 28, 2015 May DISC @ 30MG A 078708 003 Apr 28, 2015 May DISC >D> AB ZYDUS PHARMS 2MG A 090472 001 Jan 07, 2019 Jun DISC >A> @ 2MG A 090472 001 Jan 07, 2019 Jun DISC >D> AB 5MG A 090472 002 Jan 07, 2019 Jun DISC >A> @ 5MG A 090472 002 Jan 07, 2019 Jun DISC >D> AB 10MG A 090472 003 Jan 07, 2019 Jun DISC >A> @ 10MG A 090472 003 Jan 07, 2019 Jun DISC >D> AB 15MG A 090472 004 Jan 07, 2019 Jun DISC >A> @ 15MG A 090472 004 Jan 07, 2019 Jun DISC >D> AB 20MG A 090472 005 Jan 07, 2019 Jun DISC >A> @ 20MG A 090472 005 Jan 07, 2019 Jun DISC RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019 1 -8

TABLET;ORAL ARIPIPRAZOLE >D> AB 30MG A 090472 006 Jan 07, 2019 Jun DISC >A> @ 30MG A 090472 006 Jan 07, 2019 Jun DISC

ARMODAFINIL TABLET;ORAL ARMODAFINIL AB APOTEX INC 50MG A 201514 001 Mar 25, 2019 Mar NEWA AB 150MG A 201514 002 Mar 25, 2019 Mar NEWA AB 250MG A 201514 003 Mar 25, 2019 Mar NEWA AB AUROBINDO PHARMA LTD 200MG A 206069 004 Dec 07, 2018 Mar NEWA AB MYLAN PHARMS INC 100MG A 200043 004 May 09, 2019 Apr NEWA AB 200MG A 200043 005 May 09, 2019 Apr NEWA AB NATCO PHARMA LTD 100MG A 202768 004 Sep 28, 2017 Apr CTEC

ARSENIC TRIOXIDE INJECTABLE;INJECTION ARSENIC TRIOXIDE AP STI PHARMA LLC 1MG/ML A 209873 001 May 06, 2019 Apr NEWA

ASENAPINE MALEATE TABLET;SUBLINGUAL ASENAPINE MALEATE @ SIGMAPHARM LABS LLC EQ 5MG BASE A 206107 001 Jul 17, 2018 Feb DISC @ EQ 10MG BASE A 206107 002 Jul 17, 2018 Feb DISC SAPHRIS + FOREST LABS LLC EQ 5MG BASE N 022117 001 Aug 13, 2009 Feb CTEC +! EQ 10MG BASE N 022117 002 Aug 13, 2009 Feb CTEC

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE TABLET;ORAL ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE AB ! SANDOZ 770MG;60MG;50MG A 074654 002 Dec 31, 1996 May CTEC ORPHENGESIC FORTE AB GALT PHARMS 770MG;60MG;50MG A 075141 002 May 29, 1998 May CMFD

ASPIRIN; DIPYRIDAMOLE CAPSULE, EXTENDED RELEASE;ORAL ASPIRIN AND DIPYRIDAMOLE >D> AB GLENMARK PHARMS LTD 25MG;200MG A 210318 001 May 24, 2019 Jun CAHN AB 25MG;200MG A 210318 001 May 24, 2019 May NEWA >A> AB GLENMARK PHARMS SA 25MG;200MG A 210318 001 May 24, 2019 Jun CAHN AB LANNETT CO INC 25MG;200MG A 204552 001 Mar 20, 2019 Mar NEWA

ATENOLOL; CHLORTHALIDONE TABLET;ORAL ATENOLOL AND CHLORTHALIDONE AB ZYDUS PHARMS 50MG;25MG A 210028 001 Mar 08, 2019 Feb NEWA AB 100MG;25MG A 210028 002 Mar 08, 2019 Feb NEWA

ATOMOXETINE HYDROCHLORIDE CAPSULE;ORAL ATOMOXETINE HYDROCHLORIDE AB ZYDUS PHARMS USA INC 18MG A 079017 001 Sep 17, 2010 Mar CMFD AB 25MG A 079017 002 Sep 17, 2010 Mar CMFD AB 40MG A 079017 003 Sep 17, 2010 Mar CMFD AB 60MG A 079017 004 Sep 17, 2010 Mar CMFD AB 80MG A 079017 005 Sep 17, 2010 Mar CMFD AB 100MG A 079017 006 Sep 17, 2010 Mar CMFD

ATORVASTATIN CALCIUM TABLET;ORAL ATORVASTATIN CALCIUM AB LUPIN LTD EQ 10MG BASE A 204991 001 Mar 06, 2019 Feb NEWA AB EQ 20MG BASE A 204991 002 Mar 06, 2019 Feb NEWA AB EQ 40MG BASE A 204991 003 Mar 06, 2019 Feb NEWA AB EQ 80MG BASE A 204991 004 Mar 06, 2019 Feb NEWA AB MSN LABS PVT LTD EQ 10MG BASE A 211933 001 Feb 08, 2019 Feb NEWA AB EQ 20MG BASE A 211933 002 Feb 08, 2019 Feb NEWA AB EQ 40MG BASE A 211933 003 Feb 08, 2019 Feb NEWA AB EQ 80MG BASE A 211933 004 Feb 08, 2019 Feb NEWA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019 1 -9

ATOVAQUONE SUSPENSION;ORAL ATOVAQUONE AB ABHAI LLC 750MG/5ML A 210510 001 May 31, 2019 May NEWA

ATRACURIUM BESYLATE INJECTABLE;INJECTION ATRACURIUM BESYLATE AP HONG KONG 10MG/ML A 091489 001 Feb 17, 2012 Feb CAHN ATRACURIUM BESYLATE PRESERVATIVE FREE AP HONG KONG 10MG/ML A 091488 001 Feb 17, 2012 Feb CAHN

ATROPINE SOLUTION;INTRAMUSCULAR ATROPEN +! MERIDIAN MEDCL TECHN EQ 0.25MG SULFATE/0.3ML N 017106 004 Sep 17, 2004 Mar CPOT +! EQ 0.5MG SULFATE/0.7ML N 017106 003 Jun 19, 2003 Mar CPOT +! EQ 1MG SULFATE/0.7ML N 017106 002 Jun 19, 2003 Mar CPOT +! EQ 2MG SULFATE/0.7ML N 017106 001 Mar CPOT ATROPINE AB BVI E@ ABBVIE@ EQ 2MG SULFATE/0.7ML A 071295 001 Jan 30, 1987 Mar CDFR

ATROPINE SULFATE SOLUTION;INTRAVENOUS, INTRAMUSCULAR, SUBCUTANEOUS, INTRAOSSEOUS, ENDOTRACHEAL ATROPINE SULFATE +! FRESENIUS KABI USA 8MG/20ML (0.4MG/ML) N 209260 001 Jan 26, 2018 May CDFR

AZACITIDINE POWDER;INTRAVENOUS, SUBCUTANEOUS AZACITIDINE AP LUPIN LTD 100MG/VIAL A 210748 001 Feb 27, 2019 Feb NEWA

AZELAIC ACID CREAM;TOPICAL AZELEX +! ALMIRALL 20% N 020428 001 Sep 13, 1995 Apr CAHN

AZELASTINE HYDROCHLORIDE SOLUTION/DROPS;OPHTHALMIC AZELASTINE HYDROCHLORIDE AT ALEMBIC PHARMS LTD 0.05% A 209620 001 Mar 20, 2019 Mar NEWA AT SOMERSET THERAPS LLC 0.05% A 207411 001 Mar 29, 2019 Mar NEWA SPRAY, METERED;NASAL AZELASTINE HYDROCHLORIDE AB HI TECH EQ 0.125MG BASE/SPRAY A 207610 001 May 17, 2019 May NEWA

AZITHROMYCIN TABLET;ORAL AZITHROMYCIN AB BIONPHARMA INC EQ 250MG BASE A 210000 001 Feb 26, 2019 Feb NEWA AB EQ 500MG BASE A 210001 001 Feb 26, 2019 Feb NEWA AB CSPC OUYI EQ 250MG BASE A 208250 001 Apr 17, 2019 Apr NEWA

BACLOFEN TABLET;ORAL BACLOFEN AB EYWA PHARMA 10MG A 211555 001 Feb 01, 2019 Jan NEWA AB 20MG A 211555 002 Feb 01, 2019 Jan NEWA

BALSALAZIDE DISODIUM CAPSULE;ORAL BALSALAZIDE DISODIUM @ MYLAN 750MG A 077807 001 Dec 28, 2007 Feb DISC TABLET;ORAL BALSALAZIDE DISODIUM @ PAR PHARM INC 1.1GM A 206336 001 Sep 08, 2015 Apr DISC GIAZO + @ VALEANT PHARMS INTL 1.1GM N 022205 001 Feb 03, 2012 Apr DISC RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019 1 -10

BARIUM SULFATE FOR SUSPENSION;ORAL VARIBAR THIN LIQUID +! BRACCO 81% (120GM/BOT) N 208036 004 Apr 30, 2019 May NEWA

BELINOSTAT POWDER;INTRAVENOUS BELEODAQ +! ACROTECH 500MG/VIAL N 206256 001 Jul 03, 2014 Mar CAHN

BENAZEPRIL HYDROCHLORIDE TABLET;ORAL BENAZEPRIL HYDROCHLORIDE @ HERITAGE PHARMA 5MG A 076267 001 Feb 11, 2004 Feb CAHN @ 10MG A 076267 002 Feb 11, 2004 Feb CAHN @ 20MG A 076267 003 Feb 11, 2004 Feb CAHN @ 40MG A 076267 004 Feb 11, 2004 Feb CAHN

BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE TABLET;ORAL BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE @ ANI PHARMS INC 5MG;6.25MG A 076342 001 Feb 11, 2004 May CAHN @ 10MG;12.5MG A 076342 002 Feb 11, 2004 May CAHN @ 20MG;12.5MG A 076342 003 Feb 11, 2004 May CAHN @ 20MG;25MG A 076342 004 Feb 11, 2004 May CAHN

BENDAMUSTINE HYDROCHLORIDE POWDER;IV (INFUSION) TREANDA +! CEPHALON 25MG/VIAL N 022249 002 May 01, 2009 Feb CTEC +! 100MG/VIAL N 022249 001 Mar 20, 2008 Feb CTEC

BENZONATATE CAPSULE;ORAL BENZONATATE AA ASCENT PHARMS INC 100MG A 211518 001 Feb 22, 2019 Feb NEWA AA 150MG A 211518 002 Feb 22, 2019 Feb NEWA AA 200MG A 211518 003 Feb 22, 2019 Feb NEWA AA CSPC OUYI 100MG A 202765 002 Aug 25, 2017 Feb CAHN AA 200MG A 202765 001 Jul 31, 2015 Feb CAHN AA QINGDAO BAHEAL PHARM 100MG A 210562 001 Nov 09, 2018 May CAHN AA 150MG A 210562 002 Nov 09, 2018 May CAHN AA 200MG A 210562 003 Nov 09, 2018 May CAHN

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE GEL;TOPICAL CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE >D> AB GLENMARK PHARMS 5%;1% BASE A 209252 001 Mar 14, 2019 Jun CMS1 >A> AB 5%;EQ 1% BASE A 209252 001 Mar 14, 2019 Jun CMS1 AB 5%;1% BASE A 209252 001 Mar 14, 2019 Mar NEWA AB PERRIGO UK FINCO 5%;EQ 1% BASE A 202440 001 Sep 21, 2015 May CAHN @ TARO 3.75%;EQ 1.2% BASE A 208683 001 Jun 05, 2018 May DISC ONEXTON +! DOW PHARM 3.75%;EQ 1.2% BASE N 050819 002 Nov 24, 2014 May CTEC

BENZOYL PEROXIDE; ERYTHROMYCIN GEL;TOPICAL AKTIPAK +! BIOFRONTERA 5%;3% N 050769 001 Nov 27, 2000 May CAHN

BENZTROPINE MESYLATE INJECTABLE;INJECTION BENZTROPINE MESYLATE @ LUITPOLD 1MG/ML A 091152 001 Mar 29, 2010 Feb DISC TABLET;ORAL BENZTROPINE MESYLATE AA ! ASPEN GLOBAL INC 0.5MG A 204713 001 Apr 14, 2015 Apr CHRS AA ! 1MG A 204713 002 Apr 14, 2015 Apr CHRS AA ! 2MG A 204713 003 Apr 14, 2015 Apr CHRS @ OXFORD PHARMS 0.5MG A 040706 002 Feb 14, 2008 Mar DISC @ 1MG A 040706 003 Feb 14, 2008 Mar DISC RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019 1 -11

TABLET;ORAL BENZTROPINE MESYLATE @ USL PHARMA 0.5MG A 040103 001 Dec 12, 1996 Apr DISC @ 1MG A 040103 002 Dec 12, 1996 Apr DISC @ 2MG A 040103 003 Dec 12, 1996 Apr DISC

BEPOTASTINE BESILATE SOLUTION/DROPS;OPHTHALMIC BEPOTASTINE BESILATE AT APOTEX INC 1.5% A 206066 001 Mar 05, 2019 Feb NFTG AT MICRO LABS 1.5% A 206220 001 Mar 18, 2019 Mar NEWA AT MYLAN 1.5% A 206220 001 Mar 18, 2019 Apr CAHN BEPREVE AT +! BAUSCH AND LOMB INC 1.5% N 022288 001 Sep 08, 2009 Feb CFTG

BETAMETHASONE DIPROPIONATE CREAM, AUGMENTED;TOPICAL BETAMETHASONE DIPROPIONATE AB PERRIGO ISRAEL EQ 0.05% BASE A 076592 001 Dec 09, 2003 May CAHN SPRAY;TOPICAL SERNIVO +! ENCORE DERMAT EQ 0.05% BASE/SPRAY N 208079 001 Feb 05, 2016 Mar CAHN

BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE OINTMENT;TOPICAL CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE AB PERRIGO ISRAEL 0.064%;0.005% A 200174 001 Dec 12, 2014 Mar CAIN AB PERRIGO UK FINCO 0.064%;0.005% A 200174 001 Dec 12, 2014 May CAHN AB TOLMAR 0.064%;0.005% A 201615 001 Jan 14, 2013 Mar CAIN TACLONEX AB +! LEO PHARMA AS 0.064%;0.005% N 021852 001 Jan 09, 2006 Mar CAIN SUSPENSION;TOPICAL TACLONEX +! LEO PHARMA AS 0.064%;0.005% N 022185 001 May 09, 2008 Mar CAIN

BETHANECHOL CHLORIDE TABLET;ORAL DUVOID AA CHARTWELL RX 10MG A 086262 001 Mar CAHN AA 25MG A 086263 001 Mar CAHN AA 50MG A 085882 003 Mar CAHN

BEXAROTENE GEL;TOPICAL TARGRETIN >A> +! BAUSCH 1% N 021056 001 Jun 28, 2000 Jun CAHN >D> +! VALEANT LUXEMBOURG 1% N 021056 001 Jun 28, 2000 Jun CAHN

BICALUTAMIDE TABLET;ORAL BICALUTAMIDE >D> AB BOSCOGEN 50MG A 091011 001 Jun 10, 2015 Jun CAHN AB FRESENIUS KABI USA 50MG A 079045 001 May 13, 2010 Feb CAHN >A> AB KENTON 50MG A 091011 001 Jun 10, 2015 Jun CAHN

BIMATOPROST SOLUTION/DROPS;OPHTHALMIC BIMATOPROST AT ALEMBIC PHARMS LTD 0.03% A 210263 001 Apr 12, 2019 Apr NEWA AT GLAND PHARMA LTD 0.03% A 210126 001 Mar 22, 2019 Mar NEWA >A> AT SOMERSET THERAPS LLC 0.03% A 207601 001 Jun 19, 2019 Jun NEWA

BLEOMYCIN SULFATE INJECTABLE;INJECTION BLEOMYCIN SULFATE AP CIPLA EQ 15 UNITS BASE/VIAL A 209439 001 Mar 11, 2019 Feb NEWA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019 1 -12

BORTEZOMIB POWDER;INTRAVENOUS, SUBCUTANEOUS BORTEZOMIB + @ HOSPIRA INC 1MG/VIAL N 209191 002 Dec 28, 2018 Mar DISC

BOSENTAN TABLET;ORAL BOSENTAN AB ALVOGEN PINE BROOK 62.5MG A 206002 001 Apr 26, 2019 Apr NFTG AB 125MG A 206002 002 Apr 26, 2019 Apr NFTG AB AMNEAL PHARMS CO 62.5MG A 209742 001 Apr 26, 2019 Apr NFTG AB 125MG A 209742 002 Apr 26, 2019 Apr NFTG AB NATCO PHARMA LTD 62.5MG A 206987 001 Apr 26, 2019 Apr NFTG AB 125MG A 206987 002 Apr 26, 2019 Apr NFTG AB PAR PHARM INC 62.5MG A 205699 001 Apr 26, 2019 Apr NFTG AB 125MG A 205699 002 Apr 26, 2019 Apr NFTG AB SUN PHARM 62.5MG A 209324 001 Apr 26, 2019 Apr NFTG AB 125MG A 209324 002 Apr 26, 2019 Apr NFTG AB WATSON LABS INC 62.5MG A 207110 001 Apr 26, 2019 Apr NFTG AB 125MG A 207110 002 Apr 26, 2019 Apr NFTG AB WEST-WARD PHARMS INT 62.5MG A 208695 001 Apr 26, 2019 Apr NFTG AB 125MG A 208695 002 Apr 26, 2019 Apr NFTG AB ZYDUS PHARMS 62.5MG A 207760 001 Apr 26, 2019 Apr NFTG AB 125MG A 207760 002 Apr 26, 2019 Apr NFTG TRACLEER AB + ACTELION PHARMS LTD 62.5MG N 021290 001 Nov 20, 2001 Apr CFTG AB +! 125MG N 021290 002 Nov 20, 2001 Apr CFTG

>A> BREMELANOTIDE ACETATE >A> SOLUTION;SUBCUTANEOUS >A> VYLEESI (AUTOINJECTOR) >A> +! AMAG PHARMS INC EQ 1.75MG BASE/0.3ML (EQ 1.75MG N 210557 001 Jun 21, 2019 Jun NEWA BASE/0.3 ML)

BRETYLIUM TOSYLATE INJECTABLE;INJECTION BRETYLIUM TOSYLATE >D> ! ACADEMIC PHARMS INC 50MG/ML A 204386 001 Dec 21, 2018 Jun CAHN >A> ! BAS ANDA 50MG/ML A 204386 001 Dec 21, 2018 Jun CAHN

>A> BREXANOLONE >A> SOLUTION;INTRAVENOUS >A> ZULRESSO >A> +! SAGE THERAP 100MG/20ML (5MG/ML) N 211371 001 Jun 17, 2019 Jun NEWA

BRIMONIDINE TARTRATE SOLUTION/DROPS;OPHTHALMIC BRIMONIDINE TARTRATE AT SOMERSET THERAPS LLC 0.2% A 208992 001 Mar 11, 2019 Feb NEWA

BROMFENAC SODIUM SOLUTION/DROPS;OPHTHALMIC BROMFENAC SODIUM >A> AT2 ALEMBIC PHARMS LTD EQ 0.09% ACID A 210560 001 Jun 21, 2019 Jun NEWA AT2 ! HI TECH EQ 0.09% ACID A 203395 001 Jan 22, 2014 May CTEC AT2 INNOPHARMA LICENSING EQ 0.09% ACID A 203368 001 Jun 03, 2019 May NEWA

BUDESONIDE CAPSULE;ORAL BUDESONIDE AB APPCO PHARMA LLC 3MG A 207367 001 Apr 07, 2017 Feb CAHN >A> CAPSULE, EXTENDED RELEASE;ORAL >A> ORTIKOS >A> + SUN PHARMA GLOBAL 6MG N 211929 001 Jun 13, 2019 Jun NEWA >A> +! 9MG N 211929 002 Jun 13, 2019 Jun NEWA TABLET, EXTENDED RELEASE;ORAL UCERIS AB +! SALIX 9MG N 203634 001 Jan 14, 2013 Mar CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019 1 -13

BUMETANIDE TABLET;ORAL BUMETANIDE AB HERITAGE PHARMA 0.5MG A 074225 001 Apr 24, 1995 Feb CAHN AB 1MG A 074225 002 Apr 24, 1995 Feb CAHN AB 2MG A 074225 003 Apr 24, 1995 Feb CAHN

BUPIVACAINE HYDROCHLORIDE INJECTABLE;INJECTION BUPIVACAINE HYDROCHLORIDE >D> AP NOVOCOL HEALTHCARE 0.5% A 211096 001 Feb 19, 2019 Jun DISC >A> @ 0.5% A 211096 001 Feb 19, 2019 Jun DISC AP 0.5% A 211096 001 Feb 19, 2019 Feb NEWA INJECTABLE;SPINAL BUPIVACAINE HYDROCHLORIDE AP B BRAUN MEDICAL INC 0.75% A 209087 001 Apr 02, 2019 Mar NEWA

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE FILM;BUCCAL, SUBLINGUAL BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE AB ALVOGEN PINE BROOK EQ 2MG BASE;EQ 0.5MG BASE A 205954 001 Jan 24, 2019 Jan NEWA AB EQ 4MG BASE;EQ 1MG BASE A 205954 002 Jan 24, 2019 Jan NEWA AB EQ 8MG BASE;EQ 2MG BASE A 205954 003 Jan 24, 2019 Jan NEWA AB EQ 12MG BASE;EQ 3MG BASE A 205954 004 Jan 24, 2019 Jan NEWA FILM;SUBLINGUAL CASSIPA + @ TEVA PHARMS USA EQ 16MG BASE;EQ 4MG BASE N 208042 001 Sep 07, 2018 Mar DISC TABLET;SUBLINGUAL BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE @ TEVA PHARMS USA EQ 2MG BASE;EQ 0.5MG BASE A 091149 001 Sep 08, 2014 Jan DISC @ EQ 8MG BASE;EQ 2MG BASE A 091149 002 Sep 08, 2014 Jan DISC

BUPROPION HYDROCHLORIDE TABLET;ORAL BUPROPION HYDROCHLORIDE >A> AB APNAR PHARMA LP 75MG A 075584 001 Feb 07, 2000 Jun CAHN >A> AB 100MG A 075584 002 Feb 07, 2000 Jun CAHN @ HERITAGE PHARMA 75MG A 075310 001 Nov 29, 1999 May CAHN @ 100MG A 075310 002 Nov 29, 1999 May CAHN >D> AB SANDOZ 75MG A 075584 001 Feb 07, 2000 Jun CAHN >D> AB 100MG A 075584 002 Feb 07, 2000 Jun CAHN TABLET, EXTENDED RELEASE;ORAL BUPROPION HYDROCHLORIDE AB3 GRAVITI PHARMS 150MG A 211020 001 Jan 28, 2019 Jan NEWA AB3 300MG A 211020 002 Jan 28, 2019 Jan NEWA @ YICHANG HUMANWELL 100MG A 211347 001 Oct 16, 2018 Apr DISC @ 150MG A 211347 002 Oct 16, 2018 Apr DISC @ 200MG A 211347 003 Oct 16, 2018 Apr DISC

BUSPIRONE HYDROCHLORIDE TABLET;ORAL BUSPIRONE HYDROCHLORIDE AB EPIC PHARMA LLC 5MG A 208972 001 Apr 16, 2019 Apr NEWA AB 7.5MG A 208972 002 Apr 16, 2019 Apr NEWA AB 10MG A 208972 003 Apr 16, 2019 Apr NEWA AB 15MG A 208972 004 Apr 16, 2019 Apr NEWA AB 30MG A 208972 005 Apr 16, 2019 Apr NEWA

BUSULFAN INJECTABLE;INJECTION BUSULFAN AP ACCORD HLTHCARE INC 6MG/ML A 210148 001 Feb 22, 2019 Feb NEWA AP APOTEX INC 6MG/ML A 210448 001 May 07, 2019 Apr NEWA AP ATHENEX INC 6MG/ML A 205106 001 Sep 21, 2018 Jan CAHN @ HOSPIRA INC 6MG/ML A 205672 001 Jul 31, 2018 Feb DISC AP SHILPA MEDICARE LTD 6MG/ML A 210931 001 Apr 18, 2019 Apr NEWA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019 1 -14

CAFFEINE CITRATE SOLUTION;ORAL CAFFEINE CITRATE @ LUITPOLD EQ 30MG BASE/3ML (EQ 10MG BASE/ML) A 090064 001 Nov 20, 2009 Mar DISC

CALCITRIOL CAPSULE;ORAL CALCITRIOL AB SUN PHARM 0.25MCG A 204556 001 Feb 21, 2019 Feb NEWA AB 0.5MCG A 204556 002 Feb 21, 2019 Feb NEWA

CALCIUM ACETATE TABLET;ORAL CALCIUM ACETATE AB CHARTWELL MOLECULAR 667MG A 202420 001 Feb 05, 2013 Jan CAHN

CALCIUM CHLORIDE INJECTABLE;INJECTION CALCIUM CHLORIDE 10% AP MEDEFIL INC 100MG/ML A 211553 001 May 01, 2019 Apr NEWA

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE SOLUTION;INTRAPERITONEAL DIANEAL LOW CALCIUM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER >D> AT BAXTER HLTHCARE 18.3MG/100ML;1.5GM/100ML;5.08MG/10 N 020183 001 Dec 04, 1992 Jun CRLD 0ML;538MG/100ML;448MG/100ML >A> AT + 18.3MG/100ML;1.5GM/100ML;5.08MG/10 N 020183 001 Dec 04, 1992 Jun CRLD 0ML;538MG/100ML;448MG/100ML DIANEAL LOW CALCIUM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER >D> BAXTER HLTHCARE 18.3MG/100ML;2.5GM/100ML;5.08MG/10 N 020183 002 Dec 04, 1992 Jun CRLD 0ML;538MG/100ML;448MG/100ML >A> + 18.3MG/100ML;2.5GM/100ML;5.08MG/10 N 020183 002 Dec 04, 1992 Jun CRLD 0ML;538MG/100ML;448MG/100ML DIANEAL LOW CALCIUM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER >D> BAXTER HLTHCARE 18.3MG/100ML;3.5GM/100ML;5.08MG/10 N 020183 003 Dec 04, 1992 Jun CRLD 0ML;538MG/100ML;448MG/100ML >A> + 18.3MG/100ML;3.5GM/100ML;5.08MG/10 N 020183 003 Dec 04, 1992 Jun CRLD 0ML;538MG/100ML;448MG/100ML DIANEAL LOW CALCIUM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER >D> BAXTER HLTHCARE 18.3MG/100ML;4.25GM/100ML;5.08MG/1 N 020183 004 Dec 04, 1992 Jun CRLD 00ML;538MG/100ML;448MG/100ML >A> + 18.3MG/100ML;4.25GM/100ML;5.08MG/1 N 020183 004 Dec 04, 1992 Jun CRLD 00ML;538MG/100ML;448MG/100ML DIANEAL PD-2 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER >D> AT BAXTER HLTHCARE 18.3MG/100ML;1.5GM/100ML;5.08MG/10 N 017512 004 Jun CRLD 0ML;538MG/100ML;448MG/100ML >A> AT + 18.3MG/100ML;1.5GM/100ML;5.08MG/10 N 017512 004 Jun CRLD 0ML;538MG/100ML;448MG/100ML >D> AT 25.7MG/100ML;1.5GM/100ML;5.08MG/10 N 020163 001 Dec 04, 1992 Jun CRLD 0ML;538MG/100ML;448MG/100ML >A> AT + 25.7MG/100ML;1.5GM/100ML;5.08MG/10 N 020163 001 Dec 04, 1992 Jun CRLD 0ML;538MG/100ML;448MG/100ML DIANEAL PD-2 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER >D> AT BAXTER HLTHCARE 25.7MG/100ML;2.5GM/100ML;5.08MG/10 N 017512 005 Jun CRLD 0ML;538MG/100ML;448MG/100ML >A> AT + 25.7MG/100ML;2.5GM/100ML;5.08MG/10 N 017512 005 Jun CRLD 0ML;538MG/100ML;448MG/100ML >D> AT 25.7MG/100ML;2.5GM/100ML;5.08MG/10 N 020163 002 Dec 04, 1992 Jun CRLD 0ML;538MG/100ML;448MG/100ML >A> AT + 25.7MG/100ML;2.5GM/100ML;5.08MG/10 N 020163 002 Dec 04, 1992 Jun CRLD 0ML;538MG/100ML;448MG/100ML DIANEAL PD-2 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER >D> @ BAXTER HLTHCARE 25.7MG/100ML;3.5GM/100ML;5.08MG/10 N 017512 011 Nov 18, 1985 Jun CRLD 0ML;538MG/100ML;448MG/100ML >A> + @ 25.7MG/100ML;3.5GM/100ML;5.08MG/10 N 017512 011 Nov 18, 1985 Jun CRLD 0ML;538MG/100ML;448MG/100ML DIANEAL PD-2 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER >D> AT BAXTER HLTHCARE 25.7MG/100ML;4.25GM/100ML;5.08MG/1 N 017512 006 Jun CRLD 00ML;538MG/100ML;448MG/100ML >A> AT + 25.7MG/100ML;4.25GM/100ML;5.08MG/1 N 017512 006 Jun CRLD 00ML;538MG/100ML;448MG/100ML >D> AT 25.7MG/100ML;4.25GM/100ML;5.08MG/1 N 020163 003 Dec 04, 1992 Jun CRLD 00ML;538MG/100ML;448MG/100ML >A> AT + 25.7MG/100ML;4.25GM/100ML;5.08MG/1 N 020163 003 Dec 04, 1992 Jun CRLD 00ML;538MG/100ML;448MG/100ML RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019 1 -15

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE INJECTABLE;INJECTION LACTATED RINGER'S IN PLASTIC CONTAINER AP FRESENIUS KABI USA 20MG/100ML;30MG/100ML;600MG/100ML; A 209338 001 Jan 28, 2019 Jan NEWA 310MG/100ML

CAPECITABINE TABLET;ORAL CAPECITABINE >A> AB SUN PHARM 150MG A 204668 001 Jun 21, 2019 Jun NEWA >A> AB 500MG A 204668 002 Jun 21, 2019 Jun NEWA

CAPTOPRIL TABLET;ORAL CAPTOPRIL >D> @ BOSCOGEN 12.5MG A 074677 004 May 30, 1997 Jun CMFD >A> AB 12.5MG A 074677 004 May 30, 1997 Jun CMFD >D> @ 25MG A 074677 002 May 30, 1997 Jun CMFD >A> AB 25MG A 074677 002 May 30, 1997 Jun CMFD >D> @ 50MG A 074677 001 May 30, 1997 Jun CMFD >A> AB 50MG A 074677 001 May 30, 1997 Jun CMFD >D> @ 100MG A 074677 003 May 30, 1997 Jun CMFD >A> AB 100MG A 074677 003 May 30, 1997 Jun CMFD

CARBAMAZEPINE CAPSULE, EXTENDED RELEASE;ORAL CARBATROL AB + SHIRE DEV LLC 100MG N 020712 003 Sep 30, 1997 Jan CAHN AB + 200MG N 020712 001 Sep 30, 1997 Jan CAHN AB +! 300MG N 020712 002 Sep 30, 1997 Jan CAHN TABLET, EXTENDED RELEASE;ORAL CARBAMAZEPINE AB ZYDUS PHARMS 100MG A 205571 001 Feb 07, 2019 Jan NEWA AB 200MG A 205571 002 Feb 07, 2019 Jan NEWA AB 400MG A 205571 003 Feb 07, 2019 Jan NEWA

CARBIDOPA; LEVODOPA TABLET, EXTENDED RELEASE;ORAL CARBIDOPA AND LEVODOPA AB ALEMBIC PHARMS LTD 25MG;100MG A 210341 001 Jun 05, 2019 May NEWA AB 50MG;200MG A 210341 002 Jun 05, 2019 May NEWA

CARBINOXAMINE MALEATE SOLUTION;ORAL CARBINOXAMINE MALEATE >D> AA ! MIKART 4MG/5ML A 040458 001 Apr 25, 2003 Jun CTEC >A> ! 4MG/5ML A 040458 001 Apr 25, 2003 Jun CTEC >D> AA VINTAGE PHARMS 4MG/5ML A 040814 001 Feb 26, 2008 Jun DISC >A> @ 4MG/5ML A 040814 001 Feb 26, 2008 Jun DISC TABLET;ORAL CARBINOXAMINE MALEATE ! MIKART 6MG A 207484 001 May 31, 2016 Mar CHRS

CARBOPLATIN INJECTABLE;INTRAVENOUS CARBOPLATIN AP ACCORD HLTHCARE 50MG/5ML (10MG/ML) A 206775 001 Feb 09, 2017 May CDFR AP 150MG/15ML (10MG/ML) A 206775 002 Feb 09, 2017 May CDFR AP 450MG/45ML (10MG/ML) A 206775 003 Feb 09, 2017 May CDFR AP 600MG/60ML (10MG/ML) A 206775 004 Feb 09, 2017 May CDFR @ ACTAVIS TOTOWA 50MG/5ML (10MG/ML) A 078732 001 Feb 06, 2012 Mar CDFR @ 150MG/15ML (10MG/ML) A 078732 002 Feb 06, 2012 Mar CDFR @ 450MG/45ML (10MG/ML) A 078732 003 Feb 06, 2012 Mar CDFR @ 600MG/60ML (10MG/ML) A 078732 004 Feb 06, 2012 Mar CDFR AP AKORN 50MG/5ML (10MG/ML) A 090475 001 Jul 29, 2009 May CDFR AP 150MG/15ML (10MG/ML) A 090475 002 Jul 29, 2009 May CDFR AP 450MG/45ML (10MG/ML) A 090475 003 Jul 29, 2009 May CDFR AP 600MG/60ML (10MG/ML) A 091268 002 Jul 28, 2010 May CDFR AP CIPLA LTD 50MG/5ML (10MG/ML) A 077861 001 Jan 18, 2007 May CDFR AP 150MG/15ML (10MG/ML) A 077861 002 Jan 18, 2007 May CDFR AP 450MG/45ML (10MG/ML) A 077861 003 Jan 18, 2007 May CDFR RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019 1 -16

INJECTABLE;INTRAVENOUS CARBOPLATIN AP 600MG/60ML (10MG/ML) A 077861 004 Jan 18, 2007 May CDFR AP EUGIA PHARMA 50MG/5ML (10MG/ML) A 205487 001 Mar 28, 2016 May CDFR AP 150MG/15ML (10MG/ML) A 205487 002 Mar 28, 2016 May CDFR AP 450MG/45ML (10MG/ML) A 205487 003 Mar 28, 2016 May CDFR AP FRESENIUS KABI USA 50MG/5ML (10MG/ML) A 077432 001 Sep 29, 2006 May CDFR AP 150MG/15ML (10MG/ML) A 077432 002 Sep 29, 2006 May CDFR AP 450MG/45ML (10MG/ML) A 077432 003 Sep 29, 2006 May CDFR @ 50MG/5ML (10MG/ML) A 077247 001 Oct 21, 2004 Mar CDFR @ 50MG/5ML (10MG/ML) A 077266 001 Feb 15, 2006 Mar CDFR @ 150MG/15ML (10MG/ML) A 077247 002 Oct 21, 2004 Mar CDFR @ 150MG/15ML (10MG/ML) A 077266 002 Feb 15, 2006 Mar CDFR AP 450MG/45ML (10MG/ML) A 077247 003 Oct 21, 2004 Mar CDFR AP 450MG/45ML (10MG/ML) A 077266 003 Feb 15, 2006 May CDFR AP 600MG/60ML (10MG/ML) A 077266 004 Feb 15, 2006 May CDFR AP GLAND PHARMA LTD 150MG/15ML (10MG/ML) A 207324 002 Feb 15, 2017 May CDFR AP 450MG/45ML (10MG/ML) A 207324 003 Feb 15, 2017 May CDFR AP 600MG/60ML (10MG/ML) A 207324 004 Feb 15, 2017 May CDFR AP HONG KONG 50MG/5ML (10MG/ML) A 077096 001 Jun 14, 2005 May CDFR AP 150MG/15ML (10MG/ML) A 077096 002 Jun 14, 2005 May CDFR AP 450MG/45ML (10MG/ML) A 077096 003 Jun 14, 2005 May CDFR AP 600MG/60ML (10MG/ML) A 077096 004 Jun 03, 2013 May CDFR AP HOSPIRA 50MG/5ML (10MG/ML) A 076517 001 Oct 14, 2004 May CDFR AP 150MG/15ML (10MG/ML) A 076517 002 Oct 14, 2004 May CDFR AP 450MG/45ML (10MG/ML) A 076517 003 Oct 14, 2004 May CDFR AP 600MG/60ML (10MG/ML) A 077059 001 Nov 23, 2004 May CDFR AP INGENUS PHARMS LLC 50MG/5ML (10MG/ML) A 208487 001 Apr 26, 2017 May CDFR AP 150MG/15ML (10MG/ML) A 208487 002 Apr 26, 2017 May CDFR AP 450MG/45ML (10MG/ML) A 208487 003 Apr 26, 2017 May CDFR AP 600MG/60ML (10MG/ML) A 208487 004 Apr 26, 2017 May CDFR @ MYLAN INSTITUTIONAL 50MG/5ML (10MG/ML) A 077998 001 Apr 24, 2007 Apr CDFR @ 150MG/15ML (10MG/ML) A 077998 002 Apr 24, 2007 Apr CDFR @ 450MG/45ML (10MG/ML) A 077998 003 Apr 24, 2007 Apr CDFR AP MYLAN LABS LTD 50MG/5ML (10MG/ML) A 091063 001 Nov 09, 2011 May CDFR AP 150MG/15ML (10MG/ML) A 091063 002 Nov 09, 2011 May CDFR AP 450MG/45ML (10MG/ML) A 091063 003 Nov 09, 2011 May CDFR AP 600MG/60ML (10MG/ML) A 091063 004 Nov 09, 2011 May CDFR @ 1GM/100ML (10MG/ML) A 091478 001 Nov 23, 2011 Mar CDFR AP ! PHARMACHEMIE BV 50MG/5ML (10MG/ML) A 077269 001 Oct 14, 2004 May CDFR @ 50MG/5ML (10MG/ML) A 077679 001 Feb 25, 2009 Mar CDFR AP ! 150MG/15ML (10MG/ML) A 077269 002 Oct 14, 2004 May CDFR @ 150MG/15ML (10MG/ML) A 077679 002 Feb 25, 2009 Mar CDFR AP ! 450MG/45ML (10MG/ML) A 077269 003 Oct 14, 2004 May CDFR @ 450MG/45ML (10MG/ML) A 077679 003 Feb 25, 2009 Mar CDFR AP ! 600MG/60ML (10MG/ML) A 077269 004 Dec 28, 2007 May CDFR AP PLIVA LACHEMA 50MG/5ML (10MG/ML) A 078631 001 Dec 02, 2008 May CDFR AP 150MG/15ML (10MG/ML) A 078631 002 Dec 02, 2008 May CDFR AP 450MG/45ML (10MG/ML) A 078631 003 Dec 02, 2008 May CDFR AP 600MG/60ML (10MG/ML) A 078631 004 Dec 02, 2008 May CDFR AP SANDOZ INC 50MG/5ML (10MG/ML) A 078280 001 May 08, 2008 May CDFR AP 150MG/15ML (10MG/ML) A 078280 002 May 08, 2008 May CDFR AP 450MG/45ML (10MG/ML) A 078280 003 May 08, 2008 May CDFR AP SUN PHARM 50MG/5ML (10MG/ML) A 077926 001 Sep 19, 2008 May CDFR AP 150MG/15ML (10MG/ML) A 077926 002 Sep 19, 2008 May CDFR AP 450MG/45ML (10MG/ML) A 077926 003 Sep 19, 2008 May CDFR @ TEVA PARENTERAL 50MG/5ML (10MG/ML) A 077389 001 Mar 30, 2007 Mar CDFR @ 150MG/15ML (10MG/ML) A 077389 002 Mar 30, 2007 Mar CDFR @ 450MG/45ML (10MG/ML) A 077389 003 Mar 30, 2007 Mar CDFR AP ! TEVA PHARMS USA 50MG/5ML (10MG/ML) A 077139 001 Sep 21, 2005 May CDFR AP ! 150MG/15ML (10MG/ML) A 077139 002 Sep 21, 2005 May CDFR AP ! 450MG/45ML (10MG/ML) A 077139 003 Sep 21, 2005 May CDFR AP ! 600MG/60ML (10MG/ML) A 077139 004 Sep 21, 2005 May CDFR AP WEST-WARD PHARMS INT 50MG/5ML (10MG/ML) A 077244 001 Oct 15, 2004 May CDFR AP 150MG/15ML (10MG/ML) A 077244 002 Oct 15, 2004 May CDFR AP 450MG/45ML (10MG/ML) A 077244 003 Oct 15, 2004 May CDFR AP 600MG/60ML (10MG/ML) A 077244 004 Jan 20, 2006 May CDFR PARAPLATIN + @ CORDENPHARMA 50MG/5ML (10MG/ML) N 020452 001 Jul 14, 2003 Mar CDFR + @ 150MG/15ML (10MG/ML) N 020452 002 Jul 14, 2003 Mar CDFR + @ 450MG/45ML (10MG/ML) N 020452 003 Jul 14, 2003 Mar CDFR + @ 600MG/60ML (10MG/ML) N 020452 004 Jan 15, 2004 Mar CDFR RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019 1 -17

INJECTABLE;IV (INFUSION) CARBOPLATIN AP GLAND PHARMA LTD 50MG/5ML (10MG/ML) A 207324 001 Feb 15, 2017 May CDFR AP HONG KONG 50MG/5ML (10MG/ML) A 077096 001 Jun 14, 2005 Feb CAHN AP 150MG/15ML (10MG/ML) A 077096 002 Jun 14, 2005 Feb CAHN AP 450MG/45ML (10MG/ML) A 077096 003 Jun 14, 2005 Feb CAHN AP 600MG/60ML (10MG/ML) A 077096 004 Jun 03, 2013 Feb CAHN @ MYLAN INSTITUTIONAL 50MG/5ML (10MG/ML) A 077998 001 Apr 24, 2007 Mar DISC @ 150MG/15ML (10MG/ML) A 077998 002 Apr 24, 2007 Mar DISC @ 450MG/45ML (10MG/ML) A 077998 003 Apr 24, 2007 Mar DISC

CARBOPROST TROMETHAMINE INJECTABLE;INJECTION >A> CARBOPROST TROMETHAMINE >A> AP DR REDDYS LABS LTD EQ 0.25MG BASE/ML A 211941 001 Jul 02, 2019 Jun NFTG HEMABATE >D> +! PHARMACIA AND UPJOHN EQ 0.25MG BASE/ML N 017989 001 Jun CFTG >A> AP +! EQ 0.25MG BASE/ML N 017989 001 Jun CFTG

CARGLUMIC ACID TABLET;ORAL CARBAGLU +! RECORDATI RARE 200MG N 022562 001 Mar 18, 2010 May CAHN

CARISOPRODOL TABLET;ORAL CARISOPRODOL >A> @ ALLIED 350MG A 040245 001 Sep 08, 1997 Jun CAHN >D> @ VINTAGE PHARMS 350MG A 040245 001 Sep 08, 1997 Jun CAHN @ 350MG A 040245 001 Sep 08, 1997 Feb DISC

CARMUSTINE INJECTABLE;INJECTION CARMUSTINE AP STI PHARMA LLC 100MG/VIAL A 209278 001 Apr 02, 2019 Mar NEWA

CARTEOLOL HYDROCHLORIDE SOLUTION/DROPS;OPHTHALMIC CARTEOLOL HYDROCHLORIDE @ BAUSCH AND LOMB 1% A 075546 001 Jan 20, 2000 May DISC ! SANDOZ INC 1% A 075476 001 Jan 03, 2000 May CTEC

CASPOFUNGIN ACETATE POWDER;INTRAVENOUS CASPOFUNGIN ACETATE @ CIPLA 50MG/VIAL A 209489 001 Jul 12, 2018 Jan DISC @ 70MG/VIAL A 209489 002 Jul 12, 2018 Jan DISC

CEFIXIME FOR SUSPENSION;ORAL CEFIXIME @ SANDOZ INC 100MG/5ML A 206144 001 Nov 17, 2017 Feb DISC @ 200MG/5ML A 206144 002 Nov 17, 2017 Feb DISC SUPRAX AB ! LUPIN PHARMS 200MG/5ML A 065355 001 Apr 10, 2007 Apr CHRS

CEFPODOXIME PROXETIL FOR SUSPENSION;ORAL CEFPODOXIME PROXETIL AUROBINDO PHARMA LTD EQ 50MG BASE/5ML A 065409 001 Jun 08, 2007 Jan CTEC ! EQ 100MG BASE/5ML A 065409 002 Jun 08, 2007 Jan CHRS EQ 100MG BASE/5ML A 065409 002 Jun 08, 2007 Jan CTEC @ SANDOZ EQ 50MG BASE/5ML A 090031 001 Jan 14, 2009 Jan DISC @ EQ 100MG BASE/5ML A 090031 002 Jan 14, 2009 Jan DISC

CEPHALEXIN FOR SUSPENSION;ORAL CEPHALEXIN AB ALKEM LABS LTD EQ 125MG BASE/5ML A 210221 001 Mar 26, 2019 Mar NEWA AB EQ 250MG BASE/5ML A 210221 002 Mar 26, 2019 Mar NEWA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019 1 -18

>D> CERITINIB >D> CAPSULE;ORAL >D> ZYKADIA >D> +! NOVARTIS PHARMS CORP 150MG N 205755 001 Apr 29, 2014 Jun DISC >A> + @ 150MG N 205755 001 Apr 29, 2014 Jun DISC TABLET;ORAL ZYKADIA +! NOVARTIS PHARMS CORP 150MG N 211225 001 Mar 18, 2019 Mar NEWA

CETIRIZINE HYDROCHLORIDE SYRUP;ORAL CETIRIZINE HYDROCHLORIDE @ LANNETT CO INC 5MG/5ML A 078496 001 Sep 25, 2009 May DISC @ PD PARTNERS 5MG/5ML A 078412 001 Jun 18, 2008 May CAHN AA ! PERRIGO PHARMS CO 5MG/5ML A 078398 001 Jun 17, 2008 May CAHN AA SAPTALIS PHARMS 5MG/5ML A 090191 001 Nov 12, 2009 Feb CAHN AA TORRENT 5MG/5ML A 078870 001 Apr 27, 2009 Jan CAHN

CHLORDIAZEPOXIDE HYDROCHLORIDE INJECTABLE;INJECTION LIBRIUM @ BAUSCH 100MG/AMP N 012301 001 Mar CAHN

CHLORHEXIDINE GLUCONATE SOLUTION;DENTAL CHLORHEXIDINE GLUCONATE >A> AT PD PARTNERS 0.12% A 074522 001 Dec 15, 1995 Jun CAHN >D> AT TEVA 0.12% A 074522 001 Dec 15, 1995 Jun CAHN

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE SOLUTION;ORAL VITUZ AA +! PERSION 4MG/5ML;5MG/5ML N 204307 001 Feb 20, 2013 Apr CAHN

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE SOLUTION;ORAL HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE >D> AA PADDOCK LLC 4MG/5ML;5MG/5ML;60MG/5ML A 204627 001 Apr 29, 2014 Jun CHRS >A> AA ! 4MG/5ML;5MG/5ML;60MG/5ML A 204627 001 Apr 29, 2014 Jun CHRS @ TORRENT 4MG/5ML;5MG/5ML;60MG/5ML A 206660 001 May 15, 2017 Jan CAHN ZUTRIPRO AA +! PERSION 4MG/5ML;5MG/5ML;60MG/5ML N 022439 001 Jun 08, 2011 Apr CAHN

CHLORPROPAMIDE TABLET;ORAL CHLORPROPAMIDE @ MYLAN 100MG A 088549 002 Jun 01, 1984 May DISC @ 250MG A 088549 001 Jun 01, 1984 May DISC

CHLORTHALIDONE TABLET;ORAL CHLORTHALIDONE >A> AB AMNEAL PHARMS CO 25MG A 207204 001 Jul 01, 2019 Jun NEWA >A> AB 50MG A 207204 002 Jul 01, 2019 Jun NEWA AB INVATECH PHARMA 25MG A 211063 001 Feb 26, 2019 Feb NEWA AB 50MG A 211063 002 Feb 26, 2019 Feb NEWA AB ZYDUS PHARMS 25MG A 207813 001 May 10, 2019 Apr NEWA AB 50MG A 207813 002 May 10, 2019 Apr NEWA

CHOLINE C-11 INJECTABLE;INTRAVENOUS CHOLINE C-11 AP DECATUR 4-33.1mCi/ML A 206319 001 Nov 13, 2015 Apr CAHN

CHOLINE FENOFIBRATE CAPSULE, DELAYED RELEASE;ORAL FENOFIBRIC ACID @ MYLAN PHARMS INC EQ 45MG FENOFIBRIC ACID A 200913 001 Mar 25, 2013 May DISC @ EQ 135MG FENOFIBRIC ACID A 200913 002 Mar 25, 2013 May DISC >A> AB TWI PHARMS EQ 45MG FENOFIBRIC ACID A 210469 001 Jul 05, 2019 Jun NEWA >A> AB EQ 135MG FENOFIBRIC ACID A 210469 002 Jul 05, 2019 Jun NEWA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019 1 -19

CHROMIC PHOSPHATE P-32 INJECTABLE;INJECTION PHOSPHOCOL P32 @ CURIUM 5mCi/ML N 017084 001 Jan CAHN

CICLESONIDE AEROSOL, METERED;INHALATION ALVESCO +! COVIS PHARMA BV 0.08MG/INH N 021658 002 Jan 10, 2008 Mar CAHN +! 0.16MG/INH N 021658 003 Jan 10, 2008 Mar CAHN AEROSOL, METERED;NASAL ZETONNA +! COVIS PHARMA BV 0.037MG/INH N 202129 001 Jan 20, 2012 Mar CAHN SPRAY, METERED;NASAL OMNARIS +! COVIS PHARMA BV 0.05MG/INH N 022004 001 Oct 20, 2006 Mar CAHN

CICLOPIROX CREAM;TOPICAL CICLOPIROX AB PERRIGO ISRAEL 0.77% A 077364 001 Mar 03, 2006 May CAHN SHAMPOO;TOPICAL LOPROX AT +! BAUSCH 1% N 021159 001 Feb 28, 2003 Apr CAHN SOLUTION;TOPICAL CICLOPIROX AT ACELLA 8% A 078172 001 Sep 18, 2007 May CAHN

CIMETIDINE TABLET;ORAL CIMETIDINE >D> AB APOTEX 200MG A 074890 001 Dec 18, 1998 Jun CAHN >D> AB 300MG A 074890 002 Dec 18, 1998 Jun CAHN >D> AB 400MG A 074890 003 Dec 18, 1998 Jun CAHN >D> AB 800MG A 074890 004 Dec 18, 1998 Jun CAHN >A> AB HIKMA 200MG A 074890 001 Dec 18, 1998 Jun CAHN >A> AB 300MG A 074890 002 Dec 18, 1998 Jun CAHN >A> AB 400MG A 074890 003 Dec 18, 1998 Jun CAHN >A> AB 800MG A 074890 004 Dec 18, 1998 Jun CAHN

CIMETIDINE HYDROCHLORIDE SOLUTION;ORAL CIMETIDINE HYDROCHLORIDE @ PD PARTNERS EQ 300MG BASE/5ML A 075560 001 Mar 15, 2000 May CAHN

CINACALCET HYDROCHLORIDE TABLET;ORAL CINACALCET HYDROCHLORIDE AB ALKEM LABS LTD EQ 30MG BASE A 210570 001 May 17, 2019 May NEWA AB EQ 60MG BASE A 210570 002 May 17, 2019 May NEWA AB EQ 90MG BASE A 210570 003 May 17, 2019 May NEWA >A> AB LUPIN LTD EQ 30MG BASE A 210548 001 Jun 28, 2019 Jun NEWA >A> AB EQ 60MG BASE A 210548 002 Jun 28, 2019 Jun NEWA >A> AB EQ 90MG BASE A 210548 003 Jun 28, 2019 Jun NEWA

CIPROFLOXACIN INJECTABLE;INJECTION CIPROFLOXACIN @ DR REDDYS 200MG/20ML (10MG/ML) A 077782 001 Aug 28, 2006 May CAHN @ 400MG/40ML (10MG/ML) A 077782 002 Aug 28, 2006 May CAHN

CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE TABLET, EXTENDED RELEASE;ORAL CIPROFLOXACIN EXTENDED RELEASE ! ANCHEN PHARMS 212.6MG;EQ 287.5MG BASE A 078166 002 Nov 27, 2007 May CTEC AB ! 212.6MG;EQ 287.5MG BASE A 078166 002 Nov 27, 2007 May CHRS AB ! 425.2MG;EQ 574.9MG BASE A 078166 001 Nov 27, 2007 May CHRS @ ANI PHARMS INC 212.6MG;EQ 287.5MG BASE A 077417 001 Nov 30, 2010 May CAHN @ 425.2MG;EQ 574.9MG BASE A 077809 001 Nov 30, 2010 May CAHN @ MYLAN PHARMS INC 212.6MG;EQ 287.5MG BASE A 078183 001 Mar 22, 2007 May DISC @ 425.2MG;EQ 574.9MG BASE A 078183 002 Mar 22, 2007 May DISC RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019 1 -20

CISATRACURIUM BESYLATE INJECTABLE;INJECTION CISATRACURIUM BESYLATE @ ACCORD HLTHCARE EQ 2MG BASE/ML A 205873 001 Jun 16, 2017 Feb DISC AP NANJING KING-FRIEND EQ 2MG BASE/ML A 211668 001 Apr 25, 2019 Apr NEWA AP EQ 2MG BASE/ML A 211669 001 Apr 25, 2019 Apr NEWA AP EQ 10MG BASE/ML A 211668 002 Apr 25, 2019 Apr NEWA AP SOMERSET THERAPS LLC EQ 2MG BASE/ML A 209132 001 Apr 24, 2019 Apr NEWA CISATRACURIUM BESYLATE PRESERVATIVE FREE @ ACCORD HLTHCARE EQ 2MG BASE/ML A 205872 001 Jun 16, 2017 Feb DISC @ EQ 10MG BASE/ML A 205872 002 Jun 16, 2017 Feb DISC AP SOMERSET THERAPS LLC EQ 2MG BASE/ML A 206791 001 Feb 20, 2019 Feb NEWA AP EQ 10MG BASE/ML A 206791 002 Feb 20, 2019 Feb NEWA NIMBEX PRESERVATIVE FREE AP +! ABBVIE EQ 10MG BASE/ML N 020551 002 Dec 15, 1995 Feb CTEC

CITALOPRAM HYDROBROMIDE SOLUTION;ORAL CITALOPRAM HYDROBROMIDE @ PD PARTNERS EQ 10MG BASE/5ML A 077601 001 Nov 15, 2005 May CAHN TABLET;ORAL CITALOPRAM HYDROBROMIDE @ HERITAGE PHARMA EQ 10MG BASE A 077033 001 Oct 28, 2004 May CAHN @ EQ 10MG BASE A 077213 001 Mar 31, 2006 May CAHN AB EQ 10MG BASE A 077232 001 Oct 31, 2005 May CAHN @ EQ 20MG BASE A 077033 002 Oct 28, 2004 May CAHN @ EQ 20MG BASE A 077213 002 Mar 31, 2006 May CAHN AB EQ 20MG BASE A 077232 002 Oct 31, 2005 May CAHN @ EQ 40MG BASE A 077033 003 Oct 28, 2004 May CAHN @ EQ 40MG BASE A 077213 003 Mar 31, 2006 May CAHN AB EQ 40MG BASE A 077232 003 Oct 31, 2005 May CAHN

CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE FOR SOLUTION;ORAL PREPOPIK >D> + @ FERRING PHARMS INC 12GM/PACKET;3.5GM/PACKET;10MG/PACK N 202535 001 Jul 16, 2012 Jun CMFD ET >A> +! 12GM/PACKET;3.5GM/PACKET;10MG/PACK N 202535 001 Jul 16, 2012 Jun CMFD ET + @ 12GM/PACKET;3.5GM/PACKET;10MG/PACK N 202535 001 Jul 16, 2012 Apr DISC ET

CLADRIBINE TABLET;ORAL MAVENCLAD +! EMD SERONO INC 10MG N 022561 001 Mar 29, 2019 Mar NEWA

CLARITHROMYCIN TABLET;ORAL CLARITHROMYCIN AB AJANTA PHARMA LTD 250MG A 206714 001 Apr 25, 2019 Apr NEWA AB 500MG A 206714 002 Apr 25, 2019 Apr NEWA AB STRIDES PHARMA 250MG A 202710 001 Jun 10, 2013 Feb CAHN AB 500MG A 202710 002 Jun 10, 2013 Feb CAHN

CLINDAMYCIN PALMITATE HYDROCHLORIDE FOR SOLUTION;ORAL CLINDAMYCIN PALMITATE HYDROCHLORIDE @ MYLAN EQ 75MG BASE/5ML A 203063 001 May 25, 2016 Mar DISC

CLINDAMYCIN PHOSPHATE GEL;TOPICAL CLINDAGEL BT +! BAUSCH EQ 1% BASE N 050782 001 Nov 27, 2000 May CAHN SOLUTION;TOPICAL CLINDAMYCIN PHOSPHATE AT ENCUBE ETHICALS EQ 1% BASE A 209914 001 Jan 28, 2019 Jan NEWA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019 1 -21

CLINDAMYCIN PHOSPHATE; TRETINOIN GEL;TOPICAL VELTIN BX +! ALMIRALL 1.2%;0.025% N 050803 001 Jul 16, 2010 Feb CAHN

CLOBAZAM SUSPENSION;ORAL CLOBAZAM AB TARO PHARM 2.5MG/ML A 210978 001 Apr 15, 2019 Apr NEWA >A> AB VISTAPHARM 2.5MG/ML A 210746 001 Jul 10, 2019 Jun NEWA TABLET;ORAL CLOBAZAM AB ACCORD HLTHCARE 10MG A 212398 001 May 23, 2019 May NEWA AB 20MG A 212398 002 May 23, 2019 May NEWA AB MICRO LABS 10MG A 211711 001 Jan 30, 2019 Jan NEWA AB 20MG A 211711 002 Jan 30, 2019 Jan NEWA

CLOBETASOL PROPIONATE AEROSOL, FOAM;TOPICAL CLOBETASOL PROPIONATE AB1 GLENMARK PHARMS LTD 0.05% A 210809 001 Feb 15, 2019 Feb NEWA AB2 PERRIGO UK FINCO 0.05% A 201402 001 Aug 14, 2012 May CAHN OINTMENT;TOPICAL CLOBETASOL PROPIONATE AB ALEOR DERMACEUTICALS 0.05% A 211800 001 Mar 04, 2019 Feb NEWA @ AMNEAL PHARMS LLC 0.05% A 210551 001 Aug 21, 2018 Feb DISC AB TELIGENT PHARMA INC 0.05% A 208589 001 Jan 23, 2019 Jan NEWA

CLOFARABINE SOLUTION;INTRAVENOUS CLOFARABINE AP ACCORD HLTHCARE 20MG/20ML (1MG/ML) A 212034 001 Feb 22, 2019 Feb NEWA @ HOSPIRA INC 20MG/20ML (1MG/ML) A 210283 001 Dec 27, 2018 Feb DISC

CLOMIPRAMINE HYDROCHLORIDE CAPSULE;ORAL CLOMIPRAMINE HYDROCHLORIDE AB MANKIND PHARMA 25MG A 211767 001 Apr 08, 2019 Mar NEWA AB 50MG A 211767 002 Apr 08, 2019 Mar NEWA AB 75MG A 211767 003 Apr 08, 2019 Mar NEWA

CLONAZEPAM TABLET, ORALLY DISINTEGRATING;ORAL CLONAZEPAM >A> AB ALEMBIC PHARMS LTD 0.125MG A 211033 001 Jun 28, 2019 Jun NEWA >A> AB 0.25MG A 211033 002 Jun 28, 2019 Jun NEWA >A> AB 0.5MG A 211033 003 Jun 28, 2019 Jun NEWA >A> AB 1MG A 211033 004 Jun 28, 2019 Jun NEWA >A> AB 2MG A 211033 005 Jun 28, 2019 Jun NEWA

CLONIDINE HYDROCHLORIDE INJECTABLE;INJECTION CLONIDINE HYDROCHLORIDE @ LUITPOLD 1MG/10ML (0.1MG/ML) A 091104 001 Oct 08, 2009 Feb DISC @ 5MG/10ML (0.5MG/ML) A 091104 002 Oct 08, 2009 Feb DISC TABLET;ORAL CLONIDINE HYDROCHLORIDE AB FRONTIDA BIOPHARM 0.1MG A 070923 003 Sep 04, 1987 Apr CMS1 AB 0.2MG A 070923 002 Sep 04, 1987 Apr CMS1 TABLET, EXTENDED RELEASE;ORAL CLONIDINE HYDROCHLORIDE AB1 NOVAST LABS 0.1MG A 209675 001 Mar 05, 2019 Feb NEWA @ UPSHER SMITH LABS 0.1MG A 211433 001 Oct 12, 2018 May DISC

CLOPIDOGREL BISULFATE TABLET;ORAL CLOPIDOGREL BISULFATE AB ANI PHARMS INC EQ 300MG BASE A 091216 001 May 17, 2012 May CAHN >D> AB CADILA EQ 75MG BASE A 201686 001 Oct 10, 2012 Jun DISC >A> @ EQ 75MG BASE A 201686 001 Oct 10, 2012 Jun DISC AB EQ 75MG BASE A 201686 001 Oct 10, 2012 Apr CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019 1 -22

TABLET;ORAL CLOPIDOGREL BISULFATE @ MYLAN PHARMS INC EQ 300MG BASE A 077665 002 May 17, 2012 Feb DISC

CLORAZEPATE DIPOTASSIUM TABLET;ORAL CLORAZEPATE DIPOTASSIUM @ AUROLIFE PHARMA LLC 3.75MG A 072514 002 May 11, 1990 Jan CMS1 @ 7.5MG A 072514 003 May 11, 1990 Jan CMS1

CLOTRIMAZOLE SOLUTION;TOPICAL CLOTRIMAZOLE AT NOVITIUM PHARMA 1% A 209815 001 Feb 14, 2019 Feb NEWA

CLOZAPINE TABLET;ORAL CLOZARIL AB + HERITAGE LIFE 50MG N 019758 003 May 20, 2019 May NEWA AB + 200MG N 019758 004 May 20, 2019 May NEWA TABLET, ORALLY DISINTEGRATING;ORAL FAZACLO ODT >A> AB + JAZZ 12.5MG N 021590 004 May 30, 2007 Jun CAHN >A> AB + 25MG N 021590 001 Feb 10, 2004 Jun CAHN >A> @ 50MG N 021590 003 Jun 03, 2005 Jun CAHN >A> AB +! 100MG N 021590 002 Feb 10, 2004 Jun CAHN >A> AB + 150MG N 021590 005 Jul 09, 2010 Jun CAHN >A> AB + 200MG N 021590 006 Jul 09, 2010 Jun CAHN >D> AB + JAZZ PHARMS III 12.5MG N 021590 004 May 30, 2007 Jun CAHN >D> AB + 25MG N 021590 001 Feb 10, 2004 Jun CAHN >D> @ 50MG N 021590 003 Jun 03, 2005 Jun CAHN >D> AB +! 100MG N 021590 002 Feb 10, 2004 Jun CAHN >D> AB + 150MG N 021590 005 Jul 09, 2010 Jun CAHN >D> AB + 200MG N 021590 006 Jul 09, 2010 Jun CAHN

CODEINE SULFATE SOLUTION;ORAL CODEINE SULFATE HI KMA@ HIKMA@ 30MG/5ML N 202245 001 Jun 30, 2011 Mar CAHN TABLET;ORAL CODEINE SULFATE AB + HIKMA 15MG N 022402 001 Jul 16, 2009 Mar CAHN AB + 30MG N 022402 002 Jul 16, 2009 Mar CAHN AB +! 60MG N 022402 003 Jul 16, 2009 Mar CAHN

COLCHICINE CAPSULE;ORAL COLCHICINE @ PAR PHARM INC 0.6MG A 208678 001 Nov 29, 2018 May DISC MITIGARE +! HIKMA INTL PHARMS 0.6MG N 204820 001 Sep 26, 2014 May CTEC SOLUTION;ORAL GLOPERBA +! ROMEG THERAPS LLC 0.6MG/5ML N 210942 001 Jan 30, 2019 Jan NEWA TABLET;ORAL COLCHICINE AB ALKEM LABS LTD 0.6MG A 211250 001 Feb 08, 2019 Feb NEWA AB AMNEAL PHARMS 0.6MG A 204711 001 Sep 28, 2016 Jan NEWA AB ZYDUS PHARMS 0.6MG A 211519 001 Feb 19, 2019 Feb NEWA COLCRYS AB +! TAKEDA PHARMS USA 0.6MG N 022352 001 Jul 29, 2009 Jan CTEC

COLESEVELAM HYDROCHLORIDE BAR, CHEWABLE;ORAL WELCHOL +! DAIICHI SANKYO INC 3.75GM N 210895 001 Apr 03, 2019 Apr NEWA FOR SUSPENSION;ORAL COLESEVELAM HYDROCHLORIDE AB ALKEM LABS LTD 3.75GM/PACKET A 210316 001 May 06, 2019 Apr NEWA GLENMARK PHARMS LTD 1.875GM/PACKET A 202190 001 Jul 16, 2018 Mar CTEC RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019 1 -23

FOR SUSPENSION;ORAL WELCHOL + @ DAIICHI SANKYO 1.875GM/PACKET N 022362 001 Oct 02, 2009 Mar DISC

CROMOLYN SODIUM SOLUTION;INHALATION CROMOLYN SODIUM >D> @ APOTEX INC 10MG/ML A 075333 001 Apr 30, 2002 Jun CAHN >A> @ HIKMA 10MG/ML A 075333 001 Apr 30, 2002 Jun CAHN @ MYLAN SPECIALITY LP 10MG/ML A 074209 001 Apr 26, 1994 Mar DISC

CYCLOBENZAPRINE HYDROCHLORIDE CAPSULE, EXTENDED RELEASE;ORAL AMRIX AB + TEVA PHARMS INTL 15MG N 021777 001 Feb 01, 2007 Mar CTEC + 15MG N 021777 001 Feb 01, 2007 Jan CTEC AB +! 30MG N 021777 002 Feb 01, 2007 Mar CTEC +! 30MG N 021777 002 Feb 01, 2007 Jan CTEC CYCLOBENZAPRINE HYDROCHLORIDE AB APOTEX INC 15MG A 206703 001 Jul 24, 2018 Feb CMFD @ 15MG A 206703 001 Jul 24, 2018 Jan DISC AB 30MG A 206703 002 Jul 24, 2018 Feb CMFD @ 30MG A 206703 002 Jul 24, 2018 Jan DISC AB TWI PHARMS INC 15MG A 091281 001 Jan 31, 2013 Mar CMFD AB 30MG A 091281 002 Jan 31, 2013 Mar CMFD

CYCLOPHOSPHAMIDE CAPSULE;ORAL CYCLOPHOSPHAMIDE AB CIPLA 25MG A 211608 001 Jan 18, 2019 Jan NEWA AB 50MG A 211608 002 Jan 18, 2019 Jan NEWA

CYCLOSPORINE CAPSULE;ORAL CYCLOSPORINE >A> AB1 APOTEX INC 25MG A 210721 001 Jul 10, 2019 Jun NEWA >A> AB1 50MG A 210721 002 Jul 10, 2019 Jun NEWA >A> AB1 100MG A 210721 003 Jul 10, 2019 Jun NEWA >D> IVAX SUB TEVA PHARMS 50MG A 065110 001 Mar 29, 2005 Jun CTEC >A> AB1 50MG A 065110 001 Mar 29, 2005 Jun CTEC SOLUTION;ORAL CYCLOSPORINE @ PD PARTNERS 100MG/ML A 065167 001 Jan 05, 2005 May CAHN

CYPROHEPTADINE HYDROCHLORIDE SYRUP;ORAL CYPROHEPTADINE HYDROCHLORIDE AA QUAGEN 2MG/5ML A 212423 001 May 22, 2019 May NEWA AA TORRENT 2MG/5ML A 204823 001 Dec 27, 2016 Jan CAHN TABLET;ORAL CYPROHEPTADINE HYDROCHLORIDE AA BEXIMCO PHARMS USA 4MG A 206676 001 Apr 12, 2019 Apr NEWA AA ! HERITAGE PHARMA 4MG A 087056 001 Feb CAHN

CYSTEINE HYDROCHLORIDE SOLUTION;INTRAVENOUS ELCYS +! EXELA PHARMA SCS LLC 500MG/10ML (50MG/ML) N 210660 001 Apr 16, 2019 Apr NEWA

DACLATASVIR DIHYDROCHLORIDE TABLET;ORAL >D> DAKLINZA >D> + BRISTOL-MYERS SQUIBB EQ 30MG BASE N 206843 001 Jul 24, 2015 Jun DISC >A> + @ EQ 30MG BASE N 206843 001 Jul 24, 2015 Jun DISC >D> + EQ 60MG BASE N 206843 002 Jul 24, 2015 Jun DISC >A> + @ EQ 60MG BASE N 206843 002 Jul 24, 2015 Jun DISC + @ EQ 90MG BASE N 206843 003 Apr 13, 2016 Feb DISC RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019 1 -24

DACTINOMYCIN INJECTABLE;INJECTION DACTINOMYCIN @ LUITPOLD 0.5MG/VIAL A 202562 001 Aug 23, 2013 Mar DISC AP X-GEN PHARMS INC 0.5MG/VIAL A 203999 001 May 20, 2019 May NEWA

DALFAMPRIDINE TABLET, EXTENDED RELEASE;ORAL DALFAMPRIDINE AB MICRO LABS 10MG A 210158 001 Mar 11, 2019 Feb NEWA AB SUN PHARM 10MG A 208292 001 May 21, 2019 May NEWA

DANTROLENE SODIUM INJECTABLE;INJECTION DANTROLENE SODIUM @ MYLAN INSTITUTIONAL 20MG/VIAL A 205239 001 Feb 18, 2016 Mar DISC

DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE TABLET, EXTENDED RELEASE;ORAL QTERNMET XR + ASTRAZENECA AB 2.5MG;1GM;EQ 2.5MG BASE N 210874 001 May 02, 2019 May NEWA + 5MG;1GM;EQ 2.5MG BASE N 210874 002 May 02, 2019 May NEWA + 5MG;1GM;EQ 5MG BASE N 210874 003 May 02, 2019 May NEWA +! 10MG;1GM;EQ 5MG BASE N 210874 004 May 02, 2019 May NEWA

DAPAGLIFLOZIN; SAXAGLIPTIN HYDROCHLORIDE TABLET;ORAL QTERN + ASTRAZENECA AB 5MG;EQ 5MG BASE N 209091 002 May 02, 2019 May NEWA

DAPIPRAZOLE HYDROCHLORIDE SOLUTION/DROPS;OPHTHALMIC DAPIPRAZOLE HYDROCHLORIDE BARADAINA LLC 0.5% A 204902 001 May 30, 2019 May NEWA

DAPSONE GEL;TOPICAL ACZONE >D> +! ALMIRALL 7.5% N 207154 001 Feb 24, 2016 Jun CFTG >A> AB +! 7.5% N 207154 001 Feb 24, 2016 Jun CFTG +! 7.5% N 207154 001 Feb 24, 2016 Feb CAHN >A> DAPSONE >A> AB TARO PHARMS 7.5% A 210191 001 Jun 26, 2019 Jun NFTG TABLET;ORAL DAPSONE AB SAI LIFE SCIENCES 100MG A 207165 001 May 08, 2019 Apr NEWA @ TARO PHARM 25MG A 209430 001 Mar 01, 2019 May DISC AB 25MG A 209430 001 Mar 01, 2019 Feb NEWA @ 100MG A 209430 002 Mar 01, 2019 May DISC AB 100MG A 209430 002 Mar 01, 2019 Feb NEWA

DAPTOMYCIN POWDER;INTRAVENOUS DAPTOMYCIN >A> AP ACCORD HLTHCARE 500MG/VIAL A 211961 001 Jun 24, 2019 Jun NEWA >A> AP BE PHARMS 500MG/VIAL A 212513 001 Jun 26, 2019 Jun NEWA AP DR REDDYS 500MG/VIAL A 208375 001 May 01, 2019 Apr NEWA AP XELLIA PHARMS APS 500MG/VIAL A 206005 001 Jun 15, 2016 Mar CAHN

DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR TABLET, EXTENDED RELEASE;ORAL VIEKIRA XR + @ ABBVIE INC EQ 200MG BASE;8.33MG;50MG;33.33MG N 208624 001 Jul 22, 2016 Apr DISC

DAUNORUBICIN HYDROCHLORIDE INJECTABLE;INJECTION DAUNORUBICIN HYDROCHLORIDE AP HISUN PHARM HANGZHOU EQ 5MG BASE/ML A 208759 001 Apr 12, 2019 Apr NEWA AP EQ 20MG BASE/VIAL A 206195 001 Apr 25, 2019 Apr NEWA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019 1 -25

DECITABINE INJECTABLE;INTRAVENOUS DECITABINE AP WOCKHARDT BIO AG 50MG/VIAL A 209056 001 Apr 09, 2019 Mar NEWA

DEFERIPRONE TABLET;ORAL DEFERIPRONE @ TARO PHARM INDS LTD 500MG A 208800 001 Feb 08, 2019 May DISC AB 500MG A 208800 001 Feb 08, 2019 Feb NFTG FERRIPROX +! APOPHARMA INC 500MG N 021825 001 Oct 14, 2011 May CTEC AB +! 500MG N 021825 001 Oct 14, 2011 Feb CFTG

DELAVIRDINE MESYLATE TABLET;ORAL RESCRIPTOR >D> + VIIV HLTHCARE 100MG N 020705 001 Apr 04, 1997 Jun DISC >A> + @ 100MG N 020705 001 Apr 04, 1997 Jun DISC

DESLORATADINE TABLET;ORAL DESLORATADINE @ MYLAN PHARMS INC 5MG A 078351 001 Feb 10, 2012 May DISC AB PERRIGO 5MG A 078361 001 Dec 22, 2011 Apr CAHN

DESMOPRESSIN ACETATE INJECTABLE;INJECTION DESMOPRESSIN ACETATE AP LUITPOLD 0.004MG/ML A 091374 001 Feb 14, 2019 Feb NEWA AP TEVA PHARMS USA 0.004MG/ML A 074888 001 Oct 15, 1997 Mar CMFD SPRAY, METERED;NASAL >D> NOCTIVA >D> + ALYVANT 0.00083MG/SPRAY N 201656 001 Mar 03, 2017 Jun DISC >A> + @ 0.00083MG/SPRAY N 201656 001 Mar 03, 2017 Jun DISC + 0.00083MG/SPRAY N 201656 001 Mar 03, 2017 Apr CAHN >D> +! 0.00166MG/SPRAY N 201656 002 Mar 03, 2017 Jun DISC >A> + @ 0.00166MG/SPRAY N 201656 002 Mar 03, 2017 Jun DISC +! 0.00166MG/SPRAY N 201656 002 Mar 03, 2017 Apr CAHN TABLET;ORAL DESMOPRESSIN ACETATE AB ABHAI LLC 0.1MG A 210371 001 Jan 28, 2019 Jan NEWA AB 0.2MG A 210371 002 Jan 28, 2019 Jan NEWA AB NOVAST LABS 0.1MG A 208357 001 Jun 06, 2019 May NEWA AB 0.2MG A 208357 002 Jun 06, 2019 May NEWA

DESOGESTREL; ETHINYL ESTRADIOL TABLET;ORAL-28 DESOGEN @ ORGANON USA INC 0.15MG;0.03MG N 020071 002 Dec 10, 1992 May DISC DESOGESTREL AND ETHINYL ESTRADIOL @ ACCORD HLTHCARE 0.15MG;0.03MG A 207067 001 Sep 13, 2018 Mar DISC

DESONIDE AEROSOL, FOAM;TOPICAL VERDESO +! ALMIRALL 0.05% N 021978 001 Sep 19, 2006 Feb CAHN OINTMENT;TOPICAL DESONIDE AB ENCUBE ETHICALS 0.05% A 210998 001 Jan 30, 2019 Jan NEWA AB TELIGENT PHARMA INC 0.05% A 212002 001 Mar 12, 2019 Feb NEWA

DESOXIMETASONE CREAM;TOPICAL DESOXIMETASONE @ ZYDUS PHARMS 0.25% A 205620 001 Sep 28, 2018 Feb DISC RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019 1 -26

DESVENLAFAXINE TABLET, EXTENDED RELEASE;ORAL DESVENLAFAXINE +! ALEMBIC PHARMS LTD 50MG N 204150 001 Mar 04, 2013 May CTEC +! 100MG N 204150 002 Mar 04, 2013 May CTEC KHEDEZLA @ OSMOTICA PHARM CORP 50MG N 204683 001 Jul 10, 2013 May DISC @ 100MG N 204683 002 Jul 10, 2013 May DISC

DESVENLAFAXINE SUCCINATE TABLET, EXTENDED RELEASE;ORAL DESVENLAFAXINE SUCCINATE AB INTELLIPHARMACEUTICS EQ 50MG BASE A 204805 001 May 07, 2019 Apr NEWA AB EQ 100MG BASE A 204805 002 May 07, 2019 Apr NEWA @ MYLAN EQ 50MG BASE A 204095 001 Jun 29, 2015 May DISC @ EQ 100MG BASE A 204095 002 Jun 29, 2015 May DISC @ YICHANG HUMANWELL EQ 50MG BASE A 210014 001 Oct 01, 2018 Mar DISC @ EQ 100MG BASE A 210014 002 Oct 01, 2018 Mar DISC

DEXAMETHASONE SODIUM PHOSPHATE INJECTABLE;INJECTION DEXAMETHASONE SODIUM PHOSPHATE AP AUROBINDO PHARMA LTD EQ 10MG PHOSPHATE/ML A 210967 001 Jun 07, 2019 May NEWA AP ! FRESENIUS KABI USA EQ 4MG PHOSPHATE/ML A 084916 001 Feb CHRS @ LUITPOLD EQ 4MG PHOSPHATE/ML A 087440 001 Jul 21, 1982 Feb DISC AP SOMERSET THERAPS LLC EQ 10MG PHOSPHATE/ML A 211036 001 May 10, 2019 Apr NEWA SOLUTION/DROPS;OPHTHALMIC, OTIC DEXAMETHASONE SODIUM PHOSPHATE ! BAUSCH AND LOMB EQ 0.1% PHOSPHATE A 040069 001 Jul 26, 1996 May CTEC @ SANDOZ INC EQ 0.1% PHOSPHATE A 088771 001 Jan 16, 1985 May DISC

DEXMEDETOMIDINE HYDROCHLORIDE INJECTABLE;INJECTION DEXMEDETOMIDINE HYDROCHLORIDE AP CIPLA EQ 200MCG BASE/2ML (EQ 100MCG A 204843 001 Jan 18, 2019 Jan NEWA BASE/ML) @ LUITPOLD EQ 200MCG BASE/2ML (EQ 100MCG A 203773 001 May 12, 2017 Mar DISC BASE/ML) SOLUTION;INTRAVENOUS DEXMEDETOMIDINE HYDROCHLORIDE + HQ SPCLT PHARMA EQ 200MCG BASE/50ML (EQ 4MCG N 206628 003 Jun 22, 2018 Mar CPOT BASE/ML) + EQ 400MCG BASE/100ML (EQ 4MCG N 206628 004 Jun 22, 2018 Mar CPOT BASE/ML)

DEXMETHYLPHENIDATE HYDROCHLORIDE TABLET;ORAL DEXMETHYLPHENIDATE HYDROCHLORIDE @ TEVA PHARMS 2.5MG A 077107 003 Jan 29, 2007 May DISC @ 5MG A 077107 001 Jan 29, 2007 May DISC @ 10MG A 077107 002 Jan 29, 2007 May DISC

DEXTROAMPHETAMINE SULFATE CAPSULE, EXTENDED RELEASE;ORAL DEXTROAMPHETAMINE SULFATE >A> AB PII 5MG A 205077 001 Jun 21, 2019 Jun NEWA >A> AB 10MG A 205077 002 Jun 21, 2019 Jun NEWA >A> AB 15MG A 205077 003 Jun 21, 2019 Jun NEWA

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE SYRUP;ORAL PROMETHAZINE DM @ VINTAGE 15MG/5ML;6.25MG/5ML A 040649 001 Feb 14, 2006 May DISC

DIAZEPAM GEL;RECTAL DIASTAT + BAUSCH 2.5MG/0.5ML (5MG/ML) N 020648 001 Jul 29, 1997 Feb CAHN + @ 5MG/ML (5MG/ML) N 020648 002 Jul 29, 1997 Feb CAHN + @ 10MG/2ML (5MG/ML) N 020648 003 Jul 29, 1997 Feb CAHN + @ 15MG/3ML (5MG/ML) N 020648 004 Jul 29, 1997 Feb CAHN + @ 20MG/4ML (5MG/ML) N 020648 005 Jul 29, 1997 Feb CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019 1 -27

GEL;RECTAL DIASTAT ACUDIAL + BAUSCH 10MG/2ML (5MG/ML) N 020648 007 Sep 15, 2005 Feb CAHN +! 20MG/4ML (5MG/ML) N 020648 006 Sep 15, 2005 Feb CAHN INJECTABLE;INJECTION DIAZEPAM AP BELOTECA INC 10MG/2ML (5MG/ML) A 210363 001 Mar 18, 2019 Mar NEWA AP ! HOSPIRA 10MG/2ML (5MG/ML) A 072079 001 Dec 20, 1988 Mar CTEC

DICLOFENAC CAPSULE;ORAL ZORVOLEX + EGALET 18MG N 204592 001 Oct 18, 2013 Feb CAHN +! 35MG N 204592 002 Oct 18, 2013 Feb CAHN

DICLOFENAC EPOLAMINE SYSTEM;TOPICAL LICART + @ IBSA INST BIO 1.3% N 206976 001 Dec 19, 2018 Feb DISC

DICLOFENAC POTASSIUM TABLET;ORAL DICLOFENAC POTASSIUM AB AMICI 50MG A 076561 001 Mar 18, 2004 May CAHN

DICLOFENAC SODIUM GEL;TOPICAL DICLOFENAC SODIUM AB MYLAN 1% A 204306 001 May 06, 2019 Apr NEWA AB PERRIGO UK FINCO 1% A 211253 001 May 16, 2019 May NEWA SOLUTION;INTRAVENOUS >A> DICLOFENAC SODIUM >A> MYLAN LABS LTD 37.5MG/ML (37.5MG/ML) A 208786 001 Jun 18, 2019 Jun NEWA TABLET, EXTENDED RELEASE;ORAL DICLOFENAC SODIUM >D> AB MYLAN 100MG A 076152 001 Dec 13, 2001 Jun DISC >A> @ 100MG A 076152 001 Dec 13, 2001 Jun DISC

DICYCLOMINE HYDROCHLORIDE INJECTABLE;INJECTION DICYCLOMINE HYDROCHLORIDE @ APC PHARMS LLC 10MG/ML A 210979 001 Jul 02, 2018 Feb DISC AP CUSTOPHARM INC 10MG/ML A 210788 001 Feb 11, 2019 Jan NEWA AP FRESENIUS KABI USA 10MG/ML A 210257 001 Jan 25, 2019 Jan NEWA AP NEXUS PHARMS 10MG/ML A 206468 001 Feb 01, 2019 Jan NEWA AP SLATE 10MG/ML A 207076 001 Nov 02, 2018 Feb CAHN AP SUNGEN PHARMA 10MG/ML A 212058 001 Apr 26, 2019 Apr NEWA

DIGOXIN ELIXIR;ORAL DIGOXIN +! HIKMA 0.05MG/ML N 021648 001 Aug 26, 2004 Apr CAHN

DIHYDROERGOTAMINE MESYLATE INJECTABLE;INJECTION D.H.E. 45 AP +! BAUSCH 1MG/ML N 005929 001 Apr CAHN SPRAY, METERED;NASAL MIGRANAL +! BAUSCH 0.5MG/SPRAY N 020148 001 Dec 08, 1997 Apr CAHN +! VALEANT 0.5MG/SPRAY N 020148 001 Dec 08, 1997 Jan CPOT

DILTIAZEM HYDROCHLORIDE CAPSULE, EXTENDED RELEASE;ORAL CARDIZEM CD AB3 + BAUSCH 120MG N 020062 001 Aug 10, 1992 Feb CAHN AB3 + 180MG N 020062 002 Dec 27, 1991 Feb CAHN AB3 + 240MG N 020062 003 Dec 27, 1991 Feb CAHN AB3 + 300MG N 020062 004 Dec 27, 1991 Feb CAHN AB3 +! 360MG N 020062 005 Aug 24, 1999 Feb CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019 1 -28

CAPSULE, EXTENDED RELEASE;ORAL DILTIAZEM HYDROCHLORIDE AB2 ! APOTEX 240MG A 074943 001 Aug 06, 1998 May CHRS AB2 MYLAN 240MG A 075124 001 Mar 18, 1998 May CHRS >A> AB3 NOVAST LABS 120MG A 208783 001 Jun 14, 2019 Jun NEWA >A> AB3 180MG A 208783 002 Jun 14, 2019 Jun NEWA >A> AB3 240MG A 208783 003 Jun 14, 2019 Jun NEWA >A> AB3 300MG A 208783 004 Jun 14, 2019 Jun NEWA >A> AB3 360MG A 208783 005 Jun 14, 2019 Jun NEWA @ PAR PHARM 360MG A 209766 001 May 30, 2018 Mar DISC TIAZAC AB4 + BAUSCH 120MG N 020401 001 Sep 11, 1995 Feb CAHN AB4 + 180MG N 020401 002 Sep 11, 1995 Feb CAHN AB4 + 240MG N 020401 003 Sep 11, 1995 Feb CAHN AB4 + 300MG N 020401 004 Sep 11, 1995 Feb CAHN AB4 + 360MG N 020401 005 Sep 11, 1995 Feb CAHN AB4 +! 420MG N 020401 006 Oct 16, 1998 Feb CAHN INJECTABLE;INJECTION DILTIAZEM HYDROCHLORIDE @ DR REDDYS 5MG/ML A 074894 001 Aug 26, 1997 May CAHN TABLET;ORAL CARDIZEM AB + BAUSCH 30MG N 018602 001 Nov 05, 1982 Mar CAHN AB + 60MG N 018602 002 Nov 05, 1982 Mar CAHN AB + 90MG N 018602 003 Dec 08, 1986 Mar CAHN AB +! 120MG N 018602 004 Dec 08, 1986 Mar CAHN TABLET, EXTENDED RELEASE;ORAL CARDIZEM LA AB + BAUSCH 120MG N 021392 001 Feb 06, 2003 Mar CAHN AB + 180MG N 021392 002 Feb 06, 2003 Mar CAHN AB + 240MG N 021392 003 Feb 06, 2003 Mar CAHN AB + 300MG N 021392 004 Feb 06, 2003 Mar CAHN AB + 360MG N 021392 005 Feb 06, 2003 Mar CAHN AB +! 420MG N 021392 006 Feb 06, 2003 Mar CAHN

DIMETHYL SULFOXIDE SOLUTION;INTRAVESICAL DIMETHYL SULFOXIDE @ MYLAN INSTITUTIONAL 50% A 076185 001 Nov 29, 2002 Mar DISC RIMSO-50 +! MYLAN INSTITUTIONAL 50% N 017788 001 Mar CTEC

DIPHENHYDRAMINE HYDROCHLORIDE CAPSULE;ORAL DIPHENHYDRAMINE HYDROCHLORIDE ! HERITAGE PHARMA 50MG A 080738 001 May CAHN INJECTABLE;INJECTION DIPHENHYDRAMINE HYDROCHLORIDE @ DR REDDYS 10MG/ML A 080873 001 May CAHN @ 50MG/ML A 080873 002 May CAHN DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREE @ DR REDDYS 50MG/ML A 080873 003 May CAHN

DIPYRIDAMOLE INJECTABLE;INJECTION DIPYRIDAMOLE @ DR REDDYS 5MG/ML A 074952 001 Nov 26, 1997 May CAHN

DOCETAXEL INJECTABLE;INJECTION DOCETAXEL >A> AP ACTAVIS LLC 160MG/8ML (20MG/ML) N 203551 004 Sep 21, 2015 Jun NEWA @ CIPLA 20MG/2ML (10MG/ML) A 209634 001 Aug 24, 2018 Mar DISC @ 80MG/8ML (10MG/ML) A 209634 002 Aug 24, 2018 Mar DISC @ 160MG/16ML (10MG/ML) A 209634 003 Aug 24, 2018 Mar DISC AP MYLAN LABS LTD 160MG/8ML (20MG/ML) A 208137 001 Apr 01, 2019 Mar NEWA AP SHILPA MEDICARE LTD 20MG/ML (20MG/ML) A 210327 001 May 16, 2019 May NEWA AP 80MG/4ML (20MG/ML) A 210327 002 May 16, 2019 May NEWA AP 160MG/8ML (20MG/ML) A 210327 003 May 16, 2019 May NEWA AP TEIKOKU PHARMA 20MG/ML (20MG/ML) N 205934 001 Dec 22, 2015 Mar CAHN AP 80MG/4ML (20MG/ML) N 205934 002 Dec 22, 2015 Mar CAHN AP 160MG/8ML (20MG/ML) N 205934 003 Dec 22, 2015 Mar CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019 1 -29

SOLUTION;INTRAVENOUS DOCETAXEL AP SUN PHARMA GLOBAL 20MG/ML (20MG/ML) N 022534 003 Jan 08, 2019 Jan NEWA AP 80MG/4ML (20MG/ML) N 022534 004 Jan 08, 2019 Jan NEWA AP 160MG/8ML (20MG/ML) N 022534 005 Jan 08, 2019 Jan NEWA

DOFETILIDE CAPSULE;ORAL DOFETILDE AB AUROBINDO PHARMA LTD 0.125MG A 210740 001 Jan 22, 2019 Jan NEWA AB 0.25MG A 210740 002 Jan 22, 2019 Jan NEWA AB 0.5MG A 210740 003 Jan 22, 2019 Jan NEWA

DOLUTEGRAVIR SODIUM; LAMIVUDINE TABLET;ORAL DOVATO +! VIIV HLTHCARE EQ 50MG BASE;300MG N 211994 001 Apr 08, 2019 Apr NEWA

DONEPEZIL HYDROCHLORIDE TABLET;ORAL DONEPEZIL HYDROCHLORIDE AB CADILA 5MG A 090100 001 Oct 24, 2012 Mar CAHN AB 10MG A 090100 002 Oct 24, 2012 Mar CAHN AB HERITAGE PHARMA 5MG A 077344 001 May 31, 2011 May CAHN AB 10MG A 077344 002 May 31, 2011 May CAHN @ OSMOTICA PHARM US 23MG A 203114 001 Jan 26, 2016 Mar DISC AB STRIDES PHARMA 5MG A 090551 001 May 31, 2011 Apr CAHN AB 10MG A 090551 002 May 31, 2011 Apr CAHN TABLET, ORALLY DISINTEGRATING;ORAL DONEPEZIL HYDROCHLORIDE @ HERITAGE PHARMA 5MG A 078388 002 Nov 26, 2010 May CAHN @ 10MG A 078388 001 Nov 26, 2010 May CAHN

DOPAMINE HYDROCHLORIDE INJECTABLE;INJECTION DOPAMINE HYDROCHLORIDE @ LUITPOLD 40MG/ML A 070799 001 Feb 11, 1987 Feb DISC @ 80MG/ML A 070820 001 Feb 11, 1987 Feb DISC

DORZOLAMIDE HYDROCHLORIDE SOLUTION/DROPS;OPHTHALMIC DORZOLAMIDE HYDROCHLORIDE AT FDC LTD EQ 2% BASE A 205294 001 Jan 24, 2019 Jan NEWA @ LUITPOLD EQ 2% BASE A 079186 001 Nov 18, 2009 Mar DISC

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE SOLUTION/DROPS;OPHTHALMIC DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE >A> AT FDC LTD EQ 2% BASE;EQ 0.5% BASE A 205295 001 Jun 13, 2019 Jun NEWA >A> AT SOMERSET THERAPS LLC EQ 2% BASE;EQ 0.5% BASE A 207523 001 Jun 25, 2019 Jun NEWA

DOXAPRAM HYDROCHLORIDE INJECTABLE;INJECTION DOPRAM AP +! HIKMA 20MG/ML N 014879 001 Mar CAHN

DOXEPIN HYDROCHLORIDE CAPSULE;ORAL DOXEPIN HYDROCHLORIDE AB AUROBINDO PHARMA LTD EQ 10MG BASE A 211603 001 Mar 27, 2019 Mar NEWA AB EQ 25MG BASE A 211603 002 Mar 27, 2019 Mar NEWA AB EQ 50MG BASE A 211603 003 Mar 27, 2019 Mar NEWA AB EQ 75MG BASE A 211603 004 Mar 27, 2019 Mar NEWA AB EQ 100MG BASE A 211603 005 Mar 27, 2019 Mar NEWA AB PAR PHARM EQ 10MG BASE A 071697 001 Nov 09, 1987 Jan CMFD AB EQ 25MG BASE A 071437 001 Nov 09, 1987 Jan CMFD AB EQ 75MG BASE A 071608 001 Nov 09, 1987 Jan CMFD TABLET;ORAL SILENOR + CURRAX EQ 3MG BASE N 022036 001 Mar 17, 2010 Apr CAHN +! EQ 6MG BASE N 022036 002 Mar 17, 2010 Apr CAHN + PERNIX EQ 3MG BASE N 022036 001 Mar 17, 2010 Feb CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019 1 -30

TABLET;ORAL SILENOR +! EQ 6MG BASE N 022036 002 Mar 17, 2010 Feb CAHN

DOXERCALCIFEROL INJECTABLE;INJECTION DOXERCALCIFEROL >D> +! HOSPIRA INC 10MCG/5ML (2MCG/ML) N 208614 002 Jul 24, 2018 Jun DISC >A> + @ 10MCG/5ML (2MCG/ML) N 208614 002 Jul 24, 2018 Jun DISC

DOXORUBICIN HYDROCHLORIDE INJECTABLE;INJECTION DOXORUBICIN HYDROCHLORIDE AP HISUN PHARM HANGZHOU 20MG/VIAL A 206062 001 May 13, 2019 Apr NEWA

DOXYCYCLINE CAPSULE;ORAL MONODOX AB + ALMIRALL EQ 50MG BASE N 050641 002 Feb 10, 1992 Feb CAHN AB + EQ 75MG BASE N 050641 003 Oct 18, 2006 Feb CAHN AB +! EQ 100MG BASE N 050641 001 Dec 29, 1989 Feb CAHN TABLET;ORAL DOXYCYCLINE @ MYLAN EQ 50MG BASE A 065377 001 Nov 07, 2006 Apr DISC @ EQ 75MG BASE A 065377 002 Nov 07, 2006 Apr DISC @ EQ 100MG BASE A 065377 003 Nov 07, 2006 May DISC @ EQ 150MG BASE A 065427 001 Jun 07, 2007 May DISC

DOXYCYCLINE HYCLATE CAPSULE;ORAL ACTICLATE CAP + @ ALMIRALL EQ 75MG BASE N 208253 001 Apr 26, 2016 Feb CAHN DOXYCYCLINE HYCLATE @ AJANTA PHARMA LTD EQ 50MG BASE A 211012 001 Sep 24, 2018 Mar DISC @ EQ 100MG BASE A 211012 002 Sep 24, 2018 Mar DISC MY LAN@ MYLAN@ EQ 50MG BASE A 062337 001 Mar 29, 1982 Apr DISC @ EQ 100MG BASE A 062337 002 Mar 29, 1982 Apr DISC TABLET;ORAL ACTICLATE AB + ALMIRALL EQ 75MG BASE N 205931 001 Jul 25, 2014 Feb CAHN AB +! EQ 150MG BASE N 205931 002 Jul 25, 2014 Feb CAHN DOXYCYCLINE HYCLATE AB APOTEX INC EQ 75MG BASE A 209243 001 Apr 15, 2019 Apr NEWA AB EQ 150MG BASE A 209243 002 Apr 15, 2019 Apr NEWA AB CADILA EQ 100MG BASE A 207773 001 Oct 30, 2017 Feb CAHN AB HERITAGE PHARMA EQ 20MG BASE A 065163 001 May 13, 2005 May CAHN TABLET, DELAYED RELEASE;ORAL DOXYCYCLINE HYCLATE @ ZYDUS PHARMS EQ 75MG BASE A 206772 001 Dec 21, 2018 May DISC @ EQ 100MG BASE A 206772 002 Dec 21, 2018 May DISC @ EQ 150MG BASE A 206772 003 Dec 21, 2018 May DISC

DROSPIRENONE TABLET;ORAL SLYND +! EXELTIS USA INC 4MG N 211367 001 May 23, 2019 May NEWA

DROSPIRENONE; ETHINYL ESTRADIOL TABLET;ORAL DROSPIRENONE AND ETHINYL ESTRADIOL AB HETERO LABS LTD 3MG;0.02MG A 211944 001 Mar 22, 2019 Mar NEWA TABLET;ORAL-28 KEMEYA AB SUN PHARM 3MG;0.03MG A 202138 001 Mar 13, 2019 Feb NEWA

DULOXETINE HYDROCHLORIDE CAPSULE, DELAYED REL PELLETS;ORAL DULOXETINE HYDROCHLORIDE AB AJANTA PHARMA LTD EQ 40MG BASE A 208706 004 Mar 11, 2019 Feb NEWA AB QINGDAO BAHEAL PHARM EQ 20MG BASE A 210599 001 Apr 17, 2019 Apr NEWA AB EQ 30MG BASE A 210599 002 Apr 17, 2019 Apr NEWA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019 1 -31

CAPSULE, DELAYED REL PELLETS;ORAL DULOXETINE HYDROCHLORIDE AB EQ 60MG BASE A 210599 003 Apr 17, 2019 Apr NEWA

DUTASTERIDE CAPSULE;ORAL DUTASTERIDE >D> AB BRECKENRIDGE PHARM 0.5MG A 204705 001 Nov 20, 2015 Jun DISC >A> @ 0.5MG A 204705 001 Nov 20, 2015 Jun DISC >D> AB 0.5MG A 208227 001 Jun 22, 2018 Jun DISC >A> @ 0.5MG A 208227 001 Jun 22, 2018 Jun DISC AB CADILA 0.5MG A 204373 001 Oct 04, 2017 Feb CAHN

ECONAZOLE NITRATE CREAM;TOPICAL ECONAZOLE NITRATE >D> AB CASI PHARMS INC 1% A 076075 001 Nov 26, 2002 Jun DISC >A> @ 1% A 076075 001 Nov 26, 2002 Jun DISC AB ! PERRIGO ISRAEL 1% A 076479 001 Jun 23, 2004 May CAHN

EFAVIRENZ TABLET;ORAL EFAVIRENZ @ AUROBINDO PHARMA LTD 600MG A 077673 001 Sep 21, 2018 Feb DISC

EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE TABLET;ORAL EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE AB CIPLA 600MG;200MG;300MG A 206894 001 Jun 03, 2019 May NEWA @ TEVA PHARMS USA 600MG;200MG;300MG A 091215 001 Nov 09, 2018 May DISC

EFAVIRENZ; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE TABLET;ORAL >D> EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE >D> MACLEODS PHARMS LTD 400MG;300MG;300MG N 210649 001 Mar 15, 2019 Jun DISC >A> @ 400MG;300MG;300MG N 210649 001 Mar 15, 2019 Jun DISC 400MG;300MG;300MG N 210649 001 Mar 15, 2019 Mar NEWA

EFINACONAZOLE SOLUTION;TOPICAL JUBLIA +! BAUSCH 10% N 203567 001 Jun 06, 2014 Feb CAHN

ELTROMBOPAG OLAMINE TABLET;ORAL PROMACTA + @ NOVARTIS PHARMS CORP EQ 100MG ACID N 022291 005 Nov 16, 2012 Feb DISC

EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE TABLET;ORAL EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE @ AMNEAL PHARMS CO 100MG;150MG A 209721 001 Aug 22, 2018 Feb DISC @ 133MG;200MG A 209721 002 Aug 22, 2018 Feb DISC @ 167MG;250MG A 209721 003 Aug 22, 2018 Feb DISC @ 200MG;300MG A 209721 004 Aug 22, 2018 Feb DISC TRUVADA + GILEAD 100MG;150MG N 021752 002 Mar 10, 2016 Feb CTEC + 133MG;200MG N 021752 003 Mar 10, 2016 Feb CTEC + 167MG;250MG N 021752 004 Mar 10, 2016 Feb CTEC

ENALAPRIL MALEATE FOR SOLUTION;ORAL EPANED KIT + @ SILVERGATE PHARMS 1MG/ML N 204308 001 Aug 13, 2013 Mar DISC TABLET;ORAL ENALAPRIL MALEATE @ BEXIMCO PHARMS USA 2.5MG A 075621 001 Aug 22, 2000 Feb CAHN @ 5MG A 075621 002 Aug 22, 2000 Feb CAHN @ 10MG A 075621 003 Aug 22, 2000 Feb CAHN @ 20MG A 075621 004 Aug 22, 2000 Feb CAHN AB HERITAGE PHARMA 2.5MG A 075479 001 Aug 22, 2000 Feb CAHN AB 5MG A 075479 002 Aug 22, 2000 Feb CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019 1 -32

TABLET;ORAL ENALAPRIL MALEATE AB 10MG A 075479 003 Aug 22, 2000 Feb CAHN AB 20MG A 075479 004 Aug 22, 2000 Feb CAHN >D> AB MYLAN 5MG A 075480 002 Aug 22, 2000 Jun DISC >A> @ 5MG A 075480 002 Aug 22, 2000 Jun DISC @ 10MG A 075480 003 Aug 22, 2000 Feb DISC VASOTEC AB + BAUSCH 2.5MG N 018998 005 Jul 26, 1988 Mar CAHN AB + 5MG N 018998 001 Dec 24, 1985 Mar CAHN AB + 10MG N 018998 002 Dec 24, 1985 Mar CAHN AB +! 20MG N 018998 003 Dec 24, 1985 Mar CAHN

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE TABLET;ORAL VASERETIC AB + BAUSCH 5MG;12.5MG N 019221 003 Jul 12, 1995 Mar CAHN AB +! 10MG;25MG N 019221 001 Oct 31, 1986 Mar CAHN

ENALAPRILAT INJECTABLE;INJECTION ENALAPRILAT AP DR REDDYS 1.25MG/ML A 075578 001 Aug 22, 2000 May CAHN

ENOXAPARIN SODIUM INJECTABLE;INTRAVENOUS, SUBCUTANEOUS ENOXAPARIN SODIUM AB AMPHASTAR PHARMS INC 300MG/3ML (100MG/ML) A 208600 001 Mar 14, 2019 Mar NEWA

ENTECAVIR TABLET;ORAL ENTECAVIR AB MYLAN 0.5MG A 206226 001 Mar 26, 2019 Mar NEWA AB 1MG A 206226 002 Mar 26, 2019 Mar NEWA

EPINASTINE HYDROCHLORIDE SOLUTION/DROPS;OPHTHALMIC EPINASTINE HYDROCHLORIDE >D> AT CASI PHARMS INC 0.05% A 203384 001 Dec 07, 2016 Jun DISC >A> @ 0.05% A 203384 001 Dec 07, 2016 Jun DISC

EPINEPHRINE INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS EPIPEN JR. +! MYLAN SPECIALITY LP 0.15MG/DELIVERY N 019430 002 Dec 22, 1987 Mar CTEC SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS ADRENALIN AP +! PAR STERILE PRODUCTS EQ 1MG BASE/ML (EQ 1MG BASE/ML) N 204200 001 Dec 07, 2012 Jan CDFR +! EQ 30MG BASE/30ML (EQ 1MG BASE/ML) N 204640 001 Dec 18, 2013 Jan CDFR SOLUTION;INTRAVENOUS, INTRAOCULAR, INTRAMUSCULAR, SUBCUTANEOUS EPINEPHRINE +! BELCHER PHARMS LLC EQ 1MG BASE/ML (EQ 1MG BASE/ML) N 205029 001 Jul 29, 2014 May CDFR

EPIRUBICIN HYDROCHLORIDE INJECTABLE;INJECTION EPIRUBICIN HYDROCHLORIDE FRESENIUS KABI USA 150MG/75ML (2MG/ML) A 065408 003 Oct 15, 2007 Mar CTEC

EPTIFIBATIDE INJECTABLE;INJECTION EPTIFIBATIDE AP BAXTER HLTHCARE CORP 2MG/ML A 208554 001 Nov 23, 2018 Jan CAHN AP 75MG/100ML A 208554 002 Nov 23, 2018 Jan CAHN AP HAINAN POLY PHARM 2MG/ML A 209864 001 Jan 25, 2019 Jan NEWA AP 75MG/100ML A 209864 002 Jan 25, 2019 Jan NEWA AP USV 2MG/ML A 204361 001 Mar 14, 2019 Mar NEWA AP 2MG/ML A 204362 001 Mar 11, 2019 Feb NEWA AP 75MG/100ML A 204361 002 Mar 14, 2019 Mar NEWA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019 1 -33

ERDAFITINIB TABLET;ORAL BALVERSA + JANSSEN BIOTECH 3MG N 212018 001 Apr 12, 2019 Apr NEWA + 4MG N 212018 002 Apr 12, 2019 Apr NEWA +! 5MG N 212018 003 Apr 12, 2019 Apr NEWA

ERLOTINIB HYDROCHLORIDE TABLET;ORAL ERLOTINIB HYDROCHLORIDE AB MYLAN EQ 25MG BASE A 091002 001 Jun 11, 2014 Feb CMFD AB EQ 100MG BASE A 091002 002 Jun 11, 2014 Feb CMFD AB EQ 150MG BASE A 091002 003 Jun 11, 2014 Feb CMFD AB TEVA PHARMS USA EQ 100MG BASE A 091059 002 Aug 28, 2015 Mar CMFD AB EQ 150MG BASE A 091059 003 Aug 28, 2015 Mar CMFD TARCEVA AB + OSI PHARMS EQ 25MG BASE N 021743 001 Nov 18, 2004 Mar CAHN AB + EQ 25MG BASE N 021743 001 Nov 18, 2004 Feb CTEC AB + EQ 100MG BASE N 021743 002 Nov 18, 2004 Mar CAHN AB + EQ 100MG BASE N 021743 002 Nov 18, 2004 Feb CTEC AB +! EQ 150MG BASE N 021743 003 Nov 18, 2004 Mar CAHN AB +! EQ 150MG BASE N 021743 003 Nov 18, 2004 Feb CTEC

ERTAPENEM SODIUM INJECTABLE;INTRAMUSCULAR, INTRAVENOUS ERTAPENEM SODIUM AP SAVIOR LIFETEC CORP EQ 1GM BASE/VIAL A 207647 001 Mar 19, 2019 Mar NEWA

ERYTHROMYCIN OINTMENT;TOPICAL AKNE-MYCIN + BAUSCH@ 2% N 050584 001 Jan 10, 1985 Apr CAHN SOLUTION;TOPICAL ERYTHRA-DERM @ SAPTALIS PHARMS 2% A 062687 001 Feb 05, 1988 Feb CAHN TABLET, DELAYED RELEASE;ORAL ERY-TAB >D> ARBOR PHARMS LLC 250MG A 062298 001 Jun CTEC >A> AB 250MG A 062298 001 Jun CTEC >D> 333MG A 062298 003 Mar 29, 1982 Jun CTEC >A> AB 333MG A 062298 003 Mar 29, 1982 Jun CTEC >D> ! 500MG A 062298 002 Jun CTEC >A> AB ! 500MG A 062298 002 Jun CTEC ERYTHROMYCIN >A> AB AMNEAL PHARMS CO 250MG A 210954 001 Jul 02, 2019 Jun NEWA >A> AB 333MG A 210954 002 Jul 02, 2019 Jun NEWA >A> AB 500MG A 210954 003 Jul 02, 2019 Jun NEWA

ESCITALOPRAM OXALATE TABLET;ORAL ESCITALOPRAM OXALATE AB CADILA EQ 5MG BASE A 077734 001 Sep 11, 2012 Apr CAHN AB EQ 10MG BASE A 077734 002 Sep 11, 2012 Apr CAHN AB EQ 20MG BASE A 077734 003 Sep 11, 2012 Apr CAHN

ESKETAMINE HYDROCHLORIDE SPRAY;NASAL SPRAVATO +! JANSSEN PHARMS EQ 28MG BASE N 211243 001 Mar 05, 2019 Mar NEWA

ESMOLOL HYDROCHLORIDE INJECTABLE;INJECTION ESMOLOL HYDROCHLORIDE @ LUITPOLD 10MG/ML A 201126 001 Feb 20, 2015 Mar DISC

ESOMEPRAZOLE MAGNESIUM CAPSULE, DELAYED REL PELLETS;ORAL ESOMEPRAZOLE MAGNESIUM >D> AB AMNEAL PHARMS NY EQ 20MG BASE A 209647 001 Apr 10, 2019 Jun DISC >A> @ EQ 20MG BASE A 209647 001 Apr 10, 2019 Jun DISC AB EQ 20MG BASE A 209647 001 Apr 10, 2019 Mar NEWA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019 1 -34

CAPSULE, DELAYED REL PELLETS;ORAL ESOMEPRAZOLE MAGNESIUM >D> AB EQ 40MG BASE A 209647 002 Apr 10, 2019 Jun DISC >A> @ EQ 40MG BASE A 209647 002 Apr 10, 2019 Jun DISC AB EQ 40MG BASE A 209647 002 Apr 10, 2019 Mar NEWA AB GLENMARK PHARMS EQ 20MG BASE A 209495 001 May 10, 2019 Apr NEWA AB EQ 40MG BASE A 209495 002 May 10, 2019 Apr NEWA @ HEC PHARM EQ 20MG BASE A 207265 002 May 18, 2018 Mar DISC @ EQ 40MG BASE A 207265 001 May 18, 2018 Mar DISC >D> BX HETERO LABS LTD III EQ 20MG BASE A 202784 001 Sep 21, 2015 Jun CTEC >A> AB EQ 20MG BASE A 202784 001 Sep 21, 2015 Jun CTEC >D> BX EQ 40MG BASE A 202784 002 Sep 21, 2015 Jun CTEC >A> AB EQ 40MG BASE A 202784 002 Sep 21, 2015 Jun CTEC AB ZYDUS PHARMS EQ 20MG BASE A 206296 001 May 22, 2019 May NEWA AB EQ 40MG BASE A 206296 002 May 22, 2019 May NEWA

ESTRADIOL FILM, EXTENDED RELEASE;TRANSDERMAL ESTRADIOL AB1 AMNEAL PHARMS LLC 0.025MG/24HR A 211293 001 Feb 04, 2019 Jan NEWA AB1 0.0375MG/24HR A 211293 002 Feb 04, 2019 Jan NEWA AB1 0.05MG/24HR A 211293 003 Feb 04, 2019 Jan NEWA AB1 0.075MG/24HR A 211293 004 Feb 04, 2019 Jan NEWA AB1 0.1MG/24HR A 211293 005 Feb 04, 2019 Jan NEWA GEL;TRANSDERMAL DIVIGEL +! VERTICAL PHARMS LLC 0.1% N 022038 001 Jun 04, 2007 Jan CHRS

ESTRADIOL VALERATE INJECTABLE;INJECTION ESTRADIOL VALERATE @ DR REDDYS 40MG/ML A 083714 001 May CAHN

ESTRADIOL; NORETHINDRONE ACETATE TABLET;ORAL ESTRADIOL AND NORETHINDRONE ACETATE @ ACCORD HLTHCARE 1MG;0.5MG A 210233 001 Feb 28, 2018 Mar DISC AB NOVAST LABS 0.5MG;0.1MG A 210612 001 Apr 03, 2019 Mar NEWA AB 1MG;0.5MG A 210612 002 Apr 03, 2019 Mar NEWA

ESTROGENS, CONJUGATED SYNTHETIC A TABLET;ORAL CENESTIN + @ ASPEN 0.3MG N 020992 001 Jun 21, 2002 Feb CAHN + @ 0.45MG N 020992 005 Feb 05, 2004 Feb CAHN + @ 0.625MG N 020992 002 Mar 24, 1999 Feb CAHN + @ 0.9MG N 020992 003 Mar 24, 1999 Feb CAHN + @ 1.25MG N 020992 004 Mar 13, 2000 Feb CAHN

ESTROGENS, CONJUGATED SYNTHETIC B TABLET;ORAL ENJUVIA @ ASPEN 0.3MG N 021443 001 Dec 20, 2004 Feb CAHN @ 0.45MG N 021443 002 Dec 20, 2004 Feb CAHN @ 0.625MG N 021443 003 May 10, 2004 Feb CAHN @ 0.9MG N 021443 005 Apr 27, 2007 Feb CAHN @ 1.25MG N 021443 004 May 10, 2004 Feb CAHN

ESZOPICLONE TABLET;ORAL ESZOPICLONE @ BRECKENRIDGE PHARM 1MG A 203087 001 May 08, 2019 May DISC AB 1MG A 203087 001 May 08, 2019 Apr NEWA @ 2MG A 203087 002 May 08, 2019 May DISC AB 2MG A 203087 002 May 08, 2019 Apr NEWA @ 3MG A 203087 003 May 08, 2019 May DISC AB 3MG A 203087 003 May 08, 2019 Apr NEWA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019 1 -35

ETHACRYNATE SODIUM INJECTABLE;INJECTION EDECRIN AP +! BAUSCH EQ 50MG BASE/VIAL N 016093 001 Mar CAHN AP +! VALEANT PHARMS INTL EQ 50MG BASE/VIAL N 016093 001 Jan CAHN

ETHACRYNIC ACID TABLET;ORAL EDECRIN AB +! BAUSCH 25MG N 016092 001 Mar CAHN @ 50MG N 016092 002 Mar CAHN AB +! VALEANT PHARMS INTL 25MG N 016092 001 Jan CAHN @ 50MG N 016092 002 Jan CAHN

ETHINYL ESTRADIOL; ETHYNODIOL DIACETATE TABLET;ORAL-28 LO-MALMOREDE AB NOVAST LABS 0.035MG;1MG A 209548 001 Feb 11, 2019 Jan NEWA

ETHINYL ESTRADIOL; LEVONORGESTREL TABLET;ORAL SYLEVIA AB SUN PHARM 0.03MG;0.15MG A 202988 001 Feb 06, 2019 Jan NEWA TABLET;ORAL-28 LEVONORGESTREL AND ETHINYL ESTRADIOL >D> AB2 MYLAN LABS LTD 0.02MG;0.1MG A 202247 001 Dec 08, 2014 Jun DISC >A> @ 0.02MG;0.1MG A 202247 001 Dec 08, 2014 Jun DISC

ETHINYL ESTRADIOL; NORETHINDRONE TABLET;ORAL-28 NORTREL 1/35-28 AB ! BARR 0.035MG;1MG A 072696 001 Feb 28, 1992 Mar CHRS ORTHO-NOVUM 1/35-28 + @ JANSSEN PHARMS 0.035MG;1MG N 017919 002 Mar DISC TABLET, CHEWABLE;ORAL FEMCON FE + @ APIL 0.035MG;0.4MG N 021490 001 Nov 14, 2003 Mar DISC NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE AB ! MYLAN LABS LTD 0.035MG;0.4MG A 202086 001 Apr 01, 2015 Mar CHRS

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE TABLET;ORAL-21 HAILEY 1.5/30 AB GLENMARK PHARMS 0.03MG;1.5MG A 209297 001 Jun 05, 2018 Jan CDFR LOESTRIN 21 1.5/30 AB + APIL 0.03MG;1.5MG N 017875 001 Jan CRLD LOESTRIN 21 1/20 AB + APIL 0.02MG;1MG N 017876 001 Jan CRLD

ETHINYL ESTRADIOL; NORGESTIMATE TABLET;ORAL-28 NORGESTIMATE AND ETHINYL ESTRADIOL @ MYLAN LABS LTD 0.025MG,0.025MG,0.025MG;0.18MG,0.2 A 202132 001 Sep 09, 2015 Jan DISC 15MG,0.25MG ORTHO CYCLEN-28 + @ JANSSEN PHARMS 0.035MG;0.25MG N 019653 002 Dec 29, 1989 Apr DISC SPRINTEC AB ! BARR 0.035MG;0.25MG A 075804 001 Sep 25, 2002 Apr CHRS

ETHINYL ESTRADIOL; SEGESTERONE ACETATE RING;VAGINAL ANNOVERA +! THERAPEUTICSMD INC 0.013MG/24HR;0.15MG/24HR N 209627 001 Aug 10, 2018 May CMFD + @ 0.013MG/24HR;0.15MG/24HR N 209627 001 Aug 10, 2018 Feb DISC RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019 1 -36

ETHOSUXIMIDE CAPSULE;ORAL ETHOSUXIMIDE AB STRIDES PHARMA 250MG A 211928 001 Feb 19, 2019 Feb NEWA SYRUP;ORAL ETHOSUXIMIDE @ TEVA PHARMS 250MG/5ML A 081306 001 Jul 30, 1993 May DISC

ETOMIDATE INJECTABLE;INJECTION ETOMIDATE @ LUITPOLD 2MG/ML A 078867 001 Dec 22, 2009 Feb DISC @ PAR STERILE PRODUCTS 2MG/ML A 091297 001 Jun 20, 2012 Apr DISC

ETOPOSIDE PHOSPHATE INJECTABLE;INJECTION ETOPOPHOS PRESERVATIVE FREE +! CHEPLAPHARM EQ 100MG BASE/VIAL N 020457 001 May 17, 1996 May CAHN

EVEROLIMUS TABLET;ORAL AFINITOR +! NOVARTIS 5MG N 022334 001 Mar 30, 2009 Apr CHRS + 10MG N 022334 002 Mar 30, 2009 Apr CHRS ZORTRESS + NOVARTIS 1MG N 021560 004 Aug 10, 2018 Mar NEWA TABLET, FOR SUSPENSION;ORAL AFINITOR DISPERZ + NOVARTIS PHARM 2MG N 203985 001 Aug 29, 2012 Apr CTEC AB + 2MG N 203985 001 Aug 29, 2012 Apr CFTG + 3MG N 203985 002 Aug 29, 2012 Apr CTEC AB + 3MG N 203985 002 Aug 29, 2012 Apr CFTG +! 5MG N 203985 003 Aug 29, 2012 Apr CTEC AB +! 5MG N 203985 003 Aug 29, 2012 Apr CFTG EVEROLIMUS MY LAN@ MYLAN@ 2MG A 210130 001 Apr 19, 2019 Apr NFTG @ 3MG A 210130 002 Apr 19, 2019 Apr NFTG @ 5MG A 210130 003 Apr 19, 2019 Apr NFTG

EXEMESTANE TABLET;ORAL EXEMESTANE @ BRECKENRIDGE PHARM 25MG A 211031 001 Feb 21, 2019 May DISC AB 25MG A 211031 001 Feb 21, 2019 Feb NEWA

EZETIMIBE TABLET;ORAL EZETIMIBE @ ACCORD HLTHCARE 10MG A 211550 001 Oct 26, 2018 Apr DISC AB MYLAN 10MG A 201790 001 Apr 26, 2019 Apr NEWA

EZETIMIBE; SIMVASTATIN TABLET;ORAL EZETIMIBE AND SIMVASTATIN >A> AB GLENMARK PHARMS LTD 10MG;10MG A 208699 001 Jun 27, 2019 Jun NEWA >A> AB 10MG;20MG A 208699 002 Jun 27, 2019 Jun NEWA >A> AB 10MG;40MG A 208699 003 Jun 27, 2019 Jun NEWA >A> AB 10MG;80MG A 208699 004 Jun 27, 2019 Jun NEWA

FAMOTIDINE TABLET;ORAL FAMOTIDINE @ MYLAN 40MG A 075704 002 Apr 16, 2001 Apr DISC

FEBUXOSTAT TABLET;ORAL >A> FEBUXOSTAT >A> AB ALEMBIC PHARMS LTD 40MG A 205421 001 Jul 01, 2019 Jun NFTG >A> AB 80MG A 205421 002 Jul 01, 2019 Jun NFTG >A> AB MYLAN 40MG A 205385 001 Jul 01, 2019 Jun NFTG >A> AB 80MG A 205385 002 Jul 01, 2019 Jun NFTG RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019 1 -37

TABLET;ORAL >A> FEBUXOSTAT >A> AB SUN PHARM 40MG A 205467 001 Jul 01, 2019 Jun NFTG >A> AB 80MG A 205467 002 Jul 01, 2019 Jun NFTG ULORIC >D> + TAKEDA PHARMS USA 40MG N 021856 001 Feb 13, 2009 Jun CFTG >A> AB + 40MG N 021856 001 Feb 13, 2009 Jun CFTG >D> +! 80MG N 021856 002 Feb 13, 2009 Jun CFTG >A> AB +! 80MG N 021856 002 Feb 13, 2009 Jun CFTG

FELBAMATE SUSPENSION;ORAL FELBAMATE AB VISTAPHARM 600MG/5ML A 211333 001 May 31, 2019 May NEWA

FELODIPINE TABLET, EXTENDED RELEASE;ORAL FELODIPINE AB YUNG SHIN PHARM 2.5MG A 204800 001 Apr 29, 2019 Apr NEWA AB 5MG A 204800 002 Apr 29, 2019 Apr NEWA AB 10MG A 204800 003 Apr 29, 2019 Apr NEWA

FENOFIBRATE CAPSULE;ORAL FENOFIBRATE (MICRONIZED) AB AUSTARPHARMA 67MG A 207805 001 Nov 16, 2017 Jan CAHN AB 134MG A 207805 002 Nov 16, 2017 Jan CAHN AB 200MG A 207805 003 Nov 16, 2017 Jan CAHN AB INGENUS PHARMS LLC 67MG A 207564 001 Apr 19, 2019 Apr NEWA AB 134MG A 207564 002 Apr 19, 2019 Apr NEWA AB 200MG A 207564 003 Apr 19, 2019 Apr NEWA TABLET;ORAL FENOFIBRATE AB AUSTARPHARMA 54MG A 207803 001 Dec 19, 2017 Jan CAHN AB 160MG A 207803 002 Dec 19, 2017 Jan CAHN @ GRAVITI PHARMS 54MG A 210606 001 Aug 17, 2018 Feb DISC @ 160MG A 210606 002 Aug 17, 2018 Feb DISC AB ORIT LABS LLC 54MG A 209660 001 Feb 11, 2019 Jan NEWA AB 160MG A 209660 002 Feb 11, 2019 Jan NEWA FENOGLIDE AB + SALIX 40MG N 022118 001 Aug 10, 2007 Mar CAHN AB +! 120MG N 022118 002 Aug 10, 2007 Mar CAHN

FENOFIBRIC ACID TABLET;ORAL FIBRICOR + ATHENA 35MG N 022418 001 Aug 14, 2009 Feb CAHN +! 105MG N 022418 002 Aug 14, 2009 Feb CAHN

FENOPROFEN CALCIUM TABLET;ORAL FENOPROFEN CALCIUM @ ANI PHARMS INC EQ 600MG BASE A 072274 001 May 02, 1988 May CAHN

FENTANYL CITRATE INJECTABLE;INJECTION FENTANYL CITRATE PRESERVATIVE FREE AP FRESENIUS KABI USA EQ 0.05MG BASE/ML A 210762 001 May 03, 2019 Apr NEWA

FERRIC CARBOXYMALTOSE INJECTABLE;INTRAVENOUS INJECTAFER >A> +! AM REGENT 750MG IRON/15ML (50MG IRON/ML) N 203565 001 Jul 25, 2013 Jun CAHN >D> +! LUITPOLD 750MG IRON/15ML (50MG IRON/ML) N 203565 001 Jul 25, 2013 Jun CAHN

FINAFLOXACIN SUSPENSION/DROPS;OTIC XTORO + @ MERLION PHARMS GMBH 0.3% N 206307 001 Dec 17, 2014 Apr DISC RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019 1 -38

FLOXURIDINE INJECTABLE;INJECTION FLOXURIDINE @ LUITPOLD 500MG/VIAL A 203008 001 Nov 22, 2017 Mar DISC

FLUCONAZOLE INJECTABLE;INJECTION FLUCONAZOLE IN SODIUM CHLORIDE 0.9% @ DR REDDYS 200MG/100ML (2MG/ML) A 076653 001 Jul 29, 2004 May CAHN @ 400MG/200ML (2MG/ML) A 076653 002 Jul 29, 2004 May CAHN FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER @ DR REDDYS 200MG/100ML (2MG/ML) A 076837 001 Jan 13, 2005 May CAHN @ 400MG/200ML (2MG/ML) A 076837 002 Jan 13, 2005 May CAHN TABLET;ORAL FLUCONAZOLE >D> AB APOTEX 50MG A 076665 001 Jul 29, 2004 Jun CAHN >D> AB 100MG A 076665 002 Jul 29, 2004 Jun CAHN >D> AB 150MG A 076665 003 Jul 29, 2004 Jun CAHN >D> AB 200MG A 076665 004 Jul 29, 2004 Jun CAHN >A> AB CHARTWELL 50MG A 076665 001 Jul 29, 2004 Jun CAHN >A> AB 100MG A 076665 002 Jul 29, 2004 Jun CAHN >A> AB 150MG A 076665 003 Jul 29, 2004 Jun CAHN >A> AB 200MG A 076665 004 Jul 29, 2004 Jun CAHN

FLUCYTOSINE CAPSULE;ORAL ANCOBON AB + BAUSCH 250MG N 017001 001 Feb CAHN AB +! 500MG N 017001 002 Feb CAHN

FLUDEOXYGLUCOSE F-18 INJECTABLE;INTRAVENOUS FLUDEOXYGLUCOSE F18 AP DECATUR 20-300mCi/ML A 204463 001 Oct 21, 2014 Apr CAHN

FLUMAZENIL INJECTABLE;INJECTION FLUMAZENIL @ DR REDDYS 0.5MG/5ML (0.1MG/ML) A 076589 002 Oct 12, 2004 May CAHN @ 1MG/10ML (0.1MG/ML) A 076589 001 Oct 12, 2004 May CAHN

FLUNISOLIDE SPRAY, METERED;NASAL FLUNISOLIDE >D> @ APOTEX INC 0.029MG/SPRAY A 077436 001 Aug 09, 2007 Jun CMFD >A> 0.029MG/SPRAY A 077436 001 Aug 09, 2007 Jun CMFD >A> AB 0.029MG/SPRAY A 077436 001 Aug 09, 2007 Jun CMFD

FLUOCINOLONE ACETONIDE SOLUTION;TOPICAL FLUOCINOLONE ACETONIDE @ ACTAVIS LABS UT INC 0.01% A 208386 001 Oct 21, 2016 Mar DISC AT ENCUBE ETHICALS 0.01% A 209913 001 Feb 13, 2019 Jan NEWA AT GLASSHOUSE PHARMS 0.01% A 209596 001 Dec 26, 2017 Jan CMFD AT LUPIN 0.01% A 206422 001 Sep 02, 2015 Feb CAHN

FLUOCINONIDE CREAM;TOPICAL FLUOCINONIDE @ AMNEAL PHARMS LLC 0.05% A 210554 001 Aug 21, 2018 Feb DISC AB TELIGENT PHARMA INC 0.1% A 211758 001 Apr 03, 2019 Mar NEWA SOLUTION;TOPICAL FLUOCINONIDE AT TELIGENT PHARMA INC 0.05% A 207554 001 Mar 18, 2019 Mar NEWA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019 1 -39

FLUOROMETHOLONE SUSPENSION/DROPS;OPHTHALMIC FML FORTE >D> ALLERGAN 0.25% N 019216 001 Apr 23, 1986 Jun CRLD >A> +! 0.25% N 019216 001 Apr 23, 1986 Jun CHRS >A> + 0.25% N 019216 001 Apr 23, 1986 Jun CRLD

FLUOROMETHOLONE ACETATE SUSPENSION/DROPS;OPHTHALMIC FLAREX +! EYEVANCE 0.1% N 019079 001 Feb 11, 1986 Feb CAHN

FLUOROMETHOLONE ACETATE; TOBRAMYCIN SUSPENSION/DROPS;OPHTHALMIC TOBRASONE @ EYEVANCE 0.1%;0.3% N 050628 001 Jul 21, 1989 May CAHN

FLUOROURACIL CREAM;TOPICAL FLUOROPLEX +! ALMIRALL 1% N 016988 001 Feb CAHN

FLUOXETINE HYDROCHLORIDE CAPSULE;ORAL FLUOXETINE HYDROCHLORIDE >A> AB1 APNAR PHARMA LP EQ 10MG BASE A 075049 001 Aug 02, 2001 Jun CAHN >A> AB1 EQ 20MG BASE A 075049 002 Jan 29, 2002 Jun CAHN >A> AB EQ 40MG BASE A 075049 003 Jan 29, 2002 Jun CAHN @ BEXIMCO PHARMS USA EQ 10MG BASE A 075807 001 Jan 29, 2002 Feb CAHN @ EQ 20MG BASE A 075807 002 Jan 29, 2002 Feb CAHN AB1 CADILA PHARMS LTD EQ 10MG BASE A 206993 001 May 23, 2019 May NEWA AB1 EQ 20MG BASE A 206993 002 May 23, 2019 May NEWA AB EQ 40MG BASE A 206993 003 May 23, 2019 May NEWA @ PAR PHARM EQ 40MG BASE A 076922 003 Dec 16, 2004 Mar DISC >D> AB1 SANDOZ EQ 10MG BASE A 075049 001 Aug 02, 2001 Jun CAHN >D> AB1 EQ 20MG BASE A 075049 002 Jan 29, 2002 Jun CAHN >D> AB EQ 40MG BASE A 075049 003 Jan 29, 2002 Jun CAHN CAPSULE, DELAYED REL PELLETS;ORAL FLUOXETINE HYDROCHLORIDE BA RR@ BARR@ EQ 90MG BASE A 076237 001 Mar 24, 2010 Apr DISC ! DR REDDYS LABS LTD EQ 90MG BASE A 078572 001 Mar 22, 2010 Apr CTEC AB ! EQ 90MG BASE A 078572 001 Mar 22, 2010 Apr CHRS PROZAC WEEKLY + @ LILLY EQ 90MG BASE N 021235 001 Feb 26, 2001 Apr DISC SOLUTION;ORAL FLUOXETINE HYDROCHLORIDE @ NOSTRUM LABS INC EQ 20MG BASE/5ML A 075292 001 Feb 07, 2002 May CAHN TABLET;ORAL FLUOXETINE HYDROCHLORIDE AB APPCO PHARMA LLC EQ 10MG BASE A 211696 001 Jan 30, 2019 Jan NEWA AB EQ 20MG BASE A 211696 002 Jan 30, 2019 Jan NEWA AB DR REDDYS LABS LTD EQ 60MG BASE A 211721 001 Jan 25, 2019 Jan NEWA >A> AB G AND W LABS INC EQ 60MG BASE A 212191 001 Jul 05, 2019 Jun NEWA AB LUPIN LTD EQ 10MG BASE A 211653 001 Apr 15, 2019 Apr NEWA AB EQ 20MG BASE A 211653 002 Apr 15, 2019 Apr NEWA AB EQ 60MG BASE A 211632 001 Feb 08, 2019 Feb NEWA AB SCIEGEN PHARMS INC EQ 10MG BASE A 210935 001 Mar 20, 2019 Mar NEWA AB EQ 20MG BASE A 210935 002 Mar 20, 2019 Mar NEWA AB UPSHER SMITH LABS EQ 10MG BASE A 211696 001 Jan 30, 2019 May CAHN AB EQ 20MG BASE A 211696 002 Jan 30, 2019 May CAHN

FLUPHENAZINE HYDROCHLORIDE TABLET;ORAL FLUPHENAZINE HYDROCHLORIDE AB ! LANNETT CO INC 10MG A 089743 001 Aug 25, 1988 May CHRS AB MYLAN 10MG A 089804 001 Aug 12, 1988 May CHRS RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019 1 -40

FLURANDRENOLIDE CREAM;TOPICAL CORDRAN SP +! ALMIRALL 0.025% N 012806 003 Feb CAHN AT +! 0.05% N 012806 002 Feb CAHN LOTION;TOPICAL CORDRAN AT +! ALMIRALL 0.05% N 013790 001 Feb CAHN OINTMENT;TOPICAL CORDRAN + @ ALMIRALL 0.025% N 012806 004 Feb CAHN AT +! 0.05% N 012806 001 Feb CAHN TAPE;TOPICAL CORDRAN +! ALMIRALL 0.004MG/SQ CM N 016455 001 Feb CAHN

FLUTAMIDE CAPSULE;ORAL FLUTAMIDE @ ACTAVIS LABS FL INC 125MG A 075820 001 Sep 18, 2001 Apr DISC

FLUTICASONE PROPIONATE CREAM;TOPICAL FLUTICASONE PROPIONATE AB ! PERRIGO ISRAEL 0.05% A 076793 001 May 14, 2004 May CAHN

FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE POWDER;INHALATION ADVAIR DISKUS 100/50 AB +! GLAXO GRP LTD 0.1MG/INH;EQ 0.05MG BASE/INH N 021077 001 Aug 24, 2000 Jan CFTG ADVAIR DISKUS 250/50 AB +! GLAXO GRP LTD 0.25MG/INH;EQ 0.05MG BASE/INH N 021077 002 Aug 24, 2000 Jan CFTG ADVAIR DISKUS 500/50 AB +! GLAXO GRP LTD 0.5MG/INH;EQ 0.05MG BASE/INH N 021077 003 Aug 24, 2000 Jan CFTG WIXELA INHUB AB MYLAN 0.1MG/INH;EQ 0.05MG BASE/INH A 208891 001 Jan 30, 2019 Jan NFTG AB 0.25MG/INH;EQ 0.05MG BASE/INH A 208891 002 Jan 30, 2019 Jan NFTG AB 0.5MG/INH;EQ 0.05MG BASE/INH A 208891 003 Jan 30, 2019 Jan NFTG

FLUVASTATIN SODIUM TABLET, EXTENDED RELEASE;ORAL FLUVASTATIN SODIUM >D> AB MYLAN EQ 80MG BASE A 202458 001 Sep 11, 2015 Jun DISC >A> @ EQ 80MG BASE A 202458 001 Sep 11, 2015 Jun DISC

FLUVOXAMINE MALEATE TABLET;ORAL FLUVOXAMINE MALEATE @ MYLAN 25MG A 075889 001 Nov 29, 2000 May DISC @ 50MG A 075889 002 Nov 29, 2000 May DISC @ 100MG A 075889 003 Nov 29, 2000 May DISC

FOLIC ACID TABLET;ORAL FOLIC ACID AA INVATECH PHARMA 1MG A 211064 001 Mar 08, 2019 Feb NEWA AA QINGDAO BAHEAL PHARM 1MG A 091145 001 Jul 12, 2013 May CAHN

FOMEPIZOLE INJECTABLE;INJECTION >D> ANTIZOL >D> AP +! PAR PHARM INC 1.5GM/1.5ML (1GM/ML) N 020696 001 Dec 04, 1997 Jun DISC >A> + @ 1.5GM/1.5ML (1GM/ML) N 020696 001 Dec 04, 1997 Jun DISC FOMEPIZOLE >D> AP MYLAN INSTITUTIONAL 1.5GM/1.5ML (1GM/ML) A 078639 001 Mar 03, 2008 Jun CHRS >A> AP ! 1.5GM/1.5ML (1GM/ML) A 078639 001 Mar 03, 2008 Jun CHRS RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019 1 -41

FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE TABLET;ORAL FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE @ ANI PHARMS INC 10MG;12.5MG A 076608 001 Dec 03, 2004 May CAHN @ 20MG;12.5MG A 076608 002 Dec 03, 2004 May CAHN

FOSPHENYTOIN SODIUM INJECTABLE;INJECTION FOSPHENYTOIN SODIUM @ DR REDDYS EQ 50MG PHENYTOIN NA/ML A 076886 001 Aug 06, 2007 May CAHN @ LUITPOLD EQ 50MG PHENYTOIN NA/ML A 078277 001 Aug 06, 2007 Feb DISC @ EQ 50MG PHENYTOIN NA/ML A 090099 001 May 13, 2010 Feb DISC

FROVATRIPTAN SUCCINATE TABLET;ORAL FROVATRIPTAN SUCCINATE @ AMNEAL PHARMS CO EQ 2.5MG BASE A 211292 001 Nov 06, 2018 May DISC

FULVESTRANT INJECTABLE;INTRAMUSCULAR FASLODEX AO +! ASTRAZENECA 50MG/ML N 021344 001 Apr 25, 2002 Apr CMS1 AP +! 50MG/ML N 021344 001 Apr 25, 2002 Feb CFTG FULVESTRANT AO AMNEAL PHARMS CO 50MG/ML A 210044 001 Mar 04, 2019 Apr CMS1 AP 50MG/ML A 210044 001 Mar 04, 2019 Feb NFTG AO SANDOZ INC 50MG/ML A 205935 001 May 14, 2019 Apr NEWA SOLUTION;INTRAMUSCULAR FULVESTRANT FRESENIUS KABI USA 250MG/5ML (50MG/ML) N 210326 001 May 20, 2019 May NEWA

FUROSEMIDE INJECTABLE;INJECTION FUROSEMIDE AP AUROBINDO PHARMA LTD 10MG/ML A 212174 001 May 03, 2019 Apr NEWA TABLET;ORAL FUROSEMIDE AB HERITAGE PHARMA 20MG N 018413 001 Nov 30, 1983 Feb CAHN AB 40MG N 018413 002 Nov 30, 1983 Feb CAHN AB HIKMA 20MG N 018823 001 Nov 10, 1983 Apr CAHN AB 40MG N 018823 002 Nov 10, 1983 Apr CAHN

GABAPENTIN CAPSULE;ORAL GABAPENTIN >D> AB APOTEX INC 100MG A 075360 001 Apr 06, 2005 Jun CAHN >D> AB 300MG A 075360 002 Apr 06, 2005 Jun CAHN >D> AB 400MG A 075360 003 Apr 06, 2005 Jun CAHN >A> AB GRANULES INDIA LTD 100MG A 075360 001 Apr 06, 2005 Jun CAHN >A> AB 300MG A 075360 002 Apr 06, 2005 Jun CAHN >A> AB 400MG A 075360 003 Apr 06, 2005 Jun CAHN TABLET;ORAL GABAPENTIN @ LUPIN LTD 600MG A 209306 001 Aug 24, 2018 Mar DISC @ 800MG A 209306 002 Aug 24, 2018 Mar DISC

GALANTAMINE HYDROBROMIDE TABLET;ORAL GALANTAMINE HYDROBROMIDE @ HERITAGE PHARMA EQ 4MG BASE A 077585 001 Sep 15, 2009 May CAHN AB EQ 4MG BASE A 077587 001 Jul 09, 2009 May CAHN @ EQ 8MG BASE A 077585 002 Sep 15, 2009 May CAHN AB EQ 8MG BASE A 077587 002 Jul 09, 2009 May CAHN @ EQ 12MG BASE A 077585 003 Sep 15, 2009 May CAHN AB EQ 12MG BASE A 077587 003 Jul 09, 2009 May CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019 1 -42

GALLIUM CITRATE GA-67 INJECTABLE;INJECTION GALLIUM CITRATE GA 67 BS CURIUM 2mCi/ML N 018058 001 Jan CAHN

GANCICLOVIR SODIUM INJECTABLE;INJECTION GANCICLOVIR @ LUITPOLD EQ 500MG BASE/VIAL A 202624 001 Sep 18, 2013 Feb DISC GANCICLOVIR SODIUM >A> AP CUSTOPHARM INC EQ 500MG BASE/VIAL A 212001 001 Jun 20, 2019 Jun NEWA

GANIRELIX ACETATE INJECTABLE;INJECTION GANIRELIX ACETATE AP +! ORGANON USA INC 250MCG/0.5ML N 021057 001 Jul 29, 1999 Mar CPOT AP SUN PHARM 250MCG/0.5ML A 204246 001 Nov 30, 2018 Mar CPOT

GEMCITABINE HYDROCHLORIDE INJECTABLE;INJECTION GEMCITABINE HYDROCHLORIDE AP FRESENIUS KABI USA EQ 200MG BASE/VIAL A 090799 001 Jul 25, 2011 Jan CAHN AP EQ 1GM BASE/VIAL A 090799 002 Jul 25, 2011 Jan CAHN AP EQ 2GM BASE/VIAL A 090799 003 May 16, 2011 Jan CAHN AP INGENUS PHARMS LLC 200MG/5.26ML (38MG/ML) A 210383 001 Feb 14, 2019 Feb NEWA AP 1GM/26.3ML (38MG/ML) A 210383 002 Feb 14, 2019 Feb NEWA AP 2GM/52.6ML (38MG/ML) A 210383 003 Feb 14, 2019 Feb NEWA @ LUITPOLD EQ 200MG BASE/VIAL A 202031 001 May 07, 2013 Feb DISC @ EQ 1GM BASE/VIAL A 202031 002 May 07, 2013 Feb DISC AP SHILPA MEDICARE LTD EQ 200MG BASE/VIAL A 207575 001 Feb 22, 2019 Feb NEWA AP EQ 1GM BASE/VIAL A 207575 002 Feb 22, 2019 Feb NEWA

GLASDEGIB MALEATE TABLET;ORAL DAURISMO + PFIZER INC EQ 25MG BASE N 210656 001 Nov 21, 2018 Feb CAIN +! EQ 100MG BASE N 210656 002 Nov 21, 2018 Feb CAIN

GLIMEPIRIDE TABLET;ORAL GLIMEPIRIDE AB MICRO LABS 1MG A 091220 001 Jun 29, 2012 Mar CAHN AB 2MG A 091220 002 Jun 29, 2012 Mar CAHN 3MG A 091220 003 Jun 29, 2012 Mar CAHN AB 4MG A 091220 004 Jun 29, 2012 Mar CAHN 6MG A 091220 005 Jun 29, 2012 Mar CAHN AB 8MG A 091220 006 Jun 29, 2012 Mar CAHN

GLIPIZIDE TABLET;ORAL GLIPIZIDE @ BEXIMCO PHARMS USA 5MG A 074542 001 Jun 20, 1995 Feb CAHN @ 10MG A 074542 002 Jun 20, 1995 Feb CAHN TABLET, EXTENDED RELEASE;ORAL GLIPIZIDE @ MYLAN 2.5MG A 202298 001 May 19, 2015 Feb DISC @ 5MG A 202298 002 May 19, 2015 Feb DISC @ 10MG A 202298 003 May 19, 2015 Feb DISC

GLIPIZIDE; METFORMIN HYDROCHLORIDE TABLET;ORAL GLIPIZIDE AND METFORMIN HYDROCHLORIDE @ MYLAN 2.5MG;250MG A 078083 001 Apr 12, 2007 Apr DISC

GLYBURIDE TABLET;ORAL GLYBURIDE AB1 ORIENT PHARMA CO LTD 1.25MG A 206483 001 Feb 22, 2019 Feb NEWA AB1 2.5MG A 206483 002 Feb 22, 2019 Feb NEWA AB1 5MG A 206483 003 Feb 22, 2019 Feb NEWA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019 1 -43

GLYCEROL PHENYLBUTYRATE LIQUID;ORAL RAVICTI +! HORIZON THERAP 1.1GM/ML N 203284 001 Feb 01, 2013 Feb CAHN

GLYCOPYRROLATE INJECTABLE;INJECTION GLYCOPYRROLATE AP CAPLIN 0.2MG/ML A 211705 001 Mar 20, 2019 Mar NEWA >D> AP PIRAMAL CRITICAL 0.2MG/ML A 210842 001 Oct 25, 2018 Jun CAHN >A> AP 0.2MG/ML A 210842 001 Oct 25, 2018 Jun CAHN AP SANDOZ INC 0.2MG/ML A 211334 001 May 14, 2019 Apr NEWA TABLET;ORAL GLYCOPYRROLATE AA AUROLIFE PHARMA LLC 2MG A 202675 002 Oct 30, 2018 May NEWA AA KENTON 1MG A 091182 001 Feb 03, 2014 Mar CAHN AA 2MG A 091182 002 Feb 03, 2014 Mar CAHN

GRANISETRON HYDROCHLORIDE INJECTABLE;INJECTION GRANISETRON HYDROCHLORIDE AP BIONPHARMA INC EQ 0.1MG BASE/ML (EQ 0.1MG A 078863 001 Jun 30, 2008 Apr CAHN BASE/ML) AP EQ 4MG BASE/4ML (EQ 1MG BASE/ML) A 078880 001 Jun 30, 2008 Apr CAHN AP ! DR REDDYS EQ 0.1MG BASE/ML (EQ 0.1MG A 078392 001 Dec 31, 2007 May CAHN BASE/ML) AP ! EQ 4MG BASE/4ML (EQ 1MG BASE/ML) A 077297 001 Jun 30, 2008 May CAHN @ LUITPOLD EQ 1MG BASE/ML (EQ 1MG BASE/ML) A 091274 001 Sep 22, 2010 Feb DISC GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE AP BIONPHARMA INC EQ 1MG BASE/ML (EQ 1MG BASE/ML) A 078863 002 Jun 30, 2008 Apr CAHN @ DR REDDYS EQ 1MG BASE/ML (EQ 1MG BASE/ML) A 077165 001 Dec 31, 2007 May CAHN TABLET;ORAL GRANISETRON HYDROCHLORIDE @ TEVA PHARMS EQ 1MG BASE A 078080 001 Dec 31, 2007 Jan DISC AB ! WEST-WARD PHARMS INT EQ 1MG BASE A 077842 001 Dec 31, 2007 Jan CHRS

GUAIFENESIN; HYDROCODONE BITARTRATE >D> SOLUTION;ORAL >D> OBREDON >D> +! SOVEREIGN PHARMS 200MG/5ML;2.5MG/5ML N 205474 001 Nov 14, 2014 Jun DISC >A> + @ 200MG/5ML;2.5MG/5ML N 205474 001 Nov 14, 2014 Jun DISC >D> TABLET;ORAL >D> XTRELUS >D> +! ECI PHARMS LLC 400MG;5MG N 208085 001 Apr 25, 2018 Jun DISC >A> + @ 400MG;5MG N 208085 001 Apr 25, 2018 Jun DISC

GUANFACINE HYDROCHLORIDE TABLET;ORAL GUANFACINE HYDROCHLORIDE AB EPIC PHARMA LLC EQ 1MG BASE A 074673 001 Feb 28, 1997 Apr CMFD AB EQ 2MG BASE A 074673 002 Feb 28, 1997 Apr CMFD TABLET, EXTENDED RELEASE;ORAL GUANFACINE HYDROCHLORIDE @ MYLAN EQ 1MG BASE A 202578 001 Jun 02, 2015 May DISC @ EQ 2MG BASE A 202578 002 Jun 02, 2015 May DISC @ EQ 3MG BASE A 202578 003 Jun 02, 2015 May DISC @ EQ 4MG BASE A 202578 004 Jun 02, 2015 May DISC

HALOBETASOL PROPIONATE LOTION;TOPICAL BRYHALI +! BAUSCH 0.01% N 209355 001 Nov 06, 2018 Apr CAHN +! DOW PHARM 0.01% N 209355 001 Nov 06, 2018 Jan CHRS + 0.01% N 209355 001 Nov 06, 2018 Jan CRLD

HALOBETASOL PROPIONATE; TAZAROTENE LOTION;TOPICAL DUOBRII +! BAUSCH 0.01%;0.045% N 209354 001 Apr 25, 2019 Apr NEWA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019 1 -44

HALOPERIDOL TABLET;ORAL HALOPERIDOL @ INNOGENIX 0.5MG A 071173 002 Jan 02, 1987 May CMS1 @ 1MG A 071173 003 Jan 02, 1987 May CMS1 @ 2MG A 071173 004 Jan 02, 1987 May CMS1 @ 5MG A 071173 005 Jan 07, 1988 May CMS1 @ 10MG A 071173 001 Jan 07, 1988 Mar CAHN @ 20MG A 071173 006 Jan 07, 1988 May CMS1 ! MYLAN 2MG A 070278 001 Jun 10, 1986 Jan CTEC AB ! 2MG A 070278 001 Jun 10, 1986 Jan CHRS @ SANDOZ 2MG A 071208 001 Nov 17, 1986 Jan DISC

HALOPERIDOL LACTATE CONCENTRATE;ORAL HALOPERIDOL AA ! PHARM ASSOC EQ 2MG BASE/ML A 073037 001 Feb 26, 1993 May CHRS @ TEVA PHARMS EQ 2MG BASE/ML A 071617 001 Dec 01, 1988 May DISC INJECTABLE;INJECTION HALOPERIDOL >A> AP FRESENIUS KABI USA EQ 5MG BASE/ML A 210356 001 Jul 01, 2019 Jun NEWA

HEPARIN SODIUM INJECTABLE;INJECTION HEPARIN SODIUM AP +! HIKMA 1,000 UNITS/ML N 017037 001 Feb CAHN AP +! 5,000 UNITS/ML N 017037 002 Feb CAHN @ 5,000 UNITS/0.5ML N 017037 013 Apr 07, 1986 Feb CAHN AP +! 10,000 UNITS/ML N 017037 003 Feb CAHN AP NANJING KING-FRIEND 1,000 UNITS/ML A 211007 001 May 28, 2019 May NEWA AP 5,000 UNITS/ML A 211007 002 May 28, 2019 May NEWA AP 10,000 UNITS/ML A 211007 003 May 28, 2019 May NEWA

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE SYRUP;ORAL HYCODAN >D> + @ GENUS LIFESCIENCES 1.5MG/5ML;5MG/5ML N 005213 002 Jul 26, 1988 Jun CMFD >A> AA + 1.5MG/5ML;5MG/5ML N 005213 002 Jul 26, 1988 Jun CMFD HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE AA BRECKENRIDGE PHARM 1.5MG/5ML;5MG/5ML A 210663 001 Jun 11, 2019 May NEWA AA TORRENT 1.5MG/5ML;5MG/5ML A 204765 001 Mar 06, 2017 May CMFD @ 1.5MG/5ML;5MG/5ML A 204765 001 Mar 06, 2017 Jan CAHN

HYDRALAZINE HYDROCHLORIDE INJECTABLE;INJECTION HYDRALAZINE HYDROCHLORIDE @ LUITPOLD 20MG/ML A 040136 001 Jun 30, 1997 Feb DISC TABLET;ORAL HYDRALAZINE HYDROCHLORIDE >D> AA APPCO PHARMA LLC 10MG A 209251 001 Jul 09, 2018 Jun CAHN >D> AA 25MG A 209251 002 Jul 09, 2018 Jun CAHN >D> AA 50MG A 209251 003 Jul 09, 2018 Jun CAHN >D> AA 100MG A 209251 004 Jul 09, 2018 Jun CAHN >A> AA UPSHER SMITH LABS 10MG A 209251 001 Jul 09, 2018 Jun CAHN >A> AA 25MG A 209251 002 Jul 09, 2018 Jun CAHN >A> AA 50MG A 209251 003 Jul 09, 2018 Jun CAHN >A> AA 100MG A 209251 004 Jul 09, 2018 Jun CAHN

HYDROCHLOROTHIAZIDE; LISINOPRIL TABLET;ORAL LISINOPRIL AND HYDROCHLOROTHIAZIDE AB HERITAGE PHARMA 12.5MG;10MG A 075776 001 Jul 01, 2002 Feb CAHN AB 12.5MG;20MG A 075776 002 Jul 01, 2002 Feb CAHN AB 25MG;20MG A 075776 003 Jul 01, 2002 Feb CAHN

HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL TABLET;ORAL OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE AB ACCORD HLTHCARE 12.5MG;20MG A 209281 001 Feb 07, 2019 Jan NEWA AB 12.5MG;40MG A 209281 002 Feb 07, 2019 Jan NEWA AB 25MG;40MG A 209281 003 Feb 07, 2019 Jan NEWA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019 1 -45

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE TABLET;ORAL QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE @ MYLAN 12.5MG;EQ 10MG BASE A 077093 001 Mar 28, 2005 May DISC @ 12.5MG;EQ 20MG BASE A 077093 002 Mar 28, 2005 May DISC @ 25MG;EQ 20MG BASE A 077093 003 Mar 28, 2005 May DISC QUINARETIC AB LUPIN 12.5MG;EQ 10MG BASE A 076374 001 Mar 31, 2004 Feb CAHN AB 12.5MG;EQ 20MG BASE A 076374 002 Mar 31, 2004 Feb CAHN AB 25MG;EQ 20MG BASE A 076374 003 Mar 31, 2004 Feb CAHN

HYDROCHLOROTHIAZIDE; TELMISARTAN TABLET;ORAL TELMISARTAN AND HYDROCHLOROTHIAZIDE AB GLENMARK PHARMS LTD 12.5MG;40MG A 202544 001 Mar 04, 2019 Feb NEWA AB 12.5MG;80MG A 202544 002 Mar 04, 2019 Feb NEWA AB 25MG;80MG A 202544 003 Mar 04, 2019 Feb NEWA

HYDROCHLOROTHIAZIDE; TRIAMTERENE CAPSULE;ORAL TRIAMTERENE AND HYDROCHLOROTHIAZIDE >D> AB ANI PHARMS INC 25MG;50MG A 074259 001 Mar 30, 1995 Jun DISC >A> @ 25MG;50MG A 074259 001 Mar 30, 1995 Jun DISC >D> AB ! CASI PHARMS INC 25MG;50MG A 073191 001 Jul 31, 1991 Jun DISC >A> @ 25MG;50MG A 073191 001 Jul 31, 1991 Jun DISC AB ZYDUS PHARMS 25MG;37.5MG A 208358 001 Feb 11, 2019 Jan NEWA

HYDROCHLOROTHIAZIDE; VALSARTAN TABLET;ORAL VALSARTAN AND HYDROCHLOROTHIAZIDE AB ZYDUS PHARMS 12.5MG;80MG A 203000 001 Mar 15, 2019 Mar NEWA AB 12.5MG;160MG A 203000 002 Mar 15, 2019 Mar NEWA AB 12.5MG;320MG A 203000 003 Mar 15, 2019 Mar NEWA AB 25MG;160MG A 203000 004 Mar 15, 2019 Mar NEWA AB 25MG;320MG A 203000 005 Mar 15, 2019 Mar NEWA

HYDROCODONE BITARTRATE CAPSULE, EXTENDED RELEASE;ORAL ZOHYDRO ER +! PERSION 10MG N 202880 001 Oct 25, 2013 Apr CAHN + 15MG N 202880 002 Oct 25, 2013 Apr CAHN + 20MG N 202880 003 Oct 25, 2013 Apr CAHN + 30MG N 202880 004 Oct 25, 2013 Apr CAHN + 40MG N 202880 005 Oct 25, 2013 Apr CAHN + 50MG N 202880 006 Oct 25, 2013 Apr CAHN

HYDROCODONE BITARTRATE; IBUPROFEN TABLET;ORAL HYDROCODONE BITARTRATE AND IBUPROFEN @ ANI PHARMS INC 5MG;200MG A 077454 001 Jun 23, 2010 May CAHN

HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE SOLUTION;ORAL HYDROCODONE BITARTRATE AND PSEUDOEPHEDRINE HYDROCHLORIDE >D> AA MAYNE PHARMA INC 5MG/5ML;60MG/5ML A 205658 001 Nov 17, 2015 Jun DISC >A> @ 5MG/5ML;60MG/5ML A 205658 001 Nov 17, 2015 Jun DISC >D> AA PADDOCK LLC 5MG/5ML;60MG/5ML A 204658 001 Apr 29, 2014 Jun DISC >A> @ 5MG/5ML;60MG/5ML A 204658 001 Apr 29, 2014 Jun DISC @ TORRENT 5MG/5ML;60MG/5ML A 206661 001 Jan 23, 2019 Feb DISC AA 5MG/5ML;60MG/5ML A 206661 001 Jan 23, 2019 Jan NEWA >D> REZIRA >D> AA +! PERSION 5MG/5ML;60MG/5ML N 022442 001 Jun 08, 2011 Jun DISC >A> + @ 5MG/5ML;60MG/5ML N 022442 001 Jun 08, 2011 Jun DISC AA +! 5MG/5ML;60MG/5ML N 022442 001 Jun 08, 2011 Apr CAHN

HYDROCORTISONE CREAM;TOPICAL NUTRACORT @ BAUSCH 0.5% A 080442 002 Feb CAHN @ 1% A 080442 003 Feb CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019 1 -46

LOTION;TOPICAL CETACORT @ BAUSCH 0.5% A 080426 002 Feb CAHN @ 1% A 080426 001 Feb CAHN

HYDROCORTISONE BUTYRATE CREAM;TOPICAL LOCOID AB1 +! BAUSCH 0.1% N 018514 001 Mar 31, 1982 May CAHN LOTION;TOPICAL LOCOID AB +! BAUSCH 0.1% N 022076 001 May 18, 2007 May CAHN SOLUTION;TOPICAL LOCOID AT +! BAUSCH 0.1% N 019116 001 Feb 25, 1987 May CAHN

HYDROCORTISONE VALERATE CREAM;TOPICAL HYDROCORTISONE VALERATE AB PERRIGO ISRAEL 0.2% A 075666 001 May 24, 2000 May CAHN

HYDROMORPHONE HYDROCHLORIDE TABLET, EXTENDED RELEASE;ORAL EXALGO + @ SPECGX LLC 8MG N 021217 001 Mar 01, 2010 Mar DISC + @ 12MG N 021217 002 Mar 01, 2010 Mar DISC + @ 16MG N 021217 003 Mar 01, 2010 Mar DISC + @ 32MG N 021217 004 Aug 24, 2012 Mar DISC HYDROMORPHONE HYDROCHLORIDE AB ! OSMOTICA 32MG A 205629 004 Jul 07, 2016 Mar CHRS

HYDROXYCHLOROQUINE SULFATE TABLET;ORAL HYDROXYCHLOROQUINE SULFATE AB LAURUS LABS LTD 200MG A 210959 001 Jan 15, 2019 Jan CAHN @ LUPIN LTD 200MG A 210543 001 Jul 06, 2018 Feb DISC

HYDROXYPROGESTERONE CAPROATE SOLUTION;INTRAMUSCULAR HYDROXYPROGESTERONE CAPROATE AP2 ! ASPEN GLOBAL INC 1250MG/5ML (250MG/ML) A 200271 001 Aug 24, 2015 Apr CPOT AP2 ! 250MG/ML (250MG/ML) A 200271 001 Aug 24, 2015 Apr CTEC AP EUGIA PHARMA 250MG/ML (250MG/ML) A 211071 001 Apr 16, 2019 Apr NEWA AP1 1250MG/5ML (250MG/ML) A 211070 001 Apr 16, 2019 Apr NEWA AP2 1250MG/5ML (250MG/ML) A 211142 001 May 09, 2019 Apr NEWA AP SLAYBACK PHARMA LLC 250MG/ML (250MG/ML) A 210877 001 Mar 22, 2019 Mar NEWA AP1 1250MG/5ML (250MG/ML) A 210618 001 Dec 28, 2018 Apr CTEC AP1 SUN PHARM 1250MG/5ML (250MG/ML) A 208381 001 Apr 09, 2019 Apr CTEC AP 1250MG/5ML (250MG/ML) A 208381 001 Apr 09, 2019 Mar NEWA MAKENA AP1 +! AMAG PHARMA USA 1250MG/5ML (250MG/ML) N 021945 001 Feb 03, 2011 Apr CTEC

HYDROXYPROPYL CELLULOSE INSERT;OPHTHALMIC LACRISERT +! VALEANT PHARMS INTL 5MG N 018771 001 Jan CAHN

HYDROXYZINE HYDROCHLORIDE INJECTABLE;INJECTION HYDROXYZINE HYDROCHLORIDE ! LUITPOLD 50MG/ML A 087408 002 Mar CMFD @ 50MG/ML A 087408 002 Feb DISC SYRUP;ORAL HYDROXYZINE HYDROCHLORIDE AA TORRENT 10MG/5ML A 210634 001 Feb 26, 2019 Feb NEWA TABLET;ORAL HYDROXYZINE HYDROCHLORIDE AB EPIC PHARMA LLC 10MG A 040604 002 Dec 28, 2004 Jan CAHN AB 25MG A 040604 003 Dec 28, 2004 Jan CAHN AB 50MG A 040604 001 Dec 28, 2004 Jan CAHN AB KVK TECH 25MG A 040786 002 Mar 20, 2007 Feb CMS1 RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019 1 -47

TABLET;ORAL HYDROXYZINE HYDROCHLORIDE AB 50MG A 040786 003 Mar 20, 2007 Feb CMS1

HYDROXYZINE PAMOATE CAPSULE;ORAL HYDROXYZINE PAMOATE @ BEXIMCO PHARMS USA EQ 25MG HYDROCHLORIDE A 081127 001 Jun 28, 1991 Feb CAHN

IBUPROFEN SOLUTION;INTRAVENOUS CALDOLOR +! CUMBERLAND PHARMS 800MG/200ML (4MG/ML) N 022348 003 Jan 25, 2019 Jan NEWA SUSPENSION;ORAL IBUPROFEN AB L PERRIGO CO 100MG/5ML A 076925 001 Sep 23, 2004 May CAHN TABLET;ORAL IBUPROFEN @ HEC PHARM 400MG A 204062 001 Sep 10, 2018 Mar DISC @ 600MG A 204062 002 Sep 10, 2018 Mar DISC @ 800MG A 204062 003 Sep 10, 2018 Mar DISC AB PERRIGO PHARMS CO 400MG A 077114 001 Jul 18, 2005 May CAHN AB 600MG A 077114 002 Jul 18, 2005 May CAHN AB 800MG A 077114 003 Jul 18, 2005 May CAHN

IBUTILIDE FUMARATE INJECTABLE;INJECTION IBUTILIDE FUMARATE @ LUITPOLD 0.1MG/ML A 090240 001 Jan 11, 2010 Feb DISC

IMATINIB MESYLATE TABLET;ORAL IMATINIB MESYLATE AB AMNEAL PHARMS EQ 100MG BASE A 207495 001 Feb 08, 2019 Feb NEWA AB EQ 400MG BASE A 207495 002 Feb 08, 2019 Feb NEWA AB BRECKENRIDGE PHARM EQ 100MG BASE A 205990 001 Feb 08, 2019 Feb NEWA AB EQ 400MG BASE A 205990 002 Feb 08, 2019 Feb NEWA AB NATCO PHARMA LTD EQ 100MG BASE A 207818 001 Mar 01, 2019 Feb NEWA AB EQ 400MG BASE A 207818 002 Mar 01, 2019 Feb NEWA AB SHILPA MEDICARE LTD EQ 100MG BASE A 208302 001 Jan 17, 2019 Jan NEWA AB EQ 400MG BASE A 208302 002 Jan 17, 2019 Jan NEWA AB WOCKHARDT BIO AG EQ 100MG BASE A 208429 001 Jan 17, 2019 Jan NEWA AB EQ 400MG BASE A 208429 002 Jan 17, 2019 Jan NEWA

IMIPRAMINE HYDROCHLORIDE TABLET;ORAL IMIPRAMINE HYDROCHLORIDE @ OXFORD PHARMS 10MG A 040751 003 Feb 28, 2008 Mar DISC @ 25MG A 040751 002 Feb 28, 2008 Mar DISC

INDIUM IN-111 CHLORIDE INJECTABLE;INJECTION >D> INDICLOR >D> +! GE HEALTHCARE 2mCi/0.2ML N 019862 001 Dec 29, 1992 Jun DISC >A> + @ 2mCi/0.2ML N 019862 001 Dec 29, 1992 Jun DISC INDIUM IN 111 CHLORIDE +! CURIUM 5mCi/0.5ML N 019841 001 Sep 27, 1994 Jan CAHN

INDIUM IN-111 PENTETREOTIDE KIT INJECTABLE;INJECTION OCTREOSCAN +! CURIUM 3mCi/ML N 020314 001 Jun 02, 1994 Jan CAHN

INDOMETHACIN CAPSULE;ORAL INDOCIN + EGALET@ 25MG N 016059 001 Feb CAHN + @ 50MG N 016059 002 Feb CAHN INDOMETHACIN @ ANI PHARMS INC 25MG A 071148 001 Mar 18, 1987 May CAHN @ 50MG A 071149 001 Mar 18, 1987 May CAHN AB CADILA 25MG A 090403 001 Nov 15, 2010 May CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019 1 -48

CAPSULE;ORAL INDOMETHACIN AB 50MG A 090403 002 Nov 15, 2010 May CAHN AB HERITAGE PHARMA 25MG A 070719 001 Feb 12, 1986 Feb CAHN AB 50MG A 070756 001 Feb 12, 1986 Feb CAHN TIVORBEX + EGALET 20MG N 204768 001 Feb 24, 2014 Feb CAHN +! 40MG N 204768 002 Feb 24, 2014 Feb CAHN CAPSULE, EXTENDED RELEASE;ORAL INDOCIN SR + @ EGALET 75MG N 018185 001 Feb 23, 1982 Feb CAHN SUPPOSITORY;RECTAL INDOCIN + @ EGALET 50MG N 017814 001 Aug 13, 1984 Feb CAHN SUSPENSION;ORAL INDOCIN +! EGALET 25MG/5ML N 018332 001 Oct 10, 1985 Feb CAHN

INSULIN ASPART SOLUTION;SUBCUTANEOUS >A> FIASP PENFILL >A> +! NOVO 300 UNITS/3ML (100 UNITS/ML) N 208751 003 Sep 24, 2018 Jun NEWA

>D> INSULIN ASPART; INSULIN DEGLUDEC >D> SOLUTION;SUBCUTANEOUS >D> RYZODEG 70/30 >D> +! NOVO 90 UNITS/3ML;210 UNITS/3ML (30 N 203313 001 Sep 25, 2015 Jun DISC UNITS/ML;70 UNITS/ML) >A> + @ 90 UNITS/3ML;210 UNITS/3ML (30 N 203313 001 Sep 25, 2015 Jun DISC UNITS/ML;70 UNITS/ML)

INSULIN DEGLUDEC SOLUTION;SUBCUTANEOUS TRESIBA >A> NOVO 1000 UNITS/10ML (100 UNITS/ML) N 203314 003 Nov 21, 2018 Jun NEWA

INSULIN HUMAN SOLUTION;INTRAVENOUS >A> MYXREDLIN >A> +! CELERITY PHARMS 100 UNITS/100ML (1 UNIT/ML) N 208157 001 Jun 20, 2019 Jun NEWA

IOPROMIDE INJECTABLE;INJECTION ULTRAVIST (PHARMACY BULK) +! BAYER HLTHCARE 49.9% N 021425 003 Mar 12, 2004 Apr CMFD + @ 49.9% N 021425 003 Mar 12, 2004 Feb DISC ULTRAVIST 240 +! BAYER HLTHCARE 49.9% N 020220 003 May 10, 1995 Apr CMFD + @ 49.9% N 020220 003 May 10, 1995 Feb DISC

IOTHALAMATE MEGLUMINE INJECTABLE;INJECTION >D> CONRAY 43 >D> +! LIEBEL-FLARSHEIM 43% N 013295 002 Jun DISC >A> + @ 43% N 013295 002 Jun DISC

IPRATROPIUM BROMIDE SPRAY, METERED;NASAL IPRATROPIUM BROMIDE @ MYLAN SPECIALITY LP 0.021MG/SPRAY A 075552 001 Mar 31, 2003 Mar DISC @ 0.042MG/SPRAY A 075553 001 Mar 31, 2003 Mar DISC

IRINOTECAN HYDROCHLORIDE INJECTABLE;INJECTION IRINOTECAN HYDROCHLORIDE AP FRESENIUS KABI USA 40MG/2ML (20MG/ML) A 078188 001 Feb 27, 2008 Jan CAHN AP 100MG/5ML (20MG/ML) A 078188 002 Feb 27, 2008 Jan CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019 1 -49

IRON DEXTRAN INJECTABLE;INJECTION DEXFERRUM @ LUITPOLD EQ 50MG IRON/ML N 040024 001 Feb 23, 1996 Mar DISC PROFERDEX @ NEW RIVER EQ 50MG IRON/ML N 017807 001 Mar DISC

IRON SUCROSE INJECTABLE;INTRAVENOUS VENOFER + AM REGENT EQ 50MG BASE/2.5ML (EQ 20MG N 021135 002 Mar 20, 2005 Apr CAHN BASE/ML) @ EQ 65MG BASE/3.25ML (EQ 20MG N 021135 005 Mar 29, 2013 Apr CAHN BASE/ML) @ EQ 75MG BASE/3.75ML (EQ 20MG N 021135 003 Mar 29, 2005 Apr CAHN BASE/ML) +! EQ 100MG BASE/5ML (EQ 20MG N 021135 001 Nov 06, 2000 Apr CAHN BASE/ML) + EQ 200MG BASE/10ML (EQ 20MG N 021135 004 Feb 09, 2007 Apr CAHN BASE/ML)

ISOPROPYL ALCOHOL SOLUTION;TOPICAL ZURAGARD +! ZUREX PHARMA 70% (10.5ML) N 210872 001 Apr 26, 2019 Apr NEWA

ISOPROTERENOL HYDROCHLORIDE INJECTABLE;INJECTION ISOPROTERENOL HYDROCHLORIDE >A> AP CIPLA 0.2MG/ML A 211738 001 Jun 28, 2019 Jun NEWA ISUPREL AP +! BAUSCH 0.2MG/ML N 010515 001 Mar CAHN

ISOSORBIDE DINITRATE TABLET;ORAL ISORDIL AB + BAUSCH 5MG N 012093 007 Jul 29, 1988 Mar CAHN + @ 10MG N 012093 002 Jul 29, 1988 Mar CAHN + @ 20MG N 012093 006 Jul 29, 1988 Mar CAHN + @ 30MG N 012093 005 Jul 29, 1988 Mar CAHN +! 40MG N 012093 001 Jul 29, 1988 Mar CAHN

ISOSORBIDE MONONITRATE TABLET, EXTENDED RELEASE;ORAL ISOSORBIDE MONONITRATE AB HIKMA INTL PHARMS 30MG A 076813 002 Mar 30, 2006 Mar CAHN AB 60MG A 076813 001 Jan 07, 2005 Mar CAHN

ITRACONAZOLE CAPSULE;ORAL ITRACONAZOLE >A> AB PII 100MG A 206410 001 Jul 02, 2019 Jun NEWA

IVABRADINE SOLUTION;ORAL CORLANOR +! AMGEN INC 5MG/5ML (1MG/ML) N 209964 001 Apr 22, 2019 Apr NEWA

IVACAFTOR GRANULE;ORAL KALYDECO + VERTEX PHARMS INC 25MG/PACKET N 207925 003 Apr 29, 2019 May NEWA TABLET;ORAL KALYDECO + VERTEX PHARMS 75MG N 203188 002 May 20, 2019 May NEWA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019 1 -50

KETOCONAZOLE GEL;TOPICAL XOLEGEL +! ALMIRALL 2% N 021946 001 Jul 28, 2006 Feb CAHN SHAMPOO;TOPICAL KETOCONAZOLE AB PERRIGO ISRAEL 2% A 076419 001 Jan 07, 2004 May CAHN TABLET;ORAL KETOCONAZOLE @ HERITAGE PHARMA 200MG A 074971 001 Jun 15, 1999 May CAHN @ 200MG A 075362 001 Jun 15, 1999 May CAHN AB ! TARO 200MG A 075319 001 Jun 15, 1999 Apr CHRS @ TEVA 200MG A 075273 001 Jun 15, 1999 Apr DISC

KETOROLAC TROMETHAMINE INJECTABLE;INJECTION KETOROLAC TROMETHAMINE AP WEST-WARD PHARMS INT 15MG/ML A 075772 001 Jul 21, 2004 Feb CMFD AP 30MG/ML A 075772 002 Jul 21, 2004 Feb CMFD SOLUTION/DROPS;OPHTHALMIC KETOROLAC TROMETHAMINE @ AUROBINDO PHARMA LTD 0.4% A 205191 001 Nov 15, 2018 May DISC AT MICRO LABS LTD INDIA 0.5% A 203410 001 Apr 05, 2019 Mar NEWA @ SANDOZ INC 0.4% A 078721 001 Nov 05, 2009 May DISC

KETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDE SOLUTION;IRRIGATION >A> KETOROLAC TROMETHAMINE AND PHENYLEPHRINE HYDROCHLORIDE >A> AT LUPIN LTD EQ 0.3% BASE;EQ 1% BASE A 210183 001 Jul 01, 2019 Jun NFTG OMIDRIA >D> +! OMEROS EQ 0.3% BASE;EQ 1% BASE N 205388 001 May 30, 2014 Jun CFTG >A> AT +! EQ 0.3% BASE;EQ 1% BASE N 205388 001 May 30, 2014 Jun CFTG

L-GLUTAMINE FOR SOLUTION;ORAL >D> NUTRESTORE >D> +! EMMAUS MEDCL 5GM/PACKET N 021667 001 Jun 10, 2004 Jun DISC >A> + @ 5GM/PACKET N 021667 001 Jun 10, 2004 Jun DISC

LABETALOL HYDROCHLORIDE TABLET;ORAL LABETALOL HYDROCHLORIDE AB CADILA PHARMS LTD 100MG A 211325 001 May 13, 2019 Apr NEWA AB 200MG A 211325 002 May 13, 2019 Apr NEWA AB 300MG A 211325 003 May 13, 2019 Apr NEWA AB HERITAGE PHARMA 100MG A 074787 001 Aug 03, 1998 Feb CAHN AB 200MG A 074787 002 Aug 03, 1998 Feb CAHN AB 300MG A 074787 003 Aug 03, 1998 Feb CAHN AB INVATECH PHARMA 100MG A 207863 001 Feb 04, 2019 Jan NEWA AB 200MG A 207863 002 Feb 04, 2019 Jan NEWA AB 300MG A 207863 003 Feb 04, 2019 Jan NEWA TRANDATE AB + CNTY LINE PHARMS 100MG N 018716 001 May 24, 1985 Jan CRLD AB + 200MG N 018716 002 Aug 01, 1984 Jan CRLD AB + 300MG N 018716 003 Aug 01, 1984 Jan CRLD

LACTULOSE SOLUTION;ORAL LACTULOSE @ BAJAJ 10GM/15ML A 075911 001 Feb 21, 2002 Jan CAHN AA TORRENT 10GM/15ML A 207786 001 Jun 11, 2018 Jan CAHN @ XTTRIUM LABS INC 10GM/15ML A 075911 001 Feb 21, 2002 Mar CAHN SOLUTION;ORAL, RECTAL LACTULOSE @ BAJAJ 10GM/15ML A 076645 001 Jul 28, 2003 Jan CAHN AA TORRENT 10GM/15ML A 203762 001 Mar 27, 2015 Jan CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019 1 -51

LAMIVUDINE TABLET;ORAL LAMIVUDINE AB ANNORA 100MG A 211306 001 Mar 21, 2019 Mar NEWA AB MACLEODS PHARMS LTD 150MG A 090198 001 May 01, 2019 Apr NEWA AB 300MG A 090198 002 May 01, 2019 Apr NEWA @ MYLAN 150MG A 204528 001 Mar 04, 2016 Apr DISC @ 300MG A 204528 002 Mar 04, 2016 Apr DISC AB MYLAN LABS LTD 150MG A 078545 001 Mar 05, 2019 Feb NEWA AB 300MG A 078545 002 Mar 05, 2019 Feb NEWA

LAMIVUDINE; ZIDOVUDINE TABLET;ORAL LAMIVUDINE AND ZIDOVUDINE @ MYLAN 150MG;300MG A 204005 001 Aug 28, 2014 Jan DISC

LAMOTRIGINE TABLET, EXTENDED RELEASE;ORAL LAMOTRIGINE @ RUBICON 25MG A 202887 001 Jun 17, 2013 Mar CAHN @ 50MG A 202887 002 Jun 17, 2013 Mar CAHN AB 100MG A 202887 003 Jun 17, 2013 Mar CAHN AB 200MG A 202887 004 Jun 17, 2013 Mar CAHN

LANSOPRAZOLE CAPSULE, DELAYED REL PELLETS;ORAL LANSOPRAZOLE AB ALKEM LABS LTD 15MG A 207394 001 Jan 18, 2019 Jan NEWA AB 30MG A 207394 002 Jan 18, 2019 Jan NEWA @ BRECKENRIDGE PHARM 15MG A 203964 001 Oct 17, 2018 May DISC @ 30MG A 203964 002 Oct 17, 2018 May DISC @ KRKA TOVARNA ZDRAVIL 15MG A 091212 001 Sep 16, 2013 Feb DISC @ 30MG A 091212 002 Sep 16, 2013 Feb DISC

>D> LAROTRECTINIB >D> CAPSULE;ORAL >D> VITRAKVI >D> + BAYER HLTHCARE 25MG N 210861 001 Nov 26, 2018 Jun CPOT + 25MG N 210861 001 Nov 26, 2018 Feb CAHN >D> +! 100MG N 210861 002 Nov 26, 2018 Jun CPOT +! 100MG N 210861 002 Nov 26, 2018 Feb CAHN >D> SOLUTION;ORAL >D> VITRAKVI >D> +! BAYER HEALTHCARE 20MG/ML N 211710 001 Nov 26, 2018 Jun CPOT +! 20MG/ML N 211710 001 Nov 26, 2018 Feb CAHN

>A> LAROTRECTINIB SULFATE >A> CAPSULE;ORAL >A> VITRAKVI >A> + BAYER HLTHCARE EQ 25MG BASE N 210861 001 Nov 26, 2018 Jun CAIN >A> + EQ 25MG BASE N 210861 001 Nov 26, 2018 Jun CPOT >A> +! EQ 100MG BASE N 210861 002 Nov 26, 2018 Jun CAIN >A> +! EQ 100MG BASE N 210861 002 Nov 26, 2018 Jun CPOT >A> SOLUTION;ORAL >A> VITRAKVI >A> +! BAYER HEALTHCARE EQ 20MG BASE/ML N 211710 001 Nov 26, 2018 Jun CAIN >A> +! EQ 20MG BASE/ML N 211710 001 Nov 26, 2018 Jun CPOT

LATANOPROST; NETARSUDIL DIMESYLATE SOLUTION/DROPS;OPHTHALMIC ROCKLATAN +! AERIE PHARMS INC 0.005%;EQ 0.02% BASE N 208259 001 Mar 12, 2019 Mar NEWA

LEFLUNOMIDE TABLET;ORAL LEFLUNOMIDE AB ABHAI LLC 10MG A 212453 001 Jun 03, 2019 May NEWA AB 20MG A 212453 002 Jun 03, 2019 May NEWA AB ZYDUS 10MG A 212308 001 Apr 24, 2019 Apr NEWA AB 20MG A 212308 002 Apr 24, 2019 Apr NEWA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019 1 -52

LESINURAD TABLET;ORAL ZURAMPIC + @ IRONWOOD PHARMS INC 200MG N 207988 001 Dec 22, 2015 Apr DISC

LETROZOLE TABLET;ORAL LETROZOLE AB FRESENIUS KABI USA 2.5MG A 090491 001 Jun 03, 2011 Feb CAHN

LEUCOVORIN CALCIUM INJECTABLE;INJECTION LEUCOVORIN CALCIUM AP INGENUS PHARMS LLC EQ 10MG BASE/ML A 210917 001 Nov 23, 2018 Feb CPOT

LEUPROLIDE ACETATE >D> FOR SUSPENSION;INTRAMUSCULAR >D> LUTRATE DEPOT KIT >D> +! GP-PHARM SA 22.5MG/VIAL N 205054 001 Aug 28, 2018 Jun DISC >A> + @ 22.5MG/VIAL N 205054 001 Aug 28, 2018 Jun DISC

LEVETIRACETAM >A> INJECTABLE;INTRAVENOUS >A> KEPPRA >A> AP +! UCB INC 500MG/5ML (100MG/ML) N 021872 001 Jul 31, 2006 Jun CDFR >A> LEVETIRACETAM >A> AP AKORN 500MG/5ML (100MG/ML) A 209934 001 May 04, 2018 Jun CDFR >A> AP AUROBINDO PHARMA LTD 500MG/5ML (100MG/ML) A 204312 001 Feb 01, 2016 Jun CDFR >A> AP FRESENIUS KABI USA 500MG/5ML (100MG/ML) A 090813 001 May 26, 2010 Jun CDFR >A> AP 500MG/5ML (100MG/ML) A 090876 001 Aug 13, 2015 Jun CDFR >A> AP HAINAN POLY PHARM 500MG/5ML (100MG/ML) A 209781 001 Mar 20, 2018 Jun CDFR >A> AP HIKMA FARMACEUTICA 500MG/5ML (100MG/ML) A 090981 001 Oct 13, 2011 Jun CDFR >A> AP HOSPIRA INC 500MG/5ML (100MG/ML) A 202869 001 Apr 06, 2012 Jun CDFR >A> AP JUBILANT GENERICS 500MG/5ML (100MG/ML) A 206838 001 Jun 02, 2016 Jun CDFR >A> @ LUITPOLD 500MG/5ML (100MG/ML) A 202143 001 Jan 31, 2012 Jun CDFR >A> AP MYLAN LABS LTD 500MG/5ML (100MG/ML) A 203308 001 Sep 16, 2016 Jun CDFR >A> AP SAGENT PHARMS 500MG/5ML (100MG/ML) A 091627 001 Jun 26, 2013 Jun CDFR >A> AP SUN PHARM INDS LTD 500MG/5ML (100MG/ML) A 090754 001 Jun 16, 2010 Jun CDFR >A> AP X GEN PHARMS 500MG/5ML (100MG/ML) A 091485 001 Aug 05, 2011 Jun CDFR >A> LEVETIRACETAM IN SODIUM CHLORIDE >A> AP AUROBINDO PHARMA LTD 500MG/100ML (5MG/ML) A 207160 001 Jan 04, 2017 Jun CDFR >A> AP 1000MG/100ML (10MG/ML) A 207160 002 Jan 04, 2017 Jun CDFR >A> AP 1500MG/100ML (15MG/ML) A 207160 003 Jan 04, 2017 Jun CDFR >A> AP GLAND PHARMA LTD 500MG/100ML (5MG/ML) A 206880 001 Oct 25, 2017 Jun CDFR >A> AP 1000MG/100ML (10MG/ML) A 206880 002 Oct 25, 2017 Jun CDFR >A> AP 1500MG/100ML (15MG/ML) A 206880 003 Oct 25, 2017 Jun CDFR >A> AP +! HQ SPECIALITY PHARMA 500MG/100ML (5MG/ML) N 202543 001 Nov 09, 2011 Jun CDFR >A> AP +! 1000MG/100ML (10MG/ML) N 202543 002 Nov 09, 2011 Jun CDFR >A> AP +! 1500MG/100ML (15MG/ML) N 202543 003 Nov 09, 2011 Jun CDFR >D> INJECTABLE;IV (INFUSION) >D> KEPPRA >D> AP +! UCB INC 500MG/5ML (100MG/ML) N 021872 001 Jul 31, 2006 Jun CDFR >D> LEVETIRACETAM >D> AP AKORN 500MG/5ML (100MG/ML) A 209934 001 May 04, 2018 Jun CDFR >D> AP AUROBINDO PHARMA LTD 500MG/5ML (100MG/ML) A 204312 001 Feb 01, 2016 Jun CDFR >D> AP FRESENIUS KABI USA 500MG/5ML (100MG/ML) A 090813 001 May 26, 2010 Jun CDFR >D> AP 500MG/5ML (100MG/ML) A 090876 001 Aug 13, 2015 Jun CDFR >D> AP HAINAN POLY PHARM 500MG/5ML (100MG/ML) A 209781 001 Mar 20, 2018 Jun CDFR >D> AP HIKMA FARMACEUTICA 500MG/5ML (100MG/ML) A 090981 001 Oct 13, 2011 Jun CDFR >D> AP HOSPIRA INC 500MG/5ML (100MG/ML) A 202869 001 Apr 06, 2012 Jun CDFR >D> AP JUBILANT GENERICS 500MG/5ML (100MG/ML) A 206838 001 Jun 02, 2016 Jun CDFR >D> @ LUITPOLD 500MG/5ML (100MG/ML) A 202143 001 Jan 31, 2012 Jun CDFR @ 500MG/5ML (100MG/ML) A 202143 001 Jan 31, 2012 Mar DISC >D> AP MYLAN LABS LTD 500MG/5ML (100MG/ML) A 203308 001 Sep 16, 2016 Jun CDFR >D> AP SAGENT PHARMS 500MG/5ML (100MG/ML) A 091627 001 Jun 26, 2013 Jun CDFR >D> AP SUN PHARM INDS LTD 500MG/5ML (100MG/ML) A 090754 001 Jun 16, 2010 Jun CDFR >D> AP X GEN PHARMS 500MG/5ML (100MG/ML) A 091485 001 Aug 05, 2011 Jun CDFR >D> LEVETIRACETAM IN SODIUM CHLORIDE >D> AP AUROBINDO PHARMA LTD 500MG/100ML (5MG/ML) A 207160 001 Jan 04, 2017 Jun CDFR >D> AP 1000MG/100ML (10MG/ML) A 207160 002 Jan 04, 2017 Jun CDFR >D> AP 1500MG/100ML (15MG/ML) A 207160 003 Jan 04, 2017 Jun CDFR RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019 1 -53

>D> INJECTABLE;IV (INFUSION) >D> LEVETIRACETAM IN SODIUM CHLORIDE >D> AP GLAND PHARMA LTD 500MG/100ML (5MG/ML) A 206880 001 Oct 25, 2017 Jun CDFR >D> AP 1000MG/100ML (10MG/ML) A 206880 002 Oct 25, 2017 Jun CDFR >D> AP 1500MG/100ML (15MG/ML) A 206880 003 Oct 25, 2017 Jun CDFR >D> AP +! HQ SPECIALITY PHARMA 500MG/100ML (5MG/ML) N 202543 001 Nov 09, 2011 Jun CDFR >D> AP +! 1000MG/100ML (10MG/ML) N 202543 002 Nov 09, 2011 Jun CDFR >D> AP +! 1500MG/100ML (15MG/ML) N 202543 003 Nov 09, 2011 Jun CDFR

LEVOBUNOLOL HYDROCHLORIDE SOLUTION/DROPS;OPHTHALMIC LEVOBUNOLOL HYDROCHLORIDE @ SANDOZ INC 0.5% A 074850 001 Oct 28, 1996 May DISC

LEVOCETIRIZINE DIHYDROCHLORIDE SOLUTION;ORAL LEVOCETIRIZINE HYDROCHLORIDE AA HETERO LABS LTD III 2.5MG/5ML A 210914 001 Apr 01, 2019 Mar NEWA

LEVOFLOXACIN SOLUTION/DROPS;OPHTHALMIC LEVOFLOXACIN MICRO LABS LTD INDIA 1.5% A 205600 001 Feb 27, 2019 Feb NEWA TABLET;ORAL LEVOFLOXACIN AB HEC PHARM 250MG A 204968 001 Feb 05, 2019 Jan NEWA AB 500MG A 204968 002 Feb 05, 2019 Jan NEWA AB 750MG A 204968 003 Feb 05, 2019 Jan NEWA

LEVOLEUCOVORIN POWDER;INTRAVENOUS KHAPZORY +! ACROTECH 175MG/VIAL N 211226 001 Oct 19, 2018 Mar CAHN +! 300MG/VIAL N 211226 002 Oct 19, 2018 Mar CAHN

LEVOLEUCOVORIN CALCIUM POWDER;INTRAVENOUS FUSILEV AP +! ACROTECH EQ 50MG BASE/VIAL N 020140 001 Mar 07, 2008 Mar CAHN LEVOLEUCOVORIN CALCIUM >D> +! ACTAVIS LLC EQ 175MG BASE/VIAL N 208723 001 Sep 29, 2016 Jun DISC >A> + @ EQ 175MG BASE/VIAL N 208723 001 Sep 29, 2016 Jun DISC SOLUTION;INTRAVENOUS FUSILEV + @ ACROTECH EQ 175MG BASE/17.5ML (EQ 10MG N 020140 002 Apr 29, 2011 Mar CAHN BASE/ML) + @ EQ 250MG BASE/25ML (EQ 10MG N 020140 003 Apr 29, 2011 Mar CAHN BASE/ML)

LEVOMILNACIPRAN HYDROCHLORIDE CAPSULE, EXTENDED RELEASE;ORAL FETZIMA >D> AB + ALLERGAN SALES LLC EQ 20MG BASE N 204168 001 Jul 25, 2013 Jun CTEC >A> + EQ 20MG BASE N 204168 001 Jul 25, 2013 Jun CTEC AB + EQ 20MG BASE N 204168 001 Jul 25, 2013 Jan CFTG >D> AB + EQ 40MG BASE N 204168 002 Jul 25, 2013 Jun CTEC >A> + EQ 40MG BASE N 204168 002 Jul 25, 2013 Jun CTEC AB + EQ 40MG BASE N 204168 002 Jul 25, 2013 Jan CFTG >D> AB + EQ 80MG BASE N 204168 003 Jul 25, 2013 Jun CTEC >A> + EQ 80MG BASE N 204168 003 Jul 25, 2013 Jun CTEC AB + EQ 80MG BASE N 204168 003 Jul 25, 2013 Jan CFTG >D> AB +! EQ 120MG BASE N 204168 004 Jul 25, 2013 Jun CTEC >A> +! EQ 120MG BASE N 204168 004 Jul 25, 2013 Jun CTEC AB +! EQ 120MG BASE N 204168 004 Jul 25, 2013 Jan CFTG >D> LEVOMILNACIPRAN HYDROCHLORIDE >D> AB AMNEAL PHARMS CO EQ 20MG BASE A 210790 001 Feb 04, 2019 Jun DISC >A> @ EQ 20MG BASE A 210790 001 Feb 04, 2019 Jun DISC AB EQ 20MG BASE A 210790 001 Feb 04, 2019 Jan NFTG >D> AB EQ 40MG BASE A 210790 002 Feb 04, 2019 Jun DISC >A> @ EQ 40MG BASE A 210790 002 Feb 04, 2019 Jun DISC AB EQ 40MG BASE A 210790 002 Feb 04, 2019 Jan NFTG >D> AB EQ 80MG BASE A 210790 003 Feb 04, 2019 Jun DISC RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019 1 -54

CAPSULE, EXTENDED RELEASE;ORAL LEVOMILNACIPRAN HYDROCHLORIDE >A> @ EQ 80MG BASE A 210790 003 Feb 04, 2019 Jun DISC AB EQ 80MG BASE A 210790 003 Feb 04, 2019 Jan NFTG >D> AB EQ 120MG BASE A 210790 004 Feb 04, 2019 Jun DISC >A> @ EQ 120MG BASE A 210790 004 Feb 04, 2019 Jun DISC AB EQ 120MG BASE A 210790 004 Feb 04, 2019 Jan NFTG

LEVONORGESTREL TABLET;ORAL LEVONORGESTREL AB ! L PERRIGO CO 0.75MG A 090740 001 Dec 30, 2010 May CAHN

LEVORPHANOL TARTRATE TABLET;ORAL LEVORPHANOL TARTRATE @ SENTYNL THERAPS INC 1MG A 074278 002 Jun 18, 2018 Feb DISC ! 3MG A 074278 003 Jun 18, 2018 May CMFD @ 3MG A 074278 003 Jun 18, 2018 Feb DISC

LEVOTHYROXINE SODIUM POWDER;INTRAVENOUS LEVOTHYROXINE SODIUM @ PAR STERILE PRODUCTS 200MCG/VIAL A 205366 001 Dec 07, 2015 Apr DISC SOLUTION;INTRAVENOUS LEVOTHYROXINE SODIUM +! FRESENIUS KABI USA 100MCG/5ML (20MCG/ML) N 210632 001 Apr 11, 2019 Apr NEWA +! 200MCG/5ML (40MCG/ML) N 210632 002 Apr 11, 2019 Apr NEWA +! 500MCG/5ML (100MCG/ML) N 210632 003 Apr 11, 2019 Apr NEWA SOLUTION;ORAL TIROSINT-SOL + INSTITUT BIOCHIMIQUE 13MCG/ML N 206977 001 Dec 15, 2016 Jan CMFD + 25MCG/ML N 206977 002 Dec 15, 2016 Jan CMFD + 50MCG/ML N 206977 003 Dec 15, 2016 Jan CMFD + 75MCG/ML N 206977 004 Dec 15, 2016 Jan CMFD + 88MCG/ML N 206977 005 Dec 15, 2016 Jan CMFD + 100MCG/ML N 206977 006 Dec 15, 2016 Jan CMFD + 112MCG/ML N 206977 007 Dec 15, 2016 Jan CMFD + 125MCG/ML N 206977 008 Dec 15, 2016 Jan CMFD + 137MCG/ML N 206977 009 Dec 15, 2016 Jan CMFD + 150MCG/ML N 206977 010 Dec 15, 2016 Jan CMFD + 175MCG/ML N 206977 011 Dec 15, 2016 Jan CMFD +! 200MCG/ML N 206977 012 Dec 15, 2016 Jan CMFD

LEVOTHYROXINE SODIUM ** **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET;ORAL LEVOTHYROXINE SODIUM >D> AB2 AMNEAL PHARMS LLC 0.025MG A 210831 001 Feb 19, 2019 Jun DISC >A> @ 0.025MG A 210831 001 Feb 19, 2019 Jun DISC AB2 0.025MG A 210831 001 Feb 19, 2019 May CTEC AB1, 0.025MG A 210831 001 Feb 19, 2019 Feb NEWA AB2 >D> AB2 0.05MG A 210831 002 Feb 19, 2019 Jun DISC >A> @ 0.05MG A 210831 002 Feb 19, 2019 Jun DISC AB2 0.05MG A 210831 002 Feb 19, 2019 May CTEC AB1, 0.05MG A 210831 002 Feb 19, 2019 Feb NEWA AB2 >D> AB2 0.075MG A 210831 003 Feb 19, 2019 Jun DISC >A> @ 0.075MG A 210831 003 Feb 19, 2019 Jun DISC AB2 0.075MG A 210831 003 Feb 19, 2019 May CTEC AB1, 0.075MG A 210831 003 Feb 19, 2019 Feb NEWA AB2 >D> AB2 0.088MG A 210831 004 Feb 19, 2019 Jun DISC >A> @ 0.088MG A 210831 004 Feb 19, 2019 Jun DISC AB2 0.088MG A 210831 004 Feb 19, 2019 May CTEC AB1, 0.088MG A 210831 004 Feb 19, 2019 Feb NEWA AB2 >D> AB2 0.1MG A 210831 005 Feb 19, 2019 Jun DISC >A> @ 0.1MG A 210831 005 Feb 19, 2019 Jun DISC AB2 0.1MG A 210831 005 Feb 19, 2019 May CTEC AB1, 0.1MG A 210831 005 Feb 19, 2019 Feb NEWA AB2 >D> AB2 0.112MG A 210831 006 Feb 19, 2019 Jun DISC RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019 1 -55

TABLET;ORAL LEVOTHYROXINE SODIUM >A> @ 0.112MG A 210831 006 Feb 19, 2019 Jun DISC AB2 0.112MG A 210831 006 Feb 19, 2019 May CTEC AB1, 0.112MG A 210831 006 Feb 19, 2019 Feb NEWA AB2 >D> AB2 0.125MG A 210831 007 Feb 19, 2019 Jun DISC >A> @ 0.125MG A 210831 007 Feb 19, 2019 Jun DISC AB2 0.125MG A 210831 007 Feb 19, 2019 May CTEC AB1, 0.125MG A 210831 007 Feb 19, 2019 Feb NEWA AB2 >D> AB2 0.137MG A 210831 008 Feb 19, 2019 Jun DISC >A> @ 0.137MG A 210831 008 Feb 19, 2019 Jun DISC AB2 0.137MG A 210831 008 Feb 19, 2019 May CTEC AB1, 0.137MG A 210831 008 Feb 19, 2019 Feb NEWA AB2 >D> AB2 0.15MG A 210831 009 Feb 19, 2019 Jun DISC >A> @ 0.15MG A 210831 009 Feb 19, 2019 Jun DISC AB2 0.15MG A 210831 009 Feb 19, 2019 May CTEC AB1, 0.15MG A 210831 009 Feb 19, 2019 Feb NEWA AB2 >D> AB2 0.175MG A 210831 010 Feb 19, 2019 Jun DISC >A> @ 0.175MG A 210831 010 Feb 19, 2019 Jun DISC AB2 0.175MG A 210831 010 Feb 19, 2019 May CTEC AB1, 0.175MG A 210831 010 Feb 19, 2019 Feb NEWA AB2 >D> AB2 0.2MG A 210831 011 Feb 19, 2019 Jun DISC >A> @ 0.2MG A 210831 011 Feb 19, 2019 Jun DISC AB2 0.2MG A 210831 011 Feb 19, 2019 May CTEC AB1, 0.2MG A 210831 011 Feb 19, 2019 Feb NEWA AB2 >D> AB2 0.3MG A 210831 012 Feb 19, 2019 Jun DISC >A> @ 0.3MG A 210831 012 Feb 19, 2019 Jun DISC AB2 0.3MG A 210831 012 Feb 19, 2019 May CTEC AB1, 0.3MG A 210831 012 Feb 19, 2019 Feb NEWA AB2 AB2 LUPIN ATLANTIS 0.025MG A 209713 001 Jan 18, 2019 Jan NEWA AB2 0.05MG A 209713 002 Jan 18, 2019 Jan NEWA AB2 0.075MG A 209713 003 Jan 18, 2019 Jan NEWA AB2 0.088MG A 209713 004 Jan 18, 2019 Jan NEWA AB2 0.1MG A 209713 005 Jan 18, 2019 Jan NEWA AB2 0.112MG A 209713 006 Jan 18, 2019 Jan NEWA AB2 0.125MG A 209713 007 Jan 18, 2019 Jan NEWA AB2 0.137MG A 209713 008 Jan 18, 2019 Jan NEWA AB2 0.15MG A 209713 009 Jan 18, 2019 Jan NEWA AB2 0.175MG A 209713 010 Jan 18, 2019 Jan NEWA AB2 0.2MG A 209713 011 Jan 18, 2019 Jan NEWA AB2 0.3MG A 209713 012 Jan 18, 2019 Jan NEWA THYRO-TABS AB2, + ALVOGEN 0.025MG N 021116 001 Oct 24, 2002 Mar CAHN AB4 AB2, + 0.05MG N 021116 002 Oct 24, 2002 Mar CAHN AB4 AB2, + 0.075MG N 021116 003 Oct 24, 2002 Mar CAHN AB4 AB2, + 0.088MG N 021116 010 Oct 24, 2002 Mar CAHN AB4 AB2, + 0.1MG N 021116 004 Oct 24, 2002 Mar CAHN AB4 AB2, + 0.112MG N 021116 011 Oct 24, 2002 Mar CAHN AB4 AB2, + 0.125MG N 021116 005 Oct 24, 2002 Mar CAHN AB4 AB2, + 0.137MG N 021116 012 Dec 07, 2004 Mar CAHN AB4 AB2, + 0.15MG N 021116 006 Oct 24, 2002 Mar CAHN AB4 AB2, + 0.175MG N 021116 007 Oct 24, 2002 Mar CAHN AB4 AB2, + 0.2MG N 021116 008 Oct 24, 2002 Mar CAHN AB4 AB2, +! 0.3MG N 021116 009 Oct 24, 2002 Mar CAHN AB4 AB2, + LLOYD 0.025MG N 021116 001 Oct 24, 2002 Feb CMFD AB4 AB2, + 0.05MG N 021116 002 Oct 24, 2002 Feb CMFD AB4 AB2, + 0.075MG N 021116 003 Oct 24, 2002 Feb CMFD RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019 1 -56

TABLET;ORAL THYRO-TABS AB4 AB2, + 0.088MG N 021116 010 Oct 24, 2002 Feb CMFD AB4 AB2, + 0.1MG N 021116 004 Oct 24, 2002 Feb CMFD AB4 AB2, + 0.112MG N 021116 011 Oct 24, 2002 Feb CMFD AB4 AB2, + 0.125MG N 021116 005 Oct 24, 2002 Feb CMFD AB4 AB2, + 0.137MG N 021116 012 Dec 07, 2004 Feb CMFD AB4 AB2, + 0.15MG N 021116 006 Oct 24, 2002 Feb CMFD AB4 AB2, + 0.175MG N 021116 007 Oct 24, 2002 Feb CMFD AB4 AB2, + 0.2MG N 021116 008 Oct 24, 2002 Feb CMFD AB4 AB2, +! 0.3MG N 021116 009 Oct 24, 2002 Feb CMFD AB4

LIDOCAINE HYDROCHLORIDE INJECTABLE;INJECTION >A> LIDOCAINE HYDROCHLORIDE >A> AP FRESENIUS KABI USA 1% A 080404 002 Jun CTNA >A> AP 2% A 080404 003 Jun CTNA @ LUITPOLD 1% A 080850 001 Mar DISC @ 1% A 091564 001 Aug 14, 2015 Feb DISC >D> LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE >D> AP FRESENIUS KABI USA 1% A 080404 002 Jun CTNA >D> AP 2% A 080404 003 Jun CTNA JELLY;TOPICAL ANESTACON @ BIONPHARMA INC 2% A 080429 001 Apr CAHN

LIDOCAINE; PRILOCAINE CREAM;TOPICAL EMLA AB +! TEVA BRANDED PHARM 2.5%;2.5% N 019941 001 Dec 30, 1992 Apr CAHN

LINEZOLID TABLET;ORAL LINEZOLID AB CELLTRION 600MG A 210702 001 Apr 25, 2019 Apr NEWA >D> AB MYLAN 600MG A 078845 001 Dec 21, 2015 Jun DISC >A> @ 600MG A 078845 001 Dec 21, 2015 Jun DISC

LIOTHYRONINE SODIUM TABLET;ORAL CYTOMEL >D> AB +! KING PHARMS EQ 0.05MG BASE N 010379 003 Jun CHRS >A> AB + EQ 0.05MG BASE N 010379 003 Jun CHRS LIOTHYRONINE SODIUM @ MYLAN EQ 0.005MG BASE A 090326 001 Jul 14, 2009 Mar DISC @ EQ 0.025MG BASE A 090326 002 Jul 14, 2009 Mar DISC @ EQ 0.05MG BASE A 090326 003 Jul 14, 2009 Mar DISC >D> AB SIGMAPHARM LABS LLC EQ 0.05MG BASE A 200295 003 Nov 29, 2012 Jun CHRS >A> AB ! EQ 0.05MG BASE A 200295 003 Nov 29, 2012 Jun CHRS >D> AB SUN PHARM EQ 0.005MG BASE A 091382 001 Apr 20, 2016 Jun DISC >A> @ EQ 0.005MG BASE A 091382 001 Apr 20, 2016 Jun DISC >D> AB EQ 0.025MG BASE A 091382 002 Apr 20, 2016 Jun DISC >A> @ EQ 0.025MG BASE A 091382 002 Apr 20, 2016 Jun DISC >D> AB EQ 0.05MG BASE A 091382 003 Apr 20, 2016 Jun DISC >A> @ EQ 0.05MG BASE A 091382 003 Apr 20, 2016 Jun DISC @ TEVA PHARMS USA EQ 0.005MG BASE A 211510 001 Oct 26, 2018 Apr DISC @ EQ 0.025MG BASE A 211510 002 Oct 26, 2018 Apr DISC @ EQ 0.05MG BASE A 211510 003 Oct 26, 2018 Apr DISC RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019 1 -57

LISINOPRIL TABLET;ORAL LISINOPRIL AB HERITAGE PHARMA 2.5MG A 075752 001 Jul 01, 2002 Feb CAHN AB 5MG A 075752 002 Jul 01, 2002 Feb CAHN AB 10MG A 075752 003 Jul 01, 2002 Feb CAHN AB 20MG A 075752 004 Jul 01, 2002 Feb CAHN AB 30MG A 075752 005 Jul 01, 2002 Feb CAHN AB 40MG A 075752 006 Jul 01, 2002 Feb CAHN

LITHIUM CARBONATE CAPSULE;ORAL LITHIUM CARBONATE AB + HIKMA 150MG N 017812 002 Jan 28, 1987 Apr CAHN AB + 300MG N 017812 001 Apr CAHN AB +! 600MG N 017812 003 Jan 28, 1987 Apr CAHN >D> AB MYLAN 600MG A 078763 001 Apr 15, 2008 Jun DISC >A> @ 600MG A 078763 001 Apr 15, 2008 Jun DISC TABLET, EXTENDED RELEASE;ORAL LITHIUM CARBONATE @ HERITAGE PHARMA 300MG A 076170 001 Jun 10, 2002 May CAHN @ 450MG A 076366 001 Aug 21, 2003 May CAHN

LITHIUM CITRATE SYRUP;ORAL LITHIUM CITRATE AA +! HIKMA EQ 300MG CARBONATE/5ML N 018421 001 Apr CAHN

LORAZEPAM CONCENTRATE;ORAL LORAZEPAM AA SAPTALIS PHARMS 2MG/ML A 079244 001 Apr 28, 2009 Feb CAHN INJECTABLE;INJECTION ATIVAN AP +! HIKMA 2MG/ML N 018140 001 Mar CAHN AP +! 4MG/ML N 018140 002 Mar CAHN TABLET;ORAL ATIVAN AB + BAUSCH 0.5MG N 017794 001 Feb CAHN AB + 1MG N 017794 002 Feb CAHN AB +! 2MG N 017794 003 Feb CAHN

LOSARTAN POTASSIUM TABLET;ORAL LOSARTAN POTASSIUM AB HISUN PHARM HANGZHOU 25MG A 204795 001 Apr 04, 2019 Mar NEWA AB 50MG A 204795 002 Apr 04, 2019 Mar NEWA AB 100MG A 204795 003 Apr 04, 2019 Mar NEWA AB MICRO LABS 25MG A 091541 001 Sep 24, 2012 Mar CAHN AB 50MG A 091541 002 Sep 24, 2012 Mar CAHN AB 100MG A 091541 003 Sep 24, 2012 Mar CAHN AB STRIDES PHARMA 25MG A 090382 001 Oct 06, 2010 Apr CAHN AB 50MG A 090382 002 Oct 06, 2010 Apr CAHN AB 100MG A 090382 003 Oct 06, 2010 Apr CAHN

LOTEPREDNOL ETABONATE GEL;OPHTHALMIC LOTEMAX SM +! BAUSCH AND LOMB INC 0.38% N 208219 001 Feb 22, 2019 Feb NEWA SUSPENSION/DROPS;OPHTHALMIC LOTEMAX AB +! BAUSCH AND LOMB 0.5% N 020583 001 Mar 09, 1998 Apr CFTG LOTEPREDNOL ETABONATE AB HI TECH 0.5% A 207609 001 Apr 17, 2019 Apr NFTG RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019 1 -58

LOVASTATIN TABLET;ORAL LOVASTATIN AB BEXIMCO PHARMS USA 10MG A 075300 001 Dec 17, 2001 Feb CAHN AB 20MG A 075300 002 Dec 17, 2001 Feb CAHN AB 40MG A 075300 003 Dec 17, 2001 Feb CAHN @ MYLAN 10MG A 075451 001 Dec 17, 2001 Feb DISC @ 20MG A 075451 002 Dec 17, 2001 Feb DISC @ 40MG A 075451 003 Dec 17, 2001 Feb DISC

LOXAPINE HYDROCHLORIDE CONCENTRATE;ORAL LOXITANE C @ TEVA BRANDED PHARM EQ 25MG BASE/ML N 017658 001 Feb CAHN

LOXAPINE SUCCINATE CAPSULE;ORAL LOXITANE + @ TEVA BRANDED PHARM EQ 5MG BASE N 017525 001 Feb CAHN + @ EQ 10MG BASE N 017525 002 Feb CAHN + @ EQ 25MG BASE N 017525 003 Feb CAHN + @ EQ 50MG BASE N 017525 004 Feb CAHN TABLET;ORAL LOXITANE + @ TEVA BRANDED PHARM EQ 10MG BASE N 017525 006 Feb CAHN + @ EQ 25MG BASE N 017525 007 Feb CAHN + @ EQ 50MG BASE N 017525 008 Feb CAHN + @ EQ 50MG BASE N 017525 008 Feb CAHN

LURASIDONE HYDROCHLORIDE TABLET;ORAL LURASIDONE HYDROCHLORIDE >D> AB AMNEAL PHARMS CO 20MG A 208002 001 Jan 03, 2019 Jun DISC >A> @ 20MG A 208002 001 Jan 03, 2019 Jun DISC >D> AB 40MG A 208002 002 Jan 03, 2019 Jun DISC >A> @ 40MG A 208002 002 Jan 03, 2019 Jun DISC >D> AB 60MG A 208002 003 Jan 03, 2019 Jun DISC >A> @ 60MG A 208002 003 Jan 03, 2019 Jun DISC >D> AB 80MG A 208002 004 Jan 03, 2019 Jun DISC >A> @ 80MG A 208002 004 Jan 03, 2019 Jun DISC >D> AB 120MG A 208002 005 Jan 03, 2019 Jun DISC >A> @ 120MG A 208002 005 Jan 03, 2019 Jun DISC AB TEVA PHARMS USA 20MG A 208060 001 May 17, 2019 May NEWA AB 40MG A 208060 002 May 17, 2019 May NEWA AB 60MG A 208060 003 May 17, 2019 May NEWA AB 80MG A 208060 004 May 17, 2019 May NEWA AB 120MG A 208060 005 May 17, 2019 May NEWA @ TORRENT 20MG A 208055 001 Jan 03, 2019 Feb DISC @ 40MG A 208055 002 Jan 03, 2019 Feb DISC @ 80MG A 208055 003 Jan 03, 2019 Feb DISC @ 120MG A 208055 004 Jan 03, 2019 Feb DISC AB ZYDUS PHARMS 20MG A 208052 001 Mar 19, 2019 Mar NEWA AB 40MG A 208052 002 Mar 19, 2019 Mar NEWA AB 60MG A 208052 003 Mar 19, 2019 Mar NEWA AB 80MG A 208052 004 Mar 19, 2019 Mar NEWA AB 120MG A 208052 005 Mar 19, 2019 Mar NEWA

MAGNESIUM SULFATE SOLUTION;INTRAMUSCULAR, INTRAVENOUS MAGNESIUM SULFATE AP +! FRESENIUS KABI USA 10GM/20ML (500MG/ML) N 019316 003 Jan 29, 2016 Jan CTEC AP HOSPIRA INC 10GM/20ML (500MG/ML) A 202411 001 May 14, 2015 Jan CTEC

MAGNESIUM SULFATE; POTASSIUM SULFATE; SODIUM SULFATE POWDER;ORAL COLPREP KIT + @ GATOR PHARMS 1.6GM/BOT;3.13GM/BOT;17.5GM/BOT N 204553 001 Dec 27, 2016 Mar DISC RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019 1 -59

MANNITOL INJECTABLE;INJECTION MANNITOL 25% @ LUITPOLD 12.5GM/50ML A 087409 001 Jan 21, 1982 Mar DISC

MECLIZINE HYDROCHLORIDE TABLET;ORAL ANTIVERT AA + CASPER PHARMA LLC 12.5MG N 010721 006 Feb CMFD + @ 12.5MG N 010721 006 Jan CRLD AA + 25MG N 010721 004 Feb CMFD + @ 25MG N 010721 004 Jan CRLD AA + 50MG N 010721 001 Jan 20, 1982 Feb CMFD + @ 50MG N 010721 001 Jan 20, 1982 Jan CRLD MECLIZINE HYDROCHLORIDE AA ! AMNEAL PHARMS 12.5MG A 201451 001 Feb 23, 2011 Jan CHRS AA ! 25MG A 201451 002 Feb 23, 2011 Jan CHRS @ ANI PHARMS INC 12.5MG A 088732 001 Dec 11, 1985 May CAHN AA INDICUS PHARMA 12.5MG A 205136 001 Feb 22, 2019 Feb NEWA AA 25MG A 205136 002 Feb 22, 2019 Feb NEWA 50MG A 205136 003 Feb 22, 2019 Feb NEWA TABLET, CHEWABLE;ORAL ANTIVERT AA + CASPER PHARMA LLC 25MG N 010721 005 Feb CMFD + @ 25MG N 010721 005 Jan CRLD

MEDROXYPROGESTERONE ACETATE INJECTABLE;INJECTION MEDROXYPROGESTERONE ACETATE AB CIPLA 150MG/ML A 210335 001 Jan 25, 2019 Jan NEWA AB SUN PHARM 150MG/ML A 210760 001 May 01, 2019 Apr NEWA AB 150MG/ML A 210761 001 Apr 24, 2019 Apr NEWA

MEFENAMIC ACID CAPSULE;ORAL MEFENAMIC ACID @ BRECKENRIDGE PHARM 250MG A 090359 001 Feb 05, 2013 Feb DISC

MEGESTROL ACETATE SUSPENSION;ORAL MEGESTROL ACETATE @ PD PARTNERS 40MG/ML A 077404 001 Feb 16, 2006 May CAHN

MELOXICAM CAPSULE;ORAL VIVLODEX + EGALET 5MG N 207233 001 Oct 22, 2015 Feb CAHN +! 10MG N 207233 002 Oct 22, 2015 Feb CAHN SUSPENSION;ORAL MOBIC >A> + @ AVONDALE PHARMS 7.5MG/5ML N 021530 001 Jun 01, 2004 Jun CAHN >D> + @ BOEHRINGER INGELHEIM 7.5MG/5ML N 021530 001 Jun 01, 2004 Jun CAHN TABLET;ORAL MELOXICAM AB HERITAGE PHARMA 7.5MG A 077936 001 Jul 19, 2006 Feb CAHN AB 15MG A 077936 002 Jul 19, 2006 Feb CAHN

MELPHALAN HYDROCHLORIDE INJECTABLE;INJECTION ALKERAN AP + APOTEX INC EQ 50MG BASE/VIAL N 020207 001 Nov 18, 1992 Feb CMFD MELPHALAN HYDROCHLORIDE AP ALVOGEN INC EQ 50MG BASE/VIAL A 204817 001 May 17, 2019 May NEWA AP GLAND PHARMA LTD EQ 50MG BASE/VIAL A 209826 001 May 28, 2019 May NEWA AP US WORLDMEDS LLC EQ 50MG BASE/VIAL A 207032 001 May 03, 2019 Apr NEWA POWDER;INTRAVENOUS EVOMELA +! ACROTECH EQ 50MG BASE/VIAL N 207155 001 Mar 10, 2016 Mar CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019 1 -60

MEMANTINE HYDROCHLORIDE SOLUTION;ORAL MEMANTINE HYDROCHLORIDE AA ! TORRENT 2MG/ML A 205446 001 Dec 07, 2015 Jan CAHN TABLET;ORAL MEMANTINE HYDROCHLORIDE @ APOTEX INC 5MG A 090244 001 Jul 11, 2018 Jan DISC @ 10MG A 090244 002 Jul 11, 2018 Jan DISC AB CADILA 5MG A 090961 001 Jul 10, 2017 Feb CAHN AB 10MG A 090961 002 Jul 10, 2017 Feb CAHN

MEPERIDINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE INJECTABLE;INJECTION MEPERGAN >A> @ HIKMA 25MG/ML;25MG/ML N 011730 001 Jun CAHN >D> @ WEST-WARD PHARMS INT 25MG/ML;25MG/ML N 011730 001 Jun CAHN

MEQUINOL; TRETINOIN SOLUTION;TOPICAL SOLAGE @ ALMIRALL 2%;0.01% N 020922 001 Dec 10, 1999 Feb CAHN

MESALAMINE CAPSULE, DELAYED RELEASE;ORAL DELZICOL AB +! APIL 400MG N 204412 001 Feb 01, 2013 Apr CFTG MESALAMINE AB TEVA PHARMS USA 400MG A 207873 001 May 09, 2019 Apr NFTG SUPPOSITORY;RECTAL MESALAMINE >A> AB AMRING PHARMS 1GM A 208362 001 Jun 21, 2019 Jun NEWA AB PHARM SOURCING 1GM A 207448 001 Apr 19, 2019 Apr NEWA AB SANDOZ INC 1GM A 202065 001 Jun 12, 2019 May NEWA TABLET, DELAYED RELEASE;ORAL MESALAMINE AB SUN PHARM 1.2GM A 211858 001 Jan 25, 2019 Jan NEWA

METAPROTERENOL SULFATE TABLET;ORAL METAPROTERENOL SULFATE @ HERITAGE PHARMA 10MG A 072519 001 Mar 30, 1990 May CAHN @ 20MG A 072520 001 Mar 30, 1990 May CAHN

METAXALONE TABLET;ORAL METAXALONE AB APPCO PHARMA LLC 800MG A 208774 001 Sep 24, 2018 Feb CAHN

METFORMIN HYDROCHLORIDE TABLET;ORAL >D> GLUCOPHAGE >D> AB + BRISTOL MYERS SQUIBB 500MG N 020357 001 Mar 03, 1995 Jun DISC >A> + @ 500MG N 020357 001 Mar 03, 1995 Jun DISC >D> AB + 850MG N 020357 002 Mar 03, 1995 Jun DISC >A> + @ 850MG N 020357 002 Mar 03, 1995 Jun DISC >D> AB +! 1GM N 020357 005 Nov 05, 1998 Jun DISC >A> + @ 1GM N 020357 005 Nov 05, 1998 Jun DISC METFORMIN HYDROCHLORIDE >D> AB GRANULES INDIA 1GM A 090564 003 Apr 22, 2010 Jun CHRS >A> AB ! 1GM A 090564 003 Apr 22, 2010 Jun CHRS AB HERITAGE PHARMA 500MG A 075978 001 Jan 25, 2002 Feb CAHN AB 850MG A 075978 002 Jan 25, 2002 Feb CAHN AB 1GM A 075978 003 Nov 05, 2002 Feb CAHN @ SUNSHINE LAKE 500MG A 208999 001 Oct 12, 2018 Apr DISC @ 850MG A 208999 002 Oct 12, 2018 Apr DISC @ 1GM A 208999 003 Oct 12, 2018 Apr DISC TABLET, EXTENDED RELEASE;ORAL FORTAMET + @ ANDRX LABS LLC 500MG N 021574 001 Apr 27, 2004 Apr DISC + @ 1GM N 021574 002 Apr 27, 2004 Apr DISC RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019 1 -61

TABLET, EXTENDED RELEASE;ORAL >D> GLUCOPHAGE XR >D> AB1 + BRISTOL MYERS SQUIBB 500MG N 021202 001 Oct 13, 2000 Jun DISC >A> + @ 500MG N 021202 001 Oct 13, 2000 Jun DISC >D> AB +! 750MG N 021202 004 Apr 11, 2003 Jun DISC >A> + @ 750MG N 021202 004 Apr 11, 2003 Jun DISC METFORMIN HYDROCHLORIDE >D> AB AMNEAL PHARMS NY 750MG A 078596 002 Jan 03, 2008 Jun CHRS >A> AB ! 750MG A 078596 002 Jan 03, 2008 Jun CHRS AB1 CADILA 500MG A 077060 001 Apr 20, 2005 Feb CAHN AB 750MG A 077078 001 Apr 21, 2005 Feb CAHN AB2 ! LUPIN LTD 1GM A 090692 002 Jun 29, 2011 Apr CHRS >D> AB1 SUN PHARM INDS (IN) 500MG A 077336 001 Feb 09, 2006 Jun CHRS >A> AB1 ! 500MG A 077336 001 Feb 09, 2006 Jun CHRS @ YICHANG HUMANWELL 500MG A 211052 001 Sep 24, 2018 Mar DISC @ 750MG A 211052 002 Sep 24, 2018 Mar DISC

METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE TABLET, EXTENDED RELEASE;ORAL ACTOPLUS MET XR + @ TAKEDA PHARMS USA 1GM;EQ 15MG BASE N 022024 001 May 12, 2009 Mar DISC + @ 1GM;EQ 30MG BASE N 022024 002 May 12, 2009 Mar DISC

METHAZOLAMIDE TABLET;ORAL METHAZOLAMIDE @ MICRO LABS 25MG A 207438 001 Oct 05, 2018 Mar DISC @ 50MG A 207438 002 Oct 05, 2018 Mar DISC

METHOCARBAMOL SOLUTION;IM-IV METHOCARBAMOL AP SLATE 1GM/10ML (100MG/ML) A 208116 001 Jan 19, 2017 Feb CAHN ROBAXIN AP +! HIKMA 1GM/10ML (100MG/ML) N 011790 001 Feb CAHN

METHOTREXATE SOLUTION;SUBCUTANEOUS RASUVO +! MEDEXUS 7.5MG/0.15ML (7.5MG/0.15ML) N 205776 001 Jul 10, 2014 Apr CAHN +! 10MG/0.20ML (10MG/0.20ML) N 205776 002 Jul 10, 2014 Apr CAHN +! 12.5MG/0.25ML (12.5MG/0.25ML) N 205776 003 Jul 10, 2014 Apr CAHN +! 15MG/0.30ML (15MG/0.30ML) N 205776 004 Jul 10, 2014 Apr CAHN +! 17.5MG/0.35ML (17.5MG/0.35ML) N 205776 005 Jul 10, 2014 Apr CAHN +! 20MG/0.4ML (20MG/0.4ML) N 205776 006 Jul 10, 2014 Apr CAHN +! 22.5MG/0.45ML (22.5MG/0.45ML) N 205776 007 Jul 10, 2014 Apr CAHN +! 25MG/0.5ML (25MG/0.5ML) N 205776 008 Jul 10, 2014 Apr CAHN + @ 27.5MG/0.55ML (27.5MG/0.55ML) N 205776 009 Jul 10, 2014 Apr CAHN +! 30MG/0.6ML (30MG/0.6ML) N 205776 010 Jul 10, 2014 Apr CAHN

METHSCOPOLAMINE BROMIDE TABLET;ORAL METHSCOPOLAMINE BROMIDE >D> AA BRECKENRIDGE PHARM 2.5MG A 040642 001 Dec 06, 2011 Jun DISC >A> @ 2.5MG A 040642 001 Dec 06, 2011 Jun DISC >D> AA 5MG A 040642 002 Dec 06, 2011 Jun DISC >A> @ 5MG A 040642 002 Dec 06, 2011 Jun DISC

METHYLDOPA TABLET;ORAL METHYLDOPA AB HERITAGE PHARMA 250MG A 070098 001 Feb 20, 1986 Feb CAHN AB 500MG A 070343 001 Feb 20, 1986 Feb CAHN

METHYLDOPATE HYDROCHLORIDE INJECTABLE;INJECTION METHYLDOPATE HYDROCHLORIDE @ LUITPOLD 50MG/ML A 071279 001 Oct 02, 1987 Mar DISC RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019 1 -62

METHYLERGONOVINE MALEATE TABLET;ORAL METHYLERGONOVINE MALEATE AB TEVA PHARMS USA 0.2MG A 211455 001 Mar 20, 2019 Mar NEWA

METHYLPHENIDATE HYDROCHLORIDE CAPSULE, EXTENDED RELEASE;ORAL ADHANSIA XR + PURDUE PHARMA LP 25MG N 212038 001 Feb 27, 2019 Mar CRLD 25MG N 212038 001 Feb 27, 2019 Feb NEWA + 35MG N 212038 002 Feb 27, 2019 Feb NEWA + 45MG N 212038 003 Feb 27, 2019 Feb NEWA + 55MG N 212038 004 Feb 27, 2019 Feb NEWA + 70MG N 212038 005 Feb 27, 2019 Feb NEWA + 85MG N 212038 006 Feb 27, 2019 Feb NEWA METHYLPHENIDATE HYDROCHLORIDE AB1 GRANULES PHARMS 10MG A 211796 001 May 23, 2019 May NEWA AB1 20MG A 211796 002 May 23, 2019 May NEWA AB1 30MG A 211796 003 May 23, 2019 May NEWA AB1 40MG A 211796 004 May 23, 2019 May NEWA AB1 60MG A 211796 005 May 23, 2019 May NEWA AB1 ! MAYNE PHARMA 60MG A 078458 004 Jun 23, 2016 May CTEC FOR SUSPENSION, EXTENDED RELEASE;ORAL METHYLPHENIDATE HYDROCHLORIDE @ ACTAVIS LABS FL INC 5MG/ML A 206049 001 May 17, 2018 Jan DISC QUILLIVANT XR +! NEXTWAVE 5MG/ML N 202100 001 Sep 27, 2012 Feb CAHN +! NEXTWAVE PHARMS 5MG/ML N 202100 001 Sep 27, 2012 Jan CTEC TABLET;ORAL METHYLPHENIDATE HYDROCHLORIDE @ AUROLIFE PHARMA LLC 5MG A 209276 001 Oct 25, 2018 Apr DISC @ 10MG A 209276 002 Oct 25, 2018 Apr DISC @ 20MG A 209276 003 Oct 25, 2018 Apr DISC AB CEDIPROF INC 5MG A 208737 001 Feb 01, 2019 Jan NEWA AB 10MG A 208737 002 Feb 01, 2019 Jan NEWA AB 20MG A 208737 003 Feb 01, 2019 Jan NEWA @ LANNETT CO INC 5MG A 086429 001 Jan DISC @ 10MG A 085799 001 Jan DISC @ 20MG A 086428 001 Jan DISC TABLET, EXTENDED RELEASE;ORAL METADATE ER @ LANNETT CO INC 20MG A 089601 001 Jun 01, 1988 Jan DISC METHYLPHENIDATE HYDROCHLORIDE AB ! ABHAI LLC 20MG A 207488 002 Jun 09, 2015 Jan NEWA AB ANDOR PHARMS 18MG A 211918 001 Apr 24, 2019 Apr NEWA AB 27MG A 211918 002 Apr 24, 2019 Apr NEWA AB 36MG A 211918 003 Apr 24, 2019 Apr NEWA AB 54MG A 211918 004 Apr 24, 2019 Apr NEWA @ HERITAGE PHARMA 20MG A 075450 001 Dec 21, 2001 May CAHN

METHYLPREDNISOLONE TABLET;ORAL MEDROL AB + PHARMACIA AND UPJOHN 2MG N 011153 002 Mar CFTG METHYLPREDNISOLONE AB LUPIN LTD 2MG A 209097 001 Feb 22, 2019 Mar NFTG AB 2MG A 209097 001 Feb 22, 2019 Feb NEWA AB 4MG A 209097 002 Feb 22, 2019 Feb NEWA AB 8MG A 209097 003 Feb 22, 2019 Feb NEWA AB 16MG A 209097 004 Feb 22, 2019 Feb NEWA AB 32MG A 209097 005 Feb 22, 2019 Feb NEWA >A> AB SUNGEN PHARMA 4MG A 212262 001 Jun 27, 2019 Jun NEWA AB TIANJIN TIANYAO 4MG A 204072 001 May 14, 2018 Apr CMFD

METHYLPREDNISOLONE ACETATE INJECTABLE;INJECTION METHYLPREDNISOLONE ACETATE AB AMNEAL PHARMS CO 40MG/ML A 210043 001 May 20, 2019 May NEWA AB 80MG/ML A 210043 002 May 20, 2019 May NEWA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019 1 -63

METHYLPREDNISOLONE SODIUM SUCCINATE INJECTABLE;INJECTION A-METHAPRED @ HOSPIRA EQ 40MG BASE/VIAL A 040664 001 Dec 20, 2005 Mar DISC @ EQ 125MG BASE/VIAL A 040665 001 Dec 20, 2005 Mar DISC

METHYLTESTOSTERONE CAPSULE;ORAL VIRILON >A> @ CHARTWELL 10MG A 087750 001 Nov 24, 1982 Jun CAHN >D> @ STAR PHARMS FL 10MG A 087750 001 Nov 24, 1982 Jun CAHN

METIPRANOLOL HYDROCHLORIDE SOLUTION/DROPS;OPHTHALMIC METIPRANOLOL @ SANDOZ INC 0.3% A 075720 001 Aug 06, 2001 May DISC OPTIPRANOLOL +! BAUSCH AND LOMB 0.3% N 019907 001 Dec 29, 1989 May CTEC

METOPROLOL SUCCINATE TABLET, EXTENDED RELEASE;ORAL TOPROL-XL AB + TOPROL EQ 25MG TARTRATE N 019962 004 Feb 05, 2001 Mar CAHN AB +! EQ 50MG TARTRATE N 019962 001 Jan 10, 1992 Mar CAHN AB + EQ 100MG TARTRATE N 019962 002 Jan 10, 1992 Mar CAHN AB +! EQ 200MG TARTRATE N 019962 003 Jan 10, 1992 Mar CAHN

METOPROLOL TARTRATE INJECTABLE;INJECTION >D> LOPRESSOR >D> AP +! NOVARTIS 1MG/ML N 018704 001 Mar 30, 1984 Jun DISC >A> + @ 1MG/ML N 018704 001 Mar 30, 1984 Jun DISC METOPROLOL TARTRATE >D> AP HOSPIRA 1MG/ML A 078085 001 Apr 29, 2008 Jun CHRS >A> AP ! 1MG/ML A 078085 001 Apr 29, 2008 Jun CHRS @ LUITPOLD 1MG/ML A 090386 001 Sep 30, 2009 Mar DISC @ 1MG/ML A 091307 001 Dec 29, 2010 Feb DISC TABLET;ORAL METOPROLOL TARTRATE AB HERITAGE PHARMA 50MG A 074141 001 Jan 31, 1995 Apr CAHN AB 100MG A 074141 002 Jan 31, 1995 Apr CAHN

METRONIDAZOLE GEL;VAGINAL METROGEL-VAGINAL AB +! BAUSCH 0.75% N 020208 001 Aug 17, 1992 Mar CAHN METRONIDAZOLE >A> AB GAGE DEVELOPMENT 0.75% A 211786 001 Jul 02, 2019 Jun NEWA INJECTABLE;INJECTION METRONIDAZOLE IN PLASTIC CONTAINER AP INFORLIFE 500MG/100ML A 206191 001 Feb 25, 2019 Feb NEWA TABLET;ORAL METRONIDAZOLE AB CADILA 250MG A 206560 001 Nov 16, 2016 Mar CAHN AB 500MG A 206560 002 Nov 16, 2016 Mar CAHN AB STRIDES PHARMA 250MG A 070040 001 Jan 29, 1985 Apr CAHN AB 500MG A 070039 001 Jan 29, 1985 Apr CAHN

METYROSINE CAPSULE;ORAL DEMSER +! BAUSCH 250MG N 017871 001 Mar CAHN

MICAFUNGIN SODIUM INJECTABLE;INTRAVENOUS MICAFUNGIN SODIUM AP FRESENIUS KABI USA EQ 50MG BASE/VIAL A 207344 001 May 17, 2019 May NFTG AP EQ 100MG BASE/VIAL A 207344 002 May 17, 2019 May NFTG MYCAMINE AP +! ASTELLAS EQ 50MG BASE/VIAL N 021506 002 Mar 16, 2005 May CFTG RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019 1 -64

INJECTABLE;INTRAVENOUS MYCAMINE AP +! EQ 100MG BASE/VIAL N 021506 003 Jun 27, 2006 May CDFR

MIDAZOLAM SPRAY;NASAL NAYZILAM +! UCB INC 5MG/SPRAY N 211321 001 May 17, 2019 May NEWA

MIDAZOLAM HYDROCHLORIDE INJECTABLE;INJECTION MIDOZALAM HYDROCHLORIDE AP MYLAN ASI EQ 1MG BASE/ML A 090316 001 May 04, 2011 Apr CAHN AP EQ 5MG BASE/ML A 090316 002 May 04, 2011 Apr CAHN SYRUP;ORAL MIDAZOLAM HYDROCHLORIDE @ PD PARTNERS EQ 2MG BASE/ML A 077115 001 Sep 09, 2005 May CAHN

MIDODRINE HYDROCHLORIDE TABLET;ORAL MIDODRINE HYDROCHLORIDE @ CASI PHARMS INC 2.5MG A 076514 001 Sep 11, 2003 May DISC @ 5MG A 076514 002 Sep 11, 2003 May DISC @ 10MG A 076514 003 Jul 02, 2004 May DISC AB MYLAN PHARMS INC 5MG A 076577 002 Sep 10, 2003 May CHRS ORVATEN AB ! UPSHER SMITH LABS 5MG A 076725 002 Nov 03, 2004 May CHRS

MIFEPRISTONE TABLET;ORAL MIFEPREX AB +! DANCO LABS LLC 200MG N 020687 001 Sep 28, 2000 Mar CFTG MIFEPRISTONE AB GENBIOPRO 200MG A 091178 001 Apr 11, 2019 Mar NFTG

MINOCYCLINE HYDROCHLORIDE CAPSULE;ORAL MINOCIN AB + BAUSCH EQ 50MG BASE N 050649 001 May 31, 1990 May CAHN + @ EQ 75MG BASE N 050649 003 Feb 12, 2001 May CAHN AB + EQ 100MG BASE N 050649 002 May 31, 1990 May CAHN SUSPENSION;ORAL MINOCIN @ BAUSCH EQ 50MG BASE/5ML N 050445 001 May CAHN TABLET, EXTENDED RELEASE;ORAL MINOCYCLINE HYDROCHLORIDE AB BARR LABS INC EQ 80MG BASE A 065485 007 Apr 26, 2017 Jan CMFD AB EQ 105MG BASE A 065485 008 Apr 26, 2017 Jan CMFD

MIRTAZAPINE TABLET;ORAL MIRTAZAPINE @ WATSON LABS 15MG A 076312 001 Jun 19, 2003 May DISC @ 30MG A 076312 002 Jun 19, 2003 May DISC @ 45MG A 076312 003 Jun 19, 2003 May DISC

MISOPROSTOL TABLET;ORAL MISOPROSTOL >A> AB ZYDUS PHARMS 0.1MG A 210201 001 Jul 02, 2019 Jun NEWA >A> AB 0.2MG A 210201 002 Jul 02, 2019 Jun NEWA

MITOMYCIN INJECTABLE;INJECTION MITOMYCIN AP WEST-WARD PHARMS INT 20MG/VIAL A 064117 002 Apr 19, 1995 Jan CMFD AP 40MG/VIAL A 064117 003 Jun 02, 1999 Jan CMFD RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019 1 -65

MITOXANTRONE HYDROCHLORIDE INJECTABLE;INJECTION MITOXANTRONE HYDROCHLORIDE @ MYLAN INSTITUTIONAL EQ 20MG BASE/10ML (EQ 2MG BASE/ML) A 078980 001 Apr 13, 2009 Mar DISC @ EQ 30MG BASE/15ML (EQ 2MG BASE/ML) A 078980 002 Apr 13, 2009 Mar DISC

MODAFINIL TABLET;ORAL MODAFINIL @ CADILA 100MG A 209966 001 Sep 14, 2017 May CAHN @ 200MG A 209966 002 Sep 14, 2017 May CAHN @ ZYDUS PHARMS 100MG A 209966 001 Sep 14, 2017 Apr DISC @ 200MG A 209966 002 Sep 14, 2017 Apr DISC

MONTELUKAST SODIUM GRANULE;ORAL MONTELUKAST SODIUM @ MYLAN PHARMS INC EQ 4MG BASE/PACKET A 202776 001 Dec 18, 2012 Feb DISC AB TORRENT EQ 4MG BASE/PACKET A 210431 001 Jul 31, 2018 Mar CAHN TABLET;ORAL MONTELUKAST SODIUM AB L PERRIGO CO EQ 10MG BASE A 206112 001 Apr 26, 2017 May CAHN @ VINTAGE PHARMS LLC EQ 10MG BASE A 091576 001 Aug 03, 2012 Feb DISC TABLET, CHEWABLE;ORAL MONTELUKAST SODIUM @ MYLAN PHARMS INC EQ 4MG BASE A 079142 001 Aug 03, 2012 Apr DISC @ EQ 5MG BASE A 079142 002 Aug 03, 2012 Apr DISC @ VINTAGE PHARMS LLC EQ 4MG BASE A 091588 001 Aug 03, 2012 Feb DISC @ EQ 5MG BASE A 091588 002 Aug 03, 2012 Feb DISC

MORPHINE SULFATE INJECTABLE;INJECTION ASTRAMORPH PF @ FRESENIUS KABI USA 0.5MG/ML A 071050 001 Oct 07, 1986 Mar DISC @ 0.5MG/ML A 071051 001 Oct 07, 1986 Mar DISC @ 1MG/ML A 071052 001 Oct 07, 1986 Mar DISC @ 1MG/ML A 071053 001 Oct 07, 1986 Mar DISC SOLUTION;ORAL MORPHINE SULFATE @ LANNETT CO INC 10MG/5ML A 202309 001 Nov 25, 2015 Feb DISC @ 20MG/5ML A 202310 001 Oct 30, 2015 Jan DISC @ 100MG/5ML N 201517 001 Jun 23, 2011 Jan DISC TABLET;ORAL MORPHINE SULFATE >A> + HIKMA 15MG N 022207 001 Mar 17, 2008 Jun CAHN >A> +! 30MG N 022207 002 Mar 17, 2008 Jun CAHN >D> + WEST-WARD PHARMS INT 15MG N 022207 001 Mar 17, 2008 Jun CAHN >D> +! 30MG N 022207 002 Mar 17, 2008 Jun CAHN TABLET, EXTENDED RELEASE;ORAL ARYMO ER + @ EGALET 15MG N 208603 001 Jan 09, 2017 Mar CAHN + @ 30MG N 208603 002 Jan 09, 2017 Mar CAHN + @ 60MG N 208603 003 Jan 09, 2017 Mar CAHN MORPHINE SULFATE @ MYLAN PHARMS INC 200MG A 200824 005 Oct 18, 2011 Feb DISC

MOXIFLOXACIN HYDROCHLORIDE SOLUTION/DROPS;OPHTHALMIC MOXIFLOXACIN HYDROCHLORIDE AT1 ALEMBIC PHARMS LTD EQ 0.5% BASE A 209469 001 Feb 13, 2019 Jan NEWA TABLET;ORAL MOXIFLOXACIN HYDROCHLORIDE @ SUNSHINE LAKE EQ 400MG BASE A 206295 001 Sep 28, 2018 Mar DISC

MUPIROCIN OINTMENT;TOPICAL MUPIROCIN AB ! PERRIGO ISRAEL 2% A 065123 001 Nov 07, 2003 May CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019 1 -66

MYCOPHENOLATE MOFETIL SUSPENSION;ORAL MYCOPHENOLATE MOFETIL AB VISTAPHARM 200MG/ML A 210370 001 Feb 12, 2019 Jan NEWA

NADOLOL TABLET;ORAL NADOLOL AB HERITAGE PHARMA 20MG A 074229 001 Aug 30, 1996 Apr CAHN AB 40MG A 074229 002 Aug 30, 1996 Apr CAHN AB 80MG A 074255 001 Jan 24, 1996 Apr CAHN @ 120MG A 074255 002 Jan 24, 1996 Apr CAHN @ 160MG A 074255 003 Jan 24, 1996 Apr CAHN

NAFTIFINE HYDROCHLORIDE GEL;TOPICAL NAFTIFINE HYDROCHLORIDE TA RO@ TARO@ 2% A 208201 001 Apr 10, 2019 May DISC AB 2% A 208201 001 Apr 10, 2019 Mar NFTG AB TOLMAR 1% A 206165 001 Mar 20, 2019 Mar NFTG NAFTIN AB +! SEBELA IRELAND LTD 1% N 019356 001 Jun 18, 1990 Mar CFTG AB +! 2% N 204286 001 Jun 27, 2013 Mar CFTG

NALBUPHINE HYDROCHLORIDE INJECTABLE;INJECTION NALBUPHINE HYDROCHLORIDE @ DR REDDYS 10MG/ML A 074471 001 Mar 19, 1998 May CAHN @ 20MG/ML A 074471 002 Mar 19, 1998 May CAHN AP MYLAN LABS LTD 10MG/ML A 206506 001 Feb 06, 2019 Jan NEWA AP 20MG/ML A 206506 002 Feb 06, 2019 Jan NEWA

NALDEMEDINE TOSYLATE TABLET;ORAL SYMPROIC +! BDSI EQ 0.2MG BASE N 208854 001 Mar 23, 2017 Apr CAHN

NALOXONE HYDROCHLORIDE SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS EVZIO (AUTOINJECTOR) +! KALEO INC 2MG/0.4ML (2MG/0.4ML) N 209862 001 Oct 19, 2016 Feb CTNA SPRAY, METERED;NASAL NALOXONE HYDROCHLORIDE @ TEVA PHARMS USA 4MG/SPRAY A 209522 001 Apr 19, 2019 May DISC AB 4MG/SPRAY A 209522 001 Apr 19, 2019 Apr NFTG NARCAN +! ADAPT 4MG/SPRAY N 208411 001 Nov 18, 2015 May CTEC AB +! 4MG/SPRAY N 208411 001 Nov 18, 2015 Apr CFTG

NALOXONE HYDROCHLORIDE; PENTAZOCINE HYDROCHLORIDE TABLET;ORAL NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE AB LUPIN EQ 0.5MG BASE;EQ 50MG BASE A 075735 001 Jul 11, 2001 Feb CAHN

NANDROLONE DECANOATE INJECTABLE;INJECTION NANDROLONE DECANOATE @ LUITPOLD 200MG/ML A 091252 001 Aug 30, 2010 Feb DISC

NAPROXEN SUSPENSION;ORAL NAPROSYN >D> AB +! ATNAHS PHARMA US 25MG/ML N 018965 001 Mar 23, 1987 Jun CHRS >A> AB + 25MG/ML N 018965 001 Mar 23, 1987 Jun CHRS NAPROXEN >D> AB ROXANE 25MG/ML A 074190 001 Mar 30, 1994 Jun CHRS >A> AB ! WEST-WARD PHARMS INT 25MG/ML A 074190 001 Mar 30, 1994 Jun CHRS TABLET;ORAL NAPROXEN AB PERRIGO PHARMS CO 250MG A 077339 001 Apr 27, 2005 Apr CAHN AB 375MG A 077339 002 Apr 27, 2005 Apr CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019 1 -67

TABLET;ORAL NAPROXEN AB 500MG A 077339 003 Apr 27, 2005 Apr CAHN

NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE TABLET;ORAL TREXIMET + @ CURRAX 60MG;EQ 10MG BASE N 021926 002 May 14, 2015 Apr CAHN AB +! 500MG;EQ 85MG BASE N 021926 001 Apr 15, 2008 Apr CAHN

NARATRIPTAN HYDROCHLORIDE TABLET;ORAL NARATRIPTAN >D> AB CASI PHARMS INC EQ 1MG BASE A 090288 001 Jul 07, 2010 Jun DISC >A> @ EQ 1MG BASE A 090288 001 Jul 07, 2010 Jun DISC >D> AB EQ 2.5MG BASE A 090288 002 Jul 07, 2010 Jun DISC >A> @ EQ 2.5MG BASE A 090288 002 Jul 07, 2010 Jun DISC

NATEGLINIDE TABLET;ORAL NATEGLINIDE AB CADILA PHARMS LTD 60MG A 206432 001 Apr 19, 2019 Apr NEWA AB 120MG A 206432 002 Apr 19, 2019 Apr NEWA

NEOMYCIN SULFATE TABLET;ORAL NEOMYCIN SULFATE >D> AA LANNETT CO INC 500MG A 204435 001 Jun 10, 2016 Jun DISC >A> @ 500MG A 204435 001 Jun 10, 2016 Jun DISC

NEOSTIGMINE METHYLSULFATE SOLUTION;INTRAVENOUS NEOSTIGMINE METHYLSULFATE AP AMRING PHARMS 5MG/10ML (0.5MG/ML) A 210989 001 Aug 22, 2018 Jan CAHN AP 10MG/10ML (1MG/ML) A 210989 002 Aug 22, 2018 Jan CAHN AP BE PHARMS 5MG/10ML (0.5MG/ML) A 212512 001 May 13, 2019 Apr NEWA AP 10MG/10ML (1MG/ML) A 212512 002 May 13, 2019 Apr NEWA

NIACIN TABLET, EXTENDED RELEASE;ORAL NIACIN @ JUBILANT GENERICS 500MG A 209156 001 May 14, 2018 Apr DISC @ 750MG A 209156 002 May 14, 2018 Apr DISC @ 1GM A 209156 003 May 14, 2018 Apr DISC AB MYLAN 500MG A 203742 001 Feb 22, 2019 Feb NEWA AB 750MG A 203742 002 Feb 22, 2019 Feb NEWA AB 1GM A 203742 003 Feb 22, 2019 Feb NEWA AB YICHANG HUMANWELL 500MG A 212017 001 Jun 10, 2019 May NEWA AB 750MG A 212017 002 Jun 10, 2019 May NEWA AB 1GM A 212017 003 Jun 10, 2019 May NEWA

NIFEDIPINE TABLET, EXTENDED RELEASE;ORAL NIFEDIPINE AB2 NOVAST LABS 30MG A 210614 001 Mar 12, 2019 Feb NEWA AB2 60MG A 210614 002 Mar 12, 2019 Feb NEWA AB2 90MG A 210614 003 Mar 12, 2019 Feb NEWA AB2 OSMOTICA PHARM US 90MG A 077127 003 Oct 03, 2007 Apr CMS1 AB2 SPIL 30MG A 210838 001 Apr 16, 2019 Apr NEWA AB2 60MG A 210838 002 Apr 16, 2019 Apr NEWA AB2 90MG A 210838 003 Apr 16, 2019 Apr NEWA

NITROGLYCERIN AEROSOL, METERED;SUBLINGUAL NITROMIST +! EVUS 0.4MG/SPRAY N 021780 001 Nov 02, 2006 May CAHN FILM, EXTENDED RELEASE;TRANSDERMAL MINITRAN @ MEDICIS 0.4MG/HR A 089773 001 Aug 30, 1996 May DISC @ VALEANT PHARMS 0.1MG/HR A 089771 001 Aug 30, 1996 May DISC >D> AB1 0.6MG/HR A 089774 001 Aug 30, 1996 Jun DISC >A> @ 0.6MG/HR A 089774 001 Aug 30, 1996 Jun DISC RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019 1 -68

FILM, EXTENDED RELEASE;TRANSDERMAL MINITRAN @ VALEANT PHARMS NORTH 0.2MG/HR A 089772 001 Aug 30, 1996 May DISC NITRO-DUR +! USPHARMA 0.1MG/HR N 020145 001 Apr 04, 1995 May CTEC +! 0.2MG/HR N 020145 002 Apr 04, 1995 May CTEC +! 0.4MG/HR N 020145 004 Apr 04, 1995 May CTEC >D> AB1 +! 0.6MG/HR N 020145 005 Apr 04, 1995 Jun CTEC >A> +! 0.6MG/HR N 020145 005 Apr 04, 1995 Jun CTEC NITROGLYCERIN AB2 HERCON PHARM 0.1MG/HR A 089885 002 Oct 30, 2017 Feb NEWA AB2 ! MYLAN TECHNOLOGIES 0.1MG/HR A 074559 004 Feb 06, 1998 Feb CTEC TABLET;SUBLINGUAL NITROGLYCERIN AB ALVOGEN MALTA 0.3MG A 211604 001 Apr 30, 2019 Apr NEWA AB 0.4MG A 211604 002 Apr 30, 2019 Apr NEWA AB 0.6MG A 211604 003 Apr 30, 2019 Apr NEWA

NORETHINDRONE TABLET;ORAL-28 MICRONOR + @ JANSSEN PHARMS 0.35MG N 016954 001 Mar DISC NORETHINDRONE AB2 ! MYLAN LABS LTD 0.35MG A 200980 001 Jun 12, 2013 Mar CHRS

NORETHINDRONE ACETATE TABLET;ORAL NORETHINDRONE ACETATE AB RISING 5MG A 206490 001 Nov 05, 2018 May CAHN

NYSTATIN OINTMENT;TOPICAL NYSTATIN AT TORRENT 100,000 UNITS/GM A 211838 001 Jan 28, 2019 Jan NEWA POWDER;TOPICAL NYSTATIN AT LUPIN 100,000 UNITS/GM A 065138 001 Jul 23, 2004 Feb CAHN

NYSTATIN; TRIAMCINOLONE ACETONIDE OINTMENT;TOPICAL NYSTATIN AND TRIAMCINOLONE ACETONIDE @ ZYDUS PHARMS 100,000 UNITS/GM;0.1% A 207764 001 Nov 08, 2018 Mar DISC

OCTREOTIDE ACETATE INJECTABLE;INJECTION OCTREOTIDE ACETATE AP HERITAGE PHARMS INC EQ 0.05MG BASE/ML A 204669 001 Dec 27, 2018 Apr CAHN AP EQ 0.1MG BASE/ML A 204669 002 Dec 27, 2018 Apr CAHN @ EQ 0.2MG BASE/ML A 203765 001 Sep 07, 2018 Mar DISC AP EQ 0.2MG BASE/ML A 203765 001 Sep 07, 2018 Jan CAHN AP EQ 0.5MG BASE/ML A 204669 003 Dec 27, 2018 Apr CAHN @ EQ 1MG BASE/ML A 203765 002 Sep 07, 2018 Mar DISC AP EQ 1MG BASE/ML A 203765 002 Sep 07, 2018 Jan CAHN

OFLOXACIN SOLUTION/DROPS;OPHTHALMIC OFLOXACIN AT APOTEX INC 0.3% A 076513 001 May 14, 2004 Feb CMFD @ SANDOZ INC 0.3% A 076231 001 May 14, 2004 Mar DISC SOLUTION/DROPS;OTIC OFLOXACIN @ SANDOZ INC 0.3% A 078222 001 Mar 17, 2008 Mar DISC

OLANZAPINE TABLET;ORAL OLANZAPINE @ SUNSHINE LAKE 2.5MG A 206238 001 Nov 19, 2018 Apr DISC @ 5MG A 206238 002 Nov 19, 2018 Apr DISC @ 7.5MG A 206238 003 Nov 19, 2018 Apr DISC @ 10MG A 206238 004 Nov 19, 2018 Apr DISC @ 15MG A 206238 005 Nov 19, 2018 Apr DISC @ 20MG A 206238 006 Nov 19, 2018 Apr DISC RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019 1 -69

TABLET, ORALLY DISINTEGRATING;ORAL OLANZAPINE @ HEC PHARM 5MG A 208146 001 Jul 02, 2018 Feb DISC @ 10MG A 208146 002 Jul 02, 2018 Feb DISC @ 15MG A 208146 003 Jul 02, 2018 Feb DISC @ 20MG A 208146 004 Jul 02, 2018 Feb DISC

OLIVE OIL; SOYBEAN OIL >A> EMULSION;INTRAVENOUS >A> CLINOLIPID 20% >A> + @ BAXTER HLTHCARE CORP 16%(160GM/1000ML);4% N 204508 001 Oct 03, 2013 Jun CDFR (40GM/1000ML) >D> INJECTABLE;INJECTION >D> CLINOLIPID 20% >D> + @ BAXTER HLTHCARE CORP 16%(160GM/1000ML);4% N 204508 001 Oct 03, 2013 Jun CDFR (40GM/1000ML)

OLMESARTAN MEDOXOMIL TABLET;ORAL OLMESARTAN MEDOXOMIL AB SUNSHINE LAKE 5MG A 211049 001 Feb 22, 2019 Feb NEWA AB 20MG A 211049 002 Feb 22, 2019 Feb NEWA AB 40MG A 211049 003 Feb 22, 2019 Feb NEWA

OLOPATADINE HYDROCHLORIDE SOLUTION/DROPS;OPHTHALMIC OLOPATADINE HYDROCHLORIDE AT ALEMBIC PHARMS LTD EQ 0.2% BASE A 209420 001 Apr 29, 2019 Apr NEWA AT AUROBINDO PHARMA LTD EQ 0.2% BASE A 209995 001 Apr 04, 2019 Mar NEWA >A> AT USV EQ 0.1% BASE A 203152 001 Dec 07, 2015 Jun CAHN >D> AT USV NORTH AMERICA EQ 0.1% BASE A 203152 001 Dec 07, 2015 Jun CAHN

OMBITASVIR; PARITAPREVIR; RITONAVIR TABLET;ORAL TECHNIVIE + @ ABBVIE INC 12.5MG;75MG;50MG N 207931 001 Jul 24, 2015 Apr DISC

OMEGA-3-ACID ETHYL ESTERS CAPSULE;ORAL OMEGA-3-ACID ETHYL ESTERS AB ASCENT PHARMS INC 1GM CONTAINS AT LEAST 900MG OF THE A 207420 001 Feb 25, 2019 Feb NEWA ETHYL ESTERS OF OMEGA-3 FATTY ACIDS >D> AB PAR PHARM INC 1GM CONTAINS AT LEAST 900MG OF THE A 091018 001 Jun 24, 2014 Jun DISC ETHYL ESTERS OF OMEGA-3 FATTY ACIDS >A> @ 1GM CONTAINS AT LEAST 900MG OF THE A 091018 001 Jun 24, 2014 Jun DISC ETHYL ESTERS OF OMEGA-3 FATTY ACIDS >A> AB SOFGEN PHARMS 1GM CONTAINS AT LEAST 900MG OF THE A 211355 001 Jul 10, 2019 Jun NEWA ETHYL ESTERS OF OMEGA-3 FATTY ACIDS >A> AB ZYDUS 1GM CONTAINS AT LEAST 900MG OF THE A 210107 001 Jun 14, 2019 Jun NEWA ETHYL ESTERS OF OMEGA-3 FATTY ACIDS

OMEPRAZOLE CAPSULE, DELAYED REL PELLETS;ORAL OMEPRAZOLE >D> AB MYLAN 10MG A 075876 001 May 29, 2003 Jun DISC >A> @ 10MG A 075876 001 May 29, 2003 Jun DISC

OMEPRAZOLE; SODIUM BICARBONATE FOR SUSPENSION;ORAL ZEGERID AB + SALIX 20MG/PACKET;1.68GM/PACKET N 021636 001 Jun 15, 2004 Apr CAHN AB +! 40MG/PACKET;1.68GM/PACKET N 021636 002 Dec 21, 2004 Apr CAHN

ONDANSETRON HYDROCHLORIDE INJECTABLE;INJECTION ONDANSETRON HYDROCHLORIDE @ LUITPOLD EQ 2MG BASE/ML A 079039 001 Nov 18, 2008 Feb DISC RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019 1 -70

INJECTABLE;INJECTION ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE @ HIKMA FARMACEUTICA EQ 2MG BASE/ML A 076780 001 Dec 26, 2006 Feb DISC @ LUITPOLD EQ 2MG BASE/ML A 079032 001 Nov 18, 2008 Feb DISC SOLUTION;ORAL ONDANSETRON HYDROCHLORIDE AA PD PARTNERS EQ 4MG BASE/5ML A 078127 001 Jun 25, 2007 May CAHN TABLET;ORAL ONDANSETRON HYDROCHLORIDE @ MYLAN EQ 24MG BASE A 076930 004 Jun 25, 2007 Feb DISC

ORPHENADRINE CITRATE INJECTABLE;INJECTION NORFLEX + @ TELIGENT 30MG/ML N 013055 001 Jan CRLD TABLET, EXTENDED RELEASE;ORAL ORPHENADRINE CITRATE AB LUPIN 100MG A 040284 001 Jun 19, 1998 Feb CAHN

OSELTAMIVIR PHOSPHATE CAPSULE;ORAL OSELTAMIVIR PHOSPHATE >A> AB ALEMBIC PHARMS LTD EQ 30MG BASE A 211823 001 Jun 24, 2019 Jun NEWA >A> AB EQ 45MG BASE A 211823 002 Jun 24, 2019 Jun NEWA >A> AB EQ 75MG BASE A 211823 003 Jun 24, 2019 Jun NEWA FOR SUSPENSION;ORAL OSELTAMIVIR PHOSPHATE AB TEVA PHARMS USA EQ 6MG BASE/ML A 211125 001 Feb 27, 2019 Feb NEWA

OXALIPLATIN INJECTABLE;INTRAVENOUS ELOXATIN + @ SANOFI AVENTIS US 50MG/VIAL N 021492 001 Aug 09, 2002 Feb CDFR AP +! 50MG/10ML (5MG/ML) N 021759 001 Jan 31, 2005 Feb CDFR + @ 100MG/VIAL N 021492 002 Aug 09, 2002 Feb CDFR AP +! 100MG/20ML (5MG/ML) N 021759 002 Jan 31, 2005 Feb CDFR + @ 200MG/40ML (5MG/ML) N 021759 003 Nov 17, 2006 Feb CDFR OXALIPLATIN AP ACCORD HLTHCARE 50MG/10ML (5MG/ML) A 207474 001 Mar 21, 2017 Feb CDFR AP 100MG/20ML (5MG/ML) A 207474 002 Mar 21, 2017 Feb CDFR AP 200MG/40ML (5MG/ML) A 207474 003 Mar 21, 2017 Feb CDFR AP ACTAVIS LLC 50MG/10ML (5MG/ML) A 204880 001 Mar 05, 2018 Feb CDFR AP 100MG/20ML (5MG/ML) A 204880 002 Mar 05, 2018 Feb CDFR AP ACTAVIS TOTOWA 50MG/VIAL A 078803 001 Aug 08, 2012 Feb CDFR AP 100MG/VIAL A 078803 002 Aug 08, 2012 Feb CDFR AP CIPLA 50MG/10ML (5MG/ML) A 208523 001 Feb 10, 2017 Feb CDFR AP 100MG/20ML (5MG/ML) A 208523 002 Feb 10, 2017 Feb CDFR AP EUGIA PHARMA 50MG/10ML (5MG/ML) A 205529 001 Sep 06, 2017 Feb CDFR AP 100MG/20ML (5MG/ML) A 205529 002 Sep 06, 2017 Feb CDFR AP FRESENIUS KABI USA 50MG/10ML (5MG/ML) A 078811 001 Jun 10, 2010 Feb CDFR AP 100MG/20ML (5MG/ML) A 078811 002 Jun 10, 2010 Feb CDFR AP 50MG/VIAL A 078819 001 Jun 02, 2010 Feb CDFR AP 50MG/10ML (5MG/ML) A 090030 001 Jan 31, 2017 Feb CDFR AP 100MG/VIAL A 078819 002 Jun 02, 2010 Feb CDFR AP 100MG/20ML (5MG/ML) A 090030 002 Jan 31, 2017 Feb CDFR AP 200MG/40ML (5MG/ML) A 090030 003 Jan 31, 2017 Feb CDFR AP GLAND PHARMA LTD 50MG/10ML (5MG/ML) A 207325 001 Feb 10, 2017 Feb CDFR AP 50MG/VIAL A 207385 001 May 23, 2017 Feb CDFR AP 100MG/20ML (5MG/ML) A 207325 002 Feb 10, 2017 Feb CDFR AP 100MG/VIAL A 207385 002 May 23, 2017 Feb CDFR AP 200MG/40ML (5MG/ML) A 207325 003 Oct 18, 2017 Feb CDFR @ HOSPIRA INC 50MG/VIAL A 078815 001 Sep 30, 2009 Apr DISC AP 50MG/VIAL A 078815 001 Sep 30, 2009 Feb CDFR @ 100MG/VIAL A 078815 002 Sep 30, 2009 Apr DISC AP 100MG/VIAL A 078815 002 Sep 30, 2009 Feb CDFR AP HOSPIRA WORLDWIDE 50MG/10ML (5MG/ML) A 078813 001 Aug 07, 2009 Feb CDFR AP 100MG/20ML (5MG/ML) A 078813 002 Aug 07, 2009 Feb CDFR AP INGENUS PHARMS LLC 50MG/10ML (5MG/ML) A 207562 001 Oct 16, 2018 Feb CDFR AP 100MG/20ML (5MG/ML) A 207562 002 Oct 16, 2018 Feb CDFR AP JIANGSU HENGRUI MED 50MG/10ML (5MG/ML) A 203869 001 Jun 18, 2014 Feb CDFR AP 100MG/20ML (5MG/ML) A 203869 002 Jun 18, 2014 Feb CDFR @ LUITPOLD 50MG/10ML (5MG/ML) A 204378 001 May 12, 2017 Feb DISC RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019 1 -71

INJECTABLE;INTRAVENOUS OXALIPLATIN AP 50MG/10ML (5MG/ML) A 204378 001 May 12, 2017 Feb CDFR @ 100MG/20ML (5MG/ML) A 204378 002 May 12, 2017 Feb DISC AP 100MG/20ML (5MG/ML) A 204378 002 May 12, 2017 Feb CDFR AP MYLAN LABS LTD 50MG/10ML (5MG/ML) A 091358 001 Aug 07, 2012 Feb CDFR AP 50MG/VIAL A 200979 001 Aug 08, 2012 Feb CDFR AP 100MG/20ML (5MG/ML) A 091358 002 Aug 07, 2012 Feb CDFR AP 100MG/VIAL A 200979 002 Aug 08, 2012 Feb CDFR AP 200MG/40ML (5MG/ML) A 091358 003 Nov 14, 2017 Feb CDFR AP QILU PHARM CO LTD 50MG/10ML (5MG/ML) A 204368 001 Jun 07, 2016 Feb CDFR AP 50MG/VIAL A 204616 001 May 11, 2016 Feb CDFR AP 100MG/20ML (5MG/ML) A 204368 002 Jun 07, 2016 Feb CDFR AP 100MG/VIAL A 204616 002 May 11, 2016 Feb CDFR AP ! 200MG/40ML (5MG/ML) A 204368 003 Jun 07, 2016 Feb CDFR AP SANDOZ 50MG/10ML (5MG/ML) A 078817 001 Jan 24, 2011 Feb CDFR @ 50MG/VIAL A 090849 001 Apr 28, 2011 Feb CDFR AP 100MG/20ML (5MG/ML) A 078817 002 Jan 24, 2011 Feb CDFR @ 100MG/VIAL A 090849 002 Apr 28, 2011 Feb CDFR @ SANDOZ INC 50MG/10ML (5MG/ML) A 078812 001 Aug 07, 2009 Feb CDFR @ 100MG/20ML (5MG/ML) A 078812 002 Aug 07, 2009 Feb CDFR AP SUN PHARM 200MG/40ML (5MG/ML) A 202922 003 Feb 15, 2019 Apr CDFR AP +! TEVA PHARMS 50MG/10ML (5MG/ML) N 022160 001 Aug 07, 2009 Feb CDFR AP +! 100MG/20ML (5MG/ML) N 022160 002 Aug 07, 2009 Feb CDFR INJECTABLE;IV (INFUSION) OXALIPLATIN AP SUN PHARMA GLOBAL 200MG/40ML (5MG/ML) A 202922 003 Feb 15, 2019 Feb NEWA

OXAPROZIN TABLET;ORAL OXAPROZIN @ BEXIMCO PHARMS USA 600MG A 075842 001 Apr 12, 2001 Mar CAHN

OXYBUTYNIN CHLORIDE SYRUP;ORAL OXYBUTYNIN CHLORIDE @ PD PARTNERS 5MG/5ML A 074997 001 Oct 15, 1997 May CAHN TABLET;ORAL OXYBUTYNIN CHLORIDE AB EMCURE PHARMS LTD 5MG A 211682 001 May 10, 2019 Apr NEWA AB INVATECH PHARMA 5MG A 211062 001 Feb 06, 2019 Jan NEWA TABLET, EXTENDED RELEASE;ORAL OXYBUTYNIN CHLORIDE AB AJANTA PHARMA LTD 5MG A 211655 001 Feb 28, 2019 Feb NEWA AB 10MG A 211655 002 Feb 28, 2019 Feb NEWA AB 15MG A 211655 003 Feb 28, 2019 Feb NEWA

OXYCODONE HYDROCHLORIDE SOLUTION;ORAL OXYCODONE HYDROCHLORIDE AA ALKEM LABS LTD 5MG/5ML A 211748 001 Feb 07, 2019 Feb NEWA AA 100MG/5ML A 211749 001 Feb 04, 2019 Jan NEWA @ LANNETT CO INC 100MG/5ML A 204085 001 Sep 09, 2014 Jan DISC AA PHARM ASSOC 5MG/5ML A 206914 001 Feb 01, 2019 May CPOT AA 5MG/ML A 206914 001 Feb 01, 2019 Jan NEWA TABLET;ORAL OXYCODONE HYDROCHLORIDE @ VINTAGE PHARMS 5MG A 077712 003 Mar 02, 2009 Apr DISC @ 10MG A 077712 004 Apr 13, 2015 Apr DISC @ 15MG A 077712 001 Jan 31, 2007 Apr DISC @ 20MG A 077712 005 Apr 13, 2015 Apr DISC @ 30MG A 077712 002 Jan 31, 2007 Apr DISC

OXYTOCIN INJECTABLE;INJECTION OXYTOCIN @ DR REDDYS 10USP UNITS/ML (10USP UNITS/ML) A 077453 001 Jan 24, 2008 May CAHN @ 100USP UNITS/10ML (10USP UNITS/ML) A 077453 002 Jan 24, 2008 May CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019 1 -72

PACLITAXEL INJECTABLE;INJECTION PACLITAXEL @ ACCORD HLTHCARE 6MG/ML A 205720 001 Aug 17, 2018 Mar DISC >D> AP SANDOZ INC 6MG/ML A 078167 001 Dec 26, 2007 Jun DISC >A> @ 6MG/ML A 078167 001 Dec 26, 2007 Jun DISC

PALIPERIDONE TABLET, EXTENDED RELEASE;ORAL PALIPERIDONE AB INVENTIA HLTHCARE 1.5MG A 204452 001 Jun 12, 2019 May NEWA AB 3MG A 204452 002 Jun 12, 2019 May NEWA AB 6MG A 204452 003 Jun 12, 2019 May NEWA AB 9MG A 204452 004 Jun 12, 2019 May NEWA

PALONOSETRON HYDROCHLORIDE INJECTABLE;INTRAVENOUS PALONOSETRON HYDROCHLORIDE @ DR REDDYS LABS LTD EQ 0.075MG BASE/1.5ML (EQ 0.05MG A 201533 001 Apr 21, 2016 Mar DISC BASE/ML)

PAMIDRONATE DISODIUM INJECTABLE;INJECTION PAMIDRONATE DISODIUM AP DR REDDYS 30MG/10ML (3MG/ML) A 078156 001 Aug 19, 2008 May CAHN AP 60MG/10ML (6MG/ML) A 078156 002 Aug 19, 2008 May CAHN AP 90MG/10ML (9MG/ML) A 078156 003 Aug 19, 2008 May CAHN @ LUITPOLD 30MG/10ML (3MG/ML) A 078942 001 Jul 25, 2008 Mar DISC @ 90MG/10ML (9MG/ML) A 078942 002 Jul 25, 2008 Mar DISC

PANCURONIUM BROMIDE INJECTABLE;INJECTION PANCURONIUM BROMIDE AP ! DR REDDYS 1MG/ML A 072759 001 Jul 31, 1990 May CAHN ! 2MG/ML A 072760 001 Jul 31, 1990 May CAHN

PANOBINOSTAT LACTATE CAPSULE;ORAL FARYDAK >D> + NOVARTIS PHARMS CORP EQ 10MG BASE N 205353 001 Feb 23, 2015 Jun CAHN >D> + EQ 15MG BASE N 205353 002 Feb 23, 2015 Jun CAHN >D> +! EQ 20MG BASE N 205353 003 Feb 23, 2015 Jun CAHN >A> + SECURA EQ 10MG BASE N 205353 001 Feb 23, 2015 Jun CAHN >A> + EQ 15MG BASE N 205353 002 Feb 23, 2015 Jun CAHN >A> +! EQ 20MG BASE N 205353 003 Feb 23, 2015 Jun CAHN

PANTOPRAZOLE SODIUM TABLET, DELAYED RELEASE;ORAL PANTOPRAZOLE SODIUM AB INGENUS PHARMS LLC EQ 40MG BASE A 211368 001 Mar 01, 2019 Feb NEWA AB L PERRIGO CO EQ 20MG BASE A 203024 001 May 07, 2014 May CAHN

PENICILLAMINE CAPSULE;ORAL CUPRIMINE @ VALEANT PHARMS INTL 125MG N 019853 002 Jan CAHN AB +! 250MG N 019853 001 Apr CFTG +! 250MG N 019853 001 Jan CAHN PENICILLAMINE AB AMERIGEN PHARMS LTD 250MG A 209921 001 May 07, 2019 Apr NFTG >A> AB WATSON LABS INC 250MG A 210976 001 Jun 24, 2019 Jun NEWA

PENTAMIDINE ISETHIONATE FOR SOLUTION;INHALATION NEBUPENT AN +! FRESENIUS KABI USA 300MG/VIAL N 019887 001 Jun 15, 1989 Apr CFTG PENTAMIDINE ISETHIONATE AN SETON PHARMS 300MG/VIAL A 206667 001 Apr 24, 2019 Apr NFTG RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019 1 -73

PENTOSTATIN INJECTABLE;INJECTION PENTOSTATIN @ MYLAN INSTITUTIONAL 10MG/VIAL A 203554 001 Sep 19, 2014 Mar DISC

PENTOXIFYLLINE TABLET, EXTENDED RELEASE;ORAL PENTOXIFYLLINE @ ANI PHARMS INC 400MG A 074878 001 Jul 09, 1997 May CAHN >D> AB MYLAN 400MG A 074425 001 Jul 08, 1997 Jun DISC >A> @ 400MG A 074425 001 Jul 08, 1997 Jun DISC

PERMETHRIN CREAM;TOPICAL PERMETHRIN AB ENCUBE ETHICALS 5% A 211303 001 Apr 03, 2019 Mar NEWA AB PERRIGO ISRAEL 5% A 076369 001 Apr 21, 2003 May CAHN

PHENYLEPHRINE HYDROCHLORIDE SOLUTION;INTRAVENOUS PHENYLEPHRINE HYDROCHLORIDE >D> AP CIPLA 10MG/ML (10MG/ML) A 210334 001 Apr 27, 2018 Jun CAHN >D> AP 50MG/5ML (10MG/ML) A 210333 001 Apr 27, 2018 Jun CAHN >D> AP 100MG/10ML (10MG/ML) A 210333 002 Apr 27, 2018 Jun CAHN AP FRESENIUS KABI USA 10MG/ML (10MG/ML) A 210665 001 Jan 29, 2019 Jan NEWA AP 50MG/5ML (10MG/ML) A 210666 001 Jan 30, 2019 Jan NEWA AP 100MG/10ML (10MG/ML) A 210666 002 Jan 30, 2019 Jan NEWA >A> AP MEITHEAL 10MG/ML (10MG/ML) A 210334 001 Apr 27, 2018 Jun CAHN >A> AP 50MG/5ML (10MG/ML) A 210333 001 Apr 27, 2018 Jun CAHN >A> AP 100MG/10ML (10MG/ML) A 210333 002 Apr 27, 2018 Jun CAHN AP SANDOZ INC 10MG/ML (10MG/ML) A 208905 001 Jan 31, 2019 Jan NEWA AP 50MG/5ML (10MG/ML) A 208905 002 Jan 31, 2019 Jan NEWA AP 100MG/10ML (10MG/ML) A 208905 003 Jan 31, 2019 Jan NEWA SOLUTION/DROPS;OPHTHALMIC PHENYLEPHRINE HYDROCHLORIDE AT +! AKORN INC 2.5% N 207926 001 Jan 15, 2015 Jan CTEC AT +! 10% N 207926 002 Jan 15, 2015 Jan CTEC AT +! PARAGON BIOTECK 2.5% N 203510 001 Mar 21, 2013 Jan CTEC AT +! 10% N 203510 002 Mar 21, 2013 Jan CTEC

PHENYTOIN SODIUM INJECTABLE;INJECTION PHENYTOIN SODIUM @ LUITPOLD 50MG/ML A 040781 001 Dec 04, 2007 Feb DISC

PHYTONADIONE INJECTABLE;INJECTION PHYTONADIONE AB DR REDDYS LABS LTD 10MG/ML A 207719 001 May 22, 2019 May NEWA VITAMIN K1 AB ! HOSPIRA 10MG/ML A 087955 001 Jul 25, 1983 May CTEC TABLET;ORAL MEPHYTON AB +! BAUSCH 5MG N 010104 003 Feb CAHN AB +! VALEANT PHARMS INTL 5MG N 010104 003 Jan CAHN PHYTONADIONE AB ZYDUS 5MG A 210189 001 Feb 20, 2019 Feb NEWA

PIMAVANSERIN TARTRATE TABLET;ORAL NUPLAZID + @ ACADIA PHARMS INC EQ 17MG BASE N 207318 001 Apr 29, 2016 Jan DISC

PINDOLOL TABLET;ORAL PINDOLOL >D> AB ZYDUS PHARMS 5MG A 209866 001 Aug 18, 2017 Jun DISC >A> @ 5MG A 209866 001 Aug 18, 2017 Jun DISC >D> AB 10MG A 209866 002 Aug 18, 2017 Jun DISC >A> @ 10MG A 209866 002 Aug 18, 2017 Jun DISC RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019 1 -74

PIROXICAM CAPSULE;ORAL PIROXICAM AB CADILA 10MG A 205585 001 Jul 17, 2018 Feb CAHN AB 20MG A 205585 002 Jul 17, 2018 Feb CAHN

PITAVASTATIN CALCIUM TABLET;ORAL PITAVASTATIN CALCIUM @ MYLAN EQ 1MG BASE A 206070 001 Apr 04, 2019 Apr DISC @ EQ 2MG BASE A 206070 002 Apr 04, 2019 Apr DISC @ EQ 4MG BASE A 206070 003 Apr 04, 2019 Apr DISC AB MYLAN PHARMS INC EQ 1MG BASE A 206070 001 Apr 04, 2019 Mar NEWA AB EQ 2MG BASE A 206070 002 Apr 04, 2019 Mar NEWA AB EQ 4MG BASE A 206070 003 Apr 04, 2019 Mar NEWA

PLECANATIDE TABLET;ORAL TRULANCE +! BAUSCH 3MG N 208745 001 Jan 19, 2017 Mar CAHN +! SALIX 3MG N 208745 001 Jan 19, 2017 Apr CAHN

POLYETHYLENE GLYCOL 3350 FOR SOLUTION;ORAL GLYCOLAX @ LANNETT CO INC 17GM/SCOOPFUL A 076652 001 Jul 02, 2004 May DISC POLYETHYLENE GLYCOL 3350 @ NEXGEN PHARMA INC 17GM/SCOOPFUL A 077706 001 Sep 27, 2006 May DISC @ PADDOCK LLC 17GM/SCOOPFUL A 077893 001 May 26, 2006 May DISC

POTASSIUM CHLORIDE CAPSULE, EXTENDED RELEASE;ORAL POTASSIUM CHLORIDE AB PRINSTON INC 8MEQ A 209026 001 Jun 11, 2019 May NEWA AB 10MEQ A 209026 002 Jun 11, 2019 May NEWA AB ZYDUS PHARMS 8MEQ A 208445 001 Mar 11, 2019 Feb NEWA AB 10MEQ A 208445 002 Mar 11, 2019 Feb NEWA FOR SOLUTION;ORAL POTASSIUM CHLORIDE AA AMNEAL PHARMS LLC 20MEQ A 210902 001 May 23, 2019 May NEWA AA BELCHER PHARMS LLC 20MEQ A 212183 001 May 06, 2019 Apr NEWA SOLUTION;ORAL POTASSIUM CHLORIDE AA PHARM ASSOC 20MEQ/15ML A 210766 001 Mar 29, 2019 Mar NEWA AA 40MEQ/15ML A 210766 002 Mar 29, 2019 Mar NEWA TABLET, EXTENDED RELEASE;ORAL KLOR-CON M15 AB1 UPSHER SMITH LABS 15MEQ A 074726 003 Jun 06, 2003 Mar CTEC POTASSIUM CHLORIDE >A> AB1 ADARE PHARMS INC 10MEQ A 076368 002 Jun 05, 2019 Jun NEWA AB2 PII 8MEQ A 206881 001 Jan 22, 2019 Jan NEWA AB1 10MEQ A 206630 001 Mar 29, 2019 Mar NEWA AB2 10MEQ A 206881 002 Jan 22, 2019 Jan NEWA >A> AB3 10MEQ A 210097 001 Jun 17, 2019 Jun NEWA AB1 15MEQ A 206630 002 Mar 29, 2019 Mar NEWA AB1 20MEQ A 206630 003 Mar 29, 2019 Mar NEWA AB2 20MEQ A 210098 001 Apr 26, 2019 Apr NEWA AB1 PRINSTON INC 10MEQ A 209922 001 Apr 30, 2019 Apr NEWA AB1 15MEQ A 209922 002 Apr 30, 2019 Apr NEWA AB1 20MEQ A 209922 003 Apr 30, 2019 Apr NEWA

PRALATREXATE SOLUTION;INTRAVENOUS FOLOTYN + ACROTECH 20MG/ML (20MG/ML) N 022468 001 Sep 24, 2009 Mar CAHN +! 40MG/2ML (20MG/ML) N 022468 002 Sep 24, 2009 Mar CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019 1 -75

PRAMIPEXOLE DIHYDROCHLORIDE TABLET;ORAL PRAMIPEXOLE DIHYDROCHLORIDE AB HERITAGE PHARMA 0.125MG A 077724 001 Feb 19, 2008 May CAHN @ 0.125MG A 091254 001 Nov 30, 2010 May CAHN AB 0.25MG A 077724 002 Feb 19, 2008 May CAHN @ 0.25MG A 091254 002 Nov 30, 2010 May CAHN AB 0.5MG A 077724 003 Feb 19, 2008 May CAHN @ 0.5MG A 091254 003 Nov 30, 2010 May CAHN @ 0.75MG A 091254 004 Nov 30, 2010 May CAHN AB 1MG A 077724 004 Feb 19, 2008 May CAHN @ 1MG A 091254 005 Nov 30, 2010 May CAHN AB 1.5MG A 077724 005 Feb 19, 2008 May CAHN @ 1.5MG A 091254 006 Nov 30, 2010 May CAHN

PRAVASTATIN SODIUM TABLET;ORAL PRAVASTATIN SODIUM >A> AB APNAR PHARMA LP 10MG A 076397 003 Oct 23, 2006 Jun CAHN >A> AB 20MG A 076397 002 Oct 23, 2006 Jun CAHN >A> AB 40MG A 076397 001 Oct 23, 2006 Jun CAHN >A> AB 80MG A 077491 001 Feb 11, 2008 Jun CAHN >D> AB SANDOZ 10MG A 076397 003 Oct 23, 2006 Jun CAHN >D> AB 20MG A 076397 002 Oct 23, 2006 Jun CAHN >D> AB 40MG A 076397 001 Oct 23, 2006 Jun CAHN >D> AB 80MG A 077491 001 Feb 11, 2008 Jun CAHN

PREDNISOLONE SYRUP;ORAL PREDNISOLONE @ PD PARTNERS 5MG/5ML A 040570 001 Aug 25, 2005 May CAHN @ 15MG/5ML A 040571 001 Aug 25, 2005 May CAHN

PREDNISOLONE ACETATE SUSPENSION/DROPS;OPHTHALMIC ECONOPRED @ EYEVANCE 0.125% N 017468 001 May CAHN

PREDNISOLONE SODIUM PHOSPHATE; SULFACETAMIDE SODIUM SOLUTION/DROPS;OPHTHALMIC SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE ! BAUSCH AND LOMB EQ 0.23% PHOSPHATE;10% A 074449 001 Dec 29, 1995 May CTEC @ SANDOZ INC EQ 0.23% PHOSPHATE;10% A 073630 001 May 27, 1993 May DISC

PREDNISONE TABLET;ORAL PREDNISONE @ GENEYORK PHARMS 1MG A 211496 001 Dec 28, 2018 May DISC @ 2.5MG A 211495 001 Dec 07, 2018 May DISC @ 5MG A 211495 002 Dec 07, 2018 May DISC @ 10MG A 210525 001 Dec 04, 2018 May DISC @ 20MG A 210525 002 Dec 04, 2018 May DISC @ 50MG A 210525 003 Dec 04, 2018 May DISC AB SUN PHARM INDUSTRIES 5MG A 089247 002 Dec 04, 1985 Jan CMS1 AB 10MG A 089247 003 Dec 04, 1985 Jan CMS1

PROCHLORPERAZINE EDISYLATE INJECTABLE;INJECTION PROCHLORPERAZINE EDISYLATE AP NEXUS PHARMS EQ 5MG BASE/ML A 204860 001 Feb 15, 2019 Feb NEWA

PROGESTERONE INJECTABLE;INJECTION PROGESTERONE @ LUITPOLD 50MG/ML A 090845 001 Jun 22, 2009 Mar DISC RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019 1 -76

PROMETHAZINE HYDROCHLORIDE SUPPOSITORY;RECTAL PROMETHAZINE HYDROCHLORIDE AB PERRIGO ISRAEL 12.5MG A 040500 001 Jun 30, 2003 May CAHN AB 25MG A 040500 002 Jun 30, 2003 May CAHN TABLET;ORAL PROMETHAZINE HYDROCHLORIDE @ IMPAX LABS 12.5MG A 040791 002 Feb 12, 2008 Mar DISC @ 25MG A 040791 003 Feb 12, 2008 Mar DISC

PROPRANOLOL HYDROCHLORIDE TABLET;ORAL PROPRANOLOL HYDROCHLORIDE @ INNOGENIX 10MG A 070322 002 Oct 22, 1985 May CMS1 @ 20MG A 070322 003 Oct 22, 1985 May CMS1 @ 40MG A 070322 004 Oct 22, 1985 May CMS1 @ 60MG A 070322 005 Sep 24, 1986 May CMS1 @ 80MG A 070322 001 Aug 04, 1986 Mar CAHN

PROTRIPTYLINE HYDROCHLORIDE TABLET;ORAL VIVACTIL AB HERITAGE PHARMA 5MG A 073644 001 Aug 24, 1995 May CAHN AB ! 10MG A 073645 001 Aug 24, 1995 May CAHN

PYRIDOSTIGMINE BROMIDE INJECTABLE;INJECTION MESTINON AP +! BAUSCH 5MG/ML N 009830 001 Feb CAHN SYRUP;ORAL MESTINON AA +! BAUSCH 60MG/5ML N 015193 001 Feb CFTG +! 60MG/5ML N 015193 001 Feb CAHN PYRIDOSTIGMINE BROMIDE AA NOVITIUM PHARMA 60MG/5ML A 211694 001 Mar 08, 2019 Feb NFTG TABLET;ORAL MESTINON AB +! BAUSCH 60MG N 009829 002 Feb CAHN PYRIDOSTIGMINE BROMIDE APNAR PHARMA LP 30MG A 211181 002 May 14, 2019 May NEWA TABLET, EXTENDED RELEASE;ORAL MESTINON AB +! BAUSCH 180MG N 011665 001 Feb CAHN

PYRIDOXINE HYDROCHLORIDE INJECTABLE;INJECTION PYRIDOXINE HYDROCHLORIDE @ DR REDDYS 100MG/ML A 080572 001 May CAHN

QUETIAPINE FUMARATE TABLET, EXTENDED RELEASE;ORAL QUETIAPINE FUMARATE @ AMNEAL PHARMS EQ 400MG BASE A 211405 001 Oct 26, 2018 Apr DISC

QUININE SULFATE CAPSULE;ORAL QUININE SULFATE @ MYLAN PHARMS INC 324MG A 202581 001 Dec 14, 2012 Mar DISC

RABEPRAZOLE SODIUM TABLET, DELAYED RELEASE;ORAL RABEPRAZOLE SODIUM AB RUBICON 20MG A 204237 001 Nov 18, 2015 Feb CAHN

RANITIDINE HYDROCHLORIDE CAPSULE;ORAL RANITIDINE HYDROCHLORIDE AB APPCO PHARMA LLC EQ 150MG BASE A 211893 001 Apr 05, 2019 Mar NEWA AB EQ 300MG BASE A 211893 002 Apr 05, 2019 Mar NEWA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019 1 -77

SYRUP;ORAL RANITIDINE HYDROCHLORIDE AA TORRENT EQ 15MG BASE/ML A 090102 001 May 26, 2009 Jan CAHN TABLET;ORAL RANITIDINE HYDROCHLORIDE AB HERITAGE PHARMA EQ 150MG BASE A 075165 001 Sep 30, 1998 Feb CAHN AB EQ 300MG BASE A 075165 002 Sep 30, 1998 Feb CAHN AB STRIDES PHARMA EQ 150MG BASE A 210010 001 Aug 01, 2018 Apr CAHN AB EQ 300MG BASE A 210010 002 Aug 01, 2018 Apr CAHN AB VKT PHARMA PVT LTD EQ 150MG BASE A 211289 001 Jan 31, 2019 Jan NEWA AB EQ 300MG BASE A 211289 002 Jan 31, 2019 Jan NEWA

RANOLAZINE TABLET, EXTENDED RELEASE;ORAL RANEXA AB + GILEAD 500MG N 021526 002 Jan 27, 2006 Feb CTEC AB +! 1GM N 021526 001 Feb 12, 2007 Feb CTEC RANOLAZINE AB ACTAVIS ELIZABETH 500MG A 208862 001 May 28, 2019 May NEWA AB 1GM A 208862 002 May 28, 2019 May NEWA AB AJANTA PHARMA LTD 500MG A 210054 001 May 28, 2019 May NEWA AB 1GM A 210054 002 May 28, 2019 May NEWA AB CIPLA 500MG A 211291 001 May 28, 2019 May NEWA AB 1GM A 211291 002 May 28, 2019 May NEWA >A> AB GLENMARK PHARMS LTD 500MG A 211082 001 Jul 05, 2019 Jun NEWA >A> AB 1GM A 211082 002 Jul 05, 2019 Jun NEWA AB LUPIN LTD 500MG A 201046 001 Jul 29, 2013 Feb CMFD AB 1GM A 201046 002 Jul 29, 2013 Feb CMFD AB SCIEGEN PHARMS INC 500MG A 211829 001 Jun 04, 2019 May NEWA AB 1GM A 211829 002 Jun 04, 2019 May NEWA AB SUN PHARM 500MG A 211707 001 May 28, 2019 May NEWA AB 1GM A 211707 002 May 28, 2019 May NEWA

RASAGILINE MESYLATE TABLET;ORAL RASAGILINE MESYLATE AB MICRO LABS EQ 0.5MG BASE A 207004 001 Mar 29, 2019 Mar NEWA AB EQ 1MG BASE A 207004 002 Mar 29, 2019 Mar NEWA

REPAGLINIDE TABLET;ORAL PRANDIN + @ GEMINI LABS LLC 0.5MG N 020741 001 Dec 22, 1997 Mar DISC + @ 1MG N 020741 002 Dec 22, 1997 Mar DISC + @ 2MG N 020741 003 Dec 22, 1997 Mar DISC REPAGLINIDE AB ! AUROBINDO PHARMA LTD 2MG A 203820 003 Jan 22, 2014 Mar CHRS MY LAN@ MYLAN@ 0.5MG A 090252 001 Aug 23, 2013 Feb DISC

RETAPAMULIN OINTMENT;TOPICAL ALTABAX +! ALMIRALL 1% N 022055 001 Apr 12, 2007 Mar CAHN

RIBAVIRIN CAPSULE;ORAL RIBAVIRIN >D> AB CASI PHARMS INC 200MG A 076192 001 Apr 06, 2004 Jun DISC >A> @ 200MG A 076192 001 Apr 06, 2004 Jun DISC >D> SOLUTION;ORAL >D> REBETOL >D> +! SCHERING 40MG/ML N 021546 001 Jul 29, 2003 Jun DISC >A> + @ 40MG/ML N 021546 001 Jul 29, 2003 Jun DISC TABLET;ORAL RIBAVIRIN AB BEXIMCO PHARMS USA 200MG A 202546 001 Aug 12, 2014 Feb CAHN AB 400MG A 202546 002 Aug 12, 2014 Feb CAHN AB 500MG A 202546 003 Aug 12, 2014 Feb CAHN AB 600MG A 202546 004 Aug 12, 2014 Feb CAHN AB HERITAGE PHARMA 200MG A 077053 001 Dec 05, 2005 May CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019 1 -78

RILUZOLE TABLET;ORAL RILUZOLE @ DAITO PHARMS CO LTD 50MG A 204430 001 Oct 16, 2018 Mar DISC

RIMANTADINE HYDROCHLORIDE TABLET;ORAL RIMANTADINE HYDROCHLORIDE @ HERITAGE PHARMA 100MG A 076375 001 Jan 14, 2003 May CAHN

RIMEXOLONE SUSPENSION/DROPS;OPHTHALMIC VEXOL @ EYEVANCE 1% N 020474 001 Dec 30, 1994 May CAHN

RISEDRONATE SODIUM TABLET;ORAL RISEDRONATE SODIUM AB HANGZHOU BINJIANG 35MG A 207516 001 Feb 15, 2019 Feb NEWA @ MYLAN 5MG A 200477 001 Nov 30, 2015 May DISC @ 30MG A 200477 002 Nov 30, 2015 May DISC @ 35MG A 200477 003 Nov 30, 2015 May DISC @ 75MG A 200477 004 Jun 10, 2014 May DISC @ 150MG A 200477 005 Jun 10, 2014 May DISC AB ORCHID HLTHCARE 30MG A 205280 001 May 13, 2019 Apr NEWA AB 35MG A 205280 002 May 13, 2019 Apr NEWA TABLET, DELAYED RELEASE;ORAL RISEDRONATE SODIUM >A> AB SUN PHARM 35MG A 203925 001 Jul 09, 2019 Jun NEWA @ ZYDUS PHARMS 35MG A 203822 001 Sep 11, 2018 Feb DISC

RISPERIDONE SOLUTION;ORAL RISPERIDONE AA TORRENT 1MG/ML A 078909 001 Jul 29, 2009 Jan CAHN TABLET;ORAL RISPERIDONE AB HERITAGE PHARMA 0.25MG A 076228 001 Jun 30, 2008 May CAHN AB 0.25MG A 077769 001 Oct 16, 2008 May CAHN AB 0.5MG A 076228 002 Jun 30, 2008 May CAHN AB 0.5MG A 077769 002 Oct 16, 2008 May CAHN AB 1MG A 076228 003 Jun 30, 2008 May CAHN AB 1MG A 077769 003 Oct 16, 2008 May CAHN AB 2MG A 076228 004 Jun 30, 2008 May CAHN AB 2MG A 077769 004 Oct 16, 2008 May CAHN AB 3MG A 076228 005 Jun 30, 2008 May CAHN AB 3MG A 077769 005 Oct 16, 2008 May CAHN AB 4MG A 076228 006 Jun 30, 2008 May CAHN AB 4MG A 077769 006 Oct 16, 2008 May CAHN TABLET, ORALLY DISINTEGRATING;ORAL RISPERIDONE AB HERITAGE PHARMA 0.5MG A 076908 001 Mar 12, 2012 May CAHN AB 1MG A 076908 002 Mar 12, 2012 May CAHN AB 2MG A 076908 003 Mar 12, 2012 May CAHN

RIVASTIGMINE FILM, EXTENDED RELEASE;TRANSDERMAL RIVASTIGMINE AB ZYDUS NOVELTECH INC 4.6MG/24HR A 206318 001 Mar 04, 2019 Feb NEWA AB 9.5MG/24HR A 206318 002 Mar 04, 2019 Feb NEWA AB 13.3MG/24HR A 206318 003 Mar 04, 2019 Feb NEWA

ROFLUMILAST TABLET;ORAL ROFLUMILAST AB MICRO LABS 500MCG A 208180 001 Mar 22, 2019 Mar NEWA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019 1 -79

ROPINIROLE HYDROCHLORIDE TABLET;ORAL ROPINIROLE HYDROCHLORIDE AB CADILA EQ 0.25MG BASE A 090411 001 Jun 01, 2009 Feb CAHN AB EQ 0.5MG BASE A 090411 002 Jun 01, 2009 Feb CAHN AB EQ 1MG BASE A 090411 003 Jun 01, 2009 Feb CAHN AB EQ 2MG BASE A 090411 004 Jun 01, 2009 Feb CAHN AB EQ 3MG BASE A 090411 005 Jun 01, 2009 Feb CAHN AB EQ 4MG BASE A 090411 006 Jun 01, 2009 Feb CAHN AB EQ 5MG BASE A 090411 007 Jun 01, 2009 Feb CAHN AB LAX EQ 0.25MG BASE A 079165 001 Feb 07, 2012 Mar CAHN AB EQ 0.5MG BASE A 079165 002 Feb 07, 2012 Mar CAHN AB EQ 1MG BASE A 079165 003 Feb 07, 2012 Mar CAHN AB EQ 2MG BASE A 079165 004 Feb 07, 2012 Mar CAHN AB EQ 3MG BASE A 079165 005 Feb 07, 2012 Mar CAHN AB EQ 4MG BASE A 079165 006 Feb 07, 2012 Mar CAHN AB EQ 5MG BASE A 079165 007 Feb 07, 2012 Mar CAHN

ROSUVASTATIN CALCIUM TABLET;ORAL ROSUVASTATIN CALCIUM @ AMNEAL PHARMS CO 5MG A 208850 001 Oct 16, 2018 Apr DISC @ 10MG A 208850 002 Oct 16, 2018 Apr DISC @ 20MG A 208850 003 Oct 16, 2018 Apr DISC @ 40MG A 208850 004 Oct 16, 2018 Apr DISC AB SCIEGEN PHARMS INC 5MG A 206381 001 Apr 24, 2019 Apr NEWA AB 10MG A 206381 002 Apr 24, 2019 Apr NEWA AB 20MG A 206381 003 Apr 24, 2019 Apr NEWA AB 40MG A 206381 004 Apr 24, 2019 Apr NEWA AB SHANDONG 5MG A 207375 001 May 07, 2019 Apr NEWA AB 10MG A 207375 002 May 07, 2019 Apr NEWA AB 20MG A 207375 003 May 07, 2019 Apr NEWA AB 40MG A 207375 004 May 07, 2019 Apr NEWA AB UMEDICA LABS PVT LTD 5MG A 207626 001 Apr 09, 2019 Mar NEWA AB 10MG A 207626 002 Apr 09, 2019 Mar NEWA AB 20MG A 207626 003 Apr 09, 2019 Mar NEWA AB 40MG A 207626 004 Apr 09, 2019 Mar NEWA AB ZYDUS PHARMS 5MG A 206513 001 Mar 01, 2019 Feb NEWA AB 10MG A 206513 002 Mar 01, 2019 Feb NEWA AB 20MG A 206513 003 Mar 01, 2019 Feb NEWA AB 40MG A 206513 004 Mar 01, 2019 Feb NEWA

RUFINAMIDE SUSPENSION;ORAL BANZEL AB +! EISAI INC 40MG/ML N 201367 001 Mar 03, 2011 Apr CFTG RUFINAMIDE AB BIONPHARMA INC 40MG/ML A 211388 001 Apr 23, 2019 Apr NFTG AB HIKMA 40MG/ML A 207363 001 Apr 23, 2019 Apr NFTG TABLET;ORAL RUFINAMIDE MY LAN@ MYLAN@ 200MG A 205095 001 May 16, 2016 Feb DISC @ 400MG A 205095 002 May 16, 2016 Feb DISC

SAPROPTERIN DIHYDROCHLORIDE TABLET;ORAL KUVAN +! BIOMARIN PHARM 100MG N 022181 001 Dec 13, 2007 May CTEC AB +! 100MG N 022181 001 Dec 13, 2007 Apr CFTG SAPROPTERIN DIHYDROCHLORIDE @ PAR PHARM INC 100MG A 207200 001 May 10, 2019 May DISC AB 100MG A 207200 001 May 10, 2019 Apr NFTG

SCOPOLAMINE FILM, EXTENDED RELEASE;TRANSDERMAL SCOPOLAMINE >A> AB MYLAN TECHNOLOGIES 1MG/72HR A 203753 001 Jun 19, 2019 Jun NEWA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019 1 -80

SELEGILINE HYDROCHLORIDE TABLET;ORAL SELEGILINE HYDROCHLORIDE >A> AB BOSCOGEN 5MG A 074912 001 Apr 30, 1998 Jun CAHN >D> AB KENTON 5MG A 074912 001 Apr 30, 1998 Jun CAHN AB 5MG A 074912 001 Apr 30, 1998 Mar CAHN TABLET, ORALLY DISINTEGRATING;ORAL ZELAPAR +! BAUSCH 1.25MG N 021479 001 Jun 14, 2006 Mar CAHN

SELENIOUS ACID SOLUTION;INTRAVENOUS SELENIOUS ACID +! AM REGENT EQ 600MCG BASE/10ML (EQ 60MCG N 209379 001 Apr 30, 2019 Apr NEWA BASE/ML)

SERTACONAZOLE NITRATE CREAM;TOPICAL ERTACZO >A> +! BAUSCH 2% N 021385 001 Dec 10, 2003 Jun CAHN >D> +! VALEANT LUXEMBOURG 2% N 021385 001 Dec 10, 2003 Jun CAHN

SERTRALINE HYDROCHLORIDE TABLET;ORAL SERTRALINE HYDROCHLORIDE >D> AB CADILA EQ 25MG BASE A 077106 001 Feb 06, 2007 Jun DISC >A> @ EQ 25MG BASE A 077106 001 Feb 06, 2007 Jun DISC AB EQ 25MG BASE A 077106 001 Feb 06, 2007 Feb CAHN >D> AB EQ 50MG BASE A 077106 002 Feb 06, 2007 Jun DISC >A> @ EQ 50MG BASE A 077106 002 Feb 06, 2007 Jun DISC AB EQ 50MG BASE A 077106 002 Feb 06, 2007 Feb CAHN >D> AB EQ 100MG BASE A 077106 003 Feb 06, 2007 Jun DISC >A> @ EQ 100MG BASE A 077106 003 Feb 06, 2007 Jun DISC AB EQ 100MG BASE A 077106 003 Feb 06, 2007 Feb CAHN AB HERITAGE PHARMA EQ 25MG BASE A 076465 001 Aug 11, 2006 May CAHN @ EQ 25MG BASE A 077299 001 Feb 06, 2007 May CAHN @ EQ 25MG BASE A 077345 001 Feb 06, 2007 May CAHN AB EQ 50MG BASE A 076465 002 Aug 11, 2006 May CAHN @ EQ 50MG BASE A 077299 002 Feb 06, 2007 May CAHN @ EQ 50MG BASE A 077345 002 Feb 06, 2007 May CAHN AB EQ 100MG BASE A 076465 003 Aug 11, 2006 May CAHN @ EQ 100MG BASE A 077299 003 Feb 06, 2007 May CAHN @ EQ 100MG BASE A 077345 003 Feb 06, 2007 May CAHN @ MYLAN PHARMS INC EQ 25MG BASE A 078626 001 Jan 31, 2008 May DISC @ EQ 50MG BASE A 078626 002 Jan 31, 2008 May DISC

SEVELAMER HYDROCHLORIDE TABLET;ORAL RENAGEL AB + GENZYME 400MG N 021179 001 Jul 12, 2000 Feb CFTG AB +! 800MG N 021179 002 Jul 12, 2000 Feb CFTG SEVELAMER HYDROCHLORIDE AB GLENMARK PHARMS LTD 400MG A 204724 001 Feb 08, 2019 Feb NFTG AB 800MG A 204724 002 Feb 08, 2019 Feb NFTG

SILDENAFIL CITRATE FOR SUSPENSION;ORAL REVATIO AB +! PFIZER EQ 10MG BASE/ML N 203109 001 Aug 30, 2012 May CFTG SILDENAFIL CITRATE AB NOVITIUM PHARMA EQ 10MG BASE/ML A 212260 001 May 31, 2019 May NFTG TABLET;ORAL SILDENAFIL CITRATE AB LUPIN LTD EQ 25MG BASE A 212051 001 Mar 22, 2019 Mar NEWA AB EQ 50MG BASE A 212051 002 Mar 22, 2019 Mar NEWA AB EQ 100MG BASE A 212051 003 Mar 22, 2019 Mar NEWA AB MYLAN EQ 25MG BASE A 201171 001 Mar 25, 2019 Mar NEWA AB EQ 50MG BASE A 201171 002 Mar 25, 2019 Mar NEWA AB EQ 100MG BASE A 201171 003 Mar 25, 2019 Mar NEWA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019 1 -81

SIMVASTATIN TABLET;ORAL SIMVASTATIN AB MICRO LABS 5MG A 090383 001 Sep 16, 2011 Mar CAHN AB 10MG A 090383 002 Sep 16, 2011 Mar CAHN AB 20MG A 090383 003 Sep 16, 2011 Mar CAHN AB 40MG A 090383 004 Sep 16, 2011 Mar CAHN AB 80MG A 090383 005 Sep 16, 2011 Mar CAHN

SIPONIMOD TABLET;ORAL MAYZENT + NOVARTIS PHARMS CORP 0.25MG N 209884 001 Mar 26, 2019 Mar NEWA +! 2MG N 209884 002 Mar 26, 2019 Mar NEWA

SIPONIMOD FUMARIC ACID TABLET;ORAL MAYZENT + NOVARTIS PHARMS CORP EQ 0.25MG BASE N 209884 001 Mar 26, 2019 Apr CAIN +! EQ 2MG BASE N 209884 002 Mar 26, 2019 Apr CAIN

SIROLIMUS SOLUTION;ORAL RAPAMUNE AA +! PF PRISM CV 1MG/ML N 021083 001 Sep 15, 1999 Jan CFTG SIROLIMUS AA NOVITIUM PHARMA 1MG/ML A 211040 001 Jan 28, 2019 Jan NFTG

SODIUM BICARBONATE INJECTABLE;INJECTION >A> SODIUM BICARBONATE >A> EXELA PHARMA SCS LLC 0.5MEQ/ML A 211091 001 Jun 20, 2019 Jun NEWA >A> AP 0.9MEQ/ML A 211091 002 Jun 20, 2019 Jun NEWA >A> AP 1MEQ/ML A 211091 003 Jun 20, 2019 Jun NEWA

SODIUM CHLORIDE INJECTABLE;INJECTION SODIUM CHLORIDE 3% IN PLASTIC CONTAINER AP FRESENIUS KABI USA 3GM/100ML A 209476 001 Mar 13, 2019 Feb NEWA

SODIUM CHROMATE CR-51 INJECTABLE;INJECTION SODIUM CHROMATE CR 51 @ CURIUM 100uCi/ML N 016708 001 Jan CAHN

SODIUM FLUORIDE F-18 INJECTABLE;INTRAVENOUS SODIUM FLUORIDE F-18 AP DECATUR 10-200mCi/ML A 204464 001 Oct 21, 2014 Apr CAHN

SODIUM IODIDE I-131 CAPSULE;ORAL SODIUM IODIDE I 131 CU RIU M@ CURIUM@ 0.8-100mCi N 016515 002 Jan CAHN + @ 0.8-100mCi N 016517 001 Jan CAHN @ 15-100uCi N 016517 002 Jan CAHN SOLUTION;ORAL SODIUM IODIDE I 131 + CURIUM@ 3.5-150mCi/VIAL N 016515 001 Jan CAHN

SODIUM NITROPRUSSIDE INJECTABLE;INJECTION SODIUM NITROPRUSSIDE AP DR REDDYS LABS LTD 25MG/ML A 210114 001 Apr 10, 2019 Mar NEWA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019 1 -82

SODIUM PHENYLBUTYRATE POWDER;ORAL BUPHENYL AB +! HORIZON THERAP 3GM/TEASPOONFUL N 020573 001 Apr 30, 1996 Feb CAHN TABLET;ORAL BUPHENYL AB +! HORIZON THERAP 500MG N 020572 001 May 13, 1996 Feb CAHN

SOLIFENACIN SUCCINATE TABLET;ORAL SOLIFENACIN SUCCINATE AB AJANTA PHARMA LTD 5MG A 205483 001 May 20, 2019 May NEWA AB 10MG A 205483 002 May 20, 2019 May NEWA AB ALEMBIC PHARMS LTD 5MG A 205575 001 May 20, 2019 May NEWA AB 10MG A 205575 002 May 20, 2019 May NEWA AB ALKEM LABS LTD 5MG A 210224 001 May 20, 2019 May NEWA AB 10MG A 210224 002 May 20, 2019 May NEWA AB AMNEAL PHARMS CO 5MG A 209719 001 May 20, 2019 May NEWA AB 10MG A 209719 002 May 20, 2019 May NEWA AB BRECKENRIDGE PHARM 5MG A 209818 001 May 20, 2019 May NEWA AB 10MG A 209818 002 May 20, 2019 May NEWA AB CELLTRION 5MG A 210582 001 May 20, 2019 May NEWA AB 10MG A 210582 002 May 20, 2019 May NEWA AB CIPLA 5MG A 209839 001 May 20, 2019 May NEWA AB 10MG A 209839 002 May 20, 2019 May NEWA AB GLENMARK PHARMS INC 5MG A 209239 001 May 20, 2019 May NEWA AB 10MG A 209239 002 May 20, 2019 May NEWA AB JIANGXI BOYA SEEHOT 5MG A 210281 001 May 20, 2019 May NEWA AB 10MG A 210281 002 May 20, 2019 May NEWA AB MSN LABS PVT LTD 5MG A 210688 001 May 20, 2019 May NEWA AB 10MG A 210688 002 May 20, 2019 May NEWA AB QILU PHARM CO LTD 5MG A 209333 001 May 20, 2019 May NEWA AB 10MG A 209333 002 May 20, 2019 May NEWA AB SCIEGEN PHARMS INC 5MG A 211657 001 May 20, 2019 May NEWA AB 10MG A 211657 002 May 20, 2019 May NEWA AB WATSON LABS INC 5MG A 202551 001 May 20, 2019 May NEWA AB 10MG A 202551 002 May 20, 2019 May NEWA

>A> SOLRIAMFETOL >A> TABLET;ORAL >A> SUNOSI >A> + JAZZ 75MG N 211230 001 Jun 17, 2019 Jun NEWA >A> + 150MG N 211230 002 Jun 17, 2019 Jun NEWA

SOTALOL HYDROCHLORIDE TABLET;ORAL BETAPACE AB + COVIS PHARMA BV 80MG N 019865 001 Oct 30, 1992 May CTEC AB + 120MG N 019865 005 Apr 20, 1994 May CTEC AB +! 160MG N 019865 002 Oct 30, 1992 May CTEC AB + 240MG N 019865 003 Oct 30, 1992 May CTEC BETAPACE AF AB + COVIS PHARMA BV 80MG N 021151 001 Feb 22, 2000 May CTEC AB + 120MG N 021151 002 Feb 22, 2000 May CTEC AB +! 160MG N 021151 003 Feb 22, 2000 May CTEC SORINE AB UPSHER SMITH LABS 80MG A 075500 001 Apr 27, 2001 May CTEC AB 120MG A 075500 004 Apr 27, 2001 May CTEC AB 160MG A 075500 002 Apr 27, 2001 May CTEC AB 240MG A 075500 003 Apr 27, 2001 May CTEC SOTALOL HYDROCHLORIDE AB APOTEX 80MG A 076214 001 Aug 27, 2003 May CTEC AB 120MG A 076214 002 Aug 27, 2003 May CTEC AB 160MG A 076214 003 Aug 27, 2003 May CTEC AB APOTEX INC 80MG A 076140 001 Sep 26, 2002 May CTEC AB 120MG A 076140 002 Sep 26, 2002 May CTEC AB 160MG A 076140 003 Sep 26, 2002 May CTEC AB 240MG A 076140 004 Sep 26, 2002 May CTEC AB BEXIMCO PHARMS USA 80MG A 207428 001 Oct 21, 2016 May CTEC AB 80MG A 207429 001 Nov 02, 2018 May CTEC AB 120MG A 207428 002 Oct 21, 2016 May CTEC AB 120MG A 207429 002 Nov 02, 2018 May CTEC RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019 1 -83

TABLET;ORAL SOTALOL HYDROCHLORIDE AB 160MG A 207428 003 Oct 21, 2016 May CTEC AB 160MG A 207429 003 Nov 02, 2018 May CTEC AB EPIC PHARMA INC 80MG A 077070 001 Nov 04, 2005 May CTEC AB 120MG A 077070 002 Nov 04, 2005 May CTEC AB 160MG A 077070 003 Nov 04, 2005 May CTEC AB MYLAN 80MG A 077616 001 Feb 07, 2007 May CTEC AB 120MG A 077616 002 Feb 07, 2007 May CTEC AB 160MG A 077616 003 Feb 07, 2007 May CTEC AB OXFORD PHARMS 80MG A 075563 001 Nov 07, 2003 May CTEC AB 120MG A 075563 002 Nov 07, 2003 May CTEC AB 160MG A 075563 003 Nov 07, 2003 May CTEC AB 240MG A 075563 004 Nov 07, 2003 May CTEC AB TEVA 80MG A 075429 001 May 01, 2000 May CTEC AB 120MG A 075429 002 May 01, 2000 May CTEC AB 160MG A 075429 003 May 01, 2000 May CTEC AB 240MG A 075429 004 May 01, 2000 May CTEC >D> AB UPSHER SMITH LABS 80MG A 075366 001 May 01, 2000 Jun DISC >A> @ 80MG A 075366 001 May 01, 2000 Jun DISC AB 80MG A 075366 001 May 01, 2000 May CTEC >D> AB 120MG A 075366 002 May 01, 2000 Jun DISC >A> @ 120MG A 075366 002 May 01, 2000 Jun DISC AB 120MG A 075366 002 May 01, 2000 May CTEC >D> AB 160MG A 075366 003 May 01, 2000 Jun DISC >A> @ 160MG A 075366 003 May 01, 2000 Jun DISC AB 160MG A 075366 003 May 01, 2000 May CTEC >D> AB 240MG A 075366 004 May 01, 2000 Jun DISC >A> @ 240MG A 075366 004 May 01, 2000 Jun DISC AB 240MG A 075366 004 May 01, 2000 May CTEC

SPIRONOLACTONE TABLET;ORAL SPIRONOLACTONE >D> AB ACTAVIS ELIZABETH 25MG A 040353 003 Mar 15, 2006 Jun DISC >A> @ 25MG A 040353 003 Mar 15, 2006 Jun DISC >D> AB 50MG A 040353 001 Jul 29, 1999 Jun DISC >A> @ 50MG A 040353 001 Jul 29, 1999 Jun DISC >D> AB 100MG A 040353 002 Jul 29, 1999 Jun DISC >A> @ 100MG A 040353 002 Jul 29, 1999 Jun DISC >D> AB CASI PHARMS INC 25MG A 086809 001 Jun DISC >A> @ 25MG A 086809 001 Jun DISC

STAVUDINE FOR SOLUTION;ORAL ZERIT + @ BRISTOL-MYERS SQUIBB 1MG/ML N 020413 001 Sep 06, 1996 Mar DISC

STRONTIUM CHLORIDE SR-89 INJECTABLE;INJECTION METASTRON AP +! Q BIOMED 1mCi/ML N 020134 001 Jun 18, 1993 Jan CAHN

SUCCINYLCHOLINE CHLORIDE INJECTABLE;INJECTION SUCCINYLCHOLINE CHLORIDE AP AMRING PHARMS 20MG/ML A 210231 001 Jun 04, 2018 Jan CAHN

SULFAMETHOXAZOLE; TRIMETHOPRIM INJECTABLE;INJECTION SULFAMETHOXAZOLE AND TRIMETHOPRIM >A> AP SOMERSET THERAPS LLC 80MG/ML;16MG/ML A 212231 001 Jun 26, 2019 Jun NEWA TABLET;ORAL SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH AB HERITAGE PHARMA 800MG;160MG A 070037 001 Jun 02, 1987 May CAHN SULFAMETHOXAZOLE AND TRIMETHOPRIM SINGLE STRENGTH AB HERITAGE PHARMA 400MG;80MG A 070030 001 Jun 02, 1987 May CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019 1 -84

SUMATRIPTAN SPRAY;NASAL TOSYMRA +! DR REDDYS LABS LTD 10MG/SPRAY N 210884 001 Jan 25, 2019 Jan NEWA

SUMATRIPTAN SUCCINATE INJECTABLE;SUBCUTANEOUS SUMATRIPTAN SUCCINATE @ PAR STERILE PRODUCTS EQ 6MG BASE/0.5ML (EQ 12MG A 077871 001 Jul 09, 2009 Apr DISC BASE/ML) @ ZYDUS EQ 6MG BASE/0.5ML (EQ 12MG A 090310 001 Aug 11, 2010 Apr CAHN BASE/ML)

TACROLIMUS OINTMENT;TOPICAL TACROLIMUS AB ACCORD HLTHCARE 0.03% A 211688 001 Jan 31, 2019 Jan NEWA AB 0.1% A 211688 002 Jan 31, 2019 Jan NEWA

TADALAFIL TABLET;ORAL ALYQ AB2 TEVA PHARMS USA 20MG A 209942 001 Feb 05, 2019 Jan NEWA TADALAFIL AB ACCORD HLTHCARE 2.5MG A 209167 001 Mar 26, 2019 Mar NEWA AB 5MG A 209167 002 Mar 26, 2019 Mar NEWA AB1 20MG A 209167 004 Mar 26, 2019 Mar NEWA AB AJANTA PHARMA LTD 2.5MG A 209654 001 Mar 26, 2019 Mar NEWA AB 5MG A 209654 002 Mar 26, 2019 Mar NEWA AB 10MG A 209654 003 Mar 26, 2019 Mar NEWA AB1 20MG A 209654 004 Mar 26, 2019 Mar NEWA AB2 20MG A 210392 001 Feb 05, 2019 Jan NEWA AB ALEMBIC PHARMS LTD 2.5MG A 204809 001 Mar 26, 2019 Mar NEWA AB 5MG A 204809 002 Mar 26, 2019 Mar NEWA AB 10MG A 204809 003 Mar 26, 2019 Mar NEWA AB1 20MG A 204809 004 Mar 26, 2019 Mar NEWA AB AMNEAL PHARMS CO 2.5MG A 209744 001 Mar 26, 2019 Mar NEWA AB 5MG A 209744 002 Mar 26, 2019 Mar NEWA AB 10MG A 209744 003 Mar 26, 2019 Mar NEWA AB1 20MG A 209744 004 Mar 26, 2019 Mar NEWA AB AUROBINDO PHARMA LTD 2.5MG A 206285 001 Mar 26, 2019 Mar NEWA AB 5MG A 206285 002 Mar 26, 2019 Mar NEWA AB 10MG A 206285 003 Mar 26, 2019 Mar NEWA AB1 20MG A 206285 004 Mar 26, 2019 Mar NEWA AB2 20MG A 206286 001 Feb 05, 2019 Jan NEWA AB CIPLA 2.5MG A 209539 001 Mar 26, 2019 Mar NEWA AB 5MG A 209539 002 Mar 26, 2019 Mar NEWA AB 10MG A 209539 003 Mar 26, 2019 Mar NEWA AB1 20MG A 209539 004 Mar 26, 2019 Mar NEWA AB2 20MG A 210255 001 Feb 05, 2019 Jan NEWA AB DR REDDYS LABS LTD 2.5MG A 210069 001 Mar 26, 2019 Mar NEWA AB 5MG A 210069 002 Mar 26, 2019 Mar NEWA AB 10MG A 210069 003 Mar 26, 2019 Mar NEWA AB1 20MG A 210069 004 Mar 26, 2019 Mar NEWA AB2 20MG A 210145 001 Feb 05, 2019 Jan NEWA AB HETERO LABS LTD III 2.5MG A 209908 001 Mar 26, 2019 Mar NEWA AB 5MG A 209908 002 Mar 26, 2019 Mar NEWA AB 10MG A 209908 003 Mar 26, 2019 Mar NEWA AB2 20MG A 209907 001 Feb 05, 2019 Jan NEWA AB1 20MG A 209908 004 Mar 26, 2019 Mar NEWA AB LUPIN LTD 2.5MG A 210567 001 Mar 26, 2019 Mar NEWA AB 5MG A 210567 002 Mar 26, 2019 Mar NEWA AB 10MG A 210567 003 Mar 26, 2019 Mar NEWA AB1 20MG A 210567 004 Mar 26, 2019 Mar NEWA AB2 20MG A 210572 001 Feb 05, 2019 Jan NEWA AB MYLAN 2.5MG A 206956 001 Apr 29, 2019 Apr NEWA AB 5MG A 206957 001 Apr 29, 2019 Apr NEWA AB 10MG A 206956 002 Apr 29, 2019 Apr NEWA AB1 20MG A 206956 003 Apr 29, 2019 Apr NEWA AB QILU PHARM CO LTD 2.5MG A 210420 001 Mar 26, 2019 Mar NEWA AB 5MG A 210420 002 Mar 26, 2019 Mar NEWA AB 10MG A 210420 003 Mar 26, 2019 Mar NEWA AB1 20MG A 210420 004 Mar 26, 2019 Mar NEWA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019 1 -85

TABLET;ORAL TADALAFIL AB SUN PHARM 2.5MG A 208934 001 Mar 26, 2019 Mar NEWA AB 5MG A 208934 002 Mar 26, 2019 Mar NEWA AB 10MG A 208934 003 Mar 26, 2019 Mar NEWA AB1 20MG A 208934 004 Mar 26, 2019 Mar NEWA AB SUNSHINE LAKE 2.5MG A 211335 001 Mar 26, 2019 Mar NEWA AB 5MG A 211335 002 Mar 26, 2019 Mar NEWA AB 10MG A 211335 003 Mar 26, 2019 Mar NEWA AB1 20MG A 211335 004 Mar 26, 2019 Mar NEWA AB TORRENT 2.5MG A 211839 001 Mar 26, 2019 Mar NEWA AB 5MG A 211839 002 Mar 26, 2019 Mar NEWA AB 10MG A 211839 003 Mar 26, 2019 Mar NEWA AB1 20MG A 211839 004 Mar 26, 2019 Mar NEWA AB2 20MG A 212062 001 Mar 26, 2019 Mar NEWA AB UNICHEM LABS LTD 2.5MG A 209250 001 Mar 26, 2019 Mar NEWA AB 5MG A 209250 002 Mar 26, 2019 Mar NEWA AB 10MG A 209250 003 Mar 26, 2019 Mar NEWA AB1 20MG A 209250 004 Mar 26, 2019 Mar NEWA AB WATSON LABS INC 2.5MG A 205885 001 Mar 29, 2019 Mar NEWA AB 5MG A 205885 002 Mar 29, 2019 Mar NEWA AB 10MG A 205885 003 Mar 29, 2019 Mar NEWA AB1 20MG A 205885 004 Mar 29, 2019 Mar NEWA AB ZYDUS PHARMS 2.5MG A 206693 001 Mar 26, 2019 Mar NEWA AB 5MG A 206693 002 Mar 26, 2019 Mar NEWA AB 10MG A 206693 003 Mar 26, 2019 Mar NEWA AB1 20MG A 206693 004 Mar 26, 2019 Mar NEWA

TAFAMIDIS CAPSULE;ORAL VYNDAMAX +! FOLDRX PHARMS 61MG N 212161 001 May 03, 2019 May NEWA

TAFAMIDIS MEGLUMINE CAPSULE;ORAL VYNDAQEL +! FOLDRX PHARMS 20MG N 211996 001 May 03, 2019 May NEWA

TAZAROTENE CREAM;TOPICAL TAZAROTENE AB FOUGERA PHARMS INC 0.1% A 211175 001 Jan 28, 2019 May CPOT AB 1% A 211175 001 Jan 28, 2019 Jan NEWA

TECHNETIUM TC-99M MERTIATIDE KIT INJECTABLE;INJECTION TECHNESCAN MAG3 +! CURIUM N/A N 019882 001 Jun 15, 1990 Jan CAHN

TECHNETIUM TC-99M OXIDRONATE KIT INJECTABLE;INJECTION TECHNESCAN +! CURIUM N/A N 018321 001 Jan CAHN

TECHNETIUM TC-99M PYROPHOSPHATE KIT INJECTABLE;INJECTION TECHNESCAN PYP KIT AP CURIUM N/A N 017538 001 Jan CAHN

TECHNETIUM TC-99M RED BLOOD CELL KIT INJECTABLE;INJECTION ULTRATAG +! CURIUM N/A N 019981 001 Jun 10, 1991 Jan CAHN

TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR SOLUTION;INTRAVENOUS ULTRA-TECHNEKOW FM +! CURIUM 1-19 CI/GENERATOR N 017243 003 Feb 18, 2014 Jan CAHN @ 0.25-3 CI/GENERATOR N 017243 002 Jan CAHN SOLUTION;INTRAVENOUS, ORAL TECHNETIUM TC 99M GENERATOR + @ GE HEALTHCARE 68-2703mCi/GENERATOR N 017693 002 Dec 13, 2013 Feb DISC RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019 1 -86

TELMISARTAN TABLET;ORAL TELMISARTAN >D> AB CIPLA 20MG A 078710 001 Jan 08, 2014 Jun DISC >A> @ 20MG A 078710 001 Jan 08, 2014 Jun DISC AB 20MG A 078710 001 Jan 08, 2014 Feb CAHN @ 40MG A 078710 002 Jan 08, 2014 Feb CAHN @ 80MG A 078710 003 Jan 08, 2014 Feb CAHN AB HISUN PHARM HANGZHOU 20MG A 207843 001 Feb 19, 2019 Feb NEWA AB 40MG A 207843 002 Feb 19, 2019 Feb NEWA AB 80MG A 207843 003 Feb 19, 2019 Feb NEWA @ MICRO LABS 20MG A 207016 001 Oct 03, 2017 Mar DISC @ 40MG A 207016 002 Oct 03, 2017 Mar DISC @ 80MG A 207016 003 Oct 03, 2017 Mar DISC @ WATSON LABS 80MG A 078710 003 Jan 08, 2014 Feb DISC

TEMOZOLOMIDE CAPSULE;ORAL TEMOZOLOMIDE @ APOTEX INC 5MG A 204159 001 Jul 05, 2018 Jan DISC @ 20MG A 204159 002 Jul 05, 2018 Jan DISC @ 100MG A 204159 003 Jul 05, 2018 Jan DISC @ 140MG A 204159 004 Jul 05, 2018 Jan DISC @ 180MG A 204159 005 Jul 05, 2018 Jan DISC @ 250MG A 204159 006 Jul 05, 2018 Jan DISC

TENOFOVIR DISOPROXIL FUMARATE TABLET;ORAL TENOFOVIR DISOPROXIL FUMARATE @ APOTEX INC 300MG A 206481 001 Jul 26, 2018 Jan DISC

TERAZOSIN HYDROCHLORIDE CAPSULE;ORAL TERAZOSIN HYDROCHLORIDE >A> AB APNAR PHARMA LP EQ 1MG BASE A 074823 001 Mar 30, 1998 Jun CAHN >A> AB ! EQ 2MG BASE A 074823 002 Mar 30, 1998 Jun CAHN >A> AB EQ 5MG BASE A 074823 003 Mar 30, 1998 Jun CAHN >A> AB EQ 10MG BASE A 074823 004 Mar 30, 1998 Jun CAHN >D> AB APOTEX EQ 1MG BASE A 075498 001 Apr 12, 2001 Jun CAHN >D> AB EQ 2MG BASE A 075498 002 Apr 12, 2001 Jun CAHN >D> AB EQ 5MG BASE A 075498 003 Apr 12, 2001 Jun CAHN >D> AB EQ 10MG BASE A 075498 004 Apr 12, 2001 Jun CAHN @ BEXIMCO PHARMS USA EQ 1MG BASE A 075667 001 Jul 28, 2000 Feb CAHN @ EQ 2MG BASE A 075667 002 Jul 28, 2000 Feb CAHN @ EQ 5MG BASE A 075667 003 Jul 28, 2000 Feb CAHN @ EQ 10MG BASE A 075667 004 Jul 28, 2000 Feb CAHN AB HERITAGE PHARMA EQ 1MG BASE A 075614 002 Jan 30, 2001 Mar CAHN AB EQ 2MG BASE A 075614 001 Jan 30, 2001 Mar CAHN AB EQ 5MG BASE A 075614 003 Jan 30, 2001 Mar CAHN AB EQ 10MG BASE A 075614 004 Jan 30, 2001 Mar CAHN >A> AB HIKMA EQ 1MG BASE A 075498 001 Apr 12, 2001 Jun CAHN >A> AB EQ 2MG BASE A 075498 002 Apr 12, 2001 Jun CAHN >A> AB EQ 5MG BASE A 075498 003 Apr 12, 2001 Jun CAHN >A> AB EQ 10MG BASE A 075498 004 Apr 12, 2001 Jun CAHN >D> AB SANDOZ EQ 1MG BASE A 074823 001 Mar 30, 1998 Jun CAHN >D> AB ! EQ 2MG BASE A 074823 002 Mar 30, 1998 Jun CAHN >D> AB EQ 5MG BASE A 074823 003 Mar 30, 1998 Jun CAHN >D> AB EQ 10MG BASE A 074823 004 Mar 30, 1998 Jun CAHN

TERBINAFINE HYDROCHLORIDE TABLET;ORAL TERBINAFINE HYDROCHLORIDE AB HERITAGE PHARMA EQ 250MG BASE A 076377 001 Jul 02, 2007 May CAHN

TERBUTALINE SULFATE INJECTABLE;INJECTION TERBUTALINE SULFATE @ DR REDDYS 1MG/ML A 076853 001 Jul 20, 2004 May CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019 1 -87

TERCONAZOLE CREAM;VAGINAL TERCONAZOLE BX +! FOUGERA PHARMS INC 0.8% N 021735 001 Oct 01, 2004 May CAHN SUPPOSITORY;VAGINAL TERCONAZOLE AB ! PERRIGO ISRAEL 80MG A 077149 001 Mar 17, 2006 May CAHN

TERIFLUNOMIDE TABLET;ORAL TERIFLUNOMIDE AB ALEMBIC PHARMS LTD 7MG A 209572 001 Apr 19, 2019 Apr NEWA AB 14MG A 209572 002 Apr 19, 2019 Apr NEWA @ AMNEAL PHARMS CO 7MG A 209613 001 Sep 28, 2018 Feb DISC @ 14MG A 209613 002 Sep 28, 2018 Feb DISC @ APOTEX INC 7MG A 209601 001 Nov 02, 2018 Jan DISC @ 14MG A 209601 002 Nov 02, 2018 Jan DISC @ AUROBINDO PHARMA LTD 7MG A 209638 001 Oct 26, 2018 Feb DISC @ 14MG A 209638 002 Oct 26, 2018 Feb DISC AB MSN LABS PVT LTD 7MG A 209623 001 Apr 24, 2019 Apr NEWA AB 14MG A 209623 002 Apr 24, 2019 Apr NEWA @ TEVA PHARMS USA 7MG A 209700 001 Sep 04, 2018 Mar DISC @ 14MG A 209700 002 Sep 04, 2018 Mar DISC @ WATSON LABS TEVA 7MG A 209549 001 Jul 27, 2018 Feb DISC @ 14MG A 209549 002 Jul 27, 2018 Feb DISC @ ZYDUS PHARMS 7MG A 209668 001 Nov 30, 2018 May DISC @ 14MG A 209668 002 Nov 30, 2018 May DISC

TESTOSTERONE GEL;TRANSDERMAL TESTOSTERONE @ PAR PHARM 25MG/2.5GM PACKET A 076744 001 May 23, 2007 Mar DISC GEL, METERED;TRANSDERMAL TESTOSTERONE AB ACTAVIS LABS UT INC 1.62% (20.25MG/1.25GM ACTUATION) A 204570 001 Apr 10, 2019 Mar NEWA AB AMNEAL PHARMS LLC 1.62% (20.25MG/1.25GM ACTUATION) A 207373 001 Apr 10, 2019 Mar NEWA AB DR REDDYS 1.62% (20.25MG/1.25GM ACTUATION) A 208620 001 Apr 10, 2019 Mar NEWA AB LUPIN ATLANTIS 1.62% (20.25MG/1.25GM ACTUATION) A 208560 001 Apr 10, 2019 Mar NEWA

TESTOSTERONE CYPIONATE INJECTABLE;INJECTION TESTOSTERONE CYPIONATE AO LUITPOLD 200MG/ML A 207742 001 Jun 16, 2017 May CMFD @ 200MG/ML A 207742 001 Jun 16, 2017 Feb DISC @ MYLAN INSTITUTIONAL 200MG/ML A 040652 001 Dec 11, 2006 Mar DISC AO WILSHIRE PHARMS INC 200MG/ML A 206368 001 Apr 24, 2019 Apr NEWA

TESTOSTERONE UNDECANOATE CAPSULE;ORAL JATENZO + CLARUS 158MG N 206089 001 Mar 27, 2019 Mar NEWA + 198MG N 206089 002 Mar 27, 2019 Mar NEWA +! 237MG N 206089 003 Mar 27, 2019 Mar NEWA

TETRABENAZINE TABLET;ORAL TETRABENAZINE @ LUPIN LTD 12.5MG A 210544 001 Apr 20, 2018 Feb DISC @ 25MG A 210544 002 Apr 20, 2018 Feb DISC AB WEST-WARD PHARMS INT 12.5MG A 209739 001 Apr 08, 2019 Mar NEWA AB 25MG A 209739 002 Apr 08, 2019 Mar NEWA

TETRACAINE HYDROCHLORIDE SOLUTION;OPHTHALMIC TETRACAINE HYDROCHLORIDE BAUSCH 0.5% N 210821 001 Mar 12, 2019 Apr CAHN VALEANT PHARMS 0.5% N 210821 001 Mar 12, 2019 Mar NEWA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019 1 -88

THALLOUS CHLORIDE TL-201 INJECTABLE;INJECTION THALLOUS CHLORIDE TL 201 AP +! CURIUM 1mCi/ML N 018150 001 Jan CAHN

THEOPHYLLINE TABLET, EXTENDED RELEASE;ORAL THEOPHYLLINE AB ! HERITAGE PHARMA 100MG A 089807 001 Apr 30, 1990 Feb CAHN AB 300MG A 089763 001 Apr 30, 1990 Feb CAHN @ 450MG A 081236 001 Nov 09, 1992 Feb CAHN

THIOTHIXENE CAPSULE;ORAL THIOTHIXENE AB MYLAN 1MG A 071093 002 Jun 23, 1987 Mar CTEC AB 2MG A 071093 003 Jun 23, 1987 Mar CTEC AB 10MG A 071093 001 Jun 23, 1987 Mar CTEC AB NOVITIUM PHARMA 1MG A 211642 001 Apr 05, 2019 Mar NEWA AB 2MG A 211642 002 Apr 05, 2019 Mar NEWA AB 10MG A 211642 004 Apr 05, 2019 Mar NEWA

TICAGRELOR TABLET;ORAL BRILINTA >D> AB + ASTRAZENECA PHARMS 60MG N 022433 002 Sep 03, 2015 Jun CTEC >A> + 60MG N 022433 002 Sep 03, 2015 Jun CTEC TICAGRELOR >D> AB AMNEAL PHARMS CO 90MG A 208531 001 Jan 23, 2019 Jun DISC >A> @ 90MG A 208531 001 Jan 23, 2019 Jun DISC AB 90MG A 208531 001 Jan 23, 2019 Jan NEWA AB HISUN PHARM HANGZHOU 90MG A 208575 001 Jan 23, 2019 Jan NEWA @ WATSON LABS INC 60MG A 208390 001 Sep 04, 2018 Feb DISC @ 90MG A 208390 002 Sep 04, 2018 Feb DISC

TIGECYCLINE POWDER;INTRAVENOUS TIGECYCLINE AP AUROBINDO PHARMA LTD 50MG/VIAL A 206335 001 Jun 11, 2019 May NEWA

TIMOLOL MALEATE SOLUTION/DROPS;OPHTHALMIC TIMOPTIC AT + VALEANT PHARMS INTL EQ 0.25% BASE N 018086 001 Jan CAHN AT1 + EQ 0.5% BASE N 018086 002 Jan CAHN TIMOPTIC IN OCUDOSE +! VALEANT PHARMS INTL EQ 0.25% BASE N 019463 001 Nov 05, 1986 Jan CAHN +! EQ 0.5% BASE N 019463 002 Nov 05, 1986 Jan CAHN TABLET;ORAL BLOCADREN + MERCK@ 5MG N 018017 001 Apr CRLD + @ 10MG N 018017 002 Apr CRLD + @ 20MG N 018017 004 Apr CRLD TIMOLOL MALEATE AB INVATECH PHARMA 5MG A 207556 001 May 02, 2019 Apr NEWA AB 10MG A 207556 002 May 02, 2019 Apr NEWA AB 20MG A 207556 003 May 02, 2019 Apr NEWA AB MYLAN 5MG A 072668 002 Jun 08, 1990 Apr CTEC AB 10MG A 072668 003 Jun 08, 1990 Apr CTEC AB ! 20MG A 072668 001 Jun 08, 1990 Apr CTEC

TIOPRONIN >A> TABLET, DELAYED RELEASE;ORAL >A> THIOLA EC >A> + MISSION PHARMACAL CO 100MG N 211843 001 Jun 28, 2019 Jun NEWA >A> +! 300MG N 211843 002 Jun 28, 2019 Jun NEWA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019 1 -89

TIZANIDINE HYDROCHLORIDE CAPSULE;ORAL TIZANIDINE HYDROCHLORIDE AB ALKEM LABS LTD EQ 2MG BASE A 212196 001 Mar 27, 2019 Mar NEWA AB EQ 4MG BASE A 212196 002 Mar 27, 2019 Mar NEWA AB EQ 6MG BASE A 212196 003 Mar 27, 2019 Mar NEWA AB CADILA PHARMS LTD EQ 2MG BASE A 210021 001 Mar 26, 2019 Mar NEWA AB EQ 4MG BASE A 210021 002 Mar 26, 2019 Mar NEWA AB EQ 6MG BASE A 210021 003 Mar 26, 2019 Mar NEWA AB RICONPHARMA LLC EQ 2MG BASE A 210267 001 Mar 12, 2019 Feb NEWA AB EQ 4MG BASE A 210267 002 Mar 12, 2019 Feb NEWA AB EQ 6MG BASE A 210267 003 Mar 12, 2019 Feb NEWA TABLET;ORAL TIZANIDINE HYDROCHLORIDE AB ALKEM LABS LTD EQ 2MG BASE A 211798 001 Jan 25, 2019 Jan NEWA AB EQ 4MG BASE A 211798 002 Jan 25, 2019 Jan NEWA @ ANI PHARMS INC EQ 2MG BASE A 076283 001 Jul 12, 2002 May CAHN @ EQ 2MG BASE A 076371 001 Apr 09, 2003 May CAHN @ EQ 4MG BASE A 076283 002 Jul 12, 2002 May CAHN @ EQ 4MG BASE A 076371 002 Apr 09, 2003 May CAHN @ PAR PHARM INC EQ 2MG BASE A 207170 001 Jan 26, 2017 Mar DISC @ EQ 4MG BASE A 207170 002 Jan 26, 2017 Mar DISC

TOBRAMYCIN SOLUTION;INHALATION BETHKIS >D> +! CHIESI USA INC 300MG/4ML N 201820 001 Oct 12, 2012 Jun CFTG >A> AN +! 300MG/4ML N 201820 001 Oct 12, 2012 Jun CFTG TOBRAMYCIN AN DR REDDYS LABS SA 300MG/5ML A 207080 001 Jul 09, 2018 Mar CMFD @ 300MG/5ML A 207080 001 Jul 09, 2018 Jan DISC >A> AN TEVA PHARMS USA 300MG/4ML A 210915 001 Jun 26, 2019 Jun NFTG SOLUTION/DROPS;OPHTHALMIC TOBRAMYCIN AT ALEMBIC PHARMS LTD 0.3% A 211847 001 Apr 19, 2019 Apr NEWA

TOFACITINIB CITRATE TABLET;ORAL XELJANZ + PF PRISM CV EQ 5MG BASE N 203214 001 Nov 06, 2012 May CHRS

TOLAZAMIDE TABLET;ORAL TOLAZAMIDE >D> @ ACP NIMBLE 100MG N 018894 001 Nov 02, 1984 Jun CAHN >D> @ 250MG N 018894 002 Nov 02, 1984 Jun CAHN >D> @ 500MG N 018894 003 Nov 02, 1984 Jun CAHN >A> @ COSETTE 100MG N 018894 001 Nov 02, 1984 Jun CAHN >A> @ 250MG N 018894 002 Nov 02, 1984 Jun CAHN >A> @ 500MG N 018894 003 Nov 02, 1984 Jun CAHN

TOLCAPONE TABLET;ORAL TASMAR AB +! BAUSCH 100MG N 020697 001 Jan 29, 1998 Mar CAHN @ 200MG N 020697 002 Jan 29, 1998 Mar CAHN

TOLMETIN SODIUM CAPSULE;ORAL TOLMETIN SODIUM @ ANI PHARMS INC EQ 400MG BASE A 073308 001 Jan 24, 1992 May CAHN TABLET;ORAL TOLMETIN SODIUM @ ANI PHARMS INC EQ 600MG BASE A 073527 001 Jun 30, 1992 May CAHN

TOLVAPTAN TABLET;ORAL JYNARQUE >D> + OTSUKA PHARM CO LTD 45MG N 204441 003 Apr 23, 2018 Jun CHRS >A> +! 45MG N 204441 003 Apr 23, 2018 Jun CHRS >D> +! 90MG N 204441 005 Apr 23, 2018 Jun CHRS RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019 1 -90

TABLET;ORAL JYNARQUE >A> + 90MG N 204441 005 Apr 23, 2018 Jun CHRS

TOPIRAMATE CAPSULE, EXTENDED RELEASE;ORAL QUDEXY XR BC + UPSHER SMITH LABS 25MG N 205122 001 Mar 11, 2014 Feb CTEC BC + 50MG N 205122 002 Mar 11, 2014 Feb CTEC BC + 100MG N 205122 003 Mar 11, 2014 Feb CTEC BC +! 200MG N 205122 005 Mar 11, 2014 Feb CTEC TROKENDI XR BC +! SUPERNUS PHARMS 200MG N 201635 004 Aug 16, 2013 Apr CTEC

TRAMADOL HYDROCHLORIDE TABLET;ORAL TRAMADOL HYDROCHLORIDE >A> AB POLYGEN PHARMS 50MG A 206706 001 Jul 02, 2019 Jun NEWA >A> AB RUBICON 50MG A 208708 001 Jun 28, 2019 Jun NEWA >A> AB 100MG A 208708 002 Jun 28, 2019 Jun NEWA

TRANEXAMIC ACID INJECTABLE;INJECTION TRANEXAMIC ACID AP ACIC PHARMS 100MG/ML A 209326 001 Feb 22, 2019 Feb NEWA +! EXELA PHARMA SCS LLC 10MG/ML N 212020 001 Apr 15, 2019 Apr NEWA AP MICRO LABS 100MG/ML A 206713 001 Jun 27, 2017 Mar CAHN SOLUTION;INTRAVENOUS TRANEXAMIC ACID +! EXELA PHARMA SCS LLC 1GM/100ML (10MG/ML) N 212020 001 Apr 15, 2019 May CPOT

TREPROSTINIL DIOLAMINE TABLET, EXTENDED RELEASE;ORAL ORENITRAM +! UNITED THERAP EQ 1MG BASE N 203496 003 Dec 20, 2013 Feb CHRS + EQ 2.5MG BASE N 203496 004 Dec 20, 2013 Feb CHRS

TRETINOIN CREAM;TOPICAL TRETINOIN AB1 TARO PHARMS 0.05% A 211644 001 Jan 25, 2019 Jan NEWA AB 0.1% A 211645 001 Jan 22, 2019 Jan NEWA

TRIAMCINOLONE ACETONIDE CREAM;TOPICAL TRIAMCINOLONE ACETONIDE AT SAPTALIS PHARMS 0.025% A 040671 001 Jun 09, 2006 May CAHN AT 0.1% A 040671 002 Jun 09, 2006 May CAHN AT STRIDES PHARMA 0.025% A 210346 001 Feb 11, 2019 Jan NEWA AT 0.1% A 210346 002 Feb 11, 2019 Jan NEWA AT 0.5% A 210346 003 Feb 11, 2019 Jan NEWA INJECTABLE;INJECTION KENALOG-80 +! APOTHECON 80MG/ML N 014901 002 Apr 12, 2019 Apr NEWA TRIAMCINOLONE ACETONIDE @ TEVA PHARMS USA 40MG/ML A 209852 001 Oct 05, 2018 Mar DISC LOTION;TOPICAL TRIAMCINOLONE ACETONIDE AT SAPTALIS PHARMS 0.1% A 040672 002 Dec 13, 2006 May CAHN

TRICLABENDAZOLE TABLET;ORAL EGATEN +! NOVARTIS PHARMS CORP 250MG N 208711 001 Feb 13, 2019 Feb NEWA

TRIENTINE HYDROCHLORIDE CAPSULE;ORAL TRIENTINE HYDROCHLORIDE AB AMNEAL PHARMS LLC 250MG A 210619 001 Feb 08, 2019 Feb NEWA >A> AB DR REDDYS LABS LTD 250MG A 211076 001 Jul 03, 2019 Jun NEWA AB MSN LABS PVT LTD 250MG A 211134 001 May 22, 2019 May NEWA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019 1 -91

CAPSULE;ORAL TRIENTINE HYDROCHLORIDE AB ZYDUS PHARMS 250MG A 211554 001 Apr 26, 2019 Apr NEWA

TRIMETHOBENZAMIDE HYDROCHLORIDE CAPSULE;ORAL TRIMETHOBENZAMIDE HYDROCHLORIDE AB LUPIN 300MG A 076546 001 Aug 20, 2003 Feb CAHN INJECTABLE;INJECTION TIGAN +! PAR STERILE PRODUCTS 100MG/ML N 017530 001 May CTEC TRIMETHOBENZAMIDE HYDROCHLORIDE @ LUITPOLD 100MG/ML A 091330 001 Mar 08, 2011 Feb DISC TRIMETHOBENZAMIDE HYDROCHLORIDE PRESERVATIVE FREE @ LUITPOLD 100MG/ML A 091329 001 Mar 08, 2011 Feb DISC

URSODIOL CAPSULE;ORAL URSODIOL >D> @ AMNEAL PHARMS CO 300MG A 211301 001 Oct 16, 2018 Jun CMFD >A> AB 300MG A 211301 001 Oct 16, 2018 Jun CMFD @ 300MG A 211301 001 Oct 16, 2018 Apr DISC

VALACYCLOVIR HYDROCHLORIDE TABLET;ORAL VALACYCLOVIR HYDROCHLORIDE @ WATSON LABS INC EQ 500MG BASE A 090370 001 Mar 16, 2011 Apr DISC @ EQ 1GM BASE A 090370 002 Mar 16, 2011 Apr DISC

VALPROATE SODIUM INJECTABLE;INJECTION DEPACON + ABBVIE@ EQ 100MG BASE/ML N 020593 001 Dec 30, 1996 Apr DISC VALPROATE SODIUM AP ! HIKMA FARMACEUTICA EQ 100MG BASE/ML A 078523 001 Feb 17, 2010 Apr CHRS

VALPROIC ACID SYRUP;ORAL VALPROIC ACID @ PD PARTNERS 250MG/5ML A 077105 001 Jul 29, 2005 May CAHN

VALRUBICIN SOLUTION;INTRAVESICAL VALRUBICIN AO CUSTOPHARM INC 40MG/ML A 206430 001 Apr 19, 2019 Apr NFTG VALSTAR PRESERVATIVE FREE AO +! ENDO PHARM 40MG/ML N 020892 001 Sep 25, 1998 Apr CFTG

VALSARTAN TABLET;ORAL VALSARTAN AB ALKEM LABS LTD 40MG A 205536 001 Mar 12, 2019 Feb NEWA AB 80MG A 205536 002 Mar 12, 2019 Feb NEWA AB 160MG A 205536 003 Mar 12, 2019 Feb NEWA AB 320MG A 205536 004 Mar 12, 2019 Feb NEWA

VANCOMYCIN HYDROCHLORIDE CAPSULE;ORAL VANCOMYCIN HYDROCHLORIDE AB ORIENT PHARMA CO LTD EQ 125MG BASE A 210729 001 Apr 29, 2019 Apr NEWA AB EQ 250MG BASE A 210729 002 Apr 29, 2019 Apr NEWA INJECTABLE;INJECTION VANCOMYCIN HYDROCHLORIDE AP HAINAN POLY PHARM EQ 500MG BASE/VIAL A 212332 001 Jun 12, 2019 May NEWA AP EQ 1GM BASE/VIAL A 212332 002 Jun 12, 2019 May NEWA SOLUTION;INTRAVENOUS VANCOMYCIN HYDROCHLORIDE +! XELLIA PHARMS APS EQ 500MG BASE/100ML N 211962 001 Feb 15, 2019 Feb NEWA +! EQ 1GM BASE/200ML N 211962 002 Feb 15, 2019 Feb NEWA +! EQ 1.5GM BASE/300ML N 211962 003 Feb 15, 2019 Feb NEWA +! EQ 2GM BASE/400ML N 211962 004 Feb 15, 2019 Feb NEWA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019 1 -92

VARDENAFIL HYDROCHLORIDE TABLET;ORAL VARDENAFIL HYDROCHLORIDE @ AMNEAL PHARMS CO 5MG A 210738 001 Oct 31, 2018 Apr DISC @ 10MG A 210738 002 Oct 31, 2018 Apr DISC @ 20MG A 210738 003 Oct 31, 2018 Apr DISC

VASOPRESSIN SOLUTION;INTRAVENOUS VASOSTRICT +! PAR STERILE PRODUCTS 20UNITS/ML (20UNITS/ML) N 204485 001 Apr 17, 2014 Mar CDFR +! 200UNITS/10ML (20UNITS/ML) N 204485 002 Dec 17, 2016 Mar CDFR

VENLAFAXINE HYDROCHLORIDE CAPSULE, EXTENDED RELEASE;ORAL VENLAFAXINE HYDROCHLORIDE >A> AB ANNORA PHARMA EQ 37.5MG BASE A 212277 001 Jul 08, 2019 Jun NEWA >A> AB EQ 75MG BASE A 212277 002 Jul 08, 2019 Jun NEWA >A> AB EQ 150MG BASE A 212277 003 Jul 08, 2019 Jun NEWA

VERAPAMIL HYDROCHLORIDE CAPSULE, EXTENDED RELEASE;ORAL VERAPAMIL HYDROCHLORIDE @ MYLAN 300MG A 078306 003 Aug 09, 2007 May DISC VERELAN PM +! RECRO GAINESVILLE 300MG N 020943 003 Nov 25, 1998 May CTEC TABLET;ORAL CALAN + @ GD SEARLE LLC 80MG N 018817 001 Sep 10, 1984 May DISC AB + 120MG N 018817 002 Sep 10, 1984 May CHRS VERAPAMIL HYDROCHLORIDE AB ! HERITAGE PHARMS INC 120MG A 071881 001 Apr 05, 1988 May CHRS

VIGABATRIN FOR SOLUTION;ORAL VIGADRONE >A> AA AUCTA 500MG/PACKET A 210196 001 Jun 21, 2018 Jun CAHN >D> AA SHANGHAI 500MG/PACKET A 210196 001 Jun 21, 2018 Jun CAHN AA 500MG/PACKET A 210196 001 Jun 21, 2018 Mar CAHN

VINCRISTINE SULFATE INJECTABLE, LIPOSOMAL;INTRAVENOUS MARQIBO KIT +! ACROTECH 5MG/5ML (1MG/ML) N 202497 001 Aug 09, 2012 Mar CAHN

VINORELBINE TARTRATE INJECTABLE;INJECTION >D> NAVELBINE >D> AP +! PIERRE FABRE EQ 10MG BASE/ML N 020388 001 Dec 23, 1994 Jun DISC >A> + @ EQ 10MG BASE/ML N 020388 001 Dec 23, 1994 Jun DISC

VORAPAXAR SULFATE TABLET;ORAL ZONTIVITY +! TOPROL EQ 2.08MG BASE N 204886 001 May 08, 2014 May CAHN

VORICONAZOLE INJECTABLE;INTRAVENOUS VFEND AP +! PF PRISM CV 200MG/VIAL N 021267 001 May 24, 2002 May CDFR VORICONAZOLE AP ALVOGEN INC 200MG/VIAL A 206398 001 Mar 23, 2016 May CDFR AP HAINAN POLY PHARM 200MG/VIAL A 211661 001 Nov 30, 2018 May CDFR AP SANDOZ INC 200MG/VIAL A 090862 001 May 30, 2012 May CDFR AP ZYDUS PHARMS 200MG/VIAL A 208983 001 Jul 16, 2018 May CDFR POWDER;INTRAVENOUS VORICONAZOLE AP XELLIA PHARMS APS 200MG/VIAL N 208562 001 Mar 09, 2017 May CDFR RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019 1 -93

POWDER;IV (INFUSION) VORICONAZOLE AP XELLIA PHARMS APS 200MG/VIAL N 208562 001 Mar 09, 2017 Feb CTEC TABLET;ORAL VORICONAZOLE AB APPCO PHARMA LLC 50MG A 206762 001 May 24, 2016 Feb CAHN AB 200MG A 206762 002 May 24, 2016 Feb CAHN AB CADILA 50MG A 206747 001 May 24, 2016 Apr CAHN AB 200MG A 206747 002 May 24, 2016 Apr CAHN

XENON XE-133 GAS;INHALATION XENON XE 133 CURIUM 10mCi/VIAL N 018327 001 Mar 09, 1982 May CAHN 20mCi/VIAL N 018327 002 Mar 09, 1982 May CAHN

ZIDOVUDINE INJECTABLE;INJECTION ZIDOVUDINE @ LUITPOLD 10MG/ML A 091457 001 May 06, 2010 Feb DISC

ZIPRASIDONE HYDROCHLORIDE CAPSULE;ORAL ZIPRASIDONE HYDROCHLORIDE >D> AB CADILA EQ 20MG BASE A 208988 001 Aug 22, 2017 Jun DISC >A> @ EQ 20MG BASE A 208988 001 Aug 22, 2017 Jun DISC AB EQ 20MG BASE A 208988 001 Aug 22, 2017 Feb CAHN >D> AB EQ 40MG BASE A 208988 002 Aug 22, 2017 Jun DISC >A> @ EQ 40MG BASE A 208988 002 Aug 22, 2017 Jun DISC AB EQ 40MG BASE A 208988 002 Aug 22, 2017 Feb CAHN >D> AB EQ 60MG BASE A 208988 003 Aug 22, 2017 Jun DISC >A> @ EQ 60MG BASE A 208988 003 Aug 22, 2017 Jun DISC AB EQ 60MG BASE A 208988 003 Aug 22, 2017 Feb CAHN >D> AB EQ 80MG BASE A 208988 004 Aug 22, 2017 Jun DISC >A> @ EQ 80MG BASE A 208988 004 Aug 22, 2017 Jun DISC AB EQ 80MG BASE A 208988 004 Aug 22, 2017 Feb CAHN

ZOLEDRONIC ACID INJECTABLE;INTRAVENOUS RECLAST AP +! NOVARTIS EQ 5MG BASE/100ML N 021817 001 Apr 16, 2007 Mar CDFR ZOLEDRONIC AP GLAND PHARMA LTD EQ 4MG BASE/100ML A 205749 001 Jun 29, 2018 Mar CDFR ZOLEDRONIC ACID AP ACCORD HLTHCARE EQ 4MG BASE/5ML A 205279 001 Nov 28, 2016 Mar CDFR AP AKORN EQ 5MG BASE/100ML A 200918 001 Aug 21, 2014 Mar CDFR AP AKORN INC EQ 4MG BASE/5ML A 202548 001 May 22, 2014 Mar CDFR AP APOTEX INC EQ 5MG BASE/100ML A 204367 001 Dec 24, 2015 Mar CDFR AP AUROBINDO PHARMA LTD EQ 4MG BASE/5ML A 207751 001 Sep 26, 2016 Mar CDFR AP EQ 5MG BASE/100ML A 209125 001 Dec 08, 2017 Mar CDFR AP BPI LABS LLC EQ 4MG BASE/5ML A 207341 001 Dec 29, 2017 Mar CDFR AP BRECKENRIDGE PHARM EQ 4MG BASE/5ML A 091170 001 Mar 04, 2013 Mar CDFR AP EQ 4MG BASE/5ML A 202571 001 May 07, 2013 Mar CDFR AP EQ 5MG BASE/100ML A 202163 001 Aug 05, 2013 Mar CDFR AP CIPLA EQ 4MG BASE/100ML A 210174 001 Oct 27, 2017 Mar CDFR AP DR REDDYS LABS LTD EQ 4MG BASE/5ML A 091186 001 Mar 04, 2013 May CDFR AP EQ 4MG BASE/100ML A 204344 001 Nov 19, 2018 Mar CDFR AP EQ 5MG BASE/100ML A 091363 001 Mar 29, 2013 Mar CDFR AP EMCURE PHARMS LTD EQ 4MG BASE/5ML A 201783 001 Mar 12, 2013 Mar CDFR AP EQ 5MG BASE/100ML A 201801 001 Mar 29, 2013 Mar CDFR AP FRESENIUS KABI USA EQ 4MG BASE/5ML A 091516 001 Apr 23, 2015 Mar CDFR AP GLAND PHARMA LTD EQ 4MG BASE/5ML A 202930 001 Aug 05, 2013 Mar CDFR AP EQ 5MG BASE/100ML A 204217 001 Aug 18, 2016 Mar CDFR AP HIKMA FARMACEUTICA EQ 4MG BASE/5ML A 202182 001 Jun 03, 2013 Mar CDFR AP HOSPIRA INC EQ 4MG BASE/5ML A 090621 001 Mar 19, 2015 Mar CDFR AP EQ 5MG BASE/100ML A 202837 001 Apr 05, 2013 Mar CDFR AP INFORLIFE EQ 4MG BASE/100ML N 203231 001 Aug 02, 2013 Mar CDFR AP EQ 5MG BASE/100ML A 202828 001 Sep 23, 2013 Mar CDFR AP MYLAN LABS LTD EQ 4MG BASE/5ML A 202650 001 Mar 04, 2013 Mar CDFR AP EQ 5MG BASE/100ML A 203841 001 Feb 14, 2017 Mar CDFR AP EQ 5MG BASE/100ML A 205254 001 Oct 27, 2017 Mar CDFR AP SAGENT PHARMS EQ 4MG BASE/5ML A 091493 001 Nov 24, 2014 Mar CDFR AP SHILPA MEDICARE LTD EQ 4MG BASE/5ML A 208513 001 May 15, 2019 Apr NEWA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019 1 -94

INJECTABLE;INTRAVENOUS ZOLEDRONIC ACID @ SUN PHARMA GLOBAL EQ 4MG BASE/VIAL A 090018 001 Mar 04, 2013 Mar CDFR @ EQ 4MG BASE/5ML A 202746 001 Mar 04, 2013 Mar CDFR >A> AP USV EQ 4MG BASE/5ML A 202923 001 Sep 04, 2014 Jun CAHN >D> AP USV NORTH AMERICA EQ 4MG BASE/5ML A 202923 001 Sep 04, 2014 Jun CAHN AP EQ 4MG BASE/5ML A 202923 001 Sep 04, 2014 Mar CDFR ZOMETA + @ NOVARTIS EQ 4MG BASE/VIAL N 021223 001 Aug 20, 2001 Mar CDFR AP +! EQ 4MG BASE/5ML N 021223 002 Mar 07, 2003 Mar CDFR AP +! EQ 4MG BASE/100ML N 021223 003 Jun 17, 2011 Mar CDFR INJECTABLE;IV (INFUSION) ZOLEDRONIC ACID AP DR REDDYS LABS LTD EQ 4MG BASE/5ML A 091186 001 Mar 04, 2013 Mar CDFR SOLUTION;INTRAVENOUS ZOLEDRONIC ACID HOSPIRA INC EQ 4MG BASE/100ML (EQ 0.04MG N 204016 001 Dec 28, 2015 Mar CDFR BASE/ML)

ZOLPIDEM TARTRATE SPRAY, METERED;ORAL ZOLPIMIST +! AYTU 5MG/SPRAY N 022196 001 Dec 19, 2008 Feb CAHN TABLET;ORAL ZOLPIDEM TARTRATE @ STRIDES PHARMA 5MG A 076062 001 Apr 23, 2007 Apr CAHN @ 10MG A 076062 002 Apr 23, 2007 Apr CAHN TABLET;SUBLINGUAL INTERMEZZO + @ PURDUE PHARMA 1.75MG N 022328 001 Nov 23, 2011 Mar DISC + @ 3.5MG N 022328 002 Nov 23, 2011 Mar DISC ZOLPIDEM TARTRATE AB ! NOVEL LABS INC 3.5MG A 204299 002 Jun 03, 2015 Mar CHRS

ZONISAMIDE CAPSULE;ORAL ZONISAMIDE AB BIONPHARMA INC 25MG A 077813 001 Aug 16, 2006 Apr CAHN AB 50MG A 077813 002 Aug 16, 2006 Apr CAHN AB 100MG A 077813 003 Aug 16, 2006 Apr CAHN OTC DRUG PRODUCT LIST - 39TH EDITION OTC DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019 2 -1

ACETAMINOPHEN SUPPOSITORY;RECTAL ACEPHEN ACP NIMBLE 120MG N 018060 001 Feb CAHN @ 325MG N 018060 003 Dec 18, 1986 Feb CAHN @ 650MG N 018060 002 Feb CAHN TABLET, EXTENDED RELEASE;ORAL ACETAMINOPHEN GRANULES INDIA LTD 650MG A 211544 001 Apr 16, 2019 Apr NEWA @ HERITAGE PHARMA 650MG A 207035 001 May 31, 2018 Mar DISC

CETIRIZINE HYDROCHLORIDE SOLUTION;ORAL CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY QUAGEN 5MG/5ML A 212266 001 May 16, 2019 May NEWA SYRUP;ORAL CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY HETERO LABS LTD III 5MG/5ML A 210622 001 Mar 13, 2019 Feb NEWA @ PD PARTNERS 5MG/5ML A 090188 002 Apr 22, 2008 May CAHN TORRENT 5MG/5ML A 090474 002 Mar 30, 2009 Jan CAHN CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF @ PD PARTNERS 5MG/5ML A 090188 001 Apr 22, 2008 May CAHN TORRENT 5MG/5ML A 090474 001 Mar 30, 2009 Jan CAHN TABLET;ORAL CETIRIZINE HYDROCHLORIDE ALLERGY @ HERITAGE PHARMA 5MG A 078615 003 Dec 28, 2007 May CAHN @ 10MG A 078615 004 Dec 28, 2007 May CAHN

CETIRIZINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE TABLET, EXTENDED RELEASE;ORAL CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE @ PERRIGO R AND D 5MG;120MG A 210719 001 Nov 16, 2018 May DISC

CHLORHEXIDINE GLUCONATE SOLUTION;TOPICAL CHLORHEXIDINE GLUCONATE BAJAJ 0.75% N 020111 001 Sep 11, 1997 Apr CTNA 0.75% N 020111 001 Sep 11, 1997 Jan CMFD

CHLORPHENIRAMINE MALEATE TABLET, EXTENDED RELEASE;ORAL CHLORPHENIRAMINE MALEATE ! AVANTHI INC 12MG A 040829 001 May 13, 2009 Jan CHRS

DIPHENHYDRAMINE HYDROCHLORIDE; IBUPROFEN CAPSULE;ORAL IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE AUROBINDO PHARMA LTD 25MG;EQ 200MG FREE ACID AND A 210676 001 Feb 14, 2019 Jan NEWA POTASSIUM SALT

DIPHENHYDRAMINE HYDROCHLORIDE; NAPROXEN SODIUM TABLET;ORAL NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE PERRIGO R AND D 25MG;220MG A 208499 001 May 10, 2019 Apr NEWA

ESOMEPRAZOLE MAGNESIUM CAPSULE, DELAYED RELEASE;ORAL ESOMEPRAZOLE MAGNESIUM AMNEAL PHARMS NY EQ 20MG BASE A 209716 001 Jun 05, 2019 May NEWA TABLET, DELAYED RELEASE;ORAL ESOMEPRAZOLE MAGNESIUM @ ACTAVIS ELIZABETH EQ 20MG BASE A 209202 001 Mar 05, 2019 Apr DISC EQ 20MG BASE A 209202 001 Mar 05, 2019 Feb NEWA OTC DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019 2 -2

FLUTICASONE PROPIONATE SPRAY, METERED;NASAL FLUTICASONE PROPIONATE HI TECH 0.05MG/SPRAY A 208024 001 Apr 17, 2019 Apr NEWA

GUAIFENESIN TABLET, EXTENDED RELEASE;ORAL GUAIFENESIN @ OHM LABS INC 600MG A 209254 001 Jul 16, 2018 Mar DISC @ 1.2GM A 209254 002 Jul 16, 2018 Mar DISC

IBUPROFEN SUSPENSION;ORAL IBUPROFEN @ GUARDIAN DRUG 100MG/5ML A 210149 001 Aug 17, 2018 Feb DISC TABLET;ORAL IBUPROFEN >D> PERRIGO R AND D 200MG A 077349 001 Jun 21, 2005 Jun CHRS >A> ! 200MG A 077349 001 Jun 21, 2005 Jun CHRS MOTRIN IB + J AND J CONSUMER INC 200MG N 019012 003 Dec 17, 1990 May CHRS

ISOPROPYL ALCOHOL SOLUTION;TOPICAL ZURAGARD +! ZUREX PHARMA 70% (10.5ML) N 210872 001 Apr 26, 2019 May CMS2

KETOCONAZOLE SHAMPOO;TOPICAL NIZORAL A-D +! KRAMER 1% N 020310 001 Oct 10, 1997 Jan CAHN

KETOTIFEN FUMARATE SOLUTION/DROPS;OPHTHALMIC ZADITOR ! ALCON PHARMS LTD EQ 0.025% BASE A 077200 001 Sep 02, 2008 Feb CTNA

LEVOCETIRIZINE DIHYDROCHLORIDE TABLET;ORAL LEVOCETIRIZINE DIHYDROCHLORIDE PERRIGO R AND D 5MG A 211983 001 Mar 26, 2019 Mar NEWA

LEVONORGESTREL TABLET;ORAL LEVONORGESTREL ACCORD HLTHCARE 1.5MG A 207660 001 May 02, 2019 Apr NEWA @ APOTEX INC 1.5MG A 205329 001 Sep 18, 2018 Jan DISC >D> FDN CONSUMER 1.5MG A 200670 001 Jul 12, 2012 Jun DISC >A> @ 1.5MG A 200670 001 Jul 12, 2012 Jun DISC ! L PERRIGO CO 0.75MG A 090740 001 Dec 30, 2010 May CAHN

LORATADINE CAPSULE;ORAL LORATADINE @ BIONPHARMA INC 10MG A 202538 001 Dec 21, 2018 Mar DISC SYRUP;ORAL LORATADINE @ PD PARTNERS 1MG/ML A 075565 001 Oct 05, 2004 May CAHN TABLET;ORAL LORATADINE GUARDIAN DRUG 10MG A 207569 001 Mar 12, 2019 Mar CAHN NEWGEN PHARMS LLC 10MG A 207569 001 Mar 12, 2019 Feb NEWA TABLET, CHEWABLE;ORAL LORATADINE PERRIGO PHARMA INTL 5MG A 210033 001 Jun 12, 2019 May NEWA SUN PHARM 5MG A 210088 001 Apr 16, 2018 Mar CAHN OTC DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019 2 -3

LORATADINE; PSEUDOEPHEDRINE SULFATE TABLET, EXTENDED RELEASE;ORAL LORATADINE AND PSEUDOEPHEDRINE SULFATE @ HERITAGE PHARMA 5MG;120MG A 076208 001 Jan 28, 2004 May CAHN

MINOXIDIL AEROSOL, FOAM;TOPICAL MINOXIDIL (FOR WOMEN) TARO PHARM 5% A 209074 002 Apr 22, 2019 Apr NEWA

NAPROXEN SODIUM; PSEUDOEPHEDRINE HYDROCHLORIDE TABLET, EXTENDED RELEASE;ORAL ALEVE-D SINUS & COLD +! BAYER EQ 200MG BASE;120MG N 021076 001 Nov 29, 1999 Mar CPOT

NICOTINE POLACRILEX TROCHE/LOZENGE;ORAL NICOTINE POLACRILEX PLD ACQUISITIONS EQ 2MG BASE A 207868 001 Feb 07, 2019 Feb NEWA EQ 4MG BASE A 207868 002 Feb 07, 2019 Feb NEWA @ WATSON LABS INC EQ 2MG BASE A 209206 001 Jun 26, 2018 Feb DISC @ EQ 4MG BASE A 209206 002 Jun 26, 2018 Feb DISC @ WATSON LABS TEVA EQ 2MG BASE A 209519 001 Jul 02, 2018 Feb DISC @ EQ 4MG BASE A 209519 002 Jul 02, 2018 Feb DISC

OMEPRAZOLE TABLET, DELAYED RELEASE;ORAL OMEPRAZOLE APOTEX INC 20MG A 210070 001 Feb 11, 2019 Apr CTEC

POLYETHYLENE GLYCOL 3350 FOR SOLUTION;ORAL >D> GLYCOLAX >D> LANNETT CO INC 17GM/PACKET A 090600 001 Oct 06, 2009 Jun DISC >A> @ 17GM/PACKET A 090600 001 Oct 06, 2009 Jun DISC >D> 17GM/SCOOPFUL A 090600 002 Oct 06, 2009 Jun DISC >A> @ 17GM/SCOOPFUL A 090600 002 Oct 06, 2009 Jun DISC

RANITIDINE HYDROCHLORIDE TABLET;ORAL RANITIDINE HYDROCHLORIDE STRIDES PHARMA EQ 75MG BASE A 209160 001 Mar 05, 2018 Apr CAHN EQ 150MG BASE A 209161 001 Feb 22, 2018 Apr CAHN

SODIUM FLUORIDE; TRICLOSAN PASTE;DENTAL COLGATE TOTAL + @ COLGATE PALMOLIVE 0.24%;0.3% N 020231 001 Jul 11, 1997 Mar DISC

3-1

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

CUMULATIVE SUPPLEMENT NUMBER 06 JUNE 2019

NO JUNE 2019 APPROVALS

4-1

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of Orphan Designations and Approvals is available at: http://www.fda.gov/orphan/designat/list.htm

5-1

DRUG PRODUCTS WHICH MUST DEMONSTRATE IN VIVO BIOAVAILABILITY ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

NO JUNE 2019 ADDITIONS PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST - 39TH EDITION A - 1 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

ABIRATERONE ACETATE - ABIRATERONE ACETATE A 208327 001 PC Apr 29, 2019

ABIRATERONE ACETATE - YONSA N 210308 001 10292990 May 20, 2034 U-2535

ACALABRUTINIB - CALQUENCE N 210259 001 10167291 Jul 01, 2036 DP U-2145 10272083 Jan 21, 2035 U-2519

ACETAMINOPHEN; BENZHYDROCODONE HYDROCHLORIDE - APADAZ N 208653 002 8461137 Feb 22, 2031 DS DP 8748413 Jul 10, 2030 DS DP 8828978 Jul 01, 2030 DP 9132125 Jul 01, 2030 DS DP U-2249 9549923 Jul 01, 2030 DS DP

ACETAMINOPHEN; BENZHYDROCODONE HYDROCHLORIDE - APADAZ N 208653 003 8461137 Feb 22, 2031 DS DP 8748413 Jul 10, 2030 DS DP 8828978 Jul 01, 2030 DP 9132125 Jul 01, 2030 DS DP U-2249 9549923 Jul 01, 2030 DS DP

ACLIDINIUM BROMIDE - TUDORZA PRESSAIR N 202450 001 10034867 Jul 07, 2020 DP U-2513 10034867 Jul 07, 2020 DP U-2514 10085974 Mar 13, 2029 DP U-2513 7078412 Jul 07, 2020 DS DP U-2513 9056100 Jul 07, 2020 DP U-2513 9333195 Jul 07, 2020 DP U-2513 RE46417 Feb 10, 2025 DS DP U-2513

ACLIDINIUM BROMIDE; FORMOTEROL FUMARATE - DUAKLIR PRESSAIR N 210595 001 10034867 Jul 07, 2020 DP U-2513 NC Mar 29, 2022 10034867 Jul 07, 2020 DP U-2514 10085974 Mar 13, 2029 DP U-2513 6681768 Aug 07, 2022 DP 7078412 Jul 07, 2020 DS DP U-2513 7750023 Jul 07, 2020 DP U-2513 8051851 Apr 22, 2027 DP 8129405 Jul 07, 2020 DP U-2513 9056100 Jul 07, 2020 DP U-2513 9333195 Jul 07, 2020 DP U-2513 RE46417 Feb 10, 2025 DS DP U-2513

ACYCLOVIR - AVACLYR N 202408 001 ODE-235 Mar 29, 2026

AFATINIB DIMALEATE - GILOTRIF N 201292 001 ODE-230 Jan 12, 2025

AFATINIB DIMALEATE - GILOTRIF N 201292 002 ODE-230 Jan 12, 2025

AFATINIB DIMALEATE - GILOTRIF N 201292 003 ODE-230 Jan 12, 2025

ALBUTEROL SULFATE - PROAIR RESPICLICK N 205636 001 10124131 May 18, 2031 DP A - 2 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

ALBUTEROL SULFATE - PROAIR DIGIHALER N 205636 002 10022510 May 18, 2031 DP 10124131 May 18, 2031 DP 6701917 Jun 23, 2021 DP 6718972 Jun 23, 2021 DP 6748947 Jun 23, 2021 DP 6871646 Jun 23, 2021 DP 7540282 May 06, 2023 DP 8006690 Jun 23, 2021 DP 8651103 Mar 26, 2028 DP 8978966 Jan 13, 2032 DP 9216260 Jun 28, 2031 DP 9463288 May 19, 2025 DP 9731087 May 18, 2031 DP 9782550 Aug 28, 2035 DP 9782551 Aug 28, 2035 DP

ALLOPURINOL; LESINURAD - DUZALLO N 209203 001 10183012 Nov 26, 2028 U-2104

ALLOPURINOL; LESINURAD - DUZALLO N 209203 002 10183012 Nov 26, 2028 U-2104

ALPELISIB - PIQRAY N 212526 001 >A> 8227462 Sep 28, 2030 DS DP U-2539 NCE May 24, 2024 >A> 8476268 Sep 10, 2029 DS DP

ALPELISIB - PIQRAY N 212526 002 >A> 8227462 Sep 28, 2030 DS DP U-2539 NCE May 24, 2024 >A> 8476268 Sep 10, 2029 DS DP

ALPELISIB - PIQRAY N 212526 003 >A> 8227462 Sep 28, 2030 DS DP U-2539 NCE May 24, 2024 >A> 8476268 Sep 10, 2029 DS DP

AMANTADINE HYDROCHLORIDE - OSMOLEX ER N 209410 001 10213393 Feb 15, 2038 U-20 10213394 Feb 15, 2038 U-2497

AMANTADINE HYDROCHLORIDE - OSMOLEX ER N 209410 002 10213393 Feb 15, 2038 U-20 10213394 Feb 15, 2038 U-2497

AMANTADINE HYDROCHLORIDE - OSMOLEX ER N 209410 003 10213393 Feb 15, 2038 U-20 10213394 Feb 15, 2038 U-2497

AMIFAMPRIDINE - RUZURGI N 209321 001 >A> ODE-244 May 06, 2026

AMIKACIN SULFATE - ARIKAYCE KIT N 207356 001 10251900 May 15, 2035 U-2414

AMPHETAMINE SULFATE - EVEKEO ODT N 209905 001 10130580 Apr 19, 2024 DP

AMPHETAMINE SULFATE - EVEKEO ODT N 209905 002 10130580 Apr 19, 2024 DP

AMPHETAMINE SULFATE - EVEKEO ODT N 209905 003 10130580 Apr 19, 2024 DP A - 3 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

AMPHETAMINE SULFATE - EVEKEO ODT N 209905 004 10130580 Apr 19, 2024 DP

ARIPIPRAZOLE LAUROXIL - ARISTADA N 207533 001 10226458 Nov 07, 2032 U-543 10238651 Mar 19, 2035 U-2402

ARIPIPRAZOLE LAUROXIL - ARISTADA N 207533 002 10226458 Nov 07, 2032 U-543 10238651 Mar 19, 2035 U-2402

ARIPIPRAZOLE LAUROXIL - ARISTADA N 207533 003 10226458 Nov 07, 2032 U-543 10238651 Mar 19, 2035 U-2402

ARIPIPRAZOLE LAUROXIL - ARISTADA N 207533 004 10226458 Nov 07, 2032 U-543 10238651 Mar 19, 2035 U-2402

AVIBACTAM SODIUM; CEFTAZIDIME - AVYCAZ N 206494 001 7112592 Feb 24, 2022 DS DP U-2244 7112592 Feb 24, 2022 DS DP U-2508 7112592 Feb 24, 2022 DS DP U-282 8178554 Jul 24, 2021 DS DP U-2245 8178554 Jul 24, 2021 DS DP U-2509 8178554 Jul 24, 2021 DS DP U-282

AZELAIC ACID - FINACEA N 207071 001 >A> 10322085 Oct 24, 2023 DP

BALOXAVIR MARBOXIL - XOFLUZA N 210854 001 NCE Oct 24, 2023

BALOXAVIR MARBOXIL - XOFLUZA N 210854 002 NCE Oct 24, 2023

BAZEDOXIFENE ACETATE; ESTROGENS, CONJUGATED - DUAVEE N 022247 001 6479535 May 06, 2024 DP U-594 6479535 May 06, 2024 DP U-904

BECLOMETHASONE DIPROPIONATE - QNASL N 202813 001 10188811 Oct 21, 2031 DP

BECLOMETHASONE DIPROPIONATE - QNASL N 202813 002 10188811 Oct 21, 2031 DP

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE A 205128 001 PC Aug 18, 2019

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - ACANYA N 050819 001 10220049 Jun 03, 2029 DP U-916

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - ONEXTON N 050819 002 10220049 Jun 03, 2029 DP U-916

BETAMETHASONE DIPROPIONATE - SERNIVO N 208079 001 10179137 Aug 31, 2030 DP U-1858

BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - BIKTARVY N 210251 001 >A> NPP Jun 18, 2022 A - 4 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

BOSUTINIB MONOHYDRATE - BOSULIF N 203341 003 7417148 Dec 11, 2025 U-1283

BREMELANOTIDE ACETATE - VYLEESI (AUTOINJECTOR) N 210557 001 >A> 10286034 Nov 05, 2033 U-2568 >A> NCE Jun 21, 2024 >A> 6579968 Jun 28, 2020 DS DP >A> 6794489 Jun 28, 2020 DS DP >A> 9352013 Nov 05, 2033 U-2568 >A> 9700592 Nov 05, 2033 U-2568

BREXANOLONE - ZULRESSO N 211371 001 >A> 10117951 Mar 13, 2029 DP >A> NCE Jun 17, 2024 >A> 10251894 Nov 27, 2033 U-2552 >A> 10322139 Jan 23, 2033 DP >A> 7635773 Mar 13, 2029 DP >A> 8410077 Mar 13, 2029 DP >A> 9200088 Mar 13, 2029 DP >A> 9750822 Mar 13, 2029 DP

BREXPIPRAZOLE - REXULTI N 205422 001 >A> 10307419 Oct 12, 2032 DP

BREXPIPRAZOLE - REXULTI N 205422 002 >A> 10307419 Oct 12, 2032 DP

BREXPIPRAZOLE - REXULTI N 205422 003 >A> 10307419 Oct 12, 2032 DP

BREXPIPRAZOLE - REXULTI N 205422 004 >A> 10307419 Oct 12, 2032 DP

BREXPIPRAZOLE - REXULTI N 205422 005 >A> 10307419 Oct 12, 2032 DP

BRIGATINIB - ALUNBRIG N 208772 001 9012462 Jul 31, 2030 DS

BRIGATINIB - ALUNBRIG N 208772 002 9012462 Jul 31, 2030 DS

BRIGATINIB - ALUNBRIG N 208772 003 9012462 Jul 31, 2030 DS

BRIMONIDINE TARTRATE - ALPHAGAN P N 021770 001 >A> 10307368 Jul 10, 2021 DP

BRIMONIDINE TARTRATE - MIRVASO N 204708 001 10201517 Jun 13, 2031 DP

BUDESONIDE - UCERIS N 203634 001 >A> 10307375 Sep 07, 2031 DP

BUDESONIDE - ORTIKOS N 211929 001 >A> 10172802 Sep 09, 2036 U-2554 >A> 9707182 Sep 09, 2036 DP U-2554

BUDESONIDE - ORTIKOS N 211929 002 >A> 10172802 Sep 09, 2036 U-2554 >A> 9707182 Sep 09, 2036 DP U-2554 A - 5 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

BUPRENORPHINE - SUBLOCADE N 209819 001 10198218 Jun 06, 2031 U-2489

BUPRENORPHINE - SUBLOCADE N 209819 002 10198218 Jun 06, 2031 U-2489

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE N 022410 001 10285910 Oct 11, 2022 DP

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE N 022410 002 10285910 Oct 11, 2022 DP

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE N 022410 003 10285910 Oct 11, 2022 DP

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE N 022410 004 10285910 Oct 11, 2022 DP

BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE - CONTRAVE N 200063 001 10231964 Jul 02, 2034 U-1583 >A> 10307376 Nov 08, 2027 U-1585

CABAZITAXEL - JEVTANA KIT N 201023 001 8927592 Oct 27, 2030 U-1630 8927592*PED Apr 27, 2031

CABOZANTINIB S-MALATE - CABOMETYX N 208692 001 10034873 Jul 18, 2031 U-2488 I-792 Jan 14, 2022 8497284 Sep 24, 2024 U-1220 ODE-227 Jan 14, 2026 8497284 Sep 24, 2024 U-1480 8497284 Sep 24, 2024 U-2488

CABOZANTINIB S-MALATE - CABOMETYX N 208692 002 10034873 Jul 18, 2031 U-2488 I-792 Jan 14, 2022 8497284 Sep 24, 2024 U-1220 ODE-227 Jan 14, 2026 8497284 Sep 24, 2024 U-1480 8497284 Sep 24, 2024 U-2488

CABOZANTINIB S-MALATE - CABOMETYX N 208692 003 10034873 Jul 18, 2031 U-2488 I-792 Jan 14, 2022 8497284 Sep 24, 2024 U-1220 ODE-227 Jan 14, 2026 8497284 Sep 24, 2024 U-1480 8497284 Sep 24, 2024 U-2488

CALCIFEDIOL - RAYALDEE N 208010 001 10213442 Feb 02, 2027 DP >A> 10300078 Mar 14, 2034 DP

CARBOPROST TROMETHAMINE - CARBOPROST TROMETHAMINE A 211941 001 >A> CGT Dec 29, 2019

CARIPRAZINE HYDROCHLORIDE - VRAYLAR N 204370 001 >A> 7737142 Mar 27, 2027 DS DP U-1750 I-798 May 24, 2022 >A> 7737142 Mar 27, 2027 DS DP U-2543 >A> 7737142 Mar 27, 2027 DS DP U-2544 >A> 7737142 Mar 27, 2027 DS DP U-2545 >A> RE47350 Jul 16, 2029 U-1750 >A> RE47350 Jul 16, 2029 U-2543 >A> RE47350 Jul 16, 2029 U-2544 >A> RE47350 Jul 16, 2029 U-2545 A - 6 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

CARIPRAZINE HYDROCHLORIDE - VRAYLAR N 204370 002 >A> 7737142 Mar 27, 2027 DS DP U-1750 I-798 May 24, 2022 >A> 7737142 Mar 27, 2027 DS DP U-2543 >A> 7737142 Mar 27, 2027 DS DP U-2544 >A> 7737142 Mar 27, 2027 DS DP U-2545

CARIPRAZINE HYDROCHLORIDE - VRAYLAR N 204370 003 >A> 7737142 Mar 27, 2027 DS DP U-1750 I-798 May 24, 2022 >A> 7737142 Mar 27, 2027 DS DP U-2543 >A> 7737142 Mar 27, 2027 DS DP U-2544

CARIPRAZINE HYDROCHLORIDE - VRAYLAR N 204370 004 >A> 7737142 Mar 27, 2027 DS DP U-1750 I-798 May 24, 2022 >A> 7737142 Mar 27, 2027 DS DP U-2543 >A> 7737142 Mar 27, 2027 DS DP U-2544

CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM - ZERBAXA N 206829 001 >A> 10028963 Sep 07, 2032 U-2565 >A> 10028963 Sep 07, 2032 U-2566 >A> 9724353 Sep 07, 2032 U-2565 >A> 9724353 Sep 07, 2032 U-2566

CERITINIB - ZYKADIA N 211225 001 NCE Apr 29, 2019

CHLORPHENIRAMINE MALEATE; IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE - CHILDREN'S ADVIL ALLERGY SINUS N 021587 001 10238640 May 25, 2024 DP

CLADRIBINE - MAVENCLAD N 022561 001 7713947 Oct 16, 2026 U-2520 NP Mar 29, 2022 7888328 Apr 11, 2024 DP U-2521 8377903 May 31, 2026 U-2522 8785415 Apr 11, 2024 DP U-2523

COCAINE HYDROCHLORIDE - GOPRELTO N 209963 001 10231961 Feb 07, 2037 DP

COLCHICINE - GLOPERBA N 210942 001 10226423 Dec 20, 2037 DP 9907751 Nov 22, 2036 DP

COLESEVELAM HYDROCHLORIDE - WELCHOL N 210895 001 7229613 Apr 17, 2022 U-2516

CROFELEMER - MYTESI N 202292 001 7341744 Jun 02, 2022 DP U-1319 9585868 Oct 31, 2031 U-1319

CYTARABINE; DAUNORUBICIN - VYXEOS N 209401 001 10166184 Oct 15, 2032 DP U-2341

DALFAMPRIDINE - DALFAMPRIDINE A 206863 001 PC Mar 09, 2019

DALTEPARIN SODIUM - FRAGMIN N 020287 001 NPP May 16, 2022

DALTEPARIN SODIUM - FRAGMIN N 020287 002 NPP May 16, 2022 A - 7 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

DALTEPARIN SODIUM - FRAGMIN N 020287 003 NPP May 16, 2022

DALTEPARIN SODIUM - FRAGMIN N 020287 004 NPP May 16, 2022

DALTEPARIN SODIUM - FRAGMIN N 020287 005 NPP May 16, 2022

DALTEPARIN SODIUM - FRAGMIN N 020287 006 NPP May 16, 2022

DAPAGLIFLOZIN - FARXIGA N 202293 001 M-238 Feb 22, 2022

DAPAGLIFLOZIN - FARXIGA N 202293 002 M-238 Feb 22, 2022

DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - QTERNMET XR N 210874 001 6414126 Oct 04, 2020 DS DP U-493 6515117 Oct 04, 2020 DS DP U-493 6936590 Oct 04, 2020 U-493 7919598 Dec 16, 2029 DS 8501698 Jun 20, 2027 DP U-493 8628799 Jul 13, 2025 DP 8716251 Mar 21, 2028 DP 9198925 Oct 04, 2020 U-493 9616028 Nov 12, 2030 DP RE44186 Jul 31, 2023 DS DP U-493

DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - QTERNMET XR N 210874 002 6414126 Oct 04, 2020 DS DP U-493 6515117 Oct 04, 2020 DS DP U-493 6936590 Oct 04, 2020 U-493 7919598 Dec 16, 2029 DS 8501698 Jun 20, 2027 DP U-493 8628799 Jul 13, 2025 DP 8716251 Mar 21, 2028 DP 9198925 Oct 04, 2020 U-493 9616028 Nov 12, 2030 DP RE44186 Jul 31, 2023 DS DP U-493

DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - QTERNMET XR N 210874 003 6414126 Oct 04, 2020 DS DP U-493 6515117 Oct 04, 2020 DS DP U-493 6936590 Oct 04, 2020 U-493 7919598 Dec 16, 2029 DS 8501698 Jun 20, 2027 DP U-493 8628799 Jul 13, 2025 DP 8716251 Mar 21, 2028 DP 9198925 Oct 04, 2020 U-493 9616028 Nov 12, 2030 DP RE44186 Jul 31, 2023 DS DP U-493

DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - QTERNMET XR N 210874 004 6414126 Oct 04, 2020 DS DP U-493 6515117 Oct 04, 2020 DS DP U-493 6936590 Oct 04, 2020 U-493 7919598 Dec 16, 2029 DS 8501698 Jun 20, 2027 DP U-493 8628799 Jul 13, 2025 DP 8716251 Mar 21, 2028 DP 9198925 Oct 04, 2020 U-493 9616028 Nov 12, 2030 DP A - 8 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - QTERNMET XR N 210874 004 RE44186 Jul 31, 2023 DS DP U-493

DAPAGLIFLOZIN; SAXAGLIPTIN HYDROCHLORIDE - QTERN N 209091 001 6414126 Oct 04, 2020 DS DP U-1976 6414126 Oct 04, 2020 DS DP U-1977 6414126 Oct 04, 2020 DS DP U-493 6515117 Oct 04, 2020 DS DP U-1976 6515117 Oct 04, 2020 DS DP U-1977 6515117 Oct 04, 2020 DS DP U-493 6936590 Oct 04, 2020 U-1976 6936590 Oct 04, 2020 U-1977 6936590 Oct 04, 2020 U-493 8361972 Mar 21, 2028 U-1976 8361972 Mar 21, 2028 U-1977 8361972 Mar 21, 2028 U-493 8501698 Jun 20, 2027 DP U-1976 8501698 Jun 20, 2027 DP U-1977 8501698 Jun 20, 2027 DP U-493 9198925 Oct 04, 2020 U-1976 9198925 Oct 04, 2020 U-1977 9198925 Oct 04, 2020 U-493 RE44186 Jul 31, 2023 DS DP U-1976 RE44186 Jul 31, 2023 DS DP U-1977 RE44186 Jul 31, 2023 DS DP U-493

DAPAGLIFLOZIN; SAXAGLIPTIN HYDROCHLORIDE - QTERN N 209091 002 6414126 Oct 04, 2020 DS DP U-493 6515117 Oct 04, 2020 DS DP U-493 6936590 Oct 04, 2020 U-493 7919598 Dec 16, 2029 DS 8221786 Mar 21, 2028 DP 8361972 Mar 21, 2028 U-493 8501698 Jun 20, 2027 DP U-493 8628799 Jul 13, 2025 DP 8716251 Mar 21, 2028 DP 9198925 Oct 04, 2020 U-493 RE44186 Jul 31, 2023 DS DP U-493

DARUNAVIR ETHANOLATE - PREZISTA N 021976 002 9889115 Jun 23, 2019 U-1305 9889115*PED Dec 23, 2019

DARUNAVIR ETHANOLATE - PREZISTA N 021976 004 9889115 Jun 23, 2019 U-1305 9889115*PED Dec 23, 2019

DARUNAVIR ETHANOLATE - PREZISTA N 021976 005 9889115 Jun 23, 2019 U-1305 9889115*PED Dec 23, 2019

DARUNAVIR ETHANOLATE - PREZISTA N 021976 006 9889115 Jun 23, 2019 U-1305 9889115*PED Dec 23, 2019

DARUNAVIR ETHANOLATE - PREZISTA N 202895 001 9889115 Jun 23, 2019 U-1305 9889115*PED Dec 23, 2019

DASABUVIR SODIUM ; OMBITASVIR; PARITAPREVIR; RITONAVIR - VIEKIRA PAK (COPACKAGED) N 206619 001 10201542 Oct 18, 2033 DP U-1753 A - 9 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR - VIEKIRA XR N 208624 001 10201541 May 17, 2032 DP 10201584 May 17, 2032 U-1889

DASATINIB - SPRYCEL N 021986 001 ODE-225 Dec 21, 2025 PED Jun 21, 2026

DASATINIB - SPRYCEL N 021986 002 ODE-225 Dec 21, 2025 PED Jun 21, 2026

DASATINIB - SPRYCEL N 021986 003 ODE-225 Dec 21, 2025 PED Jun 21, 2026

DASATINIB - SPRYCEL N 021986 004 ODE-225 Dec 21, 2025 PED Jun 21, 2026

DASATINIB - SPRYCEL N 021986 005 ODE-225 Dec 21, 2025 PED Jun 21, 2026

DASATINIB - SPRYCEL N 021986 006 ODE-225 Dec 21, 2025 PED Jun 21, 2026

DEFERASIROX - DEFERASIROX A 203560 001 PC Apr 05, 2019

DEFERASIROX - DEFERASIROX A 203560 002 PC Apr 05, 2019

DEFERASIROX - DEFERASIROX A 203560 003 PC Apr 05, 2019

DEFERASIROX - EXJADE N 021882 001 M-239 Dec 12, 2021

DEFERASIROX - EXJADE N 021882 002 M-239 Dec 12, 2021

DEFERASIROX - EXJADE N 021882 003 M-239 Dec 12, 2021

DEFERASIROX - JADENU N 206910 001 M-239 Dec 12, 2021

DEFERASIROX - JADENU N 206910 002 M-239 Dec 12, 2021

DEFERASIROX - JADENU N 206910 003 M-239 Dec 12, 2021

DEFERASIROX - JADENU SPRINKLE N 207968 001 M-239 Dec 12, 2021 A - 10 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

DEFERASIROX - JADENU SPRINKLE N 207968 002 M-239 Dec 12, 2021

DEFERASIROX - JADENU SPRINKLE N 207968 003 M-239 Dec 12, 2021

DEFERIPRONE - FERRIPROX N 208030 002 7049328 Jun 28, 2021 U-735 8703156 Oct 29, 2029 DP U-735

DESONIDE - VERDESO N 021978 001 8460641 Aug 13, 2027 DP U-1412

DEXAMETHASONE - DEXTENZA N 208742 001 8409606 May 14, 2030 DP >A> I-800 Jun 20, 2022 8563027 Feb 12, 2030 U-2487 NP Nov 30, 2021 9254267 Sep 11, 2024 DP

DEXAMETHASONE - DEXYCU KIT N 208912 001 10159683 May 23, 2034 DP

DEXMEDETOMIDINE HYDROCHLORIDE - DEXMEDETOMIDINE HYDROCHLORIDE A 208129 001 >A> PC Nov 30, 2019

DOCETAXEL - DOCETAXEL N 205934 001 >A> 9763880 Sep 30, 2033 U-2558 >A> 9763880 Sep 30, 2033 U-2559 >A> 9763880 Sep 30, 2033 U-2560 >A> 9763880 Sep 30, 2033 U-2561 >A> 9763880 Sep 30, 2033 U-2562 >A> 9763880 Sep 30, 2033 U-2563 >A> 9763880 Sep 30, 2033 U-2564

DOCETAXEL - DOCETAXEL N 205934 002 >A> 9763880 Sep 30, 2033 U-2558 >A> 9763880 Sep 30, 2033 U-2559 >A> 9763880 Sep 30, 2033 U-2560 >A> 9763880 Sep 30, 2033 U-2561 >A> 9763880 Sep 30, 2033 U-2562 >A> 9763880 Sep 30, 2033 U-2563 >A> 9763880 Sep 30, 2033 U-2564

DOCETAXEL - DOCETAXEL N 205934 003 >A> 9763880 Sep 30, 2033 U-2558 >A> 9763880 Sep 30, 2033 U-2559 >A> 9763880 Sep 30, 2033 U-2560 >A> 9763880 Sep 30, 2033 U-2561 >A> 9763880 Sep 30, 2033 U-2562 >A> 9763880 Sep 30, 2033 U-2563 >A> 9763880 Sep 30, 2033 U-2564

DOLUTEGRAVIR SODIUM; LAMIVUDINE - DOVATO N 211994 001 8129385 Oct 05, 2027 DS DP NC Apr 08, 2022 9242986 Dec 08, 2029 DS DP

DOXEPIN HYDROCHLORIDE - SILENOR N 022036 001 10238620 May 18, 2027 U-620

DOXEPIN HYDROCHLORIDE - SILENOR N 022036 002 10238620 May 18, 2027 U-620 A - 11 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

DOXYCYCLINE - ORACEA N 050805 001 10058564 Apr 05, 2022 U-1063

DRONABINOL - SYNDROS N 205525 001 10265293 Aug 06, 2028 DS DP

DROSPIRENONE - SLYND N 211367 001 >A> 10179140 Jun 28, 2031 U-2547 NP May 23, 2022

ELTROMBOPAG OLAMINE - PROMACTA N 022291 001 7160870 Nov 20, 2022 DS DP U-1306 7160870 Nov 20, 2022 DS DP U-2451 7160870*PED May 20, 2023 7332481 May 24, 2021 U-1306 7332481 May 24, 2021 U-2451 7332481*PED Nov 24, 2021 7452874 May 24, 2021 DS DP 7452874*PED Nov 24, 2021 7473686 May 24, 2021 DS DP U-1306 7473686 May 24, 2021 DS DP U-2451 7473686*PED Nov 24, 2021 7547719 Jul 13, 2025 DS DP U-1306 7547719 Jul 13, 2025 DS DP U-1575 7547719 Jul 13, 2025 DS DP U-2451 7547719 Jul 13, 2025 DS DP U-2452 7547719*PED Jan 13, 2026 7790704 May 24, 2021 U-1306 7790704 May 24, 2021 U-2451 7790704*PED Nov 24, 2021 7795293 May 21, 2023 U-1306 7795293 May 21, 2023 U-2451 7795293*PED Nov 21, 2023 8052993 Aug 01, 2027 DP U-1306 8052993 Aug 01, 2027 DP U-1575 8052993 Aug 01, 2027 DP U-2451 8052993 Aug 01, 2027 DP U-930 8052993*PED Feb 01, 2028 8828430 Aug 01, 2027 DP U-1306 8828430 Aug 01, 2027 DP U-2451 8828430*PED Feb 01, 2028

ELTROMBOPAG OLAMINE - PROMACTA N 022291 002 7160870 Nov 20, 2022 DS DP U-1306 7160870 Nov 20, 2022 DS DP U-2451 7160870*PED May 20, 2023 7332481 May 24, 2021 U-1306 7332481 May 24, 2021 U-2451 7332481*PED Nov 24, 2021 7452874 May 24, 2021 DS DP 7452874*PED Nov 24, 2021 7473686 May 24, 2021 DS DP U-1306 7473686 May 24, 2021 DS DP U-2451 7473686*PED Nov 24, 2021 7547719 Jul 13, 2025 DS DP U-1306 7547719 Jul 13, 2025 DS DP U-1575 7547719 Jul 13, 2025 DS DP U-2451 7547719 Jul 13, 2025 DS DP U-2452 7547719 Jul 13, 2025 DS DP U-930 7547719*PED Jan 13, 2026 7790704 May 24, 2021 U-1306 7790704 May 24, 2021 U-2451 7790704*PED Nov 24, 2021 7795293 May 21, 2023 U-1306 7795293 May 21, 2023 U-2451 7795293 May 21, 2023 U-930 7795293*PED Nov 21, 2023 A - 12 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

ELTROMBOPAG OLAMINE - PROMACTA N 022291 002 8052994 Aug 01, 2027 DP U-1306 8052994 Aug 01, 2027 DP U-2451 8052994 Aug 01, 2027 DP U-930 8052994*PED Feb 01, 2028 8828430 Aug 01, 2027 DP U-1306 8828430 Aug 01, 2027 DP U-2451 8828430*PED Feb 01, 2028

ELTROMBOPAG OLAMINE - PROMACTA N 022291 003 7160870 Nov 20, 2022 DS DP U-1306 7160870 Nov 20, 2022 DS DP U-2451 7160870*PED May 20, 2023 7332481 May 24, 2021 U-1306 7332481 May 24, 2021 U-2451 7332481*PED Nov 24, 2021 7452874 May 24, 2021 DS DP 7452874*PED Nov 24, 2021 7473686 May 24, 2021 DS DP U-1306 7473686 May 24, 2021 DS DP U-2451 7473686*PED Nov 24, 2021 7547719 Jul 13, 2025 DS DP U-1306 7547719 Jul 13, 2025 DS DP U-1575 7547719 Jul 13, 2025 DS DP U-2451 7547719 Jul 13, 2025 DS DP U-2452 7547719 Jul 13, 2025 DS DP U-930 7547719*PED Jan 13, 2026 7790704 May 24, 2021 U-1306 7790704 May 24, 2021 U-2451 7790704*PED Nov 24, 2021 7795293 May 21, 2023 U-1306 7795293 May 21, 2023 U-2451 7795293 May 21, 2023 U-930 7795293*PED Nov 21, 2023 8062665 Aug 01, 2027 DP U-1306 8062665 Aug 01, 2027 DP U-2451 8062665 Aug 01, 2027 DP U-930 8062665*PED Feb 01, 2028 8828430 Aug 01, 2027 DP U-1306 8828430 Aug 01, 2027 DP U-2451 8828430*PED Feb 01, 2028

ELTROMBOPAG OLAMINE - PROMACTA N 022291 004 7160870 Nov 20, 2022 DS DP U-1306 7160870 Nov 20, 2022 DS DP U-2451 7160870*PED May 20, 2023 7332481 May 24, 2021 U-1306 7332481 May 24, 2021 U-2451 7332481*PED Nov 24, 2021 7452874 May 24, 2021 DS DP 7452874*PED Nov 24, 2021 7473686 May 24, 2021 DS DP U-1306 7473686 May 24, 2021 DS DP U-2451 7473686*PED Nov 24, 2021 7547719 Jul 13, 2025 DS DP U-1306 7547719 Jul 13, 2025 DS DP U-1575 7547719 Jul 13, 2025 DS DP U-2451 7547719 Jul 13, 2025 DS DP U-2452 7547719*PED Jan 13, 2026 7790704 May 24, 2021 U-1306 7790704 May 24, 2021 U-2451 7790704*PED Nov 24, 2021 7795293 May 21, 2023 U-1306 7795293 May 21, 2023 U-2451 7795293*PED Nov 21, 2023 8071129 Aug 01, 2027 DP U-1306 8071129 Aug 01, 2027 DP U-2451 A - 13 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

ELTROMBOPAG OLAMINE - PROMACTA N 022291 004 8071129 Aug 01, 2027 DP U-930 8071129*PED Feb 01, 2028 8828430 Aug 01, 2027 DP U-1306 8828430 Aug 01, 2027 DP U-2451 8828430*PED Feb 01, 2028

ELTROMBOPAG OLAMINE - PROMACTA KIT N 207027 001 7160870 Nov 20, 2022 DS DP U-1306 7160870 Nov 20, 2022 DS DP U-1736 7160870*PED May 20, 2023 7332481 May 24, 2021 U-1306 7332481 May 24, 2021 U-1736 7332481*PED Nov 24, 2021 7473686 May 24, 2021 DS DP U-1306 7473686 May 24, 2021 DS DP U-1736 7473686*PED Nov 24, 2021 7547719 Jul 13, 2025 DS DP U-1306 7547719 Jul 13, 2025 DS DP U-1575 7547719 Jul 13, 2025 DS DP U-1736 7547719 Jul 13, 2025 DS DP U-2452 7547719*PED Jan 13, 2026 7790704 May 24, 2021 U-1306 7790704 May 24, 2021 U-1736 7790704*PED Nov 24, 2021 7795293 May 21, 2023 U-1306 7795293 May 21, 2023 U-1736 7795293*PED Nov 24, 2023

ELTROMBOPAG OLAMINE - PROMACTA KIT N 207027 002 7160870 Nov 20, 2022 DS DP U-1306 7160870 Nov 20, 2022 DS DP U-1736 7160870*PED May 20, 2023 7332481 May 24, 2021 U-1306 7332481 May 24, 2021 U-1736 7332481*PED Nov 24, 2021 7452874 May 24, 2021 DS DP 7452874*PED Nov 24, 2021 7473686 May 24, 2021 DS DP U-1306 7473686 May 24, 2021 DS DP U-1736 7473686*PED Nov 24, 2021 7547719 Jul 13, 2025 DS DP U-1306 7547719 Jul 13, 2025 DS DP U-1575 7547719 Jul 13, 2025 DS DP U-1736 7547719 Jul 13, 2025 DS DP U-2452 7547719*PED Jan 13, 2026 7790704 May 24, 2021 U-1306 7790704 May 24, 2021 U-1736 7790704*PED Nov 24, 2021 7795293 May 21, 2023 U-1306 7795293 May 21, 2023 U-1736 7795293*PED Nov 21, 2023

ELUXADOLINE - VIBERZI N 206940 001 10188632 Mar 14, 2033 DP 10213415 Mar 14, 2025 DS U-2152

ELUXADOLINE - VIBERZI N 206940 002 10188632 Mar 14, 2033 DP 10213415 Mar 14, 2025 DS U-2152

EMPAGLIFLOZIN - JARDIANCE N 204629 001 10258637 Apr 03, 2034 U-2290 A - 14 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

EMPAGLIFLOZIN - JARDIANCE N 204629 002 10258637 Apr 03, 2034 U-2290

EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI N 206073 001 10258637 Apr 03, 2034 U-2290

EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI N 206073 002 10258637 Apr 03, 2034 U-2290

EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY N 206111 001 10258637 Apr 03, 2034 U-2290

EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY N 206111 002 10258637 Apr 03, 2034 U-2290

EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY N 206111 003 10258637 Apr 03, 2034 U-2290

EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY N 206111 004 10258637 Apr 03, 2034 U-2290

EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR N 208658 001 10258637 Apr 03, 2034 U-2290

EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR N 208658 002 10258637 Apr 03, 2034 U-2290

EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR N 208658 003 10258637 Apr 03, 2034 U-2290

EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR N 208658 004 10258637 Apr 03, 2034 U-2290

ENASIDENIB MESYLATE - IDHIFA N 209606 001 >A> 10294215 Jan 07, 2033 DP U-2087

ENASIDENIB MESYLATE - IDHIFA N 209606 002 >A> 10294215 Jan 07, 2033 DP U-2087

EPINEPHRINE - AUVI-Q N 201739 001 10314977 Nov 23, 2024 DP >A> 10335549 Apr 30, 2025 DP

EPINEPHRINE - AUVI-Q N 201739 002 10314977 Nov 23, 2024 DP >A> 10335549 Apr 30, 2025 DP

EPINEPHRINE - AUVI-Q N 201739 003 10314977 Nov 23, 2024 DP >A> 10335549 Apr 30, 2025 DP

ERAVACYCLINE DIHYDROCHLORIDE - XERAVA N 211109 001 8796245 Aug 07, 2029 U-2380 8906887 Dec 28, 2030 DP

ERDAFITINIB - BALVERSA N 212018 001 8895601 May 22, 2031 DS DP NCE Apr 12, 2024 9464071 Apr 28, 2031 U-2518 9902714 Mar 26, 2035 DP A - 15 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

ERDAFITINIB - BALVERSA N 212018 002 8895601 May 22, 2031 DS DP NCE Apr 12, 2024 9464071 Apr 28, 2031 U-2518 9902714 Mar 26, 2035 DP

ERDAFITINIB - BALVERSA N 212018 003 8895601 May 22, 2031 DS DP NCE Apr 12, 2024 9464071 Apr 28, 2031 U-2518 9902714 Mar 26, 2035 DP

ERLOTINIB HYDROCHLORIDE - ERLOTINIB HYDROCHLORIDE A 091002 001 PC Nov 05, 2019

ERLOTINIB HYDROCHLORIDE - ERLOTINIB HYDROCHLORIDE A 091002 002 PC Nov 05, 2019

ERLOTINIB HYDROCHLORIDE - ERLOTINIB HYDROCHLORIDE A 091002 003 PC Nov 05, 2019

ESKETAMINE HYDROCHLORIDE - SPRAVATO N 211243 001 8785500 Jul 09, 2031 U-2502 NCE* Mar 05, 2024 9592207 Mar 20, 2027 U-2502

ESTRADIOL - IMVEXXY N 208564 001 10258630 Dec 20, 2033 U-2316 10258630 Dec 20, 2033 U-2317

ESTRADIOL - IMVEXXY N 208564 002 10258630 Dec 20, 2033 U-2316 10258630 Dec 20, 2033 U-2317

ESTRADIOL; PROGESTERONE - BIJUVA N 210132 001 10206932 Nov 21, 2032 U-2439

FERRIC CARBOXYMALTOSE - INJECTAFER N 203565 001 >A> 7754702 Feb 15, 2028 DP U-1432 >A> 7754702 Feb 15, 2028 DP U-2555 >A> 7754702 Feb 15, 2028 DP U-2556 >A> 7754702 Feb 15, 2028 DP U-2557

FERRIC CITRATE - AURYXIA N 205874 001 >A> 10300039 Jul 21, 2030 U-2549 I-790 Nov 06, 2020 5753706 Feb 03, 2020 DP U-1577

FERRIC PYROPHOSPHATE CITRATE - TRIFERIC N 208551 001 7816404 Apr 17, 2029 U-1656 7857977 Sep 08, 2027 U-1656

FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA ALLERGY N 201373 001 8933097 Aug 02, 2030 DP

FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK N 208798 001 10195375 Feb 14, 2031 DP

FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK N 208798 002 10195375 Feb 14, 2031 DP

FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK N 208798 003 10195375 Feb 14, 2031 DP A - 16 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

FLUTICASONE PROPIONATE - XHANCE N 209022 001 10179216 Jul 08, 2033 DP U-2133 10252010 Feb 07, 2031 DP >A> 10300229 Jul 07, 2035 DP U-2133

FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK N 208799 001 10195375 Feb 14, 2031 DP

FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK N 208799 002 10195375 Feb 14, 2031 DP

FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK N 208799 003 10195375 Feb 14, 2031 DP

FORMOTEROL FUMARATE; GLYCOPYRROLATE - BEVESPI AEROSPHERE N 208294 001 >A> 8324266 May 28, 2030 U-2546 >A> 8703806 May 28, 2030 U-2546 >A> 8808713 May 28, 2030 DP U-2546 >A> 8815258 Mar 17, 2031 U-2546 >A> 9415009 May 28, 2030 U-2546 >A> 9463161 May 28, 2030 DP U-2546

FORMOTEROL FUMARATE; MOMETASONE FUROATE - DULERA N 022518 001 >A> 7067502 May 21, 2020 DP U-1068 >A> M-214 Dec 20, 2020 >A> 7067502*PED Nov 21, 2020 >A> PED Jun 20, 2021 >A> 7566705 May 21, 2020 DP U-1068 >A> 7566705*PED Nov 21, 2020

FORMOTEROL FUMARATE; MOMETASONE FUROATE - DULERA N 022518 002 >A> 7067502 May 21, 2020 DP U-1068 >A> M-214 Dec 20, 2020 >A> 7067502*PED Nov 21, 2020 >A> PED Jun 20, 2021 >A> 7566705 May 21, 2020 DP U-1068 >A> 7566705*PED Nov 21, 2020

FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE - AKYNZEO N 210493 001 10208073 May 23, 2032 U-2301

FULVESTRANT - FASLODEX N 021344 001 6774122 Jan 09, 2021 U-1826 6774122 Jan 09, 2021 U-2108 6774122 Jan 09, 2021 U-2163 6774122 Jan 09, 2021 U-2504 6774122 Jan 09, 2021 U-596 6774122*PED Jul 09, 2021 7456160 Jan 09, 2021 U-1826 7456160 Jan 09, 2021 U-2108 7456160 Jan 09, 2021 U-2163 7456160 Jan 09, 2021 U-2504 7456160 Jan 09, 2021 U-596 7456160*PED Jul 09, 2021 8329680 Jan 09, 2021 U-1826 8329680 Jan 09, 2021 U-2108 8329680 Jan 09, 2021 U-2163 8329680 Jan 09, 2021 U-2504 8329680 Jan 09, 2021 U-596 8329680*PED Jul 09, 2021 8466139 Jan 09, 2021 U-1826 8466139 Jan 09, 2021 U-2108 8466139 Jan 09, 2021 U-2163 8466139 Jan 09, 2021 U-2504 8466139 Jan 09, 2021 U-596 8466139*PED Jul 09, 2021 A - 17 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

FULVESTRANT - FULVESTRANT N 210326 001 >A> 10188663 Feb 14, 2034 DP U-2540 >A> 9271990 May 17, 2034 DP U-2540 >A> 9833459 Feb 14, 2034 DP U-2540

GILTERITINIB FUMARATE - XOSPATA N 211349 001 NCE Nov 28, 2023

GLECAPREVIR; PIBRENTASVIR - MAVYRET N 209394 001 10028937 Jun 10, 2030 U-2141 NPP Apr 30, 2022 10028937 Jun 10, 2030 U-2532 ODE-232 Apr 30, 2026 10039754 Jun 10, 2030 U-2141 ODE-233 Apr 30, 2026 10039754 Jun 10, 2030 U-2532 10286029 Mar 14, 2034 U-2532 8648037 Jan 19, 2032 DS DP U-2141 8648037 Jan 19, 2032 DS DP U-2532 9586978 Jun 10, 2030 U-2141 9586978 Jun 10, 2030 U-2532

GLYCEROL PHENYLBUTYRATE - RAVICTI N 203284 001 10183002 Sep 22, 2030 U-1816 10183003 Sep 22, 2030 U-1816 10183004 Sep 22, 2030 U-1816 10183005 Sep 22, 2030 U-1816 10183006 Sep 22, 2030 U-1816

HALOBETASOL PROPIONATE - BRYHALI N 209355 001 6517847 Aug 03, 2020 DP 8809307 Nov 02, 2031 DP

HALOBETASOL PROPIONATE; TAZAROTENE - DUOBRII N 209354 001 10251895 Jun 06, 2036 DP NP Apr 25, 2022 6517847 Aug 03, 2020 DP 8809307 Nov 02, 2031 DP

HYDROCORTISONE VALERATE - HYDROCORTISONE VALERATE A 211750 001 CGT Jul 16, 2019

IBRUTINIB - IMBRUVICA N 205552 001 10294231 Jun 03, 2033 DP M-236 Jan 25, 2022 10294232 Jun 03, 2033 DP

IBRUTINIB - IMBRUVICA N 205552 002 10294231 Jun 03, 2033 DP M-236 Jan 25, 2022 10294232 Jun 03, 2033 DP

IBRUTINIB - IMBRUVICA N 210563 001 10213386 Mar 03, 2036 DP M-236 Jan 25, 2022

IBRUTINIB - IMBRUVICA N 210563 002 10213386 Mar 03, 2036 DP M-236 Jan 25, 2022

IBRUTINIB - IMBRUVICA N 210563 003 10213386 Mar 03, 2036 DP M-236 Jan 25, 2022

IBRUTINIB - IMBRUVICA N 210563 004 10213386 Mar 03, 2036 DP M-236 Jan 25, 2022

IBUPROFEN - CHILDREN'S ADVIL-FLAVORED N 020589 002 10238640 May 25, 2024 DP A - 18 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

IMIQUIMOD - ZYCLARA N 022483 001 10238644 Dec 11, 2029 U-68 10238645 Aug 18, 2029 U-1455 10238645 Aug 18, 2029 U-172

INSULIN ASPART - FIASP FLEXTOUCH N 208751 002 10220155 Jul 17, 2026 DP 7762994 May 23, 2024 DP 8579869 Jun 30, 2023 DP RE46363 Aug 03, 2026 DP

INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT - NOVOLOG MIX 70/30 FLEXPEN N 021172 004 7762994 May 23, 2024 DP 8579869 Jun 30, 2023 DP

INSULIN ASPART RECOMBINANT - NOVOLOG PENFILL N 020986 002 7762994 May 23, 2024 DP 8579869 Jun 30, 2023 DP

INSULIN ASPART RECOMBINANT - NOVOLOG FLEXPEN N 020986 003 7762994 May 23, 2024 DP 8579869 Jun 30, 2023 DP

INSULIN ASPART RECOMBINANT - NOVOLOG FLEXTOUCH N 020986 005 10220155 Jul 17, 2026 DP 7762994 May 23, 2024 DP 8579869 Jun 30, 2023 DP

INSULIN ASPART; INSULIN DEGLUDEC - RYZODEG 70/30 N 203313 001 10220155 Jul 17, 2026 DP 7762994 May 23, 2024 DP 8579869 Jun 30, 2023 DP

INSULIN DEGLUDEC - TRESIBA N 203314 001 10220155 Jul 17, 2026 DP 7762994 May 23, 2024 DP 8579869 Jun 30, 2023 DP

INSULIN DEGLUDEC - TRESIBA N 203314 002 10220155 Jul 17, 2026 DP 7762994 May 23, 2024 DP 8579869 Jun 30, 2023 DP

INSULIN DEGLUDEC; LIRAGLUTIDE - XULTOPHY 100/3.6 N 208583 001 >A> 10220155 Jul 17, 2026 DP 6268343 Aug 22, 2022 DS DP 6268343*PED Feb 22, 2023 >A> 6899699 Jan 02, 2022 DP >A> 7615532 Jun 28, 2029 DS DP 7762994 May 23, 2024 DP 7762994*PED Nov 23, 2024 8579869 Jun 30, 2023 DP 8579869*PED Dec 30, 2023 >A> 8672898 Jan 02, 2022 DP >A> 8684969 Oct 20, 2025 DP 8846618 Jun 27, 2022 DS DP 8846618*PED Dec 27, 2022 >A> 8920383 Jul 17, 2026 DP >A> 8937042 May 05, 2029 DP >A> 9108002 Jan 20, 2026 DP >A> 9132239 Feb 01, 2032 DP >A> 9457154 Sep 27, 2027 DP >A> 9486588 Jan 02, 2022 DP >A> 9616180 Jan 20, 2026 DP A - 19 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

INSULIN DEGLUDEC; LIRAGLUTIDE - XULTOPHY 100/3.6 N 208583 001 >A> 9687611 Feb 27, 2027 DP >A> 9775953 Jul 17, 2026 DP >A> 9861757 Jan 20, 2026 DP >A> RE46363 Aug 03, 2026 DP

INSULIN DETEMIR RECOMBINANT - LEVEMIR FLEXTOUCH N 021536 005 10220155 Jul 17, 2026 DP 7762994 May 23, 2024 DP 8579869 Jun 30, 2023 DP

INSULIN GLARGINE; LIXISENATIDE - SOLIQUA 100/33 N 208673 001 9011391 Mar 26, 2024 U-1923 9011391 Mar 26, 2024 U-2496

INSULIN RECOMBINANT HUMAN - AFREZZA N 022472 001 10201672 Aug 02, 2030 DP

INSULIN RECOMBINANT HUMAN - AFREZZA N 022472 002 10201672 Aug 02, 2030 DP

INSULIN RECOMBINANT HUMAN - AFREZZA N 022472 003 10201672 Aug 02, 2030 DP

ISOPROPYL ALCOHOL - ZURAGARD N 210872 001 NP Apr 26, 2022

IVABRADINE - CORLANOR N 209964 001 7361649 Feb 22, 2026 DS DP U-1694 NCE Apr 15, 2020 7361650 Feb 22, 2026 DS DP U-1694 NP Apr 22, 2022 7867996 Feb 22, 2026 DS DP U-1694 ODE-234 Apr 22, 2026 7879842 Feb 22, 2026 DS DP U-1694 PED Oct 15, 2020 PED Oct 22, 2022 PED Oct 22, 2026

IVABRADINE HYDROCHLORIDE - CORLANOR N 206143 001 7361649 Feb 22, 2026 DS DP U-1694 NCE Apr 15, 2020 7361649*PED Aug 22, 2026 PED Oct 15, 2020 7361650 Feb 22, 2026 DS DP U-1694 7361650*PED Aug 22, 2026 7867996 Feb 22, 2026 DS DP U-1694 7867996*PED Aug 22, 2026 7879842 Feb 22, 2026 DS DP U-1694 7879842*PED Aug 22, 2026

IVABRADINE HYDROCHLORIDE - CORLANOR N 206143 002 7361649 Feb 22, 2026 DS DP U-1694 NCE Apr 15, 2020 7361649*PED Aug 22, 2026 PED Oct 15, 2020 7361650 Feb 22, 2026 DS DP U-1694 7361650*PED Aug 22, 2026 7867996 Feb 22, 2026 DS DP U-1694 7867996*PED Aug 22, 2026 7879842 Feb 22, 2026 DS DP U-1694 7879842*PED Aug 22, 2026

IVACAFTOR - KALYDECO N 203188 002 NPP Jul 31, 2020 ODE-186 Feb 21, 2021 ODE-187 Dec 29, 2021 ODE-189 Jul 31, 2024 ODE-190 May 17, 2024 ODE-199 Aug 15, 2025 A - 20 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

IVACAFTOR - KALYDECO N 207925 001 10272046 Feb 27, 2033 DP U-2531 >A> ODE-236 Apr 29, 2026 8324242 Aug 05, 2027 U-1311 8324242 Aug 05, 2027 U-1906 8324242 Aug 05, 2027 U-2527 8354427 Jul 06, 2026 U-1311 8354427 Jul 06, 2026 U-1905 8354427 Jul 06, 2026 U-2528 8629162 Jun 24, 2025 U-2234 8629162 Jun 24, 2025 U-2529 9670163 Dec 28, 2026 DP U-1311 9670163 Dec 28, 2026 DP U-2530

IVACAFTOR - KALYDECO N 207925 002 10272046 Feb 27, 2033 DP U-2531 >A> ODE-236 Apr 29, 2026 8324242 Aug 05, 2027 U-1311 8324242 Aug 05, 2027 U-1906 8324242 Aug 05, 2027 U-2527 8354427 Jul 06, 2026 U-1311 8354427 Jul 06, 2026 U-1905 8354427 Jul 06, 2026 U-2528 8629162 Jun 24, 2025 U-2234 8629162 Jun 24, 2025 U-2529 9670163 Dec 28, 2026 DP U-1311 9670163 Dec 28, 2026 DP U-2530

IVACAFTOR - KALYDECO N 207925 003 10272046 Feb 27, 2033 DP U-2531 NPP Jul 31, 2020 7495103 May 20, 2027 DS DP ODE-188 Jul 31, 2024 8324242 Aug 05, 2027 U-1311 ODE-189 May 17, 2024 8324242 Aug 05, 2027 U-1906 ODE-190 May 15, 2025 8324242 Aug 05, 2027 U-2527 ODE-199 Jul 31, 2020 8354427 Jul 06, 2026 U-1311 >A> ODE-236 Apr 29, 2026 8354427 Jul 06, 2026 U-1905 8354427 Jul 06, 2026 U-2528 8410274 Dec 28, 2026 DP 8629162 Jun 24, 2025 U-2234 8629162 Jun 24, 2025 U-2529 8754224 Dec 28, 2026 DS DP 8883206 Feb 27, 2033 DP 9670163 Dec 28, 2026 DP U-1311 9670163 Dec 28, 2026 DP U-2530

IVACAFTOR; IVACAFTOR, TEZACAFTOR - SYMDEKO (COPACKAGED) N 210491 001 10206877 Apr 14, 2035 DP U-2498 10239867 Apr 09, 2027 DS DP U-2512

IVERMECTIN - SOOLANTRA N 206255 001 10206939 Mar 13, 2034 U-1631

IVOSIDENIB - TIBSOVO N 211192 001 9474779 Aug 19, 2033 DS DP U-2350 >A> ODE-242 May 02, 2026 9474779 Aug 19, 2033 DS DP U-2533 9474779 Aug 19, 2033 DS DP U-2534 9850277 Jan 18, 2033 DS DP U-2350 9850277 Jan 18, 2033 DS DP U-2533 9850277 Jan 18, 2033 DS DP U-2534 9968595 Mar 13, 2035 DP U-2351 9968595 Mar 13, 2035 DP U-2533 9968595 Mar 13, 2035 DP U-2534

LAROTRECTINIB SULFATE - VITRAKVI N 210861 001 >A> 10172861 Nov 16, 2035 DS DP NCE Nov 26, 2023 >A> 10285993 Nov 16, 2035 U-2470 A - 21 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

LAROTRECTINIB SULFATE - VITRAKVI N 210861 002 >A> 10172861 Nov 16, 2035 DS DP NCE Nov 26, 2023 >A> 10285993 Nov 16, 2035 U-2470

LAROTRECTINIB SULFATE - VITRAKVI N 211710 001 >A> 10172861 Nov 16, 2035 DS NCE Nov 26, 2023

LATANOPROST - XELPROS N 206185 001 9539262 Oct 15, 2028 U-2400

LATANOPROST; NETARSUDIL DIMESYLATE - ROCKLATAN N 208259 001 10174017 Jan 27, 2030 DS DP U-1524 NC Mar 12, 2022 8394826 Nov 10, 2030 DS DP U-1524 NCE Dec 18, 2022 8450344 Jul 11, 2026 DS DP U-1524 9096569 Jul 11, 2026 DS DP U-1524 9415043 Mar 14, 2034 DS 9931336 Mar 14, 2034 DS DP U-1524 9993470 Mar 14, 2034 DS DP U-1524

LENALIDOMIDE - REVLIMID N 021880 001 7189740 Apr 11, 2023 U-1982 I-796 May 28, 2022 >A> 7468363 Oct 07, 2023 U-1983 I-797 May 28, 2022 >A> 7468363 Oct 07, 2023 U-2550 >A> ODE-241 May 28, 2026 >A> 7468363 Oct 07, 2023 U-2551 >A> ODE-245 May 28, 2026 7968569 Oct 07, 2023 U-1984 8404717 Apr 11, 2023 U-1982 >A> 8492406 Oct 07, 2023 U-2550 8530498 May 15, 2023 U-1984 8648095 May 15, 2023 U-1984 8741929 Mar 08, 2028 U-1983 9056120 Apr 11, 2023 U-1982 9101621 May 15, 2023 U-1985 9101622 May 15, 2023 U-1986 >A> 9155730 May 15, 2023 U-2550 >A> 9393238 May 15, 2023 U-2550

LENALIDOMIDE - REVLIMID N 021880 002 7189740 Apr 11, 2023 U-1982 I-796 May 28, 2022 >A> 7468363 Oct 07, 2023 U-1983 I-797 May 28, 2022 >A> 7468363 Oct 07, 2023 U-2550 >A> ODE-241 May 28, 2026 >A> 7468363 Oct 07, 2023 U-2551 >A> ODE-245 May 28, 2026 7968569 Oct 07, 2023 U-1984 8404717 Apr 11, 2023 U-1982 >A> 8492406 Oct 07, 2023 U-2550 8530498 May 15, 2023 U-1984 8648095 May 15, 2023 U-1984 8741929 Mar 08, 2028 U-1983 9056120 Apr 11, 2023 U-1982 9101621 May 15, 2023 U-1985 9101622 May 15, 2023 U-1986 >A> 9155730 May 15, 2023 U-2550 >A> 9393238 May 15, 2023 U-2550

LENALIDOMIDE - REVLIMID N 021880 003 7189740 Apr 11, 2023 U-1982 I-796 May 28, 2022 >A> 7468363 Oct 07, 2023 U-1983 I-797 May 28, 2022 >A> 7468363 Oct 07, 2023 U-2550 >A> ODE-241 May 28, 2026 >A> 7468363 Oct 07, 2023 U-2551 >A> ODE-245 May 28, 2026 7968569 Oct 07, 2023 U-1984 8404717 Apr 11, 2023 U-1982 >A> 8492406 Oct 07, 2023 U-2550 8530498 May 15, 2023 U-1984 8648095 May 15, 2023 U-1984 8741929 Mar 08, 2028 U-1983 9056120 Apr 11, 2023 U-1982 A - 22 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

LENALIDOMIDE - REVLIMID N 021880 003 9101621 May 15, 2023 U-1985 9101622 May 15, 2023 U-1986 >A> 9155730 May 15, 2023 U-2550 >A> 9393238 May 15, 2023 U-2550

LENALIDOMIDE - REVLIMID N 021880 004 7189740 Apr 11, 2023 U-1982 I-796 May 28, 2022 >A> 7468363 Oct 07, 2023 U-1983 I-797 May 28, 2022 >A> 7468363 Oct 07, 2023 U-2550 >A> ODE-241 May 28, 2026 >A> 7468363 Oct 07, 2023 U-2551 >A> ODE-245 May 28, 2026 7968569 Oct 07, 2023 U-1984 8404717 Apr 11, 2023 U-1982 >A> 8492406 Oct 07, 2023 U-2550 8530498 May 15, 2023 U-1984 8648095 May 15, 2023 U-1984 8741929 Mar 08, 2028 U-1983 9056120 Apr 11, 2023 U-1982 9101621 May 15, 2023 U-1985 9101622 May 15, 2023 U-1986 >A> 9155730 May 15, 2023 U-2550 >A> 9393238 May 15, 2023 U-2550

LENALIDOMIDE - REVLIMID N 021880 005 7189740 Apr 11, 2023 U-1982 I-796 May 28, 2022 >A> 7468363 Oct 07, 2023 U-1983 I-797 May 28, 2022 >A> 7468363 Oct 07, 2023 U-2550 >A> ODE-241 May 28, 2026 >A> 7468363 Oct 07, 2023 U-2551 >A> ODE-245 May 28, 2026 7968569 Oct 07, 2023 U-1984 8404717 Apr 11, 2023 U-1982 >A> 8492406 Oct 07, 2023 U-2550 8530498 May 15, 2023 U-1984 8648095 May 15, 2023 U-1984 8741929 Mar 08, 2028 U-1983 9056120 Apr 11, 2023 U-1982 9101621 May 15, 2023 U-1985 9101622 May 15, 2023 U-1986 >A> 9155730 May 15, 2023 U-2550 >A> 9393238 May 15, 2023 U-2550

LENALIDOMIDE - REVLIMID N 021880 006 7189740 Apr 11, 2023 U-1982 I-796 May 28, 2022 >A> 7468363 Oct 07, 2023 U-1983 I-797 May 28, 2022 >A> 7468363 Oct 07, 2023 U-2550 >A> ODE-241 May 28, 2026 >A> 7468363 Oct 07, 2023 U-2551 >A> ODE-245 May 28, 2026 7968569 Oct 07, 2023 U-1984 8404717 Apr 11, 2023 U-1982 >A> 8492406 Oct 07, 2023 U-2550 8530498 May 15, 2023 U-1984 8648095 May 15, 2023 U-1984 8741929 Mar 08, 2028 U-1983 9056120 Apr 11, 2023 U-1982 9101621 May 15, 2023 U-1985 9101622 May 15, 2023 U-1986 >A> 9155730 May 15, 2023 U-2550 >A> 9393238 May 15, 2023 U-2550

LENVATINIB MESYLATE - LENVIMA N 206947 001 10259791 Aug 26, 2035 DS

LENVATINIB MESYLATE - LENVIMA N 206947 002 10259791 Aug 26, 2035 DS A - 23 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

LESINURAD - ZURAMPIC N 207988 001 10183012 Nov 26, 2028 U-2311

LETROZOLE; RIBOCICLIB SUCCINATE - KISQALI FEMARA CO-PACK (COPACKAGED) N 209935 001 8962630 Dec 09, 2029 U-2505 9416136 Aug 20, 2029 U-2505 9868739 Nov 09, 2031 U-2505

LEVETIRACETAM - ELEPSIA XR N 204417 001 8470367 Oct 31, 2027 DP

LEVETIRACETAM - ELEPSIA XR N 204417 002 8470367 Oct 31, 2027 DP

LEVODOPA - INBRIJA N 209184 001 6514482 Sep 19, 2020 DP U-2484 NP Dec 21, 2021 6613308 Sep 19, 2020 U-2484 6858199 Nov 04, 2021 U-2485 6921528 Jun 19, 2020 U-2485 6979437 Sep 19, 2020 U-2484 7146978 Apr 16, 2021 U-2486 7182961 Feb 22, 2024 DP 7384649 Nov 20, 2022 DP 7556798 Nov 04, 2021 U-2485 8404276 Mar 19, 2023 U-2484 8545878 Nov 16, 2032 DP 8586093 Mar 19, 2023 U-2484 8628754 Jun 19, 2020 U-2485 8685442 Nov 16, 2032 DP 8945612 Nov 16, 2032 DP 9155699 Mar 19, 2023 DP 9393210 Nov 16, 2032 DP RE43711 Feb 03, 2029 U-2484

LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM N 210632 001 9782376 Dec 01, 2036 DP

LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM N 210632 002 9782376 Dec 01, 2036 DP

LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM N 210632 003 9782376 Dec 01, 2036 DP

LINACLOTIDE - LINZESS N 202811 001 8802628 Oct 30, 2031 DP

LINACLOTIDE - LINZESS N 202811 002 8802628 Oct 30, 2031 DP

LIRAGLUTIDE RECOMBINANT - VICTOZA N 022341 001 6268343 Aug 22, 2022 DS DP U-968 >A> NPP Jun 17, 2022 6268343*PED Feb 22, 2023 >A> PED Dec 17, 2022 7762994 May 23, 2024 DP 7762994*PED Nov 23, 2024 8114833 Aug 13, 2025 DS DP 8114833*PED Feb 13, 2026 8579869 Jun 30, 2023 DP 8579869*PED Dec 30, 2023 8846618 Jun 27, 2022 DP 8846618*PED Dec 27, 2022 9265893 Sep 23, 2032 DP 9265893*PED Mar 23, 2033 9968659 Jan 09, 2037 U-2313 9968659*PED Jul 09, 2037 A - 24 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

LIRAGLUTIDE RECOMBINANT - VICTOZA N 022341 001 RE41956 Jan 21, 2021 DP RE41956*PED Jul 21, 2021

LIRAGLUTIDE RECOMBINANT - SAXENDA N 206321 001 10220155 Jul 17, 2026 DP 10220155*PED Jan 17, 2027 6268343 Aug 22, 2022 DS DP U-1255 6268343*PED Feb 22, 2023 6899699 Jan 01, 2022 DP 6899699*PED Jul 01, 2022 7762994 May 23, 2024 DP 7762994*PED Nov 23, 2024 8114833 Aug 13, 2025 DP 8114833*PED Feb 13, 2026 8579869 Jun 30, 2023 DP 8579869*PED Dec 30, 2023 8672898 Jan 02, 2022 DP 8672898*PED Jul 02, 2022 8684969 Oct 20, 2025 DP 8684969*PED Apr 20, 2026 8846618 Jun 27, 2022 DP 8846618*PED Dec 27, 2022 8920383 Jul 17, 2026 DP 8920383*PED Jan 17, 2027 9108002 Jan 26, 2026 DP 9108002*PED Jul 26, 2026 9132239 Feb 01, 2032 DP 9132239*PED Aug 01, 2032 9457154 Sep 27, 2027 DP 9457154*PED Mar 27, 2028 9486588 Jan 02, 2022 DP 9486588*PED Jul 02, 2022 9616180 Jan 20, 2026 DP 9616180*PED Jul 20, 2026 9687611 Feb 27, 2027 DP 9687611*PED Aug 27, 2027 9775953 Jul 17, 2026 DP 9775953*PED Jan 17, 2027 9861757 Jan 20, 2026 DP 9861757*PED Jul 20, 2026 9968659 Jan 09, 2037 U-2438 9968659*PED Jul 09, 2037 RE46363 Aug 03, 2026 DP RE46363*PED Feb 03, 2027

LISINOPRIL - QBRELIS N 208401 001 10265370 Nov 06, 2035 DP

LIXISENATIDE - ADLYXIN N 208471 001 >A> 10201663 Mar 10, 2034 DP

LIXISENATIDE - ADLYXIN N 208471 002 >A> 10201663 Mar 10, 2034 DP

LORCASERIN HYDROCHLORIDE - BELVIQ XR N 208524 001 10226471 Aug 31, 2031 DP

LOTEPREDNOL ETABONATE - LOTEMAX SM N 208219 001 NS Feb 22, 2022

LOTEPREDNOL ETABONATE - INVELTYS N 210565 001 10058511 May 03, 2033 DP U-2492 9056057 May 03, 2033 DP U-2491 9393213 May 03, 2033 DP A - 25 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

LOTEPREDNOL ETABONATE - INVELTYS N 210565 001 9532955 May 03, 2033 U-2491 9737491 May 03, 2033 U-2492 9827191 May 03, 2033 DP U-2493

LUBIPROSTONE - AMITIZA N 021908 001 >A> 8779187 Jan 23, 2027 DP

MEROPENEM; VABORBACTAM - VABOMERE N 209776 001 10172874 Aug 08, 2031 DP 10183034 Aug 08, 2031 U-2490

METFORMIN HYDROCHLORIDE - RIOMET N 021591 001 6890957 Aug 07, 2021 DP

METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR N 200678 002 8628799 Jul 13, 2025 DP

METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR N 200678 003 8628799 Jul 13, 2025 DP

METHOTREXATE SODIUM - XATMEP N 208400 001 10231927 Jan 02, 2033 U-1349 10231927 Jan 02, 2033 U-1699

METHYLNALTREXONE BROMIDE - RELISTOR N 208271 001 10307417 Mar 10, 2031 DP

METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR N 205831 001 10039719 Dec 16, 2019 U-2357 10039719*PED Jun 16, 2020 6419960 Dec 16, 2019 DP 6419960*PED Jun 16, 2020 7083808 Dec 16, 2019 DP 7083808*PED Jun 16, 2020 7247318 Dec 16, 2019 DP 7247318*PED Jun 16, 2020 7438930 Dec 16, 2019 DP Y 7438930*PED Jun 16, 2020 8580310 Dec 16, 2019 DP 8580310*PED Jun 16, 2020 9066869 Dec 16, 2019 DP 9066869*PED Jun 16, 2020 9801823 Dec 16, 2019 DP 9801823*PED Jun 16, 2020

METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR N 205831 002 10039719 Dec 16, 2019 U-2357 10039719*PED Jun 16, 2020 6419960 Dec 16, 2019 DP 6419960*PED Jun 16, 2020 7083808 Dec 16, 2019 DP 7083808*PED Jun 16, 2020 7247318 Dec 16, 2019 DP 7247318*PED Jun 16, 2020 7438930 Dec 16, 2019 DP Y 7438930*PED Jun 16, 2020 8580310 Dec 16, 2019 DP 8580310*PED Jun 16, 2020 9066869 Dec 16, 2019 DP 9066869*PED Jun 16, 2020 9801823 Dec 16, 2019 DP 9801823*PED Jun 16, 2020 A - 26 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR N 205831 003 10039719 Dec 16, 2019 U-2357 10039719*PED Jun 16, 2020 6419960 Dec 16, 2019 DP 6419960*PED Jun 16, 2020 7083808 Dec 16, 2019 DP 7083808*PED Jun 16, 2020 7247318 Dec 16, 2019 DP 7247318*PED Jun 16, 2020 7438930 Dec 16, 2019 DP Y 7438930*PED Jun 16, 2020 8580310 Dec 16, 2019 DP 8580310*PED Jun 16, 2020 9066869 Dec 16, 2019 DP 9066869*PED Jun 16, 2020 9801823 Dec 16, 2019 DP 9801823*PED Jun 16, 2020

METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR N 205831 004 10039719 Dec 16, 2019 U-2357 10039719*PED Jun 16, 2020 6419960 Dec 16, 2019 DP 6419960*PED Jun 16, 2020 7083808 Dec 16, 2019 DP 7083808*PED Jun 16, 2020 7247318 Dec 16, 2019 DP 7247318*PED Jun 16, 2020 7438930 Dec 16, 2019 DP Y 7438930*PED Jun 16, 2020 8580310 Dec 16, 2019 DP 8580310*PED Jun 16, 2020 9066869 Dec 16, 2019 DP 9066869*PED Jun 16, 2020 9801823 Dec 16, 2019 DP 9801823*PED Jun 16, 2020

METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR N 205831 005 10039719 Dec 16, 2019 U-2357 10039719*PED Jun 16, 2020 6419960 Dec 16, 2019 DP 6419960*PED Jun 16, 2020 7083808 Dec 16, 2019 DP 7083808*PED Jun 16, 2020 7247318 Dec 16, 2019 DP 7247318*PED Jun 16, 2020 7438930 Dec 16, 2019 DP Y 7438930*PED Jun 16, 2020 8580310 Dec 16, 2019 DP 8580310*PED Jun 16, 2020 9066869 Dec 16, 2019 DP 9066869*PED Jun 16, 2020 9801823 Dec 16, 2019 DP 9801823*PED Jun 16, 2020

METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR N 205831 006 10039719 Dec 16, 2019 U-2357 10039719*PED Jun 16, 2020 6419960 Dec 16, 2019 DP 6419960*PED Jun 16, 2020 7083808 Dec 16, 2019 DP 7083808*PED Jun 16, 2020 7247318 Dec 16, 2019 DP 7247318*PED Jun 16, 2020 7438930 Dec 16, 2019 DP Y 7438930*PED Jun 16, 2020 8580310 Dec 16, 2019 DP A - 27 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR N 205831 006 8580310*PED Jun 16, 2020 9066869 Dec 16, 2019 DP 9066869*PED Jun 16, 2020 9801823 Dec 16, 2019 DP 9801823*PED Jun 16, 2020

METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR N 205831 007 10039719 Dec 16, 2019 U-2357 10039719*PED Jun 16, 2020 6419960 Dec 16, 2019 DP 6419960*PED Jun 16, 2020 7083808 Dec 16, 2019 DP 7083808*PED Jun 16, 2020 7247318 Dec 16, 2019 DP 7247318*PED Jun 16, 2020 7438930 Dec 16, 2019 DP Y 7438930*PED Jun 16, 2020 8580310 Dec 16, 2019 DP 8580310*PED Jun 16, 2020 9066869 Dec 16, 2019 DP 9066869*PED Jun 16, 2020 9801823 Dec 16, 2019 DP 9801823*PED Jun 16, 2020

METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM N 209311 001 10182995 Mar 23, 2032 DP >A> 10292937 Mar 23, 2032 U-2357

METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM N 209311 002 10182995 Mar 23, 2032 DP >A> 10292937 Mar 23, 2032 U-2357

METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM N 209311 003 10182995 Mar 23, 2032 DP >A> 10292937 Mar 23, 2032 U-2357

METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM N 209311 004 10182995 Mar 23, 2032 DP >A> 10292937 Mar 23, 2032 U-2357

METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM N 209311 005 10182995 Mar 23, 2032 DP >A> 10292937 Mar 23, 2032 U-2357

METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR N 212038 001 10111839 Oct 30, 2035 U-2357 NP Feb 27, 2022 10292938 Oct 30, 2035 DP 10292939 Oct 30, 2035 DP U-2357 9974752 Oct 30, 2035 DP

METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR N 212038 002 10111839 Oct 30, 2035 U-2357 NP Feb 27, 2022 10292938 Oct 30, 2035 DP 10292939 Oct 30, 2035 DP U-2357 9974752 Oct 30, 2035 DP

METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR N 212038 003 10111839 Oct 30, 2035 U-2357 NP Feb 27, 2022 10292938 Oct 30, 2035 DP 10292939 Oct 30, 2035 DP U-2357 9974752 Oct 30, 2035 DP A - 28 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR N 212038 004 10111839 Oct 30, 2035 U-2357 NP Feb 27, 2022 10292938 Oct 30, 2035 DP 10292939 Oct 30, 2035 DP U-2357 9974752 Oct 30, 2035 DP

METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR N 212038 005 10111839 Oct 30, 2035 U-2357 NP Feb 27, 2022 10292938 Oct 30, 2035 DP 10292939 Oct 30, 2035 DP U-2357 9974752 Oct 30, 2035 DP

METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR N 212038 006 10111839 Oct 30, 2035 U-2357 NP Feb 27, 2022 10292938 Oct 30, 2035 DP 10292939 Oct 30, 2035 DP U-2357 9974752 Oct 30, 2035 DP

METRONIDAZOLE - NUVESSA N 205223 001 10238634 Jun 28, 2032 DP

MIDAZOLAM - NAYZILAM N 211321 001 8217033 Jan 18, 2028 DP U-2526 NP May 21, 2022 8809322 Jan 18, 2028 DP >A> ODE-243 May 17, 2026 9289432 Jan 18, 2028 DP U-2526 9687495 Jan 18, 2028 DP U-2526

MIFEPRISTONE - KORLYM N 202107 001 10195214 Jun 19, 2037 U-1643 10231983 Aug 22, 2038 U-1643 >A> 10314850 Aug 22, 2038 U-1643

MIGALASTAT HYDROCHLORIDE - GALAFOLD N 208623 001 10251873 May 30, 2038 U-2371

MINOCYCLINE HYDROCHLORIDE - MINOCYCLINE HYDROCHLORIDE A 091424 002 PC Aug 21, 2019

MORPHINE SULFATE - MORPHABOND ER N 206544 001 >A> 10314788 Aug 12, 2028 DP

MORPHINE SULFATE - MORPHABOND ER N 206544 002 >A> 10314788 Aug 12, 2028 DP

MORPHINE SULFATE - MORPHABOND ER N 206544 003 >A> 10314788 Aug 12, 2028 DP

MORPHINE SULFATE - MORPHABOND ER N 206544 004 >A> 10314788 Aug 12, 2028 DP

NAFTIFINE HYDROCHLORIDE - NAFTIN N 204286 001 10166205 Jan 31, 2033 DP 10166206 Jan 31, 2033 DP

NALOXONE HYDROCHLORIDE - EVZIO N 205787 001 10220158 Mar 20, 2035 DP U-2500 10314977 Nov 23, 2024 DP >A> 10322239 Feb 28, 2031 U-1907 >A> 10335549 Apr 30, 2025 DP A - 29 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

NALOXONE HYDROCHLORIDE - EVZIO (AUTOINJECTOR) N 209862 001 10143792 May 24, 2031 U-2476 10220158 Mar 20, 2035 DP U-2500 10314977 Nov 23, 2024 DP >A> 10322239 Feb 28, 2031 U-1907 >A> 10335549 Apr 30, 2025 DP

NETARSUDIL DIMESYLATE - RHOPRESSA N 208254 001 10174017 Jan 27, 2030 DS DP U-1524

NETUPITANT; PALONOSETRON HYDROCHLORIDE - AKYNZEO N 205718 001 10233154 Sep 25, 2035 DS

OLAPARIB - LYNPARZA N 208558 001 8143241 Aug 12, 2027 U-2101 ODE-226 Dec 19, 2025 8143241 Aug 12, 2027 U-2103 8143241 Aug 12, 2027 U-2480 8143241 Aug 12, 2027 U-2481 8143241 Aug 12, 2027 U-2482 8143241 Aug 12, 2027 U-2483 8859562 Aug 04, 2031 U-2101 8859562 Aug 04, 2031 U-2480 8859562 Aug 04, 2031 U-2481 8859562 Aug 04, 2031 U-2482 8859562 Aug 04, 2031 U-2483 8912187 Mar 12, 2024 U-2101 8912187 Mar 12, 2024 U-2480 8912187 Mar 12, 2024 U-2481 8912187 Mar 12, 2024 U-2482 8912187 Mar 12, 2024 U-2483

OLAPARIB - LYNPARZA N 208558 002 8143241 Aug 12, 2027 U-2101 ODE-226 Dec 19, 2025 8143241 Aug 12, 2027 U-2103 8143241 Aug 12, 2027 U-2480 8143241 Aug 12, 2027 U-2481 8143241 Aug 12, 2027 U-2482 8143241 Aug 12, 2027 U-2483 8859562 Aug 04, 2031 U-2101 8859562 Aug 04, 2031 U-2480 8859562 Aug 04, 2031 U-2481 8859562 Aug 04, 2031 U-2482 8859562 Aug 04, 2031 U-2483 8912187 Mar 12, 2024 U-2101 8912187 Mar 12, 2024 U-2480 8912187 Mar 12, 2024 U-2481 8912187 Mar 12, 2024 U-2482 8912187 Mar 12, 2024 U-2483

OMEGA-3-CARBOXYLIC ACIDS - EPANOVA N 205060 001 5792795 May 13, 2020 DP 5948818 May 13, 2020 DP

OSIMERTINIB MESYLATE - TAGRISSO N 208065 001 10183020 Jan 02, 2035 DP U-1777 10183020 Jan 02, 2035 DP U-2289

OSIMERTINIB MESYLATE - TAGRISSO N 208065 002 10183020 Jan 02, 2035 DP U-1777 10183020 Jan 02, 2035 DP U-2289

OSPEMIFENE - OSPHENA N 203505 001 6245819 Jul 21, 2025 U-1370 I-793 Jan 25, 2022 6245819 Jul 21, 2025 U-905 A - 30 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

OSPEMIFENE - OSPHENA N 203505 001 8236861 Aug 11, 2026 U-1369 8236861 Aug 11, 2026 U-1370 8236861 Aug 11, 2026 U-905 8470890 Feb 13, 2024 U-1369 8470890 Feb 13, 2024 U-1370 8470890 Feb 13, 2024 U-905 8772353 Feb 13, 2024 U-1369 8772353 Feb 13, 2024 U-1370 8772353 Feb 13, 2024 U-905 9241915 Feb 13, 2024 U-1369 9241915 Feb 13, 2024 U-1370 9241915 Feb 13, 2024 U-905 9855224 Feb 13, 2024 U-1369 9855224 Feb 13, 2024 U-1370 9855224 Feb 13, 2024 U-905

OXCARBAZEPINE - OXTELLAR XR N 202810 001 10220042 Apr 13, 2027 U-2501 7910131 Apr 13, 2027 U-2041 9119791 Apr 13, 2027 U-2041

OXCARBAZEPINE - OXTELLAR XR N 202810 002 10220042 Apr 13, 2027 U-2501 7910131 Apr 13, 2027 U-2041 9119791 Apr 13, 2027 U-2041

OXCARBAZEPINE - OXTELLAR XR N 202810 003 10220042 Apr 13, 2027 U-2501 7910131 Apr 13, 2027 U-2041 9119791 Apr 13, 2027 U-2041

OXYBUTYNIN CHLORIDE - GELNIQUE N 022204 001 10272061 Apr 26, 2020 U-2525

OXYCODONE - XTAMPZA ER N 208090 001 10188644 Sep 02, 2036 DP U-1556

OXYCODONE - XTAMPZA ER N 208090 002 10188644 Sep 02, 2036 DP U-1556

OXYCODONE - XTAMPZA ER N 208090 003 10188644 Sep 02, 2036 DP U-1556

OXYCODONE - XTAMPZA ER N 208090 004 10188644 Sep 02, 2036 DP U-1556

OXYCODONE - XTAMPZA ER N 208090 005 10188644 Sep 02, 2036 DP U-1556

OXYCODONE HYDROCHLORIDE - OXYCONTIN N 022272 001 9060976 Aug 06, 2022 DP Y

OXYCODONE HYDROCHLORIDE - ROXYBOND N 209777 001 >A> 10314788 Aug 12, 2028 DP

OXYCODONE HYDROCHLORIDE - ROXYBOND N 209777 002 >A> 10314788 Aug 12, 2028 DP

OXYCODONE HYDROCHLORIDE - ROXYBOND N 209777 003 >A> 10314788 Aug 12, 2028 DP A - 31 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

OXYMETAZOLINE HYDROCHLORIDE - RHOFADE N 208552 001 >A> 10335391 Jun 11, 2035 U-2567

OZENOXACIN - XEPI N 208945 001 6335447 Apr 06, 2020 DS

PALBOCICLIB - IBRANCE N 207103 001 7456168 Jan 16, 2023 U-1998 7456168 Jan 16, 2023 U-2515

PALBOCICLIB - IBRANCE N 207103 002 7456168 Jan 16, 2023 U-1998 7456168 Jan 16, 2023 U-2515

PALBOCICLIB - IBRANCE N 207103 003 7456168 Jan 16, 2023 U-1998 7456168 Jan 16, 2023 U-2515

PENICILLAMINE - PENICILLAMINE A 210976 001 >A> CGT Dec 22, 2019

PIMAVANSERIN TARTRATE - NUPLAZID N 207318 002 NCE Apr 29, 2021

PIRFENIDONE - ESBRIET N 208780 001 10188637 Mar 28, 2037 DP

PIRFENIDONE - ESBRIET N 208780 002 10188637 Mar 28, 2037 DP

PIRFENIDONE - ESBRIET N 208780 003 10188637 Mar 28, 2037 DP

PITAVASTATIN CALCIUM - LIVALO N 022363 001 5856336 Dec 25, 2020 DS U-998 NPP May 16, 2022 5856336*PED Jun 25, 2021 PED Nov 16, 2022 7022713 Feb 19, 2024 U-998 7022713*PED Aug 19, 2024 8557993 Feb 02, 2024 DP 8557993*PED Aug 02, 2024

PITAVASTATIN CALCIUM - LIVALO N 022363 002 5856336 Dec 25, 2020 DS U-998 NPP May 16, 2022 5856336*PED Jun 25, 2021 PED Nov 16, 2022 7022713 Feb 19, 2024 U-998 7022713*PED Aug 19, 2024 8557993 Feb 02, 2024 DP 8557993*PED Aug 02, 2024

PITAVASTATIN CALCIUM - LIVALO N 022363 003 5856336 Dec 25, 2020 DS U-998 NPP May 16, 2022 5856336*PED Jun 25, 2021 PED Nov 16, 2022 7022713 Feb 19, 2024 U-998 7022713*PED Aug 19, 2024 8557993 Feb 02, 2024 DP 8557993*PED Aug 02, 2024

PREGABALIN - LYRICA N 021446 001 >A> NPP May 23, 2022 >A> PED Nov 23, 2022 A - 32 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

PREGABALIN - LYRICA N 021446 002 >A> NPP May 23, 2022 >A> PED Nov 23, 2022

PREGABALIN - LYRICA N 021446 003 >A> NPP May 23, 2022 >A> PED Nov 23, 2022

PREGABALIN - LYRICA N 021446 004 >A> NPP May 23, 2022 >A> PED Nov 23, 2022

PREGABALIN - LYRICA N 021446 005 >A> NPP May 23, 2022 >A> PED Nov 23, 2022

PREGABALIN - LYRICA N 021446 006 >A> NPP May 23, 2022 >A> PED Nov 23, 2022

PREGABALIN - LYRICA N 021446 007 >A> NPP May 23, 2022 >A> PED Nov 23, 2022

PREGABALIN - LYRICA N 021446 008 >A> NPP May 23, 2022 >A> PED Nov 23, 2022

PREGABALIN - LYRICA N 022488 001 >A> NPP May 23, 2022 >A> PED Nov 23, 2022

PROPRANOLOL HYDROCHLORIDE - HEMANGEOL N 205410 001 8987262 Oct 16, 2028 U-1988

PYRIDOSTIGMINE BROMIDE - PYRIDOSTIGMINE BROMIDE A 211694 001 CGT Sep 04, 2019

RANOLAZINE - RANOLAZINE A 201046 001 PC May 27, 2019

RANOLAZINE - RANOLAZINE A 201046 002 PC May 27, 2019

REGADENOSON - LEXISCAN N 022161 001 RE47301 Feb 02, 2027 DP RE47351 Jun 22, 2019 DS DP U-869

REVEFENACIN - YUPELRI N 210598 001 8541451 Aug 25, 2031 DS 9765028 Jul 14, 2030 DS

RIFAXIMIN - XIFAXAN N 021361 001 >A> 10314828 Oct 02, 2029 U-1481

RUCAPARIB CAMSYLATE - RUBRACA N 209115 001 10278974 Feb 10, 2031 DP

RUCAPARIB CAMSYLATE - RUBRACA N 209115 002 10278974 Feb 10, 2031 DP A - 33 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

RUCAPARIB CAMSYLATE - RUBRACA N 209115 003 10278974 Feb 10, 2031 DP

RUXOLITINIB PHOSPHATE - JAKAFI N 202192 001 10016429 Jun 12, 2028 U-2536 >A> I-799 May 24, 2022 9814722 Dec 12, 2026 U-2536 >A> ODE-238 May 24, 2026

RUXOLITINIB PHOSPHATE - JAKAFI N 202192 002 10016429 Jun 12, 2028 U-2536 >A> I-799 May 24, 2022 9814722 Dec 12, 2026 U-2536 >A> ODE-238 May 24, 2026

RUXOLITINIB PHOSPHATE - JAKAFI N 202192 003 10016429 Jun 12, 2028 U-2536 >A> I-799 May 24, 2022 9814722 Dec 12, 2026 U-2536 >A> ODE-238 May 24, 2026

RUXOLITINIB PHOSPHATE - JAKAFI N 202192 004 10016429 Jun 12, 2028 U-2536 >A> I-799 May 24, 2022 9814722 Dec 12, 2026 U-2536 >A> ODE-238 May 24, 2026

RUXOLITINIB PHOSPHATE - JAKAFI N 202192 005 10016429 Jun 12, 2028 U-2536 >A> I-799 May 24, 2022 9814722 Dec 12, 2026 U-2536 >A> ODE-238 May 24, 2026

SELENIOUS ACID - SELENIOUS ACID N 209379 001 NCE Apr 30, 2024

SEMAGLUTIDE - OZEMPIC N 209637 001 10220155 Jul 17, 2026 DP

SILDENAFIL CITRATE - SILDENAFIL CITRATE A 212260 001 CGT Nov 27, 2019

SIPONIMOD FUMARIC ACID - MAYZENT N 209884 001 7939519 May 19, 2024 DS DP NCE Mar 26, 2024 8492441 Nov 30, 2030 U-2511

SIPONIMOD FUMARIC ACID - MAYZENT N 209884 002 7939519 May 19, 2024 DS DP NCE Mar 26, 2024 8492441 Nov 30, 2030 U-2511

SODIUM OXYBATE - XYREM N 021196 001 10213400 Mar 15, 2033 U-2499 ODE-231 Oct 26, 2025

SODIUM ZIRCONIUM CYCLOSILICATE - LOKELMA N 207078 001 9913860 Oct 22, 2033 DS U-2312

SODIUM ZIRCONIUM CYCLOSILICATE - LOKELMA N 207078 002 9913860 Oct 22, 2033 DS U-2312

SOLRIAMFETOL - SUNOSI N 211230 001 >A> 10195151 Sep 05, 2037 DP >A> NCE Jun 17, 2024 >A> 8440715 Aug 25, 2027 U-2548 >A> 8877806 Jun 07, 2026 U-2548 >A> 9604917 Jun 07, 2026 U-2548

SOLRIAMFETOL - SUNOSI N 211230 002 >A> 10195151 Sep 05, 2037 DP >A> NCE Jun 17, 2024 >A> 8440715 Aug 25, 2027 U-2548 >A> 8877806 Jun 07, 2026 U-2548 >A> 9604917 Jun 07, 2026 U-2548 A - 34 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO N 021148 008 10220155 Jul 17, 2026 DP 7762994 May 23, 2024 DP 8579869 Jun 30, 2023 DP

SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO N 021148 009 10220155 Jul 17, 2026 DP 7762994 May 23, 2024 DP 8579869 Jun 30, 2023 DP

SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO N 021148 010 10220155 Jul 17, 2026 DP 7762994 May 23, 2024 DP 8579869 Jun 30, 2023 DP

SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO N 021148 011 10220155 Jul 17, 2026 DP 7762994 May 23, 2024 DP 8579869 Jun 30, 2023 DP

SOTALOL HYDROCHLORIDE - SOTYLIZE N 205108 001 10206895 Apr 01, 2034 DP U-2096 10206895 Apr 01, 2034 DP U-2494

SUFENTANIL CITRATE - DSUVIA N 209128 001 10245228 Jan 05, 2027 DP U-1351

SULFUR HEXAFLUORIDE LIPID-TYPE A MICROSPHERES - LUMASON N 203684 001 10232061 Jul 06, 2038 DP

SUMATRIPTAN - TOSYMRA N 210884 001 8268791 May 09, 2026 DP 8440631 May 09, 2026 DP U-1719 9211282 Jul 19, 2031 DP U-1719 9283280 Jul 01, 2025 DP 9610280 Jun 16, 2030 DP U-1719 9974770 Jun 16, 2030 DP U-1719

SUNITINIB MALATE - SUTENT N 021938 001 6573293 Feb 15, 2021 DS DP U-1154 I-755 Nov 16, 2020 6573293 Feb 15, 2021 DS DP U-2171 PED May 16, 2021 6573293*PED Aug 15, 2021 7125905 Feb 15, 2021 DS DP 7125905*PED Aug 15, 2021 7211600 Dec 22, 2020 U-883 7211600*PED Jun 22, 2021

SUNITINIB MALATE - SUTENT N 021938 002 6573293 Feb 15, 2021 DS DP U-1154 I-755 Nov 16, 2020 6573293 Feb 15, 2021 DS DP U-2171 PED May 16, 2021 6573293*PED Aug 15, 2021 7125905 Feb 15, 2021 DS DP 7125905*PED Aug 15, 2021 7211600 Dec 22, 2020 U-883 7211600*PED Jun 22, 2021

SUNITINIB MALATE - SUTENT N 021938 003 6573293 Feb 15, 2021 DS DP U-1154 I-755 Nov 16, 2020 6573293 Feb 15, 2021 DS DP U-2171 PED May 16, 2021 6573293*PED Aug 15, 2021 7125905 Feb 15, 2021 DS DP 7125905*PED Aug 15, 2021 7211600 Dec 22, 2020 U-883 7211600*PED Jun 22, 2021 A - 35 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

SUNITINIB MALATE - SUTENT N 021938 004 6573293 Feb 15, 2021 DS DP U-1154 I-755 Nov 16, 2020 6573293 Feb 15, 2021 DS DP U-2171 PED May 16, 2021 6573293*PED Aug 15, 2021 7125905 Feb 15, 2021 DS DP 7125905*PED Aug 15, 2021 7211600 Dec 22, 2020 U-883 7211600*PED Jun 22, 2021

TACROLIMUS - ENVARSUS XR N 206406 001 10166190 May 30, 2028 DP

TACROLIMUS - ENVARSUS XR N 206406 002 10166190 May 30, 2028 DP

TACROLIMUS - ENVARSUS XR N 206406 003 10166190 May 30, 2028 DP

TADALAFIL - CIALIS N 021368 003 7182958 Apr 26, 2020 DP U-155 Y 7182958*PED Oct 26, 2020

TADALAFIL - CIALIS N 021368 004 7182958 Apr 26, 2020 DP U-155 Y 7182958*PED Oct 26, 2020

TAFAMIDIS - VYNDAMAX N 212161 001 7214695 Apr 27, 2024 DS DP NCE May 03, 2024 7214696 Dec 19, 2023 U-2524 >A> ODE-237 May 03, 2026 9770441 Aug 31, 2035 DS DP U-2524

TAFAMIDIS MEGLUMINE - VYNDAQEL N 211996 001 7214695 Apr 27, 2024 DS DP NCE May 03, 2024 7214696 Dec 19, 2023 U-2524 >A> ODE-237 May 03, 2026 8168663 Dec 19, 2023 DS DP 8653119 Jan 28, 2024 U-2524

TALAZOPARIB TOSYLATE - TALZENNA N 211651 001 10189837 Oct 20, 2031 DS DP

TALAZOPARIB TOSYLATE - TALZENNA N 211651 002 10189837 Oct 20, 2031 DS DP

TAVABOROLE - KERYDIN N 204427 001 NCE Jul 07, 2019 PED Jan 07, 2020

TEDIZOLID PHOSPHATE - SIVEXTRO N 205435 001 10065947 Feb 03, 2030 DP 9624250 Feb 03, 2030 DS DP U-2507 9988406 Feb 03, 2030 DP A - 36 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

TEDIZOLID PHOSPHATE - SIVEXTRO N 205436 001 10065947 Feb 03, 2030 DP 9624250 Feb 03, 2030 DS DP U-2507 9988406 Feb 03, 2030 DP

TEDUGLUTIDE RECOMBINANT - GATTEX KIT N 203441 001 5789379 Apr 14, 2020 DS DP U-1320 >A> ODE-240 May 16, 2026 5789379*PED Oct 14, 2020 ODE-37 Dec 21, 2019 7056886 Sep 18, 2022 DP U-1320 PED Jun 21, 2020 7056886*PED Mar 18, 2023 7847061 Nov 01, 2025 U-1320 7847061*PED May 01, 2026 9060992 Nov 01, 2025 U-1320 9060992*PED May 01, 2026 9539310 Nov 01, 2025 U-1320 9539310*PED May 01, 2026 9545434 Nov 01, 2025 U-1320 9545434*PED May 01, 2026 9545435 Nov 01, 2025 U-1320 9545435*PED May 01, 2026 9555079 Nov 01, 2025 U-1320 9555079*PED May 01, 2026 9572867 Nov 01, 2025 U-1320 9572867*PED May 01, 2026 9592273 Nov 01, 2025 U-1320 9592273*PED May 01, 2026 9592274 Nov 01, 2025 U-1320 9592274*PED May 01, 2026 9968655 Nov 01, 2025 U-2308 9968655*PED May 01, 2026 9968656 Nov 01, 2025 U-2308 9968656*PED May 01, 2026 9968658 Nov 01, 2025 U-1320 9968658*PED May 01, 2026 9974835 Nov 01, 2025 U-1320 9974835*PED May 01, 2026 9974837 Nov 01, 2025 U-1320 9974837*PED May 01, 2026 9981014 Nov 01, 2025 U-1320 9981014*PED May 01, 2026 9981016 Nov 01, 2025 U-1320 9981016*PED May 01, 2026 9987334 Nov 01, 2025 U-1320 9987334*PED May 01, 2026 9987335 Nov 01, 2025 U-1320 9987335*PED May 01, 2026 9993528 Nov 01, 2025 U-1320 9993528*PED May 01, 2026

TESTOSTERONE UNDECANOATE - JATENZO N 206089 001 8241664 Mar 29, 2029 DP U-2506 8492369 Dec 20, 2030 DP U-2506 8778916 Apr 12, 2030 DP

TESTOSTERONE UNDECANOATE - JATENZO N 206089 002 8241664 Mar 29, 2029 DP U-2506 8492369 Dec 20, 2030 DP U-2506 8778916 Apr 12, 2030 DP

TESTOSTERONE UNDECANOATE - JATENZO N 206089 003 8241664 Mar 29, 2029 DP U-2506 8492369 Dec 20, 2030 DP U-2506 8778916 Apr 12, 2030 DP A - 37 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

THIOTHIXENE - THIOTHIXENE A 211642 001 CGT Oct 02, 2019

THIOTHIXENE - THIOTHIXENE A 211642 002 CGT Oct 02, 2019

THIOTHIXENE - THIOTHIXENE A 211642 003 CGT Oct 02, 2019

THIOTHIXENE - THIOTHIXENE A 211642 004 CGT Oct 02, 2019

TICAGRELOR - BRILINTA N 022433 001 >A> 10300065 Jan 27, 2036 U-2541 >A> 10300065 Jan 27, 2036 U-2542

TICAGRELOR - BRILINTA N 022433 002 >A> 10300065 Jan 27, 2036 U-2541 >A> 10300065 Jan 27, 2036 U-2542

TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE - LONSURF N 207981 001 RE46284 Dec 16, 2026 U-1751 I-794 Feb 24, 2022 RE46284 Dec 16, 2026 U-2503 ODE-229 Feb 22, 2026

TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE - LONSURF N 207981 002 RE46284 Dec 16, 2026 U-1751 I-794 Feb 24, 2022 RE46284 Dec 16, 2026 U-2503 ODE-229 Feb 22, 2026

TOPIRAMATE - TROKENDI XR N 201635 001 >A> 10314790 Nov 16, 2027 DP U-1675 >A> 10314790 Nov 16, 2027 DP U-1992

TOPIRAMATE - TROKENDI XR N 201635 002 >A> 10314790 Nov 16, 2027 DP U-1675 >A> 10314790 Nov 16, 2027 DP U-1992

TOPIRAMATE - TROKENDI XR N 201635 003 >A> 10314790 Nov 16, 2027 DP U-1675 >A> 10314790 Nov 16, 2027 DP U-1992

TOPIRAMATE - TROKENDI XR N 201635 004 >A> 10314790 Nov 16, 2027 DP U-1675 >A> 10314790 Nov 16, 2027 DP U-1992

TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST N 204114 001 8703781 Oct 15, 2030 DS DP U-1712 8703781 Oct 15, 2030 DS DP U-2020 8703781 Oct 15, 2030 DS DP U-2037 8703781 Oct 15, 2030 DS DP U-2302 8703781 Oct 15, 2030 DS DP U-2305

TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST N 204114 002 8703781 Oct 15, 2030 DS DP U-1712 8703781 Oct 15, 2030 DS DP U-2020 8703781 Oct 15, 2030 DS DP U-2037 8703781 Oct 15, 2030 DS DP U-2302 8703781 Oct 15, 2030 DS DP U-2305

TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST N 204114 003 8703781 Oct 15, 2030 DS DP U-1712 8703781 Oct 15, 2030 DS DP U-2020 8703781 Oct 15, 2030 DS DP U-2037 A - 38 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST N 204114 003 8703781 Oct 15, 2030 DS DP U-2302 8703781 Oct 15, 2030 DS DP U-2305

TREPROSTINIL - TREPROSTINIL A 203649 001 >A> PC Sep 21, 2019

TREPROSTINIL - TREPROSTINIL A 203649 002 >A> PC Sep 21, 2019

TREPROSTINIL - TREPROSTINIL A 203649 003 >A> PC Sep 21, 2019

TREPROSTINIL - TREPROSTINIL A 203649 004 >A> PC Sep 21, 2019

TRETINOIN - ALTRENO N 209353 001 6517847 Aug 03, 2020 DP U-2368

TRICLABENDAZOLE - EGATEN N 208711 001 NCE Feb 13, 2024 ODE-228 Feb 13, 2026

TRIPTORELIN PAMOATE - TRELSTAR N 022437 001 10166181 Feb 10, 2029 DP

TRIPTORELIN PAMOATE - TRIPTODUR KIT N 208956 001 10166181 Feb 10, 2029 DP

ULIPRISTAL ACETATE - ELLA N 022474 001 10159681 Apr 13, 2030 U-2510 9844510 Dec 08, 2028 DP

URIDINE TRIACETATE - VISTOGARD N 208159 001 6258795 Jul 10, 2023 DP

URIDINE TRIACETATE - XURIDEN N 208169 001 6258795 Jul 10, 2023 DP

VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE N 211962 001 10039804 Nov 06, 2035 DP U-282 10188697 Nov 06, 2035 DP U-282

VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE N 211962 002 10039804 Nov 06, 2035 DP U-282 10188697 Nov 06, 2035 DP U-282

VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE N 211962 003 10039804 Nov 06, 2035 DP U-282 10188697 Nov 06, 2035 DP U-282

VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE N 211962 004 10039804 Nov 06, 2035 DP U-282 10188697 Nov 06, 2035 DP U-282

VARENICLINE TARTRATE - CHANTIX N 021928 001 M-237 Feb 22, 2022 PED Aug 22, 2022 A - 39 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2019 See List footnote for information regarding List content

APPL/PROD PATENT PATENT EXCLUSIVITY NO PATENT NO EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION DATE CODES REQUESTED CODE(S) DATE

VARENICLINE TARTRATE - CHANTIX N 021928 002 M-237 Feb 22, 2022 PED Aug 22, 2022

VENETOCLAX - VENCLEXTA N 208573 001 >A> 9539251 Sep 06, 2033 U-2538 I-795 May 15, 2022 >A> ODE-239 May 15, 2026

VENETOCLAX - VENCLEXTA N 208573 002 >A> 9539251 Sep 06, 2033 U-2538 I-795 May 15, 2022 >A> ODE-239 May 15, 2026

VENETOCLAX - VENCLEXTA N 208573 003 >A> 9539251 Sep 06, 2033 U-2538 I-795 May 15, 2022 >A> ODE-239 May 15, 2026

VORICONAZOLE - VFEND N 021266 001 >A> NPP Jan 29, 2022

VORICONAZOLE - VFEND N 021266 002 >A> NPP Jan 29, 2022

VORICONAZOLE - VFEND N 021267 001 >A> NPP Jan 29, 2022

VORICONAZOLE - VFEND N 021630 001 >A> NPP Jan 29, 2022

Footnote:

1. Patents are published upon receipt by the Orange book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).

2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.

B-1

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG th PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 39 Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/results_patent.cfm

The current complete list of exclusivity terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/results_exclusivity.cfm